<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">9856475</PMID><DateCompleted><Year>1999</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>1998</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Effects of PS1 deficiency on membrane protein trafficking in neurons.</ArticleTitle><Pagination><StartPage>1213</StartPage><EndPage>1221</EndPage><MedlinePgn>1213-21</MedlinePgn></Pagination><Abstract><AbstractText>We have examined the trafficking and metabolism of the beta-amyloid precursor protein (APP), an APP homolog (APLP1), and TrkB in neurons that lack PS1. We report that PS1-deficient neurons fail to secrete Abeta, and that the rate of appearance of soluble APP derivatives in the conditioned medium is increased. Remarkably, carboxyl-terminal fragments (CTFs) derived from APP and APLP1 accumulate in PS1-deficient neurons. Hence, PS1 plays a role in promoting intramembrane cleavage and/or degradation of membrane-bound CTFs. Moreover, the maturation of TrkB and BDNF-inducible TrkB autophosphorylation is severely compromised in neurons lacking PS1. We conclude that PS1 plays an essential role in modulating trafficking and metabolism of a selected set of membrane and secretory proteins in neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naruse</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacological and Physiological Sciences, The University of Chicago, Illinois 60637, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thinakaran</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>J J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Kusiak</LastName><ForeName>J W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Tomita</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>X</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Ginty</LastName><ForeName>D D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Borchelt</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>S S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1PO1 AG14248</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS 20471</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>12</Month><Day>18</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>12</Month><Day>18</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9856475</ArticleId><ArticleId IdType="doi">10.1016/s0896-6273(00)80637-6</ArticleId><ArticleId IdType="pii">S0896-6273(00)80637-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">9878186</PMID><DateCompleted><Year>1999</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0014-4886</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><Issue>2</Issue><PubDate><Year>1998</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Experimental neurology</Title><ISOAbbreviation>Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>511</StartPage><EndPage>521</EndPage><MedlinePgn>511-21</MedlinePgn></Pagination><Abstract><AbstractText>We studied the multifunctional protein clusterin (apolipoprotein J, SGP-2, SP-40,40) in brain tissue using quantitative Western blotting and immunohistochemistry. The material included postmortem brains from 19 patients with Alzheimer's disease (AD), 6 with vascular dementia (VAD), and 7 age-matched control subjects. Intense clusterin staining was found in the soma of both neuronal and astroglial cells. In addition, positive staining was found in a portion of senile plaques (SP) in AD brains. Quantitative analysis showed that clusterin levels were significantly increased in AD, both in frontal cortex (150% of the control value, P = 0.002) and in the hippocampus (179% of the control value, P &lt; 0.001), while normal clusterin levels were found in cerebellum (104% of the control value). No significant changes were found in VAD. Within the AD group, there was a significant negative correlation between clusterin levels in hippocampus and severity of dementia (r = -0.40), while no such correlation was found in frontal cortex (r = 0.12). No significant correlations were found between clusterin levels and the number of SP or neurofibrillary tangles. No significant differences in clusterin levels were found in any brain region between AD patients possessing different numbers of the ApoE4 allele. The increased clusterin levels in AD brain, together with the absence of a correlation between SP counts and clusterin levels, and the finding that clusterin is only found in a smaller portion of SP do not suggest a link between clusterin and beta-amyloid dependence. Instead we hypothesize that the increase is part of a regional response in AD brain.</AbstractText><CopyrightInformation>Copyright 1998 Academic Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lidstr&#xf6;m</LastName><ForeName>A M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, G&#xf6;teborg University, Sahlgrenska University Hospital, M olndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanovic</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hesse</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Volkman</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Davidsson</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Exp Neurol</MedlineTA><NlmUniqueID>0370712</NlmUniqueID><ISSNLinking>0014-4886</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003169">Complement Inactivator Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006023">Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003169" MajorTopicYN="N">Complement Inactivator Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006023" MajorTopicYN="N">Glycoproteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="Y">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>1</Month><Day>8</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>1</Month><Day>8</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9878186</ArticleId><ArticleId IdType="doi">10.1006/exnr.1998.6892</ArticleId><ArticleId IdType="pii">S0014-4886(98)96892-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18640457</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>9634</Issue><PubDate><Year>2008</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.</ArticleTitle><Pagination><StartPage>207</StartPage><EndPage>215</EndPage><MedlinePgn>207-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(08)61074-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although treatments for Alzheimer's disease sometimes improve cognition, functional ability, or behaviour compared with baseline levels, such improvements are inconsistent across studies and measures, and effects diminish over time. More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We enrolled 183 patients with mild-to-moderate Alzheimer's disease (mini-mental state examination [MMSE] scores 10-24) at 11 sites in Russia. Patients were randomly assigned by a computer-generated randomisation scheme to receive oral dimebon, 20 mg three times a day (60 mg/day [n=89]), or matched placebo (n=94). Other antidementia drugs were not allowed. The primary outcome measure assessed cognition, the difference in mean change from baseline to week 26, or last completed observation on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog). All patients and study personnel were blinded throughout the study. We compared dimebon with placebo with an intention-to-treat analysis, with last observation carried forward (ITT-LOCF) imputation. Analyses were repeated on the fully evaluable population, defined as all patients in the intention-to-treat population who had an ADAS-cog at week 26 and at least 80% compliance. 134 patients (68 in dimebon group, 66 in placebo group) enrolled in the 6-month blinded extension phase of the study. This trial is registered with Clinicaltrials.gov, number NCT00377715.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">155 (85%) patients completed the trial (78 [88%] in dimebon group, 77 [82%] in placebo group). Treatment with dimebon resulted in significant benefits in ADAS-cog compared with placebo (ITT-LOCF) at week 26 (mean drug-placebo difference -4.0 [95% CI -5.73 to -2.28]; p&lt;0.0001). Results of the ITT-LOCF and the evaluable population analyses were much the same for all measures. Patients given dimebon were significantly improved over baseline for ADAS-cog (mean difference -1.9 [-2.92 to -0.85]; p=0.0005). Dimebon was well tolerated: dry mouth and depressed mood or depression were the most common adverse events associated with dimebon (12 [14%] patients for each symptom by week 26). The percentage of patients who had adverse events in the two groups did not differ.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Dimebon was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gavrilova</LastName><ForeName>Svetlana I</ForeName><Initials>SI</Initials></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Bachurin</LastName><ForeName>Sergey O</ForeName><Initials>SO</Initials></Author><Author ValidYN="Y"><LastName>Seely</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><CollectiveName>dimebon investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00377715</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>OD9237K1Z6</RegistryNumber><NameOfSubstance UI="C010119">latrepirdine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2008 Jul 19;372(9634):179-80. doi: 10.1016/S0140-6736(08)61046-6.</RefSource><PMID Version="1">18640436</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2008 Oct 18;372(9647):1382-3; author reply 1383. doi: 10.1016/S0140-6736(08)61581-0.</RefSource><PMID Version="1">18940460</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2009 Feb;12(1):21. doi: 10.1136/ebmh.12.1.21.</RefSource><PMID Version="1">19176780</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="Y">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012426" MajorTopicYN="N" Type="Geographic">Russia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Gavrilova</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paraschenko</LastName><ForeName>A F</ForeName><Initials>AF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sluchevskaya</LastName><ForeName>S F</ForeName><Initials>SF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kontsevoy</LastName><ForeName>V A</ForeName><Initials>VA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odinak</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gekht</LastName><ForeName>A B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neznanov</LastName><ForeName>N G</ForeName><Initials>NG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuzmicheva</LastName><ForeName>N Y</ForeName><Initials>NY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>O S</ForeName><Initials>OS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strachunskaya</LastName><ForeName>E Y</ForeName><Initials>EY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gustov</LastName><ForeName>A V</ForeName><Initials>AV</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18640457</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(08)61074-0</ArticleId><ArticleId IdType="pii">S0140-6736(08)61074-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19657023</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>31</Issue><PubDate><Year>2009</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations.</ArticleTitle><Pagination><StartPage>9704</StartPage><EndPage>9713</EndPage><MedlinePgn>9704-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2292-09.2009</ELocationID><Abstract><AbstractText>A central question in Alzheimer's disease research is what role synaptic activity plays in the disease process. Synaptic activity has been shown to induce beta-amyloid peptide release into the extracellular space, and extracellular beta-amyloid has been shown to be toxic to synapses. We now provide evidence that the well established synaptotoxicity of extracellular beta-amyloid requires gamma-secretase processing of amyloid precursor protein. Recent evidence supports an important role for intraneuronal beta-amyloid in the pathogenesis of Alzheimer's disease. We show that synaptic activity reduces intraneuronal beta-amyloid and protects against beta-amyloid-related synaptic alterations. We demonstrate that synaptic activity promotes the transport of the amyloid precursor protein to synapses using live cell imaging, and that the protease neprilysin is involved in reduction of intraneuronal beta-amyloid with synaptic activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tampellini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Nawreen</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Gallo</LastName><ForeName>Eduardo F</ForeName><Initials>EF</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhenyong</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Dumont</LastName><ForeName>Magali</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Capetillo-Zarate</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Tao</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Rong</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bao</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nanus</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>Gunnar K</ForeName><Initials>GK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS045677</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG20729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG028174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501447">Dlg4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058255">Protease Nexins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.8</RegistryNumber><NameOfSubstance UI="D051528">Guanylate Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.11</RegistryNumber><NameOfSubstance UI="D015260">Neprilysin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001693" MajorTopicYN="N">Biological Transport, Active</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051528" MajorTopicYN="N">Guanylate Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015260" MajorTopicYN="N">Neprilysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058255" MajorTopicYN="N">Protease Nexins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19657023</ArticleId><ArticleId IdType="mid">NIHMS140176</ArticleId><ArticleId IdType="pmc">PMC2763626</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2292-09.2009</ArticleId><ArticleId IdType="pii">29/31/9704</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci. 2006;26:4277&#x2013;4288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="pubmed">16624948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambr&#xe9;e O, Leimer U, Herring A, G&#xf6;rtz N, Sachser N, Heneka MT, Paulus W, Keyvani K. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol. 2006;169:544&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1698805</ArticleId><ArticleId IdType="pubmed">16877355</ArticleId></ArticleIdList></Reference><Reference><Citation>Belinson H, Lev D, Masliah E, Michaelson DM. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci. 2008;28:4690&#x2013;4701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844816</ArticleId><ArticleId IdType="pubmed">18448646</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Bingol B, Schuman EM. Activity-dependent dynamics and sequestration of proteasomes in dendritic spines. Nature. 2006;441:1144&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">16810255</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, Yankner BA. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 2002;33:677&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Pan PY, Sheng ZH. Syntabulin-kinesin-1 family member 5B-mediated axonal transport contributes to activity-dependent presynaptic assembly. J Neurosci. 2007;27:7284&#x2013;7296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6794594</ArticleId><ArticleId IdType="pubmed">17611281</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese B, Shaked GM, Tabarean IV, Braga J, Koo EH, Halpain S. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci. 2007;35:183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268524</ArticleId><ArticleId IdType="pubmed">17368908</ArticleId></ArticleIdList></Reference><Reference><Citation>Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol. 2004;165:1289&#x2013;1300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618627</ArticleId><ArticleId IdType="pubmed">15466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004;25:1263&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ. Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003;24:1023&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai LH. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001;38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci. 2009;29:4004&#x2013;4015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665357</ArticleId><ArticleId IdType="pubmed">19339596</ArticleId></ArticleIdList></Reference><Reference><Citation>Echeverria V, Ducatenzeiler A, Dowd E, J&#xe4;nne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience. 2004;129:583&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci. 2003;6:231&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res. 2002;43:39&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12074840</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Osta A, Alberini CM. Amyloid beta mediates memory formation. Learn Mem. 2009;16:267&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661754</ArticleId><ArticleId IdType="pubmed">19318468</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging. 2005;26:1235&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC. Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001;125:489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">11260621</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6:143&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">10655101</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC. Metabolic regulation of brain Abeta by neprilysin. Science. 2001;292:1550&#x2013;1552.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375493</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002;70:493&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaether C, Skehel P, Dotti CG. Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol Biol Cell. 2000;11:1213&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14842</ArticleId><ArticleId IdType="pubmed">10749925</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JS, Tian JH, Pan PY, Zald P, Li C, Deng C, Sheng ZH. Docking of axonal mitochondria by syntaphilin controls their mobility and affects short-term facilitation. Cell. 2008;132:137&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2259239</ArticleId><ArticleId IdType="pubmed">18191227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienlen-Campard P, Miolet S, Tasiaux B, Octave JN. Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis. J Biol Chem. 2002;277:15666&#x2013;15670.</Citation><ArticleIdList><ArticleId IdType="pubmed">11861655</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007;28:1297&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876915</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem. 1994;269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell. 2005;120:701&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">15766532</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Calingasan NY, Yu F, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, Flint Beal M, Lin MT, Gouras GK. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem. 2004;89:1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147524</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298242</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, Yuan M, Zhang Z, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Vigo FS, Sommer B, Yankner BA. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci. 2000;3:460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B, Gerard NP, Kolakowski LF, Jr, Bozza M, Zurakowski D, Finco O, Carroll MC, Gerard C. Neutral endopeptidase modulation of septic shock. J Exp Med. 1995;181:2271&#x2013;2275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2192063</ArticleId><ArticleId IdType="pubmed">7760013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Man H, Ju W, Trimble WS, MacDonald JF, Wang YT. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron. 2001;29:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182095</ArticleId></ArticleIdList></Reference><Reference><Citation>Magran&#xe9; J, Rosen KM, Smith RC, Walsh K, Gouras GK, Querfurth HW. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J Neurosci. 2005;25:10960&#x2013;10969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725865</ArticleId><ArticleId IdType="pubmed">16306409</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002;9:88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440481</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol. 2006;168:184&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592652</ArticleId><ArticleId IdType="pubmed">16400022</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Perestenko PV, Henley JM. Characterization of the intracellular transport of GluR1 and GluR2 alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor subunits in hippocampal neurons. J Biol Chem. 2003;278:43525&#x2013;43532.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314505</ArticleId><ArticleId IdType="pubmed">12909632</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, F&#xe0; M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Kn&#xf6;lker HJ, Simons K. Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science. 2008;320:520&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">18436784</ArticleId></ArticleIdList></Reference><Reference><Citation>Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T. Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci. 2002;22:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pubmed">11880497</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked GM, Kummer MP, Lu DC, Galvan V, Bredesen DE, Koo EH. Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597&#x2013;624) FASEB J. 2006;20:1254&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847355</ArticleId><ArticleId IdType="pubmed">16636103</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis. 2003;14:133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678674</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:S69&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917199</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK Advance online publication. Co-occurrence of Alzheimer's disease beta-amyloid and tau pathologies at synapses. Neurobiol Aging. 2008 doi: 10.1016/j.neurobiolaging.2008.07.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.07.021</ArticleId><ArticleId IdType="pmc">PMC2909664</ArticleId><ArticleId IdType="pubmed">18771816</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Magran&#xe9; J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations. J Biol Chem. 2007;282:18895&#x2013;18906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468102</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Edwards JG, Riley N, Provance DW, Jr, Karcher R, Li XD, Davison IG, Ikebe M, Mercer JA, Kauer JA, Ehlers MD. Myosin Vb mobilizes recycling endosomes and AMPA receptors for postsynaptic plasticity. Cell. 2008;135:535&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2585749</ArticleId><ArticleId IdType="pubmed">18984164</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001;306:116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403971</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong-Riley MT, Welt C. Histochemical changes in cytochrome oxidase of cortical barrels after vibrissal removal in neonatal and adult mice. Proc Natl Acad Sci U S A. 1980;77:2333&#x2013;2337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC348709</ArticleId><ArticleId IdType="pubmed">6246540</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AJ, Chandswangbhuvana D, Shu T, Henschen A, Glabe CG. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1-42. J Biol Chem. 1999;274:20650&#x2013;20656.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173346</ArticleId><ArticleId IdType="pubmed">11815632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8059599</PMID><DateCompleted><Year>1994</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>5</Issue><PubDate><Year>1994</Year></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders.</ArticleTitle><Pagination><StartPage>469</StartPage><EndPage>480</EndPage><MedlinePgn>469-80</MedlinePgn></Pagination><Abstract><AbstractText>Alterations of the cerebral microvasculature have been reported in aging and in neurodegenerative disorders such as Alzheimer's disease. However, the exact role of microvascular alterations in the pathogenesis of neurodegeneration remains unknown. In the present report, the cerebral cortex microvasculature was studied by immunohistochemistry using a monoclonal antibody against vascular heparan sulfate proteoglycan protein core in normal aging controls. Alzheimer's disease, Down syndrome, Guam amyotrophic lateral sclerosis/parkinsonian dementia complex, Pick's disease and dementia pugilistica. In all dementing illnesses, increased microvascular pathology was evident compared to normal controls. Decreased microvascular density and numerous atrophic vessels were the primary abnormalities observed in all dementing disorders. These microvascular abnormalities demonstrated regional and laminar selectivity, and were primarily found in layers III and V of frontal and temporal cortex. Quantitative analysis employing computer-assisted microscopy demonstrated that the decrease in microvascular density in Alzheimer's disease was statistically significant compared to age-matched controls. In addition, extracellular heparan sulfate proteoglycan deposits were observed which colocalized with thioflavine S-positive senile plaques in Alzheimer's disease, Down syndrome and selected Guam dementia cases. In some cases, heparan sulfate proteoglycan was seen in senile plaques that appeared to be diffuse or primitive plaques that stained weakly with thioflavine. Heparan sulfate proteoglycan-containing neurons were also observed in Alzheimer's disease, as well as in Down syndrome and Guam cases. Glial staining for heparan sulfate proteoglycan was never observed. Our data support previous observations that microvascular pathology is found in aging and in Alzheimer's disease. The changes in Alzheimer's disease exceed those found in normal aging controls. We also found microvascular pathology in all other dementing disorders studied. Our studies further demonstrated that the microvascular pathology displays regional and laminar patterns which parallel patterns of neuronal loss. Finally, we also found that heparan sulfate proteoglycan is present in senile plaques and neurons not only as previously reported in Alzheimer's disease, but also in Down syndrome and Guam cases. Heparan sulfate proteoglycan in senile plaques may be derived from either the degenerating microvasculature or from degenerating neurons.(ABSTRACT TRUNCATED AT 400 WORDS)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bu&#xe9;e</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Geriatrics and Adult Development, Mount Sinai Medical Center, New York, NY 10029-6574.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hof</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Bouras</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Delacourte</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Perl</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Fillit</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG05138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08802</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019812">Heparan Sulfate Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011509">Proteoglycans</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001808" MajorTopicYN="N">Blood Vessels</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002560" MajorTopicYN="Y">Cerebrovascular Circulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019812" MajorTopicYN="N">Heparan Sulfate Proteoglycans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="N">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011509" MajorTopicYN="N">Proteoglycans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8059599</ArticleId><ArticleId IdType="doi">10.1007/BF00294173</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brain Res. 1993 Nov 12;627(2):199-204</Citation><ArticleIdList><ArticleId IdType="pubmed">8298962</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1992 Mar-Apr;13(2):239-53</Citation><ArticleIdList><ArticleId IdType="pubmed">1522941</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1990 Jul-Aug;11(4):359-70</Citation><ArticleIdList><ArticleId IdType="pubmed">2381495</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 1990 May;24(5):677-86</Citation><ArticleIdList><ArticleId IdType="pubmed">2192775</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1992 Spring;6(1):7-34</Citation><ArticleIdList><ArticleId IdType="pubmed">1605946</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1993 Aug 13;261(5123):921-3</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Neurol. 1978;20:487-501</Citation><ArticleIdList><ArticleId IdType="pubmed">676912</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1984 May 16;120(3):885-90</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1988 Jan-Feb;9(1):46-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3380253</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1993 Jan 22;601(1-2):154-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8431762</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1992;83(2):170-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1373017</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 1991 Jan-Feb;1(1):103-16</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1991 Nov;11(11):3679-83</Citation><ArticleIdList><ArticleId IdType="pubmed">1941102</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1990;79(6):672-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2360411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1991 Oct;30(4):572-80</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Virchows Arch A Pathol Anat Histopathol. 1988;413(2):141-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2455379</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1986 Sep-Oct;7(5):321-30</Citation><ArticleIdList><ArticleId IdType="pubmed">3785532</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1981;53(4):299-318</Citation><ArticleIdList><ArticleId IdType="pubmed">7223373</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1991 Nov 15;564(2):306-13</Citation><ArticleIdList><ArticleId IdType="pubmed">1810629</ArticleId></ArticleIdList></Reference><Reference><Citation>J Histochem Cytochem. 1984 Apr;32(4):455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">6323574</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1992 Dec 15;31(49):12345-52</Citation><ArticleIdList><ArticleId IdType="pubmed">1463722</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1991 Jul-Aug;12(4):295-312</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1993 Jan-Feb;14(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">8450928</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1985 Oct;5(10):2801-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4045553</ArticleId></ArticleIdList></Reference><Reference><Citation>Carbohydr Res. 1974 Oct;37(1):181-92</Citation><ArticleIdList><ArticleId IdType="pubmed">4279141</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1990 Jan 29;508(1):13-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2140065</ArticleId></ArticleIdList></Reference><Reference><Citation>Connect Tissue Res. 1988;18(1):9-25</Citation><ArticleIdList><ArticleId IdType="pubmed">2972530</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1992 Oct;59(4):1531-40</Citation><ArticleIdList><ArticleId IdType="pubmed">1402902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1987 Jun;7(6):1799-808</Citation><ArticleIdList><ArticleId IdType="pubmed">2439665</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 1992 Oct 15;188(1):395-401</Citation><ArticleIdList><ArticleId IdType="pubmed">1417860</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1989 Sep-Oct;10(5):481-97</Citation><ArticleIdList><ArticleId IdType="pubmed">2682326</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer Dis Assoc Disord. 1987;1(1):19-37</Citation><ArticleIdList><ArticleId IdType="pubmed">3453741</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1991 Jul 15;266(20):12878-83</Citation><ArticleIdList><ArticleId IdType="pubmed">1906461</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1992 Dec;51(4):801-13</Citation><ArticleIdList><ArticleId IdType="pubmed">1488123</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 1981 Nov;7(5):519-79</Citation><ArticleIdList><ArticleId IdType="pubmed">7317796</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1992 Feb 3;135(2):235-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1625800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lab Invest. 1992 Dec;67(6):734-42</Citation><ArticleIdList><ArticleId IdType="pubmed">1460864</ArticleId></ArticleIdList></Reference><Reference><Citation>Lab Invest. 1990 Nov;63(5):589-91</Citation><ArticleIdList><ArticleId IdType="pubmed">2232711</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1993 Jan-Feb;14(1):51-4; discussion 55-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8450933</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1990 Nov 1;301(1):44-54</Citation><ArticleIdList><ArticleId IdType="pubmed">2127598</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1991;82(4):321-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1759563</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Pathol. 1987 May;18(5):506-10</Citation><ArticleIdList><ArticleId IdType="pubmed">3570282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1986 Feb 15;261(5):2068-76</Citation><ArticleIdList><ArticleId IdType="pubmed">2418019</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1992;83(5):510-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1621507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1970 Sep;11(3):205-42</Citation><ArticleIdList><ArticleId IdType="pubmed">5505685</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1990;80(2):111-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2117840</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerebrovasc Brain Metab Rev. 1992 Fall;4(3):226-60</Citation><ArticleIdList><ArticleId IdType="pubmed">1389957</ArticleId></ArticleIdList></Reference><Reference><Citation>Arteriosclerosis. 1988 Jan-Feb;8(1):1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3277611</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1992;84(2):117-27</Citation><ArticleIdList><ArticleId IdType="pubmed">1381856</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1992;85(1):23-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1285493</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1965 Oct 4;5(1):40-53</Citation><ArticleIdList><ArticleId IdType="pubmed">4161278</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1988 Jan-Feb;9(1):41-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3380250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10858586</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Inflammation and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>383</StartPage><EndPage>421</EndPage><MedlinePgn>383-421</MedlinePgn></Pagination><Abstract><AbstractText>Inflammation clearly occurs in pathologically vulnerable regions of the Alzheimer's disease (AD) brain, and it does so with the full complexity of local peripheral inflammatory responses. In the periphery, degenerating tissue and the deposition of highly insoluble abnormal materials are classical stimulants of inflammation. Likewise, in the AD brain damaged neurons and neurites and highly insoluble amyloid beta peptide deposits and neurofibrillary tangles provide obvious stimuli for inflammation. Because these stimuli are discrete, microlocalized, and present from early preclinical to terminal stages of AD, local upregulation of complement, cytokines, acute phase reactants, and other inflammatory mediators is also discrete, microlocalized, and chronic. Cumulated over many years, direct and bystander damage from AD inflammatory mechanisms is likely to significantly exacerbate the very pathogenic processes that gave rise to it. Thus, animal models and clinical studies, although still in their infancy, strongly suggest that AD inflammation significantly contributes to AD pathogenesis. By better understanding AD inflammatory and immunoregulatory processes, it should be possible to develop anti-inflammatory approaches that may not cure AD but will likely help slow the progression or delay the onset of this devastating disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiyama</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sun Health Research Institute, 10515 West Santa Fe Drive, P.O. Box 1278, 85372, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barger</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Barnum</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bradt</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>N R</ForeName><Initials>NR</Initials></Author><Author ValidYN="Y"><LastName>Eikelenboom</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Emmerling</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fiebich</LastName><ForeName>B L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Finch</LastName><ForeName>C E</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Frautschy</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>W S</ForeName><Initials>WS</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hull</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Landreth</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lue</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mrak</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>I R</ForeName><Initials>IR</Initials></Author><Author ValidYN="Y"><LastName>McGeer</LastName><ForeName>P L</ForeName><Initials>PL</Initials></Author><Author ValidYN="Y"><LastName>O'Banion</LastName><ForeName>M K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Pachter</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pasinetti</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Plata-Salaman</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rydel</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Streit</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Strohmeyer</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Tooyoma</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Van Muiswinkel</LastName><ForeName>F L</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Veerhuis</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Webster</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wegrzyniak</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Wenk</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG012411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>9</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10858586</ArticleId><ArticleId IdType="mid">NIHMS542954</ArticleId><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="doi">10.1016/s0197-4580(00)00124-x</ArticleId><ArticleId IdType="pii">S019745800000124X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>. The Canadian Study of Health and Aging: risk factors for Alzheimer&#x2019;s disease in Canada. Neurology. 1994;44:2073&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969962</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham CR, Selkoe DJ, Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer&#x2019;s disease. Cell. 1988;52:487&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">3257719</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams DO, Hamilton TA. The Macrophage. Oxford: IRL; 1992. Molecular basis of macrophage activation.</Citation></Reference><Reference><Citation>Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Localization and cell association of C1q in Alzheimer&#x2019;s disease brain. Exp Neurol. 1996;138:22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8593893</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguado F, Ballabriga J, Pozas E, Ferrer I. TrkA immunoreactivity in reactive astrocytes in human neurodegenerative diseases and colchicine-treated rats. Acta Neuropathol (Berlin) 1998;96:495&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">9829813</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer&#x2019;s disease: implications for therapy. Am J Psychiatry. 1994;151:1105&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">7518651</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Pasinetti GM. Glucocorticoids in Alzheimer&#x2019;s disease. The story so far Drugs Aging. 1998;12:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9467682</ArticleId></ArticleIdList></Reference><Reference><Citation>Akassoglou K, Probert L, Kontogeorgos G, Kollias G. Astrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol. 1997;158:438&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">8977220</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira S, Taga T, Kishimoto T. IL-6 in biology and medicine. Adv Immunol. 1993;54:1&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">8379461</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in brains of patients with Alzheimer&#x2019;s disease. Neurosci Lett. 1992;146:152&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1491781</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Kawamata T, Dedhar S, McGeer PL. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J Neuroimmunol. 1991;32:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">1705945</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishii T, McGeer PL. Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol (Berlin) 1993;85:628&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">8337942</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Kondo H, Ikeda K, Arai T, Kato M, McGleer PL. Immunohistochemical detection of coagulation factor XIIIa in postmortem human brain tissue. Neurosci Lett. 1995;202:29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8787823</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. J Neuroimmunol. 1990;30:81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">1977769</ArticleId></ArticleIdList></Reference><Reference><Citation>Akwa Y, Hassett DE, Eloranta ML, et al. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol. 1998;161:5016&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9794439</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer&#x2019;s disease? The Rotterdam Study. Neurology. 1995;45:1441&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW. The myeloperoxidase system of human phagocytes generates nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408396</ArticleId><ArticleId IdType="pubmed">10393704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ando Y, Brannstrom T, Uchida K, et al. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J Neurol Sci. 1998;156:172&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9588853</ArticleId></ArticleIdList></Reference><Reference><Citation>Antel JP, Becher B, Owens T. Immunotherapy for multiple sclerosis: from theory to practice [comment] Nat Med. 1996;2:1074&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837599</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki W, Kitaguchi N, Tokushima Y, et al. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun. 1991;181:265&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">1958195</ArticleId></ArticleIdList></Reference><Reference><Citation>Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD. Scavenging of Alzheimer&#x2019;s Amyloid &#x3b2;-protein by microglia in culture. J Neurosci Res. 1996;43:190&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">8820967</ArticleId></ArticleIdList></Reference><Reference><Citation>Asensio VC, Campell IL. Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 1999;22:504&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10529818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ata AK, Funa K, Olsson Y. Expression of various TGF-beta isoforms and type I receptor in necrotizing human brain lesions. Acta Neuropathol (Berlin) 1997;93:326&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9113197</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagasra O, Michaels FH, Zheng YM, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA. 1995;92:12041&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40292</ArticleId><ArticleId IdType="pubmed">8618840</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Du Y, Dodel RC, Yan GM, Hamilton&#x2013;Byrd E, Paul SM. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Mol Brain Res. 1998;57:63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630519</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati RB, Gehrmann J, Kreutzberg GW. Glial beta-amyloid precursor protein: expression in the dentate gyrus after entorhinal cortex lesion. Neuroreport. 1994;5:1359&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">7919199</ArticleId></ArticleIdList></Reference><Reference><Citation>Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia. 1993;7:111&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423058</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;388:878&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278049</ArticleId></ArticleIdList></Reference><Reference><Citation>Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MP. TNFs alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA. 1995;92:9328&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40978</ArticleId><ArticleId IdType="pubmed">7568127</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnum SR, Jones JL. Transforming growth factor-beta 1 inhibits inflammatory cytokine-induced C3 gene expression in astrocytes. J Immunol. 1994;152:765&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">8283050</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnum SR, Jones JL, Muller&#x2013;Ladner U, Samimi A, Campbell IL. Chronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted IL-6 expression. Glia. 1996;18:107&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8913774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer J, Ganter U, Abel J, et al. Effects of IL-1 and IL-6 on metallothionein and amyloid precursor protein expression in human neuroblastoma cells. Evidence that IL-6 possibly acts via a receptor different from the 80-kDa IL-6 receptor. J Neuroimmunol. 1993;45:163&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">8392518</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer J, Konig G, Strauss S, Jonas U, Ganter U, Weidemann A, Monning U, Masters CL, Volk B, Berger M. In-vitro matured human macrophages express Alzheimer&#x2019;s beta A4-amyloid precursor protein indicating synthesis in microglial cells. FEBS Lett. 1991;282:335&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">1903718</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer J, Strauss S, Schreiter&#x2013;Gasser U, et al. IL-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer&#x2019;s disease cortices. FEBS Lett. 1991;285:111&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1712317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer MK, Lieb K, Schulze&#x2013;Osthoff K, et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997;243:726&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9057838</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9024663</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard CM, Kokman E, Kurland LT. Rheumatoid arthritis and susceptibility to Alzheimer&#x2019;s disease. Lancet. 1991;337:1426.</Citation><ArticleIdList><ArticleId IdType="pubmed">1674811</ArticleId></ArticleIdList></Reference><Reference><Citation>Beffert U, Arguin C, Poirier J. The polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer&#x2019;s disease. Neurosci Lett. 1999;259:29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027548</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl C. Alzheimer&#x2019;s disease, and oxidative stress. Implications for novel therapeutic approaches. Prog Neurobiol. 1999;57:301&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10096843</ArticleId></ArticleIdList></Reference><Reference><Citation>Betmouni S, Perry VH, Gordon JL. Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience. 1996;74:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8843071</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitting L, Naidu A, Cordell B, Murphy GMJ. &#x3b2;-amyloid peptide secretion by a microglial cell line is induced by b-amyloid (25&#x2013;35) and lipopolysaccharide. J Biol Chem. 1996;271:16084&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8663228</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Wilcox MA, Laird NM, et al. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9697696</ArticleId></ArticleIdList></Reference><Reference><Citation>Blin J, Ivanoiu A, Coppens A, et al. Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer&#x2019;s disease patients. Neuroimage. 1997;6:335&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9417975</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom MA, van Twillert MG, de Vries SC, Engels F, Finch CE, Veerhuis R, Eikelenboom P. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human postmortem astrocytes: the involvement of prostaglandin E2. Brain Res. 1997;777:210&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9449430</ArticleId></ArticleIdList></Reference><Reference><Citation>Bluthe RM, Dantzer R, Kelley KW. Effects of IL-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res. 1992;573:318&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">1387028</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Convit A, et al. MRI of entorhinal cortex in mild Alzheimer&#x2019;s disease. Lancet. 1999;353:38&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023955</ArticleId></ArticleIdList></Reference><Reference><Citation>Border WA, Noble NA. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 1997;51:1388&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150449</ArticleId></ArticleIdList></Reference><Reference><Citation>Borth W. &#x3b1;2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992;6:3345&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">1281457</ArticleId></ArticleIdList></Reference><Reference><Citation>Botchkina GI, Meistrell ME, Botchkina IL, Tracey KJ. Expression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med. 1997;3:765&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2230243</ArticleId><ArticleId IdType="pubmed">9407552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottner M, Unsicker K, Suter&#x2013;Crazzolara C. Expression of TGF-beta type II receptor mRNA in the CNS. Neuroreport. 1996;7:2903&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116206</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer&#x2019;s disease beta-peptide. J Exp Med. 1998;188:431&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212467</ArticleId><ArticleId IdType="pubmed">9687521</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10 (Suppl 2):81&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899106</ArticleId></ArticleIdList></Reference><Reference><Citation>Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB. Distribution and characterization of TNF-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol. 1993;337:543&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">8288770</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer&#x2019;s disease: initial results of a co-twin control study. Neurology. 1994;44:227&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8309563</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer&#x2019;s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995;16:523&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8544901</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer&#x2019;s disease in Australia. Neurology. 1990;40:1698&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">2146525</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown P. Immunologic mechanisms in Neurologic and Psychiatric Disease. New York: Raven Press; 1990. The phantagasmagoric immunology of transmissible spongiform encephalopathy.</Citation></Reference><Reference><Citation>Bruccoleri A, Pennypacker KR, Harry GJ. Effect of dexamethasone on elevated cytokine mRNA levels in chemical-induced hippocampal injury. J Neurosci Res. 1999;57:916&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10467263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce&#x2013;Keller AJ, Geddes JW, Knapp PE, et al. Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. J Neuroimmunol. 1999;93:53&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">10378869</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce AJ, Boling W, Kindy MS, et al. Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996;2:788&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8673925</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Mir A, Appel K, et al. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. Br J Pharmacol. 1997;122:1483&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565066</ArticleId><ArticleId IdType="pubmed">9421299</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Liu KN, Luo Y, et al. Evidence that TNF alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 1998;273:27765&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9774383</ArticleId></ArticleIdList></Reference><Reference><Citation>Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA. 1992;89:10075&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50280</ArticleId><ArticleId IdType="pubmed">1359534</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacabelos R, Alvarez XA, Fernandez&#x2013;Novoa L, et al. Brain IL-1 beta in Alzheimer&#x2019;s disease and vascular dementia. Methods Find Exp Clin Pharmacol. 1994;16:141&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8007743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron HA, Gould E. Adult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience. 1994;61:203&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969902</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL. Transgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res Rev. 1998;26:327&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651549</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL, Abraham CR, Masliah E, et al. Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA. 1993;90:10061&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47713</ArticleId><ArticleId IdType="pubmed">7694279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardinaux J-R, Allaman I, Magistretti PJ. Pro-inflammatory cytokines induce the transcription factors C/EBP-beta and C/EBP-delta in astrocytes. Glia. 2000;29:91&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10594926</ArticleId></ArticleIdList></Reference><Reference><Citation>Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC433057</ArticleId><ArticleId IdType="pubmed">1103152</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano A, Lawson LJ, Fearn S, Perry VH. Activation and proliferation of murine microglia are insensitive to glucocorticoids in Wallerian degeneration. Eur J Neurosci. 1996;8:581&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8963450</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano EM, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer&#x2019;s disease of amyloid &#x3b2; peptides and apolipoprotein E. Biochem J. 1995;306:599&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1136559</ArticleId><ArticleId IdType="pubmed">7534068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CC, Ala TA, Hu S, et al. Serum cytokine levels in patients with Alzheimer&#x2019;s disease. Clin Diagn Lab Immunol. 1994;1:433&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC368282</ArticleId><ArticleId IdType="pubmed">8556481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CC, Hu S, Frey WH, Ala TA, Tourtellotte WW, Peterson PK. Transforming growth factor beta in Alzheimer&#x2019;s disease. Clin Diagn Lab Immunol. 1994;1:109&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC368205</ArticleId><ArticleId IdType="pubmed">7496909</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992;149:2736&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">1383325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PK. Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia. 1996;16:276&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8833198</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao CC, Hu S, Tsang M, et al. Effects of transforming growth factor-beta on murine astrocyte glutamine synthetase activity. Implications in neuronal injury. J Clin Invest. 1992;90:1786&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC443237</ArticleId><ArticleId IdType="pubmed">1358919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Marsh T, Zhang JS, Graham SH. Expression of cyclooxygenase 2 in rat brain following kainate treatment. Neuroreport. 1995;6:245&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7756602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Frederickson RC, Brunden KR. Neuroglial-mediated immunoinflammatory responses in Alzheimer&#x2019;s disease: complement activation and therapeutic approaches. Neurobiol Aging. 1996;17:781&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892352</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang CS, Powell HC, Gold LH, Samimi A, Campbell IL. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of IL-3 in transgenic mice. J Clin Invest. 1996;97:1512&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC507212</ArticleId><ArticleId IdType="pubmed">8617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong Y. Effect of a carboxy-terminal fragment of the Alzheimer&#x2019;s amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 1997;61:2323&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9408055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chun JT, Wang L, Pasinetti GM, Finch CE, Zlokovic BV. Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp Neurol. 1999;157:194&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">10222122</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaco&#x2013;Morales Y, Aspey B, Harrison M, de Belleroche J. Cyclooxygenase-2 messenger RNA induction in focal cerebral ischemia. J Cereb Blood Flow Metab. 1996;16:1366&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8898713</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Gilbert DL. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 1987;223:284&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2822487</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GE. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci. 1999;19:928&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782151</ArticleId><ArticleId IdType="pubmed">9920656</ArticleId></ArticleIdList></Reference><Reference><Citation>Combs CK, Johnson DE, Karlo C, Cannady SB, Landreth GE. Inflammatory mechanisms in Alzheimer&#x2019;s disease: inhibition of &#x3b2;-amyloid stimulated proinflammatory responses and neurotoxicity by PPAR&#x3b3; agonists. J Neurosci. 2000;20:558&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772401</ArticleId><ArticleId IdType="pubmed">10632585</ArticleId></ArticleIdList></Reference><Reference><Citation>Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148:1404&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">1538124</ArticleId></ArticleIdList></Reference><Reference><Citation>Coria F, Castano E, Prelli F, et al. Isolation and characterization of amyloid P component from Alzheimer&#x2019;s disease and other types of cerebral amyloidosis. Lab Invest. 1988;58:454&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2965774</ArticleId></ArticleIdList></Reference><Reference><Citation>Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor FJ. The cellular pathology associated with Alzheimer beta-amyloid deposits in nondemented aged individuals. Neuropathol Appl Neurobiol. 1993;19:261&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8355812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Tenner AJ. &#x3b2;-amyloid converts an acute phase injury response to chronic injury response. Neurobiol Aging. 1996;17:723&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892345</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford F, Town T, Freeman M, et al. The alpha-2 macroglobulin gene is not associated with Alzheimer&#x2019;s disease in a case-control sample. Neurosci Lett. 1999;270:133&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10462112</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991;266:2647&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">1846631</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuenod CA, Denys A, Michot JL, et al. Amygdala atrophy in Alzheimer&#x2019;s disease. An in vivo magnetic resonance imaging study. Arch Neurol. 1993;50:941&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8363448</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis&#x2013;Prior P, Vere D, Fray P. Therapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. J Pharm Pharmacol. 1999;51:535&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411212</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Souza SD, Bonetti B, Balasingam V, et al. Multiple sclerosis: fas signaling in oligodendrocyte cell death. J Exp Med. 1996;184:2361&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196365</ArticleId><ArticleId IdType="pubmed">8976190</ArticleId></ArticleIdList></Reference><Reference><Citation>da Cunha A, Jefferson JA, Jackson RW, Vitkovic L. Glial cell-specific mechanisms of TGF-beta 1 induction by IL-1 in cerebral cortex. J Neuroimmunol. 1993;42:71&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423208</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Potter H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron. 1995;14:447&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857652</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis EJ, Foster TD, Thomas WE. Cellular forms and functions of brain microglia. Brain Res Bull. 1994;34:73&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8193937</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis JB, McMurray HF, Schubert D. The amyloid beta-protein of Alzheimer&#x2019;s disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun. 1992;189:1096&#x2013;1100.</Citation><ArticleIdList><ArticleId IdType="pubmed">1472019</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia. 1999;26:201&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10340761</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat. 1996;10:179&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">8811421</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, McRae T, Rusinek H, et al. Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer&#x2019;s disease. J Clin Endocrinol Metab. 1997;82:3251&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329348</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos K, Goossens V, Boone E, et al. The 55-kDa TNF receptor induces clustering of mitochondria through its membrane-proximal region. J Biol Chem. 1998;273:9673&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545301</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb S, Gottschall PE. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem. 1996;66:1641&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627321</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci Lett. 1995;188:70&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783982</ArticleId></ArticleIdList></Reference><Reference><Citation>Della&#x2013;Bianca V, Dusi S, Bianchini E, et al. &#x3b2; amyloid activates the O2 forming NADPH oxidase in microglia, monocytes and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer&#x2019;s disease. J Biol Chem. 1999;274:15493&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336441</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWitt DA, Perry G, Cohen M, Doller C, Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer&#x2019;s disease. Exp Neurol. 1998;149:329&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9500964</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer&#x2019;s disease. Glia. 1993;7:75&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423065</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly RJ, Friedhoff AJ, Beer B, Blume AJ, Vitek MP. IL-1 stimulates the beta-amyloid precursor protein promoter. Cell Mol Neurobiol. 1990;10:485&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11567380</ArticleId><ArticleId IdType="pubmed">2091832</ArticleId></ArticleIdList></Reference><Reference><Citation>Droillard MJ, Guclu J, Le Caer JP, Mathieu Y, Guern J, Lauriere C. Identification of calreticulin-like protein as one of the phosphoproteins modulated in response to oligogalacturonides in tobacco cells. Planta. 1997;202:341&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9232905</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Bales KR, Dodel RC, et al. Alpha2-macroglobulin attenuates beta-amyloid peptide 1&#x2013;40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem. 1998;70:1182&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9489740</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, Ni B, Glinn M, et al. Alpha2-macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem. 1997;69:299&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202323</ArticleId></ArticleIdList></Reference><Reference><Citation>Duong T, Pommier EC, Scheibel AB. Immunodetection of the amyloid P component in Alzheimer&#x2019;s disease. Acta Neuropathol (Berlin) 1989;78:429&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">2551124</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzenko KA, Weltzien RB, Pachter JS. Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds. J Neuroimmunol. 1997;80:6&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413254</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder J. Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? Trends Pharmacol Sci. 1997;18:319&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345850</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 1982;57:239&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">6812382</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelenboom P, Stam FC. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer&#x2019;s dementia. Virchows Arch B Cell Pathol. 1984;47:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">6151285</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996;382:716&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751442</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SC. Microglia, scavenger receptors, and the pathogenesis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1998;19:S81&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562474</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson S, Janciauskiene S, Lannfelt L. Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc Natl Acad Sci USA. 1995;92:2313&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42805</ArticleId><ArticleId IdType="pubmed">7892264</ArticleId></ArticleIdList></Reference><Reference><Citation>Espey MG, Chernyshev ON, Reinhard JFJ, Namboodiri MA, Colton CA. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport. 1997;8:431&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9080423</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PTJ. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA. 1995;92:763&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC42700</ArticleId><ArticleId IdType="pubmed">7846048</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan FS, Shen HH, Tseng WP, Chen PM, Tsai SF. Molecular cloning and characterization of a human brain-specific gene implicated in neuronal differentiation. Mol Brain Res. 1998;54:113&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">9526061</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB. Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by IL-1, TNF-alpha, and lipopolysaccharide. J Clin Invest. 1995;95:1669&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC295674</ArticleId><ArticleId IdType="pubmed">7706475</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of TNF-alpha. Cerebrovasc Brain Metab Rev. 1994;6:341&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">7880718</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiebich BL, Hofer TJ, Lieb K, et al. The non-steroidal anti-inflammatory drug tepoxalin inhibits IL-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha. Neuropharmacology. 1999;38:1325&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471086</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiebich BL, Hull M, Lieb K, Gyufko K, Berger M, Bauer J. Prostaglandin E2 induces IL-6 synthesis in human astrocytoma cells. J Neurochem. 1997;68:704&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9003059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiebich BL, Lieb K, Hull M, Berger M, Bauer J. Effects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport. 1996;7:1209&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817534</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H, Ding WH, Buee L, et al. Elevated circulating TNF levels in Alzheimer&#x2019;s disease. Neurosci Lett. 1991;129:318&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">1745413</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H, Leveugle B. Disorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer&#x2019;s type. Lab Invest. 1995;72:249&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">7898045</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE, editor. Clusterin in normal brain functions and during neurodegeneration. Austin, TX: RG Landes; 1999.</Citation></Reference><Reference><Citation>Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GM. TGF-beta 1 is an organizer of responses to neurodegeneration. J Cell Biochem. 1993;53:314&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8300749</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer B, Schmoll H, Riederer P, Bauer J, Platt D, Popa&#x2013;Wagner A. Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer&#x2019;s patients. J Mol Med. 1995;73:465&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">8528750</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MB. Altered expression of transforming growth factor-beta in Alzheimer&#x2019;s disease. Neurology. 1995;45:1561&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543987</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanders KC, Ren RF, Lippa CF. Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol. 1998;54:71&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">1339449</ArticleId></ArticleIdList></Reference><Reference><Citation>Forloni G. Neurotoxicity of beta-amyloid and prion peptides. Curr Opin Neurol. 1996;9:492&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007411</ArticleId></ArticleIdList></Reference><Reference><Citation>Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by IL-1. Mol Brain Res. 1992;16:128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">1334190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DA. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem. 1993;61:298&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">8515277</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Cole GM, Baird A. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol. 1992;140:1389&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886549</ArticleId><ArticleId IdType="pubmed">1376558</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Calderon L, Cole GM. Rodent models of Alzheimer&#x2019;s disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging. 1996;17:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">8744413</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Yang F, Irrizarry M, et al. Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858113</ArticleId><ArticleId IdType="pubmed">9422548</ArticleId></ArticleIdList></Reference><Reference><Citation>Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989;19:689&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">2543584</ArticleId></ArticleIdList></Reference><Reference><Citation>French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol. 1985;121:414&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">4014131</ArticleId></ArticleIdList></Reference><Reference><Citation>Frucht SJ, Koo EH. beta-Amyloid protein is higher in Alzheimer&#x2019;s disease brains: description of a quantitative biochemical assay. J Neuropathol Exp Neurol. 1993;52:640&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229083</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadient RA, Otten UH. IL-6&#x2014;a molecule with both beneficial and destructive potentials. Prog Neurobiol. 1997;52:379&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9304698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganter U, Strauss S, Jonas U, et al. Alpha 2-macroglobulin synthesis in IL-6-stimulated human neuronal (SH-SY5Y neuroblastoma) cells. Potential significance for the processing of Alzheimer beta-amyloid precursor protein. FEBS Lett. 1991;282:127&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">1709116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gary DS, Bruce&#x2013;Keller AJ, Kindy MS, Mattson MP. Ischemic and excitotoxic brain injury is enhanced in mice lacking the p55 TNF receptor. J Cereb Blood Flow Metab. 1998;18:1283&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9850139</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Chan P, Fontaine M, et al. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol. 1995;155:4882&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7594492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Fontaine M, Morgan BP. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol. 1995;154:4726&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">7536777</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Ischenko A, Legoedec J, Mauger C, Schouft MT, Fontaine M. Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. J Biol Chem. 1993;268:25068&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8227070</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol. 1997;150:31&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858516</ArticleId><ArticleId IdType="pubmed">9006319</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasque P, Tenner AJ, Morgan BP. Expression of the C1q/MBL/SPA receptor involved in phagocytosis and innate immune defense on human glia. Mol Immunol. 1998;35:379.</Citation></Reference><Reference><Citation>Gayle D, Ilyin SE, Miele ME, Plata&#x2013;Salaman CR. Modulation of TNF-alpha mRNA production in rat C6 glioma cells by TNF-alpha, IL-1beta, IL-6, and IFN-alpha: in vitro analysis of cytokine-cytokine interactions. Brain Res Bull. 1998;47:231&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9865855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehrmann J, Mies G, Bonnekoh P, Banati R, Iijima T, Kreutzberg GW, Hossmann KA. Microglial reaction in the rat cerebral cortex induced by cortical spreading depression. Brain Pathol. 1993;3:11&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8269080</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA. Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med. 1998;4:827&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gewurz H, Ying SC, Jiang H, Lint TF. Nonimmune activation of the classical complement pathway. Behring Inst Mitt. 1993:138&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">8172561</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Baker TJ, Shih LC, Lachman LB. Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med. 1986;164:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2188228</ArticleId><ArticleId IdType="pubmed">3487617</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Li J, et al. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int. 1995;27:119&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">7655344</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Yu J, et al. The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer&#x2019;s disease. J Biol Chem. 1998;273:29719&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9792685</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Haverkamp LJ, Yu JH, et al. Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci. 1996;16:6021&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579176</ArticleId><ArticleId IdType="pubmed">8815885</ArticleId></ArticleIdList></Reference><Reference><Citation>Giulian D, Woodward J, Young DG, Krebs JF, Lachman LB. IL-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci. 1988;8:2485&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569517</ArticleId><ArticleId IdType="pubmed">2470873</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabinski AR, Ransohoff RM. Chemokines and chemokine receptors in CNS pathology. J Neurovirol. 1999;5:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190685</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A. The future of Alzheimer&#x2019;s disease research: a molecular genetic perspective. Neurobiol Aging. 1994;15(Suppl 2):S161&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7700443</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldgaber D, Harris HW, Hla T, et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA. 1989;86:7606&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298115</ArticleId><ArticleId IdType="pubmed">2508093</ArticleId></ArticleIdList></Reference><Reference><Citation>Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer&#x2019;s disease. Neuroreport. 1992;3:201&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">1623174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong C, Qin Z, Betz AL, Liu XH, Yang GY. Cellular localization of TNF alpha following focal cerebral ischemia in mice. Brain Res. 1998;801:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9729236</ArticleId></ArticleIdList></Reference><Reference><Citation>Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer&#x2019;s disease. Am J Pathol. 1996;149:21&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865248</ArticleId><ArticleId IdType="pubmed">8686745</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin JL, Uemura E, Cunnick JE. Microglia release of nitric oxide by the synergistic action of &#x3b2;-amyloid and IFN-&#x3b3;. Brain Res. 1995:207&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8548305</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer&#x2019;s disease. Ann Neurol. 1990;28:766&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">2285263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray CW, Patel AJ. Regulation of beta-amyloid precursor protein isoform mRNAs by transforming growth factor-beta 1 and IL-1 beta in astrocytes. Mol Brain Res. 1993;19:251&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8412571</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991;5:3071&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1683845</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM. Cerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology. 1998;51:690&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748011</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GW. Microglial IL-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett. 1994;176:133&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833643</ArticleId><ArticleId IdType="pubmed">7830934</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Roberts GW, Mrak RE. IL-1 expression in different plaque types in Alzheimer&#x2019;s disease: significance in plaque evolution. J Neuropathol Exp Neurol. 1995;54:276&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876895</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, et al. Glial-neuronal interactions in Alzheimer&#x2019;s disease: the potential role of a &#x2018;cytokine cycle&#x2019; in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:7611&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Grilli M, Goffi F, Memo M, Spano P. IL-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem. 1996;271:15002&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8663145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruol DL, Nelson TE. Physiological and pathological roles of IL-6 in the central nervous system. Mol Neurobiol. 1997;15:307&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9457704</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta&#x2013;Bansal R, Frederickson RC, Brunden KR. Proteoglycan-mediated inhibition of A&#x3b2; hydrolysis. J Biol Chem. 1995;270:18666&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">7629198</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga S, Aizawa T, Ishii T, Ikeda K. Complement gene expression in mouse microglia and astrocytes in culture: comparisons with mouse peritoneal macrophages. Neurosci Lett. 1996;216:191&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8897490</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol (Berlin) 1989;77:569&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">2750476</ArticleId></ArticleIdList></Reference><Reference><Citation>Haga S, Ikeda K, Sato M, Ishii T. Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 1993;601:88&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8431789</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkier D. In: Mechanisms in blood coagulation, fibrinolysis, and the complement system. Woolley P, editor. Cambridge, UK: Cambridge University Press; 1991. pp. 88&#x2013;103.</Citation></Reference><Reference><Citation>Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. IL-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience. 1991;40:445&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">2027469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamazaki H. Amyloid P component promotes aggregation of Alzheimer&#x2019;s beta amyloid peptide. Biochem Biophys Res Commun. 1995;211:349&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">7794242</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Schoen D, Schwarz MJ, et al. IL-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer&#x2019;s disease. Neurosci Lett. 1997;228:143&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Sunderland T, Kotter HU, et al. Decreased soluble IL-6 receptor in cerebrospinal fluid of patients with Alzheimer&#x2019;s disease. Brain Res. 1998;780:356&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9507194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Teipel SJ, Padberg F, et al. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble IL-6 receptor complex in the diagnosis of Alzheimer&#x2019;s disease. Brain Res. 1999;823:104&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10095017</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris&#x2013;White ME, Chu T, Balverde Z, Sigel JJ, Flanders KC, Frautschy SA. Effects of transforming growth factor-beta (isoforms 1&#x2013;3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures. J Neurosci. 1998;18:10366&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793343</ArticleId><ArticleId IdType="pubmed">9852574</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris&#x2013;White ME, Teter B, Chut T, et al. Effects of ApoE on A&#x3b2; deposition in murine organotypic slice cultures. Neurosci. 1998;24:2136. Abstract.</Citation></Reference><Reference><Citation>Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer&#x2019;s and Parkinson&#x2019;s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18:285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9263193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol. 1997;92:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzinger M, Seifritz E, Hemmeter U, Holsboer&#x2013;Trachsler E. Kortisoninduzierte wahnhafte Depression bei systemischem Lupus erythematodes [Cortisone-induced delusional depression in systemic lupus erythematosus] Psychiatr Prax. 1994;21:199&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">7972564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzinger M, Z&#x2019;Brun A, Hemmeter U, et al. Hypothalamic-pituitary-adrenal system function in patients with Alzheimer&#x2019;s disease. Neurobiol Aging. 1995;16:205&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7777138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss&#x2013;Wegrzyniak B, Dobrzanski P, Stoehr JD, Wenk GL. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer&#x2019;s disease. Brain Res. 1998;780:294&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">9507169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss&#x2013;Wegrzyniak B, Galons JP, Wenk GL. Quantitative volumetric analysis of brain magnetic resonance imaging from rat with chronic neuroinflammation and correlation with histology. Exp Neurol. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">10993694</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss&#x2013;Wegrzyniak B, Vraniak P, Wenk GL. The effects of a novel NSAID upon chronic neuroinflammation are age dependent. Neurobiol Aging. 1999;20:305&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588578</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauss&#x2013;Wegrzyniak B, Willard LB, Del Soldato P, Pepeu G, Wenk GL. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res. 1999;815:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9974120</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkey CJ. Cox-2 inhibitors. Lancet. 1999;353:307&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">9929039</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedrick JA, Saylor V, Figueroa D, et al. Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol. 1997;158:1533&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">9029087</ArticleId></ArticleIdList></Reference><Reference><Citation>Heine UI, Munoz EF, Flanders KC, et al. Role of transforming growth factor-b in the development of the mouse embryo. J Cell Biol. 1987;105:2861&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2114724</ArticleId><ArticleId IdType="pubmed">3320058</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinrich PC, Horn F, Graeve L, et al. IL-6 and related cytokines: effect on the acute phase reaction. Z Ernahrungswiss. 1998;37:43&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci. 1998;18:8126&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792852</ArticleId><ArticleId IdType="pubmed">9763459</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselgesser J, Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurov. 1999;5:13&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190686</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg T. Alzheimer&#x2019;s disease: a study of epidemiological aspects. Ann Neurol. 1984;15:335&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">6742780</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LH. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice overexpressing interleukin 6 in the brain. Proc Natl Acad Sci. 1997;94:1500&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19820</ArticleId><ArticleId IdType="pubmed">9037082</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">2261637</ArticleId></ArticleIdList></Reference><Reference><Citation>Hibi M, Nakajima K, Hirano T. IL-6 cytokine family and signal transduction:a model of the cytokine system. J Mol Med. 1996;74:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8834766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey WF, Kimura H. Graft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. Proc Natl Acad Sci USA. 1987;84:2082&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC304589</ArticleId><ArticleId IdType="pubmed">3550805</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239:290&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">3276004</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9620640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirst WD, Young KA, Newton R, Allport VC, Marriott DR, Wilkin GP. Expression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci. 1999;13:57&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10049531</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Osaka H, Aisen PS, Pasinetti GM. Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol. 1998;89:142&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9726836</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer&#x2019;s disease. J Neurosci Res. 1999;57:295&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">10412020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoff SF, Scheff SW, Cotman CW. Lesion-induced synaptogenesis in the dentate gyrus of aged rats: II. Demonstration of an impaired degeneration clearing response. J Comp Neurol. 1982;205:253&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7076896</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenbach E, Ackermann S, Hyman BT, Rebeck GW. Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer&#x2019;s disease. Neurology. 1998;50:1905&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633759</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Wu S, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer&#x2019;s disease. J Clin Invest. 1999;103:15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408154</ArticleId><ArticleId IdType="pubmed">10079115</ArticleId></ArticleIdList></Reference><Reference><Citation>Horuk R, Martin AW, Wang Z, et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol. 1997;158:2882&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9058825</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">8565075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes SR, Khorkova O, Goyal S, et al. Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA. 1998;95:3275&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19732</ArticleId><ArticleId IdType="pubmed">9501253</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugo F, Hamdoch T, Mathey D, Schafer H, Bhakdi S. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1535001</ArticleId><ArticleId IdType="pubmed">2379317</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull M, Berger M, Volk B, Bauer J. Occurrence of IL-6 in cortical plaques of Alzheimer&#x2019;s disease patients may precede transformation of diffuse into neuritic plaques. Ann NY Acad Sci. 1996;777:205&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull M, Fiebich BL, Schumann G, Lieb K, Bauer J. Anti-inflammatory substances&#x2014;a new therapeutic option in Alzheimer&#x2019;s disease. Drug Discovery Today. 1999;4:275&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">10354542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson&#x2019;s Disease. Neurosci. 1996;72:355&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8737406</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley SD, Walter SA, Semple&#x2013;Rowland SL, Streit WJ. Cytokine transcripts expressed by microglia in vitro are not expressed by ameboid microglia of the developing rat central nervous system. Glia. 1999;25:304&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9932876</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden n Alzheimer&#x2019;s disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993;52:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">8229078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ignotz RA, Massague J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">3456347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Kinoshita M, Tagaya N, et al. Coadministration of IL-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease. Brain Res. 1996;726:91&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8836549</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">9390561</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer&#x2019;s disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">9389593</ArticleId></ArticleIdList></Reference><Reference><Citation>In&#x2019;t Veldt V, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer&#x2019;s disease. The Rotterdam Study. Neurobiol Aging. 1998;19:607&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10192221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip NY, Nye SH, Boulton TG, et al. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell. 1992;69:1121&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">1617725</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T, Haga S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol. 1984;63:296&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">6382906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishizuka K, Kimura T, Igata&#x2013;yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer&#x2019;s disease. Psychiatry Clin Neurosci. 1997;51:135&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225377</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastuctural localization of complment membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer&#x2019;s disease. Brain Res. 1994;645:78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8062101</ArticleId></ArticleIdList></Reference><Reference><Citation>Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">2808689</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto N, Nishiyama E, Ohwada J, Arai H. Demonstration of CRP immunoreactivity in brains of Alzheimer&#x2019;s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett. 1994;177:23&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824175</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CRJ, Petersen RC, O&#x2019;Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer&#x2019;s disease. Neurology. 1992;42:183&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Janabi N, Hau I, Tardieu M. Negative feedback between prostaglandin and alpha- and beta-chemokine synthesis in human microglial cells and astrocytes. J Immunol. 1999;162:1701&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9973432</ArticleId></ArticleIdList></Reference><Reference><Citation>Janciauskiene S, Garcia DF, Carlemalm E, Dahlback B, Eriksson S. Inhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem. 1995;270:26041&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592799</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson ML, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer&#x2019;s type. Br J Rheumatol. 1989;28:86&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2917245</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang C, Ting AT, Seed B. PPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422509</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. &#x3b2;-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q a chain. Journal of Immunology. 1994;152:5050&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8176223</ArticleId></ArticleIdList></Reference><Reference><Citation>Johns TG, Bernard CC. Binding of complement component C1q to myelin oligodendrocyte glycoprotein:a novel mechanism for regulating CNS inflammation. Mol Immunol. 1997;34:33&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9182874</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SA, Lampert&#x2013;Etchells M, Pasinetti GM, Rozovsky I, Finch CE. Complement mRNA in the mammalian brain: responses to Alzheimer&#x2019;s disease and experimental brain lesioning. Neurobiol Aging. 1992;13:641&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1362796</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SA, Young&#x2013;Chan CS, Laping NJ, Finch CE. Perforant path transection induces complement C9 deposition in hippocampus. Exp Neurol. 1996;138:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">8620918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Golde T, Kroon SN, Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer&#x2019;s disease. Am J Pathol. 1993;143:886&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887201</ArticleId><ArticleId IdType="pubmed">8362984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Kroon SN. Complement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer&#x2019;s disease. Biochem Biophys Res Comm. 1992;186:461&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1632784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:2642&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20142</ArticleId><ArticleId IdType="pubmed">9122249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Sanghera DK, Ferrell RE, DeKosky ST. APOE*4-associated Alzheimer&#x2019;s disease risk is modified by alpha 1- antichymotrypsin polymorphism [published erratum appears in Nat Genet 1995 Sep;11:104] Nat Genet. 1995;10:486&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7670501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang DE, Saitoh T, Chen X, et al. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer&#x2019;s disease. Neurology. 1997;49:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">9222170</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpus WJ, Lukacs NW, McRae BL, Streiter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 1995;155:5003&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">7594507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur C, Wu CH, Wen CY, Ling EA. The effects of subcutaneous injections of glucocorticoids on amoeboid microglia in postnatal rats. Arch Histol Cytol. 1994;57:449&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">7734174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PL. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol. 1993;142:1574&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886898</ArticleId><ArticleId IdType="pubmed">8494052</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Kindy MS, Holtsberg FW, et al. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998;18:687&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792529</ArticleId><ArticleId IdType="pubmed">9425011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999;155:995&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866889</ArticleId><ArticleId IdType="pubmed">10487857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelner GS, Kennedy J, Bacon KB, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994;266:1395&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7973732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer&#x2019;s disease. Neurology. 1991;41:51&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1985296</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer&#x2019;s disease. Arch Neurol. 1993;50:949&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">8363449</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto T, Akira S, Narazaki M, Taga T. IL-6 family of cytokines and gp130. Blood. 1995;86:1243&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">7632928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisilevsky R. Proteoglycans, glycosaminoglycans, amyloid-enhancing factor, and amyloid deposition. J Intern Med. 1992;232:515&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1474355</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisilevsky R. Proteoglycans and other basement membrane proteins in amyloidoses. Mol Neurobiol. 1994;9:23&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y, Shimohama S, Koike H, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer&#x2019;s disease brains. Biochem Biophys Res Commun. 1999;254:582&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9920782</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, McGeer PL. &#x3b2;-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J Neurosci Res. 1997;49:229&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9272645</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer &#x3b2; amyloid peptide. Biochem Biophys Res Commun. 1994;199:984&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">7510964</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Walker DG, McGeer PL. Interaction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of TNF-alpha. Brain Res. 1997;747:114&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9042534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kligman D, Marshak DR. Purification and characterization of a neurite extension factor from bovine brain. Proc Natl Acad Sci USA. 1985;82:7136&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC391325</ArticleId><ArticleId IdType="pubmed">3863143</ArticleId></ArticleIdList></Reference><Reference><Citation>Knuckey NW, Finch P, Palm DE, et al. Differential neuronal and astrocytic expression of transforming growth factor beta isoforms in rat hippocampus following transient forebrain ischemia. Mol Brain Res. 1996;40:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">8840007</ArticleId></ArticleIdList></Reference><Reference><Citation>Komori T, Shibata N, Kobayashi M, Sasaki S, Iwata M. Inducible nitric oxide synthase (iNOS)-like immunoreactivity in argyrophilic, tau-positive astrocytes in progressive supranuclear palsy. Acta Neuropathol (Berlin) 1998;95:338&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9560010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopec KK, Carroll RT. Alzheimer&#x2019;s beta-amyloid peptide 1&#x2013;42 induces a phagocytic response in murine microglia. J Neurochem. 1998;71:2123&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">9798938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7543026</ArticleId></ArticleIdList></Reference><Reference><Citation>Krieglstein K, Rufer M, Suter&#x2013;Crazzolara C, Unsicker K. Neural functions of the transforming growth factors beta. Int J Dev Neurosci. 1995;13:301&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">7572283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuby J. Immunology. 2. New York: WH Freeman; 1994. p. 402.</Citation></Reference><Reference><Citation>Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolog. J Biol Chem. 1991;266:12866&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">1712772</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushima Y, Hama T, Hatanaka H. IL-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains. Neurosci Res. 1992;13:267&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1321390</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushima Y, Hatanaka H. IL-6 and leukemia inhibitory factor promote the survival of acetylcholinesterase-positive neurons in culture from embryonic rat spinal cord. Neurosci Lett. 1992;143:110&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">1436652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SR. Expression of the receptors for the C5a anaphylatoxin, IL-8 and FMLP by human astrocytes and microglia. J Neuroimmunol. 1995;61:71&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7560015</ArticleId></ArticleIdList></Reference><Reference><Citation>LaDu MJ, Gilligan SM, Lukens JR, et al. Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9572293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahiri DK, Nall C. Promoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and IL-1. Mol Brain Res. 1995;32:233&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7500834</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lampert&#x2013;Etchells M, Pasinetti GM, Finch CE, Johnson SA. Regional localization of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer&#x2019;s disease. Neurodegeneration. 1993;2:111&#x2013;21.</Citation></Reference><Reference><Citation>Lappin DF, Whaley K. Modulation of complement gene expression by glucocorticoids. Biochem J. 1991;280:117&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1130608</ArticleId><ArticleId IdType="pubmed">1741740</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowitz DT, Goel S, Bennett ER, Matthew WD. Apolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol. 1997;76:70&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9184634</ArticleId></ArticleIdList></Reference><Reference><Citation>Laskowitz DT, Matthew WD, Bennett ER, et al. Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. Neuroreport. 1998;9:615&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlman S. Transfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Differ. 1995;6:727&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">7669728</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc A. Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci. 1995;15:7837&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577962</ArticleId><ArticleId IdType="pubmed">8613723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee RK, Knapp S, Wurtman RJ. Prostaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J Neurosci. 1999;19:940&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782137</ArticleId><ArticleId IdType="pubmed">9920657</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SC, Dickson DW, Liu W, Brosnan CF. Induction of nitric oxide synthase activity in human astrocytes by IL-1 beta and interferon-gamma. J Neuroimmunol. 1993;46:19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">7689587</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9013583</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann JM, Moore LB, Smith&#x2013;Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma) J Biol Chem. 1995;270:12953&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7768881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12:335&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8970730</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemercier C, Julen N, Coulpier M, et al. Differential modulation by glucocorticoids of alternative complement protein secretion in cells of the monocyte/macrophage lineage. Eur J Immunol. 1992;22:909&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">1532362</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveugle B, Fillit H. Proteoglycans and the acute-phase response in Alzheimer&#x2019;s disease brain. Mol Neurobiol. 1994;9:25&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">7888102</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi&#x2013;Strauss M, Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol. 1987;139:2361&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3655365</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer&#x2019;s disease in China. Neurology. 1992;42:1481&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1641140</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Liu L, Kang J, et al. Neuronal-glial interactions mediated by IL-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci. 2000;20:149&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6774108</ArticleId><ArticleId IdType="pubmed">10627591</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao A, Nitsch RM, Greenberg SM, et al. Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer&#x2019;s disease. Hum Mol Genet. 1998;7:1953&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9811940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Tran T, Ubeda O, et al. The effect of ibuprofen on synaptic markers and open field activity in HuAAPPsw mice. Neuroscience. 1999;25:1863. Abstract.</Citation></Reference><Reference><Citation>Limoges J, Persidsky Y, Bock P, Gendelman HE. Dexamethasone therapy worsens the neuropathology of human immunodeficiency virus type 1 encephalitis in SCID mice. J Infect Dis. 1997;175:1368&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9180176</ArticleId></ArticleIdList></Reference><Reference><Citation>Linder E, Lehto VP, Stenman S. Activation of complement by cytoskeletal intermediate filaments. Nature. 1979;278:176&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">763362</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindholm D, Castren E, Kiefer R, Zafra F, Thoenen H. Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol. 1992;117:395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289420</ArticleId><ArticleId IdType="pubmed">1560032</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling EA, Wong WC. The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia. 1993;7:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423067</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer&#x2019;s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153:1365&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853391</ArticleId><ArticleId IdType="pubmed">9811326</ArticleId></ArticleIdList></Reference><Reference><Citation>Littman DR. Chemokine receptors: keys to AIDS pathogenesis? Cell. 1998;93:677&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Bowes RC, van de Water B, Sillence C, Nagelkerke JF, Stevens JL. Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. J Biol Chem. 1997;272:21751&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9268304</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, Baird A. Effects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur J Neurosci. 1994;6:355&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8019673</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan A, Frautschy SA, Gonzalez AM, Sporn MB, Baird A. Enhanced expression of transforming growth factor beta 1 in the rat brain after a localized cerebral injury. Brain Res. 1992;587:216&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310563</ArticleId><ArticleId IdType="pubmed">1525658</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi VR, Garcia M, Cacabelos R. Microglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J Neurosci Res. 1998;54:539&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">9822164</ArticleId></ArticleIdList></Reference><Reference><Citation>Louis JC, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and TNF-induced death. Science. 1993;259:689&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">8430320</ArticleId></ArticleIdList></Reference><Reference><Citation>Luber&#x2013;Narod J, Rogers J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett. 1988;94:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">3266526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal anti-inflammatory drug use in Alzheimer&#x2019;s disease. Biol Psychiatry. 1994;36:854&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7893851</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Brachova L, Civin WH, Rogers J. Inflammation, A&#x3b2; deposition, and neurofibrillary tangle formation as correlates of Alzheimer&#x2019;s disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858005</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Brachova L, Shen Y, Rogers J. Modeling A&#x3b2; deposition in cultures of Alzheimer&#x2019;s glia and hNT neurons. Neuroscience. 1999;23:533. Abstract.</Citation></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer&#x2019;s disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Shen Y, Yang LB, Rydel RE, Hampel H, Rogers J. Constitutive and amyloid &#x3b2; peptide-stimulated secretion of inflammatory mediators by Alzheimer&#x2019;s disease and control microglia. In: Rogers J, editor. Neuroinflammation and Alzheimer&#x2019;s disease. Basel: Birkhauser Press; In press.</Citation></Reference><Reference><Citation>Luo J, Lang JA, Miller MW. Transforming growth factor beta1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons. J Neurochem. 1998;71:526&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9681442</ArticleId></ArticleIdList></Reference><Reference><Citation>Luster AD. Chemokines&#x2014;chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9459648</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated protein &#x3b1;1-antichymotrypsin and apolipoprotein-E promote assembly of Alzheimer &#x3b2;-protein into filaments. Nature. 1999;372:92&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR. Anti-inflammatory drugs and Alzheimer type pathology in aging. Neurology. 2000;54:732&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Hao C, Munoz DG. Role of microglia in senile plaque formation. Neurobiol Aging. 1995;16:797&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532113</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9566383</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M, Krause KH, Clark RA, Kihlstr A, Stendahl O. Localization of intracellular Ca2+ stores in HeLa cells during infection with chlamydia trachomatis. J Cell Sci. 1998;112:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9841902</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 1997;385:540&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9020361</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcheselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem. 1996;271:24794&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8798751</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR. Oxidative stress hypothesis in Alzheimer&#x2019;s disease. Free Radic Biol Med. 1997;23:134&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">9165306</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Carney JM. Oxidative alterations in Alzheimer&#x2019;s disease. Brain Pathol. 1999;9:133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098393</ArticleId><ArticleId IdType="pubmed">9989456</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshak DR, Pesce SA, Stanley LC, Griffin WS. Increased S100 beta neurotrophic activity in Alzheimer&#x2019;s disease temporal lobe. Neurobiol Aging. 1992;13:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1371849</ArticleId></ArticleIdList></Reference><Reference><Citation>Marz P, Cheng JG, Gadient RA, et al. Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA. 1998;95:3251&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19728</ArticleId><ArticleId IdType="pubmed">9501249</ArticleId></ArticleIdList></Reference><Reference><Citation>Marz P, Gadient RA, Otten U. Expression of IL-6 receptor (IL-6R) and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by TNF alpha (TNF-alpha) Brain Res. 1996;706:71&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8720493</ArticleId></ArticleIdList></Reference><Reference><Citation>Masferrer JL, Reddy ST, Zweifel BS, et al. In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther. 1994;270:1340&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7932188</ArticleId></ArticleIdList></Reference><Reference><Citation>Masferrer JL, Seibert K. Regulation of prostaglandin synthesis by glucocorticoids. Receptor. 1994;4:25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">8038703</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Westland CE, Rockenstein EM, et al. Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience. 1997;78:135&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9135095</ArticleId></ArticleIdList></Reference><Reference><Citation>Massague J. TGF-&#x3b2; signal transduction. Annu Rev Biochem. 1998;67:753&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759503</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastorakos G, Chrousos GP, Weber JS. Recombinant IL-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8263159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Central role of oxyradicals in the mechanism of amyloid beta peptide cytotoxicity. Alz Dis Rev. 1997;2:1&#x2013;14.</Citation></Reference><Reference><Citation>Mattson MP, Barger SW. Roles for calcium signaling in structural plasticity and pathology in the hippocampal system. Hippocampus. 1993;3:73&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">7904514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Baldwin SA, et al. Brain injury and TNFs induce calbindin D-28k in astrocytes: evidence for a cytoprotective response. J Neurosci Res. 1995;42:357&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8583504</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 1993;10:243&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Pedersen WA. Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer&#x2019;s disease. Int J Dev Neurosci. 1998;16:737&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">10198821</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazur&#x2013;Kolecka B, Frackowiak J, Wisniewski HM. Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer&#x2019;s beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 1995;698:217&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">8581485</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol. 1994;159:51&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7511146</ArticleId></ArticleIdList></Reference><Reference><Citation>McComb RD, Miller KA, Carson SD. Tissue factor antigen in senile plaques of Alzheimer&#x2019;s disease. Am J Pathol. 1991;139:491&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886219</ArticleId><ArticleId IdType="pubmed">1887858</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Bamberger ME, Combs CK, Landreth GE. beta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci. 1998;18:4451&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792680</ArticleId><ArticleId IdType="pubmed">9614222</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573513</ArticleId><ArticleId IdType="pubmed">9065490</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS, Sapolsky RM. Stress and cognitive function. Curr Opin Neurobiol. 1995;5:205&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620309</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989;107:341&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2559373</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Akiyama H, Itagaki S, McGeer EG. Immune system response in Alzheimer&#x2019;s disease. Can J Neurol Sci. 1989;16:516&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">2804814</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson&#x2019;s and Alzheimer&#x2019;s disease brains. Neurology. 1988;38:1285&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">3399080</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer E, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335:1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">1970087</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev. 1995;21:195&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">8866675</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer&#x2019;s disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Kowall NW, Schumacher JS, Beal MF. The neurotoxicity of amyloid beta protein in aged primates. Amyloid. 1998;5:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546999</ArticleId></ArticleIdList></Reference><Reference><Citation>McRae A, Ling EA, Schubert P, Rudolphi K. Properties of activated microglia and pharmacologic interference by propentofylline. Alzheimer Dis Assoc Disord. 1998;12:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9769025</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Baron P, Prat E, et al. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25&#x2013;35] J Neuroimmunol. 1999;93:45&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10378868</ArticleId></ArticleIdList></Reference><Reference><Citation>Meda L, Bonaiuto C, Baron P, Otvos LJ, Rossi F, Cassatella MA. Priming of monocyte respiratory burst by beta-amyloid fragment (25&#x2013;35) Neurosci Lett. 1996;219:91&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8971787</ArticleId></ArticleIdList></Reference><Reference><Citation>Mega MS, Chen SS, Thompson PM, et al. Mapping histology to metabolism: coregistration of stained whole-brain sections to pre-mortem PET in Alzheimer&#x2019;s disease. Neuroimage. 1997;5:147&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345544</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer&#x2019;s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 1996;47:454&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757020</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentlein R, Ludwig R, Martensen I. Proteolytic degradation of Alzheimer&#x2019;s disease amyloid beta-peptide by a metalloproteinase from microglia cells. J Neurochem. 1998;70:721&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9453567</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer&#x2019;s disease and vascular dementia. J Neural Transm. 1998;53:237&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9700661</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RJ, Meucci O. AIDS and the brain: is there a chemokine connection? Trends Neurosci. 1999;22:471&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10481195</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TP, Taylor J, Rogerson S, et al. Cognitive and noncognitive symptoms in dementia patients: relationship to cortisol and dehydroepiandrosterone. Int Psychogeriatr. 1998;10:85&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629527</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L, Nicolini A, Polazzi E, et al. Down-regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol. 1999;126:1307&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1565901</ArticleId><ArticleId IdType="pubmed">10217523</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L, Polazzi E, Nicolini A, Creminon C, Levi G. Interferon-gamma and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression. J Neurochem. 1996;66:1963&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">8780024</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L, Polazzi E, Nicolini A, Levi G. Opposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures. J Neuroimmunol. 1998;82:31&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9526843</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer&#x2019;s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. TNF-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8015728</ArticleId></ArticleIdList></Reference><Reference><Citation>Monning U, Sandbrink R, Banati RB, Masters CL, Beyreuther K. Transforming growth factor beta mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Lett. 1994;342:267&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8150082</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsma FJJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680751</ArticleId></ArticleIdList></Reference><Reference><Citation>Montero&#x2013;Julian FA, Brailly H, Sautes C, et al. Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family. Clin Cancer Res. 1997;3:1443&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9815830</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan TE, Nichols NR, Pasinetti GM, Finch CE. TGF-beta 1 mRNA increases in macrophage/microglial cells of the hippocampus in response to deafferentation and kainic acid-induced neurodegeneration. Exp Neurol. 1993;120:291&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">8491285</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan TE, Xie Z, Goldsmith S, et al. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience. 1999;89:687&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">10199605</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka T, Baba T, Black KL, Streit WJ. Immunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma. Acta Neuropathol (Berlin) 1992;83:590&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1636377</ArticleId></ArticleIdList></Reference><Reference><Citation>Morioka T, Kalehua AN, Streit WJ. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. J Comp Neurol. 1993;327:123&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8432904</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse JK, DeKosky ST, Scheff SW. Neurotrophic effects of steroids on lesion-induced growth in the hippocampus. II. Hormone replacement. Exp Neurol. 1992;118:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">1397175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak RE, Sheng JG, Griffin WS. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer&#x2019;s disease. J Neuropathol Exp Neurol. 1996;55:273&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833601</ArticleId><ArticleId IdType="pubmed">8786385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Abraham CR, Ruppe MD, et al. Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. J Exp Med. 1995;181:1551&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2191956</ArticleId><ArticleId IdType="pubmed">7699335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Johnson WB, et al. Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res. 1994;666:151&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">7882025</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullberg J, Dittrich E, Graeve L, et al. Differential shedding of the two subunits of the IL-6 receptor. FEBS Lett. 1993;332:174&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8405437</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullberg J, Durie FH, Otten&#x2013;Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol. 1995;155:5198&#x2013;5205.</Citation><ArticleIdList><ArticleId IdType="pubmed">7594530</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullberg J, Schooltink H, Stoyan T, et al. The soluble IL-6 receptor is generated by shedding. Eur J Immunol. 1993;23:473&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8436181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullberg J, Schooltink H, Stoyan T, Heinrich PC, Rose&#x2013;John S. Protein kinase C activity is rate limiting for shedding of the IL-6 receptor. Biochem Biophys Res Commun. 1992;189:794&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">1335247</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller&#x2013;Newen G, Kuster A, Hemmann U, et al. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol. 1998;161:6347&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834125</ArticleId></ArticleIdList></Reference><Reference><Citation>Multhaup G, Ruppert T, Schlicksupp A, et al. Reactive oxygen species and Alzheimer&#x2019;s disease. Biochem Pharmacol. 1997;54:533&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9337068</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple Author Issue. Neurobiol Aging. 1996:17. Special Issue.</Citation></Reference><Reference><Citation>Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997;51:1376&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9150447</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy PG, Altares M, Gauldie J, Richardson PM. IL-6 promotes survival of sensory neurons. Neuroscience. 1997;23:890. Abstract.</Citation></Reference><Reference><Citation>Murphy PG, Borthwick LS, Johnston RS, Kuchel G, Richardson PM. Nature of the retrograde signal from injured nerves that induces IL-6 mRNA in neurons. J Neurosci. 1999;19:3791&#x2013;3800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782706</ArticleId><ArticleId IdType="pubmed">10234011</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SH. Polymorphisms of the IL-6 gene are associated with bone mineral density. Bone. 1997;21:89&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">9213013</ArticleId></ArticleIdList></Reference><Reference><Citation>Myllykangas&#x2013;Luosujarvi R, Isomaki H. Alzheimer&#x2019;s disease and rheumatoid arthritis. Br J Rheumatol. 1994;33:501&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">8173862</ArticleId></ArticleIdList></Reference><Reference><Citation>Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days&#x2019; corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996;21:25&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">8778901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima K, Shimojo M, Hamanoue M, Ishiura S, Sugita H, Kohsaka S. Identification of elastase as a secretory protease from cultured rat microglia. J Neurochem. 1992;58:1401&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1548474</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima K, Tsuzaki N, Nagata K, Takemoto N, Kohsaka S. Production and secretion of plasminogen in cultured rat brain microglia. FEBS Lett. 1992;308:179&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">1499728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakajima K, Tsuzaki N, Shimojo M, Hamanoue M, Kohsaka S. Microglia isolated from rat brain secrete a urokinase-type plasminogen activator. Brain Res. 1992;577:285&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">1376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima K, Wiese S, Yanagisawa M, et al. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci. 1999;19:5429&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782325</ArticleId><ArticleId IdType="pubmed">10377352</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayama M, Uchimura K, Zhu RL, et al. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA. 1998;95:10954&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28002</ArticleId><ArticleId IdType="pubmed">9724811</ArticleId></ArticleIdList></Reference><Reference><Citation>Narazaki M, Yasukawa K, Saito T, et al. Soluble forms of the IL-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8353278</ArticleId></ArticleIdList></Reference><Reference><Citation>Narita M, Holtzman DM, Schwartz AL, Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9349534</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasman B, Olsson T, Fagerlund M, Eriksson S, Viitanen M, Carlstrom K. Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer&#x2019;s disease. Biol Psychiatry. 1996;39:311&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8704061</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. 1999;22:397&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441300</ArticleId></ArticleIdList></Reference><Reference><Citation>Natoli G, Costanzo A, Guido F, Moretti F, Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of TNF signalling. Biochem Pharmacol. 1998;56:915&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">9776301</ArticleId></ArticleIdList></Reference><Reference><Citation>Netland EE, Newton JL, Majocha RE, Tate BA. Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging. 1998;19:201&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9661994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997;17:2746&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573095</ArticleId><ArticleId IdType="pubmed">9092596</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol. 1999;13:45&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">10223523</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD. IL-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem. 1996;66:2532&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632179</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991;266:23261&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1744122</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA. 1992;89:4888&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49193</ArticleId><ArticleId IdType="pubmed">1594589</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Hara J, Paul WE. Receptors for B-cell stimulatory factor-1 expressed on cells of hematopoietic lineage. Nature. 1987;325:537&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">3100961</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka A, Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down&#x2019;s syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport. 1997;8:1161&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9175105</ArticleId></ArticleIdList></Reference><Reference><Citation>Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55:1409&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">9823823</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver JD, Van der Wal FJ, Bulleid NJ, High S. Interaction of the thiol-dependent reductase ERp57 with nascent glycoproteins. Science. 1997;275:86&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8974399</ArticleId></ArticleIdList></Reference><Reference><Citation>Orzylowska O, Oderfeld&#x2013;Nowak B, Zaremba M, Januszewski S, Mossakowski M. Prolonged and concomitant induction of astroglial immunoreactivity of IL-1beta and IL-6 in the rat hippocampus after transient global ischemia. Neurosci Lett. 1999;263:72&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">10218914</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GM. Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience. 1999;88:1073&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">10336122</ArticleId></ArticleIdList></Reference><Reference><Citation>Osaka H, Mukherjee P, Aisen PS, Pasinetti GM. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999;73:303&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321830</ArticleId></ArticleIdList></Reference><Reference><Citation>Padberg F, Feneberg W, Schmidt S, et al. CSF and serum levels of soluble IL-6 receptors (sIL-6R and sgp130), but not of IL-6 are altered in multiple sclerosis. J Neuroimmunol. 1999;99:218&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10505978</ArticleId></ArticleIdList></Reference><Reference><Citation>Paonessa G, Graziani R, De Serio A, et al. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J. 1995;14:1942&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC398293</ArticleId><ArticleId IdType="pubmed">7744001</ArticleId></ArticleIdList></Reference><Reference><Citation>Papassotiropoulos A, Bagli M, Jessen F, et al. A genetic variation of the inflammatory cytokine IL-6 delays the initial onset and reduces the risk for sporadic Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:666&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319892</ArticleId></ArticleIdList></Reference><Reference><Citation>Paradisis PM, Campbell IL, Barnum SR. Elevated complement C5a receptor expression on neurons and glia in astrocyte-targeted IL-3 transgenic mice. Glia. 1998;24:338&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">9775985</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer&#x2019;s disease amyloid beta-protein by microglial cells. J Biol Chem. 1997;272:29390&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361021</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM. Cyclooxygenase and inflammation in Alzheimer&#x2019;s disease: experimental approaches and clinical interventions. J Neurosci Res. 1998;54:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9778144</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer&#x2019;s disease brain. Neuroscience. 1998;87:319&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740394</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Hassler M, Stone D, Finch CE. Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions. Synapse. 1999;31:278&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">10051108</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Johnson SA, Rozovsky I, et al. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp Neurol. 1992;118:117&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">1426121</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Nichols NR, Tocco G, Morgan T, Laping N, Finch CE. Transforming growth factor beta 1 and fibronectin messenger RNA in rat brain: responses to injury and cell-type localization. Neuroscience. 1993;54:893&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">8341423</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasinetti GM, Tocco G, Sakhi S, et al. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis. 1996;3:197&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980020</ArticleId></ArticleIdList></Reference><Reference><Citation>Patthy L. Evolution of blood coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 1990;1:153&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">2130927</ArticleId></ArticleIdList></Reference><Reference><Citation>Pennica D, Wood WI, Chien KR. Cardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev. 1996;7:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8864356</ArticleId></ArticleIdList></Reference><Reference><Citation>Peress NS, Perillo E. Differential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer&#x2019;s disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol. 1995;54:802&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">7595653</ArticleId></ArticleIdList></Reference><Reference><Citation>Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA. 1997;278:1237&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333264</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NS. Medicinal plants and Alzheimer&#x2019;s disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999;51:527&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411211</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Matyszak MK, Fearn S. Altered antigen expression of microglia in the aged rodent CNS. Glia. 1993;7:60&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8423063</ArticleId></ArticleIdList></Reference><Reference><Citation>Piani D, Spranger M, Frei K, Schaffner A, Fontana A. Macrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines. Eur J Immunol. 1992;22:2429&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">1355433</ArticleId></ArticleIdList></Reference><Reference><Citation>Plata&#x2013;Salaman CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev. 1991;15:185&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">1852312</ArticleId></ArticleIdList></Reference><Reference><Citation>Plata&#x2013;Salaman CR. Cytokine-induced anorexia. Behavioral, cellular, and molecular mechanisms. Ann NY Acad Sci. 1998;856:160&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">9917876</ArticleId></ArticleIdList></Reference><Reference><Citation>Plata&#x2013;Salaman CR, Ilyin SE, Gayle D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol. 1998;275:R566&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9688694</ArticleId></ArticleIdList></Reference><Reference><Citation>Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC408366</ArticleId><ArticleId IdType="pubmed">10359564</ArticleId></ArticleIdList></Reference><Reference><Citation>Poller W, Faber JP, Klobeck G, Olek K. Cloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet. 1992;88:313&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370808</ArticleId></ArticleIdList></Reference><Reference><Citation>Prehn JH, Bindokas VP, Jordan J, et al. Protective effect of transforming growth factor beta-1 on beta amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol. 1996;49:319&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632765</ArticleId></ArticleIdList></Reference><Reference><Citation>Prieschl EE, Kulmburg PA, Baumruker T. The nomenclature of chemokines. Int Arch Allergy Immunol. 1995;107:475&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620363</ArticleId></ArticleIdList></Reference><Reference><Citation>Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G. Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of TNF alpha. Proc Natl Acad Sci USA. 1995;92:11294&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40618</ArticleId><ArticleId IdType="pubmed">7479982</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. The prion diseases. Sci Am. 1995;272:48&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824915</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJ. Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem. 1997;272:6641&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9045694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37:211&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7531418</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer&#x2019;s disease: allelic variation and receptor interactions. Neuron. 1993;11:575&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8398148</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer&#x2019;s disease. Ann Neurol. 1998;44:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9708558</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds WF, Rhees J, Maciejewski D, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer&#x2019;s disease. Exp Neurol. 1999;155:31&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">9918702</ArticleId></ArticleIdList></Reference><Reference><Citation>Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer&#x2019;s disease. Neurology. 1995;45:51&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422508</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringheim GE, Szczepanik AM, Petko W, Burgher KL, Zhu SZ, Chao CC. Enhancement of beta-amyloid precursor protein transcription and expression by the soluble IL-6 receptor/IL-6 complex. Mol Brain Res. 1998;55:35&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9645958</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts AB, Sporn MB. The molecular and cellular biology of wound repair. New York: Plenum Press; 1996. Transforming growth factor-b; pp. 275&#x2013;308.</Citation></Reference><Reference><Citation>Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83:4167&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323692</ArticleId><ArticleId IdType="pubmed">2424019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JL. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol. 1994;153:3811&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">7930598</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Cooper NR, Webster S, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1992;89:10016&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50268</ArticleId><ArticleId IdType="pubmed">1438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Griffin WST. Inflammatory mechanisms of Alzheimer&#x2019;s disease. In: Wood PL, editor. Neuroinflammation: mechanisms and management. Totowa, NY: Humana Press; 1998. pp. 177&#x2013;93.</Citation></Reference><Reference><Citation>Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer&#x2019;s disease. Neurology. 1993 Aug;43:1609&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">8351023</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Luber&#x2013;Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer&#x2019;s disease. Neurobiol Aging. 1988;9:339&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">3263583</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, Lue LF, Yang LB, et al. Complement activation by neurofibrillary tangles in Alzheimer&#x2019;s disease. Neuroscience. 1998;24:1268. Abstract.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403931</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J, O&#x2019;Barr S. Inflammatory mediators in Alzheimer&#x2019;s disease. In: Tanzi RE, Wasco W, editors. Molecular approaches to Alzheimer&#x2019;s Disease. Totawa, N.J: Humana Press; 1996. pp. 177&#x2013;97.</Citation></Reference><Reference><Citation>Rogers JT, Leiter LM, McPhee J, et al. Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by IL-1 through 5&#x2032;-untranslated region sequences. J Biol Chem. 1999;274:6421&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblatt DE, Geula C, Mesulam MM. Protease nexin 1 immunostaining in Alzheimer&#x2019;s disease. Ann Neurol. 1989;26:628&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">2554792</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Saunders AM. ApoE, Alzheimer&#x2019;s disease, and recovery from brain stress. Ann NY Acad Sci. 1997;826:200&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329691</ArticleId></ArticleIdList></Reference><Reference><Citation>Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I. Propentofylline in the treatment of Alzheimer&#x2019;s disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord. 1998;9:36&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9716243</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller JM, Eikelenboom P, Pals ST, Stam FC. Microglial cells around amyloid plaques in Alzheimer&#x2019;s disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett. 1989;101:288&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">2549464</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CL. A4 protein in Alzheimer&#x2019;s disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol. 1989;48:674&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2677252</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozovsky I, Laping NJ, Krohn K, Teter B, O&#x2019;Callaghan JP, Finch CE. Transcriptional regulation of glial fibrillary acidic protein by corticosterone in rat astrocytes in vitro is influenced by the duration of time in culture and by astrocyte-neuron interactions. Endocrinology. 1995;136:2066&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7720656</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozovsky I, Morgan TE, Willoughby DA, et al. Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience. 1994;62:741&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">7870303</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Yasukawa K, Suzuki H, et al. Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies. J Immunol. 1991;147:168&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">2051018</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci. 1997;53:576&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11147392</ArticleId><ArticleId IdType="pubmed">9312403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer&#x2019;s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94:860&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296168</ArticleId><ArticleId IdType="pubmed">8040342</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandi C, Loscertales M. Opposite effects on NCAM expression in the rat frontal cortex induced by acute vs. chronic corticosterone treatments. Brain Res. 1999;828:127&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10320732</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer&#x2019;s disease. The Alzheimer&#x2019;s Disease Cooperative Study. N Engl J Med. 1997;336:1216&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5:1222&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6565052</ArticleId><ArticleId IdType="pubmed">3998818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM, Packan DR, Vale WW. Glucocorticoid toxicity in the hippocampus: in vitro demonstration. Brain Res. 1988;453:367&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">3401775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato Y. Microglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berlin) 1997;94:316&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">9341931</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, Nakamura S, Taga T, et al. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol. 1988;8:3546&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC363593</ArticleId><ArticleId IdType="pubmed">3264880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of TNF-alpha by microglia and astrocytes in culture. Brain Res. 1989;491:394&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2765895</ArticleId></ArticleIdList></Reference><Reference><Citation>Schall TJ. The Chemokines. In: Thompson A, editor. The cytokine handbook. San Diego: Academic Press; 1994. pp. 419&#x2013;60.</Citation></Reference><Reference><Citation>Scheloske M, Haslinger A, Unger J, et al. Expression of the IL-6 receptor complex (IL-6RC) in human rapid autopsy tissue. Neuroscience. 1999;25:1536. Abstract.</Citation></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmaier AH, Dahl LD, Rozemuller AJ, et al. Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. J Clin Invest. 1993;92:2540&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC288440</ArticleId><ArticleId IdType="pubmed">8227367</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt LA, Fox NA, Goldberg MC, Smith CC, Schulkin J. Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroendocrinology. 1999;24:461&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">10341371</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Pauels HG, Lugering N, Lugering A, Domschke W, Kucharzik T. Glucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. J Immunol. 1999;163:3484&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert P, Ogata T, Rudolphi K, Marchini C, McRae A, Ferroni S. Support of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline. Ann NY Acad Sci. 1997;826:337&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329704</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumann G, Huell M, Machein U, Hocke G, Fiebich BL. IL-6 activates signal transducer and activator of transcription and mitogen-activated protein kinase signal transduction pathways and induces de novo protein synthesis in human neuronal cells. J Neurochem. 1999;73:2009&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">10537060</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzman AL, Gregori L, Vitek MP, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA. 1994;91:8368&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44607</ArticleId><ArticleId IdType="pubmed">8078889</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott SA, Johnson SA, Zarow C, Perlmutter LS. Inability to detect &#x3b2;-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia. Exp Neurol. 1993;121:113&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8495706</ArticleId></ArticleIdList></Reference><Reference><Citation>Seab JP, Jagust WJ, Wong ST, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements of hippocampal atrophy in Alzheimer&#x2019;s disease. Magn Reson Med. 1988;8:200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3210957</ArticleId></ArticleIdList></Reference><Reference><Citation>Selye H. Stress in health, and disease. Boston: Butterworths; 1976.</Citation></Reference><Reference><Citation>Shaffer LM, Dority MD, Gupta&#x2013;Bansal R, Frederickson RC, Younkin SG, Brunden KR. Amyloid beta protein (A&#x3b2;) removal by neuroglial cells in culture. Neurobiol Aging. 1995;16:737&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">8532106</ArticleId></ArticleIdList></Reference><Reference><Citation>Shago M, Flock G, Leung HC, et al. Modulation of the retinoic acid and retinoid X receptor signaling pathways in P19 embryonal carcinoma cells by calreticulin. Exp Cell Res. 1997;230:50&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">9013706</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Halperin JA, Lee CM. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 1995;671:282&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">7743216</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9374212</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CW. Induced expression of neuronal membrane attack complex and cell death by Alzheimer&#x2019;s beta-amyloid peptide. Brain Res. 1998;796:187&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9689469</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen Y, Yang L-B, Rogers J. Complement defense protein CD59 is deficient in the Alzheimer&#x2019;s brain. Neuroscience. 1999;25:1102. Abstract.</Citation></Reference><Reference><Citation>Sheng JG, Boop FA, Mrak RE, Griffin WS. Increased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with IL-1 alpha immunoreactivity. J Neurochem. 1994;63:1872&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3833617</ArticleId><ArticleId IdType="pubmed">7931344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Ito K, Skinner RD, et al. In vivo and in vitro evidence supporting a role for the inflammatory cytokine IL-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3886636</ArticleId><ArticleId IdType="pubmed">8892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Mrak RE, Griffin WS. S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res. 1994;39:398&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884819</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin WS. Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer&#x2019;s disease. Neurobiol Aging. 1996;17:359&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">8725896</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigematsu K, McGeer PL, Walker DG, Ishii T, McGeer EG. Reactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage. J Neurosci Res. 1992;31:443&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">1640496</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirahama T, Miura K, Ju ST, Kisilevsky R, Gruys E, Cohen AS. Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest. 1990;62:61&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2296158</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrikant P, Weber E, Jilling T, Benveniste EN. Intercellular adhesion molecule-1 gene expression by glial cells. Differential mechanisms of inhibition by IL-10 and IL-6. J Immunol. 1995;155:1489&#x2013;1501.</Citation><ArticleIdList><ArticleId IdType="pubmed">7636212</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert P. Differential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 1998;812:97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">9813261</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotkin TA, Wang XF, Symonds HS, Seidler FJ. Expression of mRNAs coding for the transforming growth factor-beta receptors in brain regions of euthyroid and hypothyroid neonatal rats and in adult brain. Dev Brain Res. 1997;99:61&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9088566</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, La Rue A, Komo S, Kaplan A, Mandelkern MA. Predictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry. 1995;152:1757&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8526242</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884953</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith&#x2013;Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MP. Secreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem. 1994;63:781&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8035204</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith MA, Richey HP, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer&#x2019;s disease. J Neurosci. 1997;17:2653&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573097</ArticleId><ArticleId IdType="pubmed">9092586</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RP, Higuchi DA, Broze GJJ. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science. 1990;248:1126&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111585</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell JC, Chernyshev O, Gilbert DL, Colton CA. Polyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. J Leukoc Biol. 1997;62:369&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">9307076</ArticleId></ArticleIdList></Reference><Reference><Citation>Snow AD, Mar H, Nochlin D, et al. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer&#x2019;s disease. Am J Pathol. 1988;133:456&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1880818</ArticleId><ArticleId IdType="pubmed">2974240</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers W, Stahl M, Seehra JS. 1. 9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997;16:989&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169699</ArticleId><ArticleId IdType="pubmed">9118960</ArticleId></ArticleIdList></Reference><Reference><Citation>Sottrup&#x2013;Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem. 1989;264:11539&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2473064</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks DL. Coronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer&#x2019;s disease? Ann NY Acad Sci. 1997;826:128&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329686</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel K, Emmerling MR, Barnum SR. Inflammatory mechanisms and management of neurodegeneration. Totowa, NJ: Humana Press; 1999. Acute phase proteins: strategies for inhibition of complement activation in the treatment of neurodegenerative disorders; pp. 129&#x2013;76.</Citation></Reference><Reference><Citation>Stalder AK, Carson MJ, Pagenstecher A, et al. Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of TNF. Am J Pathol. 1998;153:767&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852999</ArticleId><ArticleId IdType="pubmed">9736027</ArticleId></ArticleIdList></Reference><Reference><Citation>Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866618</ArticleId><ArticleId IdType="pubmed">10362792</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein BA, Sapolsky RM. Chemical adrenalectomy reduces hippocampal damage induced by kainic acid. Brain Res. 1988;473:175&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">3208122</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman L. Some misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med. 1997;185:2039&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2196345</ArticleId><ArticleId IdType="pubmed">9221283</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterneck E, Kaplan DR, Johnson PF. IL-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem. 1996;67:1365&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">8858917</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer&#x2019;s disease and duration of NSAID use. Neurology. 1997;48:626&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of IL-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer&#x2019;s disease patients. Lab Invest. 1992;66:223&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370967</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Sparks DL. Activation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med. 1997;75:130&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9083930</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol. 1999;57:563&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">10221782</ArticleId></ArticleIdList></Reference><Reference><Citation>Streiter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">7592998</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:8098&#x2013;8102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in Alzheimer&#x2019;s disease brain. Mol Brain Res. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">11000474</ArticleId></ArticleIdList></Reference><Reference><Citation>Stubner S, Schon T, Padberg F, et al. IL-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci Lett. 1999;259:145&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10025579</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Civin WH, Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer&#x2019;s disease brain. Exp Neurol. 1990;110:93&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">1698655</ArticleId></ArticleIdList></Reference><Reference><Citation>Su JH, Deng G, Cotman CW. Neuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer&#x2019;s disease brain. Brain Res. 1997;774:193&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9452208</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PG, Bruce&#x2013;Keller AJ, Rabchevsky AG, et al. Exacerbation of damage and altered NF-kappaB activation in mice lacking TNF receptors after traumatic brain injury. J Neurosci. 1999;19:6248&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782813</ArticleId><ArticleId IdType="pubmed">10414954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundsmo JS, Fair DS. Relationship among the complement, kinin, coagulation, and fibrinolytic systems in the inflammatory reaction. Clin Physiol Biochem. 1983;1:225&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">6241121</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M. Alzheimer&#x2019;s beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res. 1998;807:110&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9757011</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S, Tanaka K, Nagata E, Ito D, Dembo T, Fukuuchi Y. Cerebral neurons express IL-6 after transient forebrain ischemia in gerbils. Neurosci Lett. 1999;262:117&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10203245</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanwick GR, Kirby M, Bruce I, et al. Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer&#x2019;s disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry. 1998;155:286&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9464214</ArticleId></ArticleIdList></Reference><Reference><Citation>Taga T. Gp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem. 1996;67:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8666978</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Yasuda T, Miyata T, et al. Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer&#x2019;s disease brain. Acta Neuropathol (Berlin) 1998;95:555&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9650745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamatani M, Che YH, Matsuzaki H, et al. TNF induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem. 1999;274:8531&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10085086</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka J, Fujita H, Matsuda S, Toku K, Sakanaka M, Maeda N. Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia. 1997;20:23&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">9145302</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarkowski E, Blennow K, Wallin A, Tarkowski A. Intracerebral production of TNF-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19:223&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchelingerian JL, Vignais L, Jacque C. TNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport. 1994;5:585&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8025249</ArticleId></ArticleIdList></Reference><Reference><Citation>Teipel SJ, Hampel H, Alexander GE, et al. Dissociation between corpus callosum atrophy and white matter pathology in Alzheimer&#x2019;s disease. Neurology. 1998;51:1381&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9818864</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA. 1995;92:4299&#x2013;4303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41931</ArticleId><ArticleId IdType="pubmed">7753801</ArticleId></ArticleIdList></Reference><Reference><Citation>Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 1997;769:385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9374211</ArticleId></ArticleIdList></Reference><Reference><Citation>Tocco G, Freire&#x2013;Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GM. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer&#x2019;s disease. Exp Neurol. 1997;144:339&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">9168834</ArticleId></ArticleIdList></Reference><Reference><Citation>Tooyama I, Kawamata T, Akiyama H, Moestrup SK, Gliemann J, McGeer PL. Immunohistochemical study of alpha 2 macroglobulin receptor in Alzheimer and control postmortem human brain. Mol Chem Neuropathol. 1993;18:153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8466589</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinder PK, Faust D, Petry F, Loos M. Modulation of mRNA expression and secretion of C1q in mouse macrophages by anti-inflammatory drugs and cAMP: evidence for the partial involvement of a pathway that includes cyclooxygenase, prostaglandin E2 and adenylate cyclase. Immunology. 1995;84:638&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1415162</ArticleId><ArticleId IdType="pubmed">7790039</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Antel J, Matre R. Human microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc Biol. 1994;56:732&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7996050</ArticleId></ArticleIdList></Reference><Reference><Citation>Unlap T, Jope RS. Diurnal variation in kainate-induced AP-1 activation in rat brain: influence of glucocorticoids. Mol Brain Res. 1995;28:193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">7723618</ArticleId></ArticleIdList></Reference><Reference><Citation>Unlap T, Jope RS. Inhibition of NFkB DNA binding activity by glucocorticoids in rat brain. Neurosci Lett. 1995;198:41&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8570092</ArticleId></ArticleIdList></Reference><Reference><Citation>Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MB. Transforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience. 1991;44:613&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">1754055</ArticleId></ArticleIdList></Reference><Reference><Citation>Uz T, Dwivedi Y, Savani PD, Impagnatiello F, Pandey G, Manev H. Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. J Neurochem. 1999;73:693&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428066</ArticleId></ArticleIdList></Reference><Reference><Citation>Vakeva A, Laurila P, Meri S. Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest. 1992;67:608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">1279272</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallieres L, Rivest S. Regulation of the genes encoding IL-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine IL-1beta. J Neurochem. 1997;69:1668&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">9326296</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CD. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of TNF-alpha and nitric oxide. J Neuroimmunol. 1996;70:145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">8898723</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wal EA, Gomez&#x2013;Pinilla F, Cotman CW. Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport. 1993;4:69&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453039</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eldik LJ, Griffin WS. S100 beta expression in Alzheimer&#x2019;s disease: relation to neuropathology in brain regions. Biochim Biophys Acta. 1994;1223:398&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">7918676</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Muiswinkel FL, DeGroot C, Rozemuller-Kwakkel J, Eikelenboom P. Alzheimer&#x2019;s disease and related disorders. London: John Wiley &amp; Sons; 1999. Enhanced expression of microglial NADPH-oxidase (p22-phox) in Alzheimer&#x2019;s disease; pp. 451&#x2013;6.</Citation></Reference><Reference><Citation>Van Muiswinkel FL, Raupp SF, de Vos NM, et al. The amino-terminus of the amyloid-beta protein is critical for the cellular binding and consequent activation of the respiratory burst of human macrophages. J Neuroimmunol. 1999;96:121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10227431</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Muiswinkel FL, Veerhuis R, Eikelenboom P. Amyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. J Neurochem. 1996;66:2468&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8632171</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Nostrand WE, Wagner SL, Suzuki M, et al. Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature. 1989;341:546&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2507928</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Wagoner NJ, Oh JW, Repovic P, Benveniste EN. IL-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci. 1999;19:5236&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782316</ArticleId><ArticleId IdType="pubmed">10377335</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer&#x2019;s disease due to an IL-1/IL-6 mediated &#x2018;acute phase&#x2019; response in the brain. Immunol Today. 1991;12:217&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1909530</ArticleId></ArticleIdList></Reference><Reference><Citation>Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">9597150</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerhuis R, Janssen CJA, De Groot FI, Van Muiswinkel FL, Hack P, Eikelenboom P. Cytokines associated with amyloid plaques in Alzheimer&#x2019;s disease brains stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol. 1999;160:289&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">10630213</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerhuis R, Janssen I, Hoozemans JJ, De Groot CJ, Hack CE, Eikelenboom P. Complement C1-inhibitor expression in Alzheimer&#x2019;s disease. Acta Neuropathol. 1998;96:287&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754962</ArticleId></ArticleIdList></Reference><Reference><Citation>Velazquez P, Cribbs DH, Poulos TL, Tenner AJ. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer&#x2019;s disease pathogenesis. Nat Med. 1997;3:77&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986745</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergeli M, Mazzanti B, Ballerini C, Gran B, Amaducci L, Massacesi L. Transforming growth factor-beta 1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. J Neurosci Res. 1995;40:127&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">7714920</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayan VK, Cotman CW. Hydrocortisone administration alters glial reaction to entorhinal lesion in the rat dentate gyrus. Exp Neurol. 1987;96:307&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">3569457</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitek MP, Snell J, Dawson H, Colton CA. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem Biophys Res Commun. 1997;240:391&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9388488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner SL, Geddes JW, Cotman CW, et al. Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:8284&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298265</ArticleId><ArticleId IdType="pubmed">2813392</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahl SM, Allen JB, McCartney&#x2013;Francis N, et al. Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med. 1991;173:981&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2190818</ArticleId><ArticleId IdType="pubmed">2007861</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG. Expression and regulation of complement C1q by human THP-1-derived macrophages. Mol Chem Neuropathol. 1998;34:197&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">10327418</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res. 1995;40:478&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">7616608</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Kim SU, McGeer PL. Expression of complement C4 and C9 genes by human astrocytes. Brain Res. 1998;809:31&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9795119</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, McGeer PL. Complement gene expression in human brains: comparison between normal and Alzheimer Disease cases. Mol Brain Res. 1992;14:109&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">1323007</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PL. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 1995;675:75&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">7796155</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YQ, Sizeland A, Wang XF, Sassoon D. Restricted expression of type-II TGF beta receptor in murine embryonic development suggests a central role in tissue modeling and CNS patterning. Mech Dev. 1995;52:275&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">8541216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward LD, Howlett GJ, Discolo G, et al. High affinity IL-6 receptor is a hexameric complex consisting of two molecules each of IL-6, IL-6 receptor, and gp- 130. J Biol Chem. 1994;269:23286&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8083235</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe D, Yoshimura R, Khalil M, et al. Characteristic localization of gp130 (the signal-transducing receptor component used in common for IL-6/IL-11/CNTF/LIF/OSM) in the rat brain. Eur J Neurosci. 1996;8:1630&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">8921254</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson MD, Roher AE, Kim KS, Spiegel K, Emmerling MR. Complement interactions with amyloid-&#x3b2; 1&#x2013;42: a nidus for inflammation in AD brains. Amyloid. 1997;4:147&#x2013;56.</Citation></Reference><Reference><Citation>Wavrant&#x2013;DeVrieze F, Rudrasingham V, Lambert JC, et al. No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer&#x2019;s disease. Neurosci Lett. 1999;262:137&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10203250</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb DJ, Atkins TL, Crookston KP, Burmester JK, Qian SW, Gonias SL. Transforming growth factor beta isoform 2-specific high affinity binding to native alpha 2-macroglobulin. Chimeras identify a sequence that determines affinity for native but not activated alpha 2-macroglobulin. J Biol Chem. 1994;269:30402&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">7527030</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Bradt B, Rogers J, Cooper N. Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem. 1997;69:388&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202333</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 1995;217:869&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">8554610</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Lue LF, Brachova L, et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:415&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330973</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, O&#x2019;Barr S, Rogers J. Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 1994;39:448&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7884823</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Park M, Fonseca MI, Tenner A. J Structural and functional evidence for a microglial C1q receptor that enhances phagocytosis. J Leukoc Biol. 2000;67:109&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">10648005</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Rogers J. Relative efficacies of amyloid beta peptide (A&#x3b2;) binding proteins in A beta aggregation. J Neurosci Res. 1996;46:58&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">8892106</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Tenner AJ, Poulos TL, Cribbs D. The mouse C1q A chain sequence alters beta-amyloid induced complement activation. Neurobiol Aging. 1999;20:297&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">10588577</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster S, Yang AJ, Margol L, Garzon&#x2013;Rodaquez W, Glabe C, Tenner AJ. Complement component C1q modulates the phagocytosis of A&#x3b2; by rat microglia. Exp Neurol. 2000;161:127&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10683279</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Vobach S, Olsson K, Svetlik D, Risser RC. Cortisol secretion and Alzheimer&#x2019;s disease progression. Biol Psychiatry. 1997;42:1030&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9386855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wekerle H, Linnington C, Lassmann H, Meyermann R. Cellular immune reactivity within the CNS. Trends Neurosci. 1986;9:271&#x2013;7.</Citation></Reference><Reference><Citation>Wekerle H, Sun D, Oropeza&#x2013;Wekerle RL, Meyermann R. Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J Exp Biol. 1987;132:43&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">3323405</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng Y, Siciliano SJ, Walburger KE, et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998;273:18288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">9660793</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk GL, Hauss&#x2013;Wegrzyniak B, Willard LB. Research and perspectives in neurosciences: neuroimmune neurodegenerative and psychiatric disorders. Heidelberg: Springer-Verlag; 2000. Pathological and biochemical studies of chronic neuroinflammation may lead to therapies for Alzheimer&#x2019;s Disease; pp. 73&#x2013;7.</Citation></Reference><Reference><Citation>Wenk GL, Willard LB. The neural mechanisms underlying cholinergic cell death within the basal forebrain. Int J Dev Neurosci. 1998;16:729&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10198820</ArticleId></ArticleIdList></Reference><Reference><Citation>Willard LB, Hauss&#x2013;Wegrzyniak B, Wenk GL. Pathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience. 1999;88:193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">10051200</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SE, Kounnas MZ, Argraves KM, Argraves WS, Strickland DK. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and the receptor-associated protein. An overview. Ann NY Acad Sci. 1994;737:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">7524391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Wegiel J, Wang KC, Kujawa M, Lach B. Ultrastructural studies of the cells forming amyloid fibers in classical plaques. Can J Neurol Sci. 1989;16:535&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2553231</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer&#x2019;s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf BB, Lopes MB, VandenBerg SR, Gonias SL. Characterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol. 1992;141:37&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886577</ArticleId><ArticleId IdType="pubmed">1632469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolkowitz OM, Reus VI, Canick J, Levin B, Lupien S. Glucocorticoid medication, memory and steroid psychosis in medical illness. Ann NY Acad Sci. 1997;823:81&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9292035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JA, Wood PL, Ryan R, et al. Cytokine indices in Alzheimer&#x2019;s temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993;629:245&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7509248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JG, Zinsmeister P. Tyrosine phosphorylation systems in Alzheimer&#x2019;s disease pathology. Neurosci Lett. 1991;121:12&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1708471</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood SJ, Chan W, Wetzel R. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry. 1996;35:12623&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8823200</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods AG, Poulsen FR, Gall CM. Dexamethasone selectively suppresses microglial trophic responses to hippocampal deafferentation. Neuroscience. 1999;91:1277&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10391435</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu MF, Chang HL, Tseng J. Dehydroepiandrosterone induces the transforming growth factor-beta production by murine macrophages. Int J Tissue React. 1997;19:141&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9506315</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss&#x2013;Coray T, Feng L, Masliah E, et al. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol. 1995;147:53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1869892</ArticleId><ArticleId IdType="pubmed">7604885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Lacombe P, Lin C, Sanan DA, Mucke L, Masliah E. Alzheimer&#x2019;s disease-like cerebrovascular pathology in transforming growth factor-&#x3b2;1 transgenic mice and functional metabolic correlates. Ann NY Acad Sci. In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">10818521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss&#x2013;Coray T, Lacombe P, Von Euw D, et al. TGF-&#x3b2;1 modulates brain amyloid deposition and induces Alzheimer&#x2019;s disease like microvascular abnormalities in transgenic mice. Neurosci. 1999;25:22. Abstract.</Citation></Reference><Reference><Citation>Wyss&#x2013;Coray T, Lin C, Sanan DA, Mucke L, Masliah E. Chronic overproduction of TGF-&#x3b2;1 in astrocytes promotes Alzheimer&#x2019;s disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868631</ArticleId><ArticleId IdType="pubmed">10623661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss&#x2013;Coray T, Masliah E, et al. Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer&#x2019;s disease. Nature. 1997;389:603&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9335500</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia MQ, Hyman B. Chemokines/chemokine receptors in the central nervous system and Alzheimer&#x2019;s disease. J Neurovirol. 1999;5:32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190688</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia MQ, Qin SX, McNamara M, Mackay CR, Hyman B. IL-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer&#x2019;s disease. Am J Pathol. 1997;150:1267&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858175</ArticleId><ArticleId IdType="pubmed">9094983</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer&#x2019;s disease brains. Am J Pathol. 1998;153:31&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852933</ArticleId><ArticleId IdType="pubmed">9665462</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagisawa M, Yuo A, Yonemaru M, et al. Superoxide release and NADPH oxidase components in mature human phagocytes: correlation between functional capacity and amount of functional proteins. Biochem Biophys Res Commun. 1996;228:510&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">8920944</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993;11:371&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">8352945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-IL-6 in the TNF alpha-dependent induction of cyclooxygenase-2 in MC3T3&#x2013;E1 cells. J Biol Chem. 1995;270:31315&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8537402</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K, Miyoshi T, Yae T, et al. The survival of rat cerebral cortical neurons in the presence of trophic APP peptides. J Neurobiol. 1994;25:585&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">8071662</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Zhu H, Fu J, et al. Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:5296&#x2013;5301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24672</ArticleId><ArticleId IdType="pubmed">9144231</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer&#x2019;s disease. Nature. 1996;382:685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan SD, Yan SF, Chen X, et al. Non-enzymatically glycated tau in Alzheimer&#x2019;s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med. 1995;1:693&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7585153</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Quitschke WW, Brewer GJ. Upregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Mol Brain Res. 1998;60:40&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9748493</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Harvath L, Gilbert DL, Colton CA. Chemotaxis by a CNS macrophage, the microglia. J Neurosci Res. 1990;27:36&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">2254955</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao J, Keri JE, Taffs RE, Colton CA. Characterization of IL-1 production by microglia in culture. Brain Res. 1992;591:88&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">1446236</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, McGeer EG, McGeer PL. Complement regulator C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer&#x2019;s disease. Brain Res. 1999;833:297&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">10375708</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer&#x2019;s disease brain. Am J Pathol. 1999;154:927&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866427</ArticleId><ArticleId IdType="pubmed">10079271</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuhara O, Walker DG, McGeer PL. Hageman factor and its binding sites are present in senile plaques of Alzheimer&#x2019;s disease. Brain Res. 1994;654:234&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">7987673</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasukawa K, Saito T, Fukunaga T, et al. Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem (Tokyo) 1990;108:673&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">2292596</ArticleId></ArticleIdList></Reference><Reference><Citation>Yermakova A, Rollins J, Callahan LM, Rogers J, O&#x2019;Banion MK. Cyclooxygenase-1 in human Alzheimer&#x2019;s and control brain:quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol. 1999;58:1135&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">10560656</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi H, Yoshie O. Identification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem. 1998;273:16551&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">9632725</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarow C, Schlueter KE, Zhang Q. IL-6 mRNA is elevated in Alzheimer Disease Brain. Neurosci. 1996;22:214. Abstract.</Citation></Reference><Reference><Citation>Zhang JG, Owczarek CM, Ward LD, et al. Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution. Biochem J. 1997;325:693&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218613</ArticleId><ArticleId IdType="pubmed">9271090</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J, Dietzel ID, Wahle P, Kopf M, Heumann R. Sensory impairments and delayed regeneration of sensory axons in IL-6-deficient mice. J Neurosci. 1999;19:4305&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782624</ArticleId><ArticleId IdType="pubmed">10341234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Martel CL, Mackic JB, et al. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer&#x2019;s amyloid beta. Biochem Biophys Res Commun. 1994;205:1431&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">7802679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Martel CL, Matsubara E, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA. 1996;93:4229&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39517</ArticleId><ArticleId IdType="pubmed">8633046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17553989</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>23</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>06</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.</ArticleTitle><Pagination><StartPage>6174</StartPage><EndPage>6184</EndPage><MedlinePgn>6174-84</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid cascade hypothesis suggests that the aggregation and deposition of amyloid-beta protein is an initiating event in Alzheimer's disease (AD). Using amyloid imaging technology, such as the positron emission tomography (PET) agent Pittsburgh compound-B (PiB), it is possible to explore the natural history of preclinical amyloid deposition in people at high risk for AD. With this goal in mind, asymptomatic (n = 5) and symptomatic (n = 5) carriers of presenilin-1 (PS1) mutations (C410Y or A426P) that lead to early-onset AD and noncarrier controls from both kindreds (n = 2) were studied with PiB-PET imaging and compared with sporadic AD subjects (n = 12) and controls from the general population (n = 18). We found intense and focal PiB retention in the striatum of all 10 PS1 mutation carriers studied (ages 35-49 years). In most PS1 mutation carriers, there also were increases in PiB retention compared with controls in cortical brain areas, but these increases were not as great as those observed in sporadic AD subjects. The two PS1 mutation carriers with a clinical diagnosis of early-onset AD did not show the typical regional pattern of PiB retention observed in sporadic AD. Postmortem evaluation of tissue from two parents of PS1C410Y subjects in this study confirmed extensive striatal amyloid deposition, along with typical cortical deposition. The early, focal striatal amyloid deposition observed in these PS1 mutation carriers is often is not associated with clinical symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA. klunkwe@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Tsopelas</LastName><ForeName>Nicholas D</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Lopresti</LastName><ForeName>Brian J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Ziolko</LastName><ForeName>Scott K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Bi</LastName><ForeName>Wenzhu</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Hoge</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Ikonomovic</LastName><ForeName>Milos D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Saxton</LastName><ForeName>Judith A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Snitz</LastName><ForeName>Beth E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>Pollen</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Moonis</LastName><ForeName>Majaz</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lippa</LastName><ForeName>Carol F</ForeName><Initials>CF</Initials></Author><Author ValidYN="Y"><LastName>Swearer</LastName><ForeName>Joan M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Fischman</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH001976</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020226</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG001039</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="Y">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2007</Year><Month>12</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17553989</ArticleId><ArticleId IdType="mid">NIHMS344526</ArticleId><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0730-07.2007</ArticleId><ArticleId IdType="pii">27/23/6174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006;60:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802294</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JT, Boller F, Saxton J, McGonigle-Gibson KL. Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex. 1987;23:59&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">3568706</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia. 1968;6:53&#x2013;60.</Citation></Reference><Reference><Citation>Benton AL, Sivan AB, Hamsher KD, Varney NR, Spreen O. A clinical manual. Ed 2. New York: Oxford UP; 1994. Contributions to neuropsychological assessment.</Citation></Reference><Reference><Citation>Beyreuther K, Dyrks T, Hilbich C, Monning U, Konig G, Multhaup G, Pollwein P, Masters CL. Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome. Prog Clin Biol Res. 1992;379:159&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">1409743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2548561</ArticleId><ArticleId IdType="pubmed">7833759</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135&#x2013;140.</Citation></Reference><Reference><Citation>Braak H, Braak E. Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol. 1990;49:215&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">1692337</ArticleId></ArticleIdList></Reference><Reference><Citation>Brilliant MJ, Elble RJ, Ghobrial M, Struble RG. The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathol Appl Neurobiol. 1997;23:322&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">9292871</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buschke H. Cued recall in amnesia. J Clin Neuropsychol. 1984;6:433&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">6501581</ArticleId></ArticleIdList></Reference><Reference><Citation>Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, Moreau V, Charbonnier F, Didierjean O, Tardieu S, Penet C, Puel M, Pasquier F, Ledoze F, Bellis G, Calenda A, Heilig R, Martinez M, Mallet J, Bellis M, et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet. 1995;4:2373&#x2013;2377.</Citation><ArticleIdList><ArticleId IdType="pubmed">8634712</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Van Broeckhoven C. Presenilin mutations in Alzheimer's disease. Hum Mutat. 1998;11:183&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521418</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler NR, Haxby JV, Duara R, Grady CL, Moore AM, Parisi JE, White J, Heston L, Margolin RM, Rapoport SI. Brain metabolism as measured with positron emission tomography: serial assessment in a patient with familial Alzheimer's disease. Neurology. 1985;35:1556&#x2013;1561.</Citation><ArticleIdList><ArticleId IdType="pubmed">3877253</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Grimmer T, Henriksen G, Wester HJ, Kurz A, Schwaiger M. Imaging of cerebral amyloid plaque load and glucose metabolism in semantic dementia and Alzheimer's disease. J Nucl Med. 2006;47(Suppl 1):73P.</Citation></Reference><Reference><Citation>Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, Hotton G, Cutler D, Fox N, Kennedy A, Rossor M, Brooks DJ. Amyloid, hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDG PET study. Neurology. 2006;68:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129:2805&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, Larossa GN, Spinner ML, Klunk WE, Mathis CA, Dekosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, editors. Recent developments in Parkinson's disease. Florham Park, NJ: Macmillan Health Care Information; 1987. pp. 153&#x2013;164.</Citation></Reference><Reference><Citation>Ferrer I, Boada R, Sanchez G, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein M, Folstein S, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B. Mild cognitive impairment. Lancet. 2006;367:1262&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">16631882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Guze BH, Hoffman JM, Mazziotta JC, Baxter LR, Jr, Phelps ME. Positron emission tomography and familial Alzheimer's disease: a pilot study. J Am Geriatr Soc. 1992;40:120&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">1740595</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci. 1998;1:355&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256:184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Perl D, Purohit D, Marin D, Khan K, Lantz M, Davis K. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Arch Neurol. 1998;55:1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollander M, Wolfe DA. New York: Wiley; 1973. Nonparametric statistical methods.</Citation></Reference><Reference><Citation>Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, Clark RS, Marion DW, Wisniewski SR, DeKosky ST. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol. 2004;190:192&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15473992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Abrahamson EE, Isanski BA, Mathis CA, DeKosky ST, Klunk WE. X34, a histofluorescent marker of abnormal protein aggregates with amyloid structure, in neuropathological studies of preclinical and clinical Alzheimer's disease. Methods Enzymol. 2006;412:123&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046656</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Selkoe DJ. The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord. 1992;6:7&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">1605946</ArticleId></ArticleIdList></Reference><Reference><Citation>Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol. 1989;135:309&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1879919</ArticleId><ArticleId IdType="pubmed">2675616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, Oikonen V, Kailajarvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575&#x2013;1580.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy AM, Rossor MN, Frackowiak RS. Positron emission tomography in familial Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9:17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605617</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Synaptic targeting by A&#x3b2; oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement. 2006;2:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595855</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-&#x3b2; in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci. 2005;25:10598&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725842</ArticleId><ArticleId IdType="pubmed">16291932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakides T, Silbert PL, Kakulas BA. Cerebral amyloid angiopathy and intracerebral hemorrhage with special reference to the pons. Clin Neuropathol. 1994;13:71&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">8205729</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo D, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, George-Hyslop SP, Roses AD, Pollen DA. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 1996;96:406&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pubmed">8614503</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler AH, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST. Res evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology. 2000;55:1854&#x2013;1862.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134385</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, Dekosky ST, Price JC. Simplified Quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T. Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1linked Alzheimer's disease. Am J Pathol. 2001;158:2165&#x2013;2175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891993</ArticleId><ArticleId IdType="pubmed">11395394</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. A&#x3b2; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, Maruyama M, Iwatsubo T, Higuchi S. Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry. 2002;52:907&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399144</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19:541&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">7622680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005;65:323&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16043812</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2771064</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Jr, Rubin EH, Price JL, Grant EA, Berg L. Cerebral amyloid deposition and diffuse plaques in &#x201c;normal&#x201d; aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor P, Goate AM. Molecular genetics of Alzheimer's disease. Curr Psychiatry Rep. 2004;6:125&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">15038915</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ. Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PS1&#x394;E9 transgenic mice. J Neurosci. 2005;25:10220&#x2013;10229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725777</ArticleId><ArticleId IdType="pubmed">16267229</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Sharma V, Anderson L, Nemens E, Alonso ME, Orr H, White J, Heston L, Bird TD, Schellenberg GD. Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene. Hum Mutat. 1998;11:216&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">9521423</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, Dekosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, Klunk WE, Mathis CA, Rosen HJ, Miller BL, Jagust WJ. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Reitan RM. Validity of the trail-making tests as an indication of organic brain damage. Percept Motor Skills. 1958;8:271&#x2013;276.</Citation></Reference><Reference><Citation>Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol. 2006;5:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossor MN, Kennedy AM, Frackowiak RS. Clinical and neuroimaging features of familial Alzheimer's disease. Ann NY Acad Sci. 1996;777:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624126</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Ratcliff G, Newman A, Belle S, Fried L, Yee J, Kuller L. Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology. 2000;19:312&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060505</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, Jenkins R, Rossor MN. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol. 2003;53:181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">12557284</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790632</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop PH. Molecular genetics of Alzheimer disease. Semin Neurol. 1999;19:371&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">10716660</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Kamboh MI, DeKosky ST. Expression of differential immune factors in temporal cortex and cerebellum: the role of alpha-1-antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. J Comp Neurol. 1998;396:511&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">9651008</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem. 2000;48:1223&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Suenaga T, Hirano A, Llena JF, Yen SH, Dickson DW. Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol (Berl) 1990;80:280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">1698005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis. 1996;3:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">8980016</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Rub U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S, Bormans G, Brouwers N, Van den Broeck M, Vennekens K, Corsmit E, Cruts M, De Strooper B, Van Broeckhoven C, Vandenberghe R. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat. 2006;27:888&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917905</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, Kung HF, Kung MP, Houle S. In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545326</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne V, Ng S, Gong S, Ackermann U, Pike K, Savage G, Klunk W, Mathis C, Masters C, Rowe C. 11C-PIB PET imaging in the differential diagnosis of dementia. J Nucl Med. 2006;47(Suppl 1):74P.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlund LO, Basun H, Almkvist O, Julin P, Axelman K, Shigeta M, Jelic V, Nordberg A, Lannfelt L. A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dement Geriatr Cogn Disord. 1999;10:526&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10559570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale. Ed 3. New York: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Welsh-Bohmer KA, Butters N, Mohs RC. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). V. A normative study of the neuropsychological battery. Neurology. 1994;44:609&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">8164812</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker C, Eckman C, Almeida C, Feinstein D, Atwood C, Eckman E, Crutcher K, Hersh L, Leissring M, LaVoie M, Ertekin-Taner N, Shapiro P, Takahashi R, Yamin R, Mansourian S, Estus S, Lesne S, Turner T, Farris W, Stroebel G. Live discussion: amyloid-beta degradation: the forgotten half of Alzheimer's disease. J Alzheimers Dis. 2003;5:491&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">14765518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson AA, Garcia A, Chestakova A, Kung HF, Houle S. A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[C-11]2-(4&#x2032;-methylaminophenyl)-6hydroxybenzothiazole ([C-11]-6-OH-BTA-1) J Label Compd Radiopharm. 2004;47:679&#x2013;682.</Citation></Reference><Reference><Citation>Xia W, Ostaszewski BL, Kimberly WT, Rahmati T, Moore CL, Wolfe MS, Selkoe DJ. FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gammasecretase cleavage complex. Neurobiol Dis. 2000;7:673&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">11114265</ArticleId></ArticleIdList></Reference><Reference><Citation>Younkin SG. The APP and PS1/2 mutations linked to early onset familial Alzheimer's disease increase the extracellular concentration and A beta 1&#x2013;42 (43) Rinsho Shinkeigaku. 1997;37:1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">9577655</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Resnick S, Ye W, Fan H, Holt D, Klunk W, Mathis C, Dannals R, Wong D. Evaluation of reference tissue models for quantification of [11C] Pittsburgh compound B dynamic PET studies. J Nucl Med. 2006;47(Suppl 1):117P.</Citation></Reference><Reference><Citation>Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, Dekosky ST, Price JC. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. NeuroImage. 2006;33:94&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">16905334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19346482</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>16</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6820</StartPage><EndPage>6825</EndPage><MedlinePgn>6820-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0900345106</ELocationID><Abstract><AbstractText>Fibrillar amyloid-beta (Abeta) is found in the brains of many cognitively normal older people. Whether or not this reflects a predisposition to Alzheimer's disease (AD) is unknown. We used Pittsburgh Compound B (PiB) PET to characterize the relationship between fibrillar Abeta burden and this predisposition in cognitively normal older people at 3 mean levels of genetic risk for AD. Dynamic PiB PET scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest (ROIs) were used to characterize and compare cerebral-to-cerebellar PIB distribution volume ratios, reflecting fibrillar Abeta burden, in 28 cognitively normal persons (mean age, 64 years) with a reported family history of AD and 2 copies, 1 copy, and no copies of the apolipoprotein E (APOE) epsilon4 allele. The 8 epsilon4 homozygotes, 8 heterozygotes, and 12 noncarriers did not differ significantly in terms of age, sex, or cognitive scores. Fibrillar Abeta was significantly associated with APOE epsilon4 carrier status and epsilon4 gene dose in AD-affected mean cortical, frontal, temporal, posterior cingulate-precuneus, parietal, and basal ganglia ROIs, and was highest in an additional homozygote who had recently developed mild cognitive impairment. These findings suggest that fibrillar Abeta burden in cognitively normal older people is associated with APOE epsilon4 gene dose, the major genetic risk factor for AD. Additional studies are needed to track fibrillar Abeta accumulation in persons with different kinds and levels of AD risk; to determine the extent to which fibrillar Abeta, alone or in combination with other biomarkers and risk factors, predicts rates of cognitive decline and conversion to clinical AD; and to establish the role of fibrillar Abeta imaging in primary prevention trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute and the Positron Emission Tomography Center, Good Samaritan Regional Medical Center, Phoenix, AZ 85006, USA. eric.reiman@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaofen</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Bandy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Meixiang</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Ayutyanont</LastName><ForeName>Napatkamon</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Keppler</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B S</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Caselli</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH057899</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025526</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018402</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH070729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH70729</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of interest statement: GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript and may eventually benefit from the results of the study. Drs. Klunk and Mathis are coinventors of PiB and as such have a financial interest in this license agreement. GE Healthcare provided no grant support for this study, did not charge for our use of PiB, and had no role in the design or interpretation of results or preparation of this manuscript. None of the other authors declares any conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>4</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19346482</ArticleId><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="doi">10.1073/pnas.0900345106</ArticleId><ArticleId IdType="pii">0900345106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, et al. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68:613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the &#x3b5;4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Alexander GE, Chen K. Tracking the decline in cerebral glucose metablolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin Neurosci Res. 2001;1:194&#x2013;206.</Citation></Reference><Reference><Citation>Reiman EM, et al. Declining brain activity in cognitively normal apolipoprotein E &#x3b5;4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Correlations between apolipoprotein E &#x3b5;4 gene dose and brain imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A. 2005;102:8299&#x2013;8302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1149416</ArticleId><ArticleId IdType="pubmed">15932949</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174&#x2013;6184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265970</ArticleId><ArticleId IdType="pubmed">17553989</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, et al. Cholesterol-related genetic risk scores are associated with hypometabolism in Alzheimer's-affected brain regions. Neuroimage. 2008;40:1214&#x2013;1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2441925</ArticleId><ArticleId IdType="pubmed">18280754</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS. In: Imaging and the Aging Brain. Jagust WJ, D'Esposito M, editors. New York: Oxford Univ Press; (in press)</Citation></Reference><Reference><Citation>Schmechel DE, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:9649&#x2013;9653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC47627</ArticleId><ArticleId IdType="pubmed">8415756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM. Apolipoprotein E, amyloid, and Alzheimer disease. Mol Interv. 2002;2:363&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">14993413</ArticleId></ArticleIdList></Reference><Reference><Citation>Koistinaho M, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med. 2004;10:719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15195085</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Risner ME, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6:246&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">16446752</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SM, et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. Ann Neurol. 2008;64:587&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605158</ArticleId><ArticleId IdType="pubmed">19067370</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A&#x3b2;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, et al. Cerebrospinal fluid beta-amyloid1&#x2013;42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE epsilon4 allele. Biol Psychiatry. 2004;56:670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522251</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, et al. Mild cognitive impairment: Beyond controversies, towards a consensus. Report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. New York: Thieme; 1988.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21245183</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>305</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Use of florbetapir-PET for imaging beta-amyloid pathology.</ArticleTitle><Pagination><StartPage>275</StartPage><EndPage>283</EndPage><MedlinePgn>275-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2010.2008</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">The ability to identify and quantify brain &#x3b2;-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if florbetapir F 18 positron emission tomographic (PET) imaging performed during life accurately predicts the presence of &#x3b2;-amyloid in the brain at autopsy.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Prospective clinical evaluation conducted February 2009 through March 2010 of florbetapir-PET imaging performed on 35 patients from hospice, long-term care, and community health care facilities near the end of their lives (6 patients to establish the protocol and 29 to validate) compared with immunohistochemistry and silver stain measures of brain &#x3b2;-amyloid after their death used as the reference standard. PET images were also obtained in 74 young individuals (18-50 years) presumed free of brain amyloid to better understand the frequency of a false-positive interpretation of a florbetapir-PET image.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Correlation of florbetapir-PET image interpretation (based on the median of 3 nuclear medicine physicians' ratings) and semiautomated quantification of cortical retention with postmortem &#x3b2;-amyloid burden, neuritic amyloid plaque density, and neuropathological diagnosis of Alzheimer disease in the first 35 participants autopsied (out of 152 individuals enrolled in the PET pathological correlation study).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Florbetapir-PET imaging was performed a mean of 99 days (range, 1-377 days) before death for the 29 individuals in the primary analysis cohort. Fifteen of the 29 individuals (51.7%) met pathological criteria for Alzheimer disease. Both visual interpretation of the florbetapir-PET images and mean quantitative estimates of cortical uptake were correlated with presence and quantity of &#x3b2;-amyloid pathology at autopsy as measured by immunohistochemistry (Bonferroni &#x3c1;, 0.78 [95% confidence interval, 0.58-0.89]; P &lt;.001]) and silver stain neuritic plaque score (Bonferroni &#x3c1;, 0.71 [95% confidence interval, 0.47-0.86]; P &lt;.001). Florbetapir-PET images and postmortem results rated as positive or negative for &#x3b2;-amyloid agreed in 96% of the 29 individuals in the primary analysis cohort. The florbetapir-PET image was rated as amyloid negative in the 74 younger individuals in the nonautopsy cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Florbetapir-PET imaging was correlated with the presence and density of &#x3b2;-amyloid. These data provide evidence that a molecular imaging procedure can identify &#x3b2;-amyloid pathology in the brains of individuals during life. Additional studies are required to understand the appropriate use of florbetapir-PET imaging in the clinical diagnosis of Alzheimer disease and for the prediction of progression to dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA. clark@avidrp.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Bedell</LastName><ForeName>Barry J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Bilker</LastName><ForeName>Warren B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hefti</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>Alan P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Flitter</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Krautkramer</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Hank F</ForeName><Initials>HF</Initials></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric P</ForeName><Initials>EP</Initials></Author><Author ValidYN="Y"><LastName>Zehntner</LastName><ForeName>Simone P</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><CollectiveName>AV45-A07 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-0222559</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA. 2011 Mar 16;305(11):1096</RefSource><Note>Reiman, P Eric M [corrected to Reiman, Eric M]</Note></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 Jan 19;305(3):304-5. doi: 10.1001/jama.2010.2017.</RefSource><PMID Version="1">21245188</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2011 May 11;305(18):1857; author reply 1857-8. doi: 10.1001/jama.2011.579.</RefSource><PMID Version="1">21558513</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="Y">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="Y">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Clark, Mintun, Pontecorvo, Hefti, Carpenter, and Skovronsky and Messrs Flitter and Krautkramer reported owning Avid stock and/or stock options and being employed by Avid Radiopharmaceuticals Inc. Dr Schneider reported being a consultant for Avid Radiopharmaceuticals and receiving compensation for services. Drs Bedell and Zehntner reported receiving compensation and shares from Biospective Inc. Dr Beach reported receiving funding related to the topic of this article from the National Institute on Aging (grant P30 AG19610), the Arizona Department of Health Services (contract 211002 awarded to the Arizona Alzheimer&#x2019;s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05&#x2013;901 and 1001), Avid Radiopharmaceuticals, Bayer Healthcare Inc, and GE Healthcare. Dr Bilker reported working as consultant for Avid Radiopharmaceuticals on issues related to this study. Dr Kung reported receiving financial support from National Institutes of Health grant AG-0222559; serving on the Avid Scientific Advisory board; participating in the formation of Avid; and being an Avid stockholder. Dr Coleman reported being on the medical advisory board for General Electric Healthcare from 2003&#x2013;2008; being a consultant for General Electric Healthcare from 2003&#x2013;2008; receiving a research grant from General Electric Healthcare in 2010; receiving funding for a clinical trial from Molecular Insights Pharmaceuticals in 2010; serving on a medical advisory board for Molecular Insights Pharmaceuticals from 2004&#x2013;2009; and receiving a grant from Avid to support his participation in this study. Dr Doraiswamy reported receiving research grants (awarded to Duke University); currently or previously serving as an advisor to Forest, Bristol-Myers Squibb, Avid Radiopharmaceuticals, Lundbeck, Medivation, Pfizer, Elan, Eli Lilly, Bayer, Neuroptix, Neuronetrix, Sonexa, Accera, TauRx, Myriad, National Institute on Aging, AstraZeneca, Labopharm, Clarimedix, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, Alzheimer&#x2019;s Association, Alzheimer&#x2019;s Foundation, Rutgers University, and the University of California; owning stock in Sonexa; and receiving a grant from Avid (awarded to Duke University) for his participation in this study. Dr Fleisher reported receiving research contracts from Avid Radiopharmaceuticals to the Banner Alzheimer&#x2019;s Institute, from which he receives no personal compensation; being a consultant on a scientific advisory board for Eli Lilly; serving on an advisory board for Elan Pharmaceuticals; and having a pending investigator-initiated grant from Avid Radiopharmaceuticals. Dr Sabbagh reported working as a consultant for Eisai, Pfizer, Amerisciences, Takeda, and GlaxoSmithKline; receiving royalties from Wiley, FT Pearson Press, and Amerisciences; and having grants and contracts with Eli Lilly, Baxter, Bayer, General Electric Healthcare, Bristol-Myers Squibb, Eisai, Janssen, Wyeth/Elan, Avid, and Medivation. Dr Sadowsky reported being on the speaker&#x2019;s bureau and receiving honoraria from Novartis, Forrest, Accera, and Pamlab; and serving on the advisory board for Novartis. Dr Reiman reported serving as a scientific advisor to Amnestix/Sygnis, AstraZeneca, Elan, Eli Lilly, GlaxoSmithKline, Intellect, Siemens, Bayer, Takeda, and Eisai; having research contracts with the National Institute on Aging, Arizona Department of Health Services, AstraZeneca, Avid Radiopharmaceuticals, and Kronos Life Sciences; receiving research grants from the National Institute on Aging, National Institute for Mental Health, the Anonymous Foundation, Nomis Foundation, Banner Alzheimer&#x2019;s Foundation, and the State of Arizona; holding patents for imaging strategy for the screening of AD treatments in laboratory animals (active), biomarker strategy for the evaluation of presymptomatic AD treatments (pending, through Banner Health), statistical strategy for the analysis of complementary complex data sets (pending, through Banner Health), and <i>GAB2</i> testing in clinical assessment of AD (pending, through Translational Genomics Research Institute); and serving as the executive director for the Banner Alzheimer&#x2019;s Institute and the director of the Arizona Alzheimer&#x2019;s Consortium.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21245183</ArticleId><ArticleId IdType="mid">NIHMS1047252</ArticleId><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId><ArticleId IdType="pii">305/3/275</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer&#x2019;s disease and the differential diagnosis of dementia. Int Psychogeriatr. 1998;10(3):271&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">9785148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer&#x2019;s disease. N Engl J Med. 1998;338(8):506&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">9468467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranginwala NA, Hynan LS, Weiner MF, White CL III. Clinical criteria for the diagnosis of Alzheimer disease. Am J Geriatr Psychiatry. 2008;16(5):384&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">18448850</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf6;pp&#xf6;nen M, R&#xe4;ih&#xe4; I, Isoaho R. Diagnosing cognitive impairment and dementia in primary health care. Age Ageing. 2003;32(6):606&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">14600001</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal LJ, Kantarci K, Reiman EM, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(1): 6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820855</ArticleId><ArticleId IdType="pubmed">16493230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Lopresti BJ, Klunk WE. Impact of amyloid imaging on drug development in Alzheimer&#x2019;s disease. Nucl Med Biol. 2007;34(7):809&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2078205</ArticleId><ArticleId IdType="pubmed">17921032</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer&#x2019;s disease. Neurology. 1984; 34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institute on Aging; Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997; 18(4 suppl):S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci. 2001;69(13):1471&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pubmed">11554609</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Koole M, Lewis DM, Buckley C, et al. Whole-body biodistribution and radiation dosimetry of 18F-GE067. J Nucl Med. 2009;50(5):818&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">19372469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung HF, Choi SR, Qu W, et al. 18F Stilbenes and styrylpyridines for PET imaging of a beta plaques in Alzheimer&#x2019;s disease. J Med Chem. 2010;53(3): 933&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818335</ArticleId><ArticleId IdType="pubmed">19845387</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer&#x2019;s disease with 18F-BAY94&#x2013;9172, a novel PET tracer. Lancet Neurol. 2008; 7(2):129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355(25):2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6(3):221&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KJ, Hsu WC, Hsiao IT, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent. Nucl Med Biol. 2010; 37(4):497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">20447562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Evolution of the neuropathology of Alzheimer&#x2019;s disease. Acta Neurol Scand Suppl. 1996;165:3&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging. J Neuropathol Exp Neurol. 1998; 57(12):1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010; 9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Price AL. Pathologic correlates of non-demented aging, mild cognitive impairment, and earlystage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001; 17(2):101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in non-demented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45(3):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeat P, Ch&#xe9;telat G, Villemagne VL, et al. Betaamyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74(2):121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20065247</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Darby D, et al. A beta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer&#x2019;s disease. Neuropsychologia. 2008;46(6):1688&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343463</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010; 74(10):807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, et al. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease. Lancet Neurol. 2007;6(8):734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66(12):1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009; 66(2):200&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B. Arch Neurol. 2009;66 (12):1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A beta 42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16960575</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>9</Issue><PubDate><Year>2006</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Inflammation in Alzheimer disease: driving force, bystander or beneficial response?</ArticleTitle><Pagination><StartPage>1005</StartPage><EndPage>1015</EndPage><MedlinePgn>1005-15</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer disease is a progressive dementia with unknown etiology that affects a growing number of the aging population. Increased expression of inflammatory mediators in postmortem brains of people with Alzheimer disease has been reported, and epidemiological studies link the use of anti-inflammatory drugs with reduced risk for the disorder. On the initial basis of this kind of evidence, inflammation has been proposed as a possible cause or driving force of Alzheimer disease. If true, this could have important implications for the development of new treatments. Alternatively, inflammation could simply be a byproduct of the disease process and may not substantially alter its course. Or components of the inflammatory response might even be beneficial and slow the disease. To address these possibilities, we need to determine whether inflammation in Alzheimer disease is an early event, whether it is genetically linked with the disease and whether manipulation of inflammatory pathways changes the course of the pathology. Although there is still little evidence that inflammation triggers or promotes Alzheimer disease, increasing evidence from mouse models suggests that certain inflammatory mediators are potent drivers of the disease. Related factors, on the other hand, elicit beneficial responses and can reduce disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Geriatric Research, Education and Clinical Center, Veterans Administration Palo Alto Health Care System, 3801 Miranda Avenue, Palo Alto, California 94304, USA. twc@stanford.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018836">Inflammation Mediators</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D011451">Prostaglandin-Endoperoxide Synthases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018836" MajorTopicYN="N">Inflammation Mediators</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011451" MajorTopicYN="N">Prostaglandin-Endoperoxide Synthases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>119</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>9</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId><ArticleId IdType="doi">10.1038/nm1484</ArticleId><ArticleId IdType="pii">nm1484</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2360787</PMID><DateCompleted><Year>1990</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>1990</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity.</ArticleTitle><Pagination><StartPage>457</StartPage><EndPage>464</EndPage><MedlinePgn>457-64</MedlinePgn></Pagination><Abstract><AbstractText>Ultrastructural studies of biopsied cortical tissue from the right frontal lobe of 8 patients with mild to moderate Alzheimer's disease (AD) revealed that the number of synapses in lamina III of Brodmann's area 9 was significantly decreased when compared with the number in age-matched control brains (n = 9; postmortem time, less than 13 hours). Further decline in synaptic number was seen in age-matched autopsied AD specimens. In the AD brains there was significant enlargement of the mean apposition length, which correlated with degree of synapse loss; as synapse density declined, synapse size increased. The enlargement of synapses, coupled with the decrease in synaptic number, allowed the total synaptic contact area per unit volume to remain stable in the patients who underwent biopsy. In autopsied subjects who had AD, there was no further enlargement of mean synaptic contact area. There was a significant correlation between synapse counts and scores on the Mini-Mental State examination in the patients who underwent biopsy. Lower mental status scores were associated with greater loss of synapses. Choline acetyltransferase activity was significantly decreased in the biopsied group and declined further in the autopsied specimens of AD. There was no relationship between choline acetyltransferase activity and scores on the Mini-Mental State examination or synapse number. There is evidence of neural plasticity in the AD neuropil; synaptic contact size increased in patients who had biopsy and possibly compensated for the numerical loss of synapses. But by end stage of the disease, the ability of the cortex to compensate was exceeded and both synapse number and synaptic contact area declined.(ABSTRACT TRUNCATED AT 250 WORDS)</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>S T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology, Lexington Veterans Administration, Medical Center, KY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheff</LastName><ForeName>S W</ForeName><Initials>SW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG 05119</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG 05144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.3.1.6</RegistryNumber><NameOfSubstance UI="D002795">Choline O-Acetyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002795" MajorTopicYN="N">Choline O-Acetyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId><ArticleId IdType="doi">10.1002/ana.410270502</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21436112</PMID><DateCompleted><Year>2011</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>Pt 4</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1089</StartPage><EndPage>1100</EndPage><MedlinePgn>1089-100</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awr038</ELocationID><Abstract><AbstractText>While considerable effort has focused on developing positron emission tomography &#x3b2;-amyloid imaging radiotracers for the early diagnosis of Alzheimer's disease, no radiotracer is available for the non-invasive quantification of tau. In this study, we detail the characterization of (18)F-THK523 as a novel tau imaging radiotracer. In vitro binding studies demonstrated that (18)F-THK523 binds with higher affinity to a greater number of binding sites on recombinant tau (K18&#x394;280K) compared with &#x3b2;-amyloid(1-42) fibrils. Autoradiographic and histofluorescence analysis of human hippocampal serial sections with Alzheimer's disease exhibited positive THK523 binding that co-localized with immunoreactive tau pathology, but failed to highlight &#x3b2;-amyloid plaques. Micro-positron emission tomography analysis demonstrated significantly higher retention of (18)F-THK523 (48%; P&#x2009;&lt;&#x2009;0.007) in tau transgenic mice brains compared with their wild-type littermates or APP/PS1 mice. The preclinical examination of THK523 has demonstrated its high affinity and selectivity for tau pathology both in vitro and in vivo, indicating that (18)F-THK523 fulfils ligand criteria for human imaging trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fodero-Tavoletti</LastName><ForeName>Michelle T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Pathology, The University of Melbourne, Victoria, 3010, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okamura</LastName><ForeName>Nobuyuki</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Furumoto</LastName><ForeName>Shozo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mulligan</LastName><ForeName>Rachel S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Connor</LastName><ForeName>Andrea R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Catriona A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Diana</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rigopoulos</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cartwright</LastName><ForeName>Glenn A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Graeme</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Adlard</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Barnham</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>Yukitsuka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cappai</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C559040">2-(4-aminophenyl)-6-(2-fluoroethoxy)quinoline</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011804">Quinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001345" MajorTopicYN="N">Autoradiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011804" MajorTopicYN="N">Quinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21436112</ArticleId><ArticleId IdType="doi">10.1093/brain/awr038</ArticleId><ArticleId IdType="pii">awr038</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22133718</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>111</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Testing the right target and right drug at the right stage.</ArticleTitle><Pagination><StartPage>111cm33</StartPage><MedlinePgn>111cm33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3002609</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the only leading cause of death for which no disease-modifying therapy is currently available. Recent disappointing trial results at the dementia stage of AD have raised multiple questions about our current approaches to the development of disease-modifying agents. Converging evidence suggests that the pathophysiological process of AD begins many years before the onset of dementia. So why do we keep testing drugs aimed at the initial stages of the disease process in patients at the end-stage of the illness?</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02446, USA. reisa@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22133718</ArticleId><ArticleId IdType="mid">NIHMS479558</ArticleId><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3002609</ArticleId><ArticleId IdType="pii">3/111/111cm33</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17:1060&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900936</ArticleId></ArticleIdList></Reference><Reference><Citation>Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, Glodzik-Sobanska L, De Santi S, Zinkowski R, Mehta P, Pratico D, Saint Louis LA, Wallin A, Blennow K, de Leon MJ. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30:682&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774781</ArticleId><ArticleId IdType="pubmed">17889968</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Langstrom B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, De-Kosky ST. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR., Jr MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology. 2009;73:287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715210</ArticleId><ArticleId IdType="pubmed">19636048</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer'sdisease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol. 2010;68:825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC. An operational approach to NIA-AA criteria for preclinical Alzheimer's disease. Annals of Neurology. 2011 e-pub.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15:169&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">12584433</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Darby DG, Brodtmann A, Pietrzak RH, Fredrickson J, Woodward M, Villemagne VL, Fredrickson A, Maruff P, Rowe C. Episodic Memory Decline Predicts Cortical Amyloid Status in Community-Dwelling Older Adults. J Alzheimers Dis. 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">21876253</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, Ackermann U, Jones G, Szoeke C, Salvado O, Martins R, O'Keefe G, Mathis CA, Klunk WE, Ames D, Masters CL, Rowe CC. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, Klunk WE, Ashford E, Yoo K, Xu ZX, Loetscher H, Santarelli L. Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Arch Neurol. 2011</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D, Seubert P, Schenk D, Holmes C. Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tauaggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol. 2011;68:1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18587388</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4469</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>8</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature chemical biology</Title><ISOAbbreviation>Nat Chem Biol</ISOAbbreviation></Journal><ArticleTitle>A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.</ArticleTitle><Pagination><StartPage>483</StartPage><EndPage>490</EndPage><MedlinePgn>483-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchembio.96</ELocationID><Abstract><AbstractText>Pathological hyperphosphorylation of the microtubule-associated protein tau is characteristic of Alzheimer's disease (AD) and the associated tauopathies. The reciprocal relationship between phosphorylation and O-GlcNAc modification of tau and reductions in O-GlcNAc levels on tau in AD brain offers motivation for the generation of potent and selective inhibitors that can effectively enhance O-GlcNAc in vertebrate brain. We describe the rational design and synthesis of such an inhibitor (thiamet-G, K(i) = 21 nM; 1) of human O-GlcNAcase. Thiamet-G decreased phosphorylation of tau in PC-12 cells at pathologically relevant sites including Thr231 and Ser396. Thiamet-G also efficiently reduced phosphorylation of tau at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus, which reveals the rapid and dynamic relationship between O-GlcNAc and phosphorylation of tau in vivo. We anticipate that thiamet-G will find wide use in probing the functional role of O-GlcNAc in vertebrate brain, and it may also offer a route to blocking pathological hyperphosphorylation of tau in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yuzwa</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Molecular Biology and Biochemistry, Simon Fraser University, 8888 University Drive, Burnaby, British Columbia V5A 1S6, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macauley</LastName><ForeName>Matthew S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Heinonen</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Rebecca J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Whitworth</LastName><ForeName>Garrett E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Stubbs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>McEachern</LastName><ForeName>Ernest J</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Gideon J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Vocadlo</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>2VVN</AccessionNumber></AccessionNumberList></DataBank><DataBank><DataBankName>PubChem-Substance</DataBankName><AccessionNumberList><AccessionNumber>49754855</AccessionNumber><AccessionNumber>49754856</AccessionNumber><AccessionNumber>49754857</AccessionNumber><AccessionNumber>49754858</AccessionNumber><AccessionNumber>49754859</AccessionNumber><AccessionNumber>49754860</AccessionNumber><AccessionNumber>49754861</AccessionNumber><AccessionNumber>49754862</AccessionNumber><AccessionNumber>49754863</AccessionNumber><AccessionNumber>49754864</AccessionNumber><AccessionNumber>49754865</AccessionNumber><AccessionNumber>49754866</AccessionNumber><AccessionNumber>49754867</AccessionNumber><AccessionNumber>49754868</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>BB/F007124/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Chem Biol</MedlineTA><NlmUniqueID>101231976</NlmUniqueID><ISSNLinking>1552-4450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.50</RegistryNumber><NameOfSubstance UI="C110628">hexosaminidase C</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.52</RegistryNumber><NameOfSubstance UI="D001619">beta-N-Acetylhexosaminidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Chem Biol. 2008 Aug;4(8):448-9. doi: 10.1038/nchembio0808-448.</RefSource><PMID Version="1">18641620</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001619" MajorTopicYN="N">beta-N-Acetylhexosaminidases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18587388</ArticleId><ArticleId IdType="doi">10.1038/nchembio.96</ArticleId><ArticleId IdType="pii">nchembio.96</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16624948</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>16</Issue><PubDate><Year>2006</Year><Month>Apr</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system.</ArticleTitle><Pagination><StartPage>4277</StartPage><EndPage>4288</EndPage><MedlinePgn>4277-88</MedlinePgn></Pagination><Abstract><AbstractText>Increasing evidence links intraneuronal beta-amyloid (Abeta42) accumulation with the pathogenesis of Alzheimer's disease (AD). In Abeta precursor protein (APP) mutant transgenic mice and in human AD brain, progressive intraneuronal accumulation of Abeta42 occurs especially in multivesicular bodies (MVBs). We hypothesized that this impairs the MVB sorting pathway. We used the trafficking of the epidermal growth factor receptor (EGFR) and TrkB receptor to investigate the MVB sorting pathway in cultured neurons. We report that, during EGF stimulation, APP mutant neurons demonstrated impaired inactivation, degradation, and ubiquitination of EGFR. EGFR degradation is dependent on translocation from MVB outer to inner membranes, which is regulated by the ubiquitin-proteasome system (UPS). We provide evidence that Abeta accumulation in APP mutant neurons inhibits the activities of the proteasome and deubiquitinating enzymes. These data suggest a mechanism whereby Abeta accumulation in neurons impairs the MVB sorting pathway via the UPS in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Claudia G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Reisuke H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>Gunnar K</ForeName><Initials>GK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS045677</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061988">Proteasome Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>62229-50-9</RegistryNumber><NameOfSubstance UI="D004815">Epidermal Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.25.1</RegistryNumber><NameOfSubstance UI="D046988">Proteasome Endopeptidase Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004815" MajorTopicYN="N">Epidermal Growth Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046988" MajorTopicYN="N">Proteasome Endopeptidase Complex</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061988" MajorTopicYN="Y">Proteasome Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16624948</ArticleId><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5078-05.2006</ArticleId><ArticleId IdType="pii">26/16/4277</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK (2005). Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan HA, van Zoelen EJ, van Leeuwen JE (2003). Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 278:35781&#x2013;35790.</Citation><ArticleIdList><ArticleId IdType="pubmed">12829707</ArticleId></ArticleIdList></Reference><Reference><Citation>Babst M (2005). A protein&#x2019;s final ESCRT. Traffic 6:2&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15569240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE (2005). The genetic epidemiology of neurodegenerative disease. J Clin Invest 115:1449&#x2013;1457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137006</ArticleId><ArticleId IdType="pubmed">15931380</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C, Ramasamy K, Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker KD, Blacker D, Tanzi RE (2005). Family-based association between Alzheimer&#x2019;s disease and variants in UBQLN1. N Engl J Med 352:884&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">15745979</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard V, Moussaoui S, Czech C, Touchet N, Bonici B, Planche M, Canton T, Jedidi I, Gohin M, Wirths O, Bayer TA, Langui D, Duyckaerts C, Tremp G, Pradier L (2003). Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 184:247&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">14637096</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000). Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Christoforidis S, McBride HM, Burgoyne RD, Zerial M (1999). The Rab5 effector EEA1 is a core component of endosome docking. Nature 397:621&#x2013;625.</Citation><ArticleIdList><ArticleId IdType="pubmed">10050856</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung CH, Baek SH (1999). Deubiquitinating enzymes: their diversity and emerging roles. Biochem Biophys Res Commun 266:633&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">10603300</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001). Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer&#x2019;s disease. Histopathology 38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang LC, Melandri FD, Stein RL (1998). Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 37:1868&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">9485312</ArticleId></ArticleIdList></Reference><Reference><Citation>d&#x2019;Azzo A, Bongiovanni A, Nastasi T (2005). E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic 6:429&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pubmed">15882441</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong J, Chen W, Welford A, Wandinger-Ness A (2004). The proteasome alpha-subunit XAPC7 interacts specifically with Rab7 and late endosomes. J Biol Chem 279:21334&#x2013;21342.</Citation><ArticleIdList><ArticleId IdType="pubmed">14998988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD (2003). Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 6:231&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577062</ArticleId></ArticleIdList></Reference><Reference><Citation>Futter CE, Pearse A, Hewlett LJ, Hopkins CR (1996). Multivesicular endosomes containing internalized EGF-EGF receptor complexes mature and then fuse directly with lysosomes. J Cell Biol 132:1011&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120766</ArticleId><ArticleId IdType="pubmed">8601581</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000). Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Almeida CG, Takahashi RH (2005). Intraneuronal Abeta accumulation and origin of plaques in Alzheimer&#x2019;s disease. Neurobiol Aging 26:1235&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023263</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE, Goldgaber D (1995). Amyloid beta-protein inhibits ubiquitin-dependent protein degradation in vitro. J Biol Chem 270:19702&#x2013;19708.</Citation><ArticleIdList><ArticleId IdType="pubmed">7649980</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregori L, Hainfeld JF, Simon MN, Goldgaber D (1997). Binding of amyloid beta protein to the 20 S proteasome. J Biol Chem 272:58&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8995227</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenberg J (2001). The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol 2:721&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584299</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruenberg J, Stenmark H (2004). The biogenesis of multivesicular endosomes. Nat Rev Mol Cell Biol 5:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">15071556</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC (2001). Intraneuronal Abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125:489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">11260621</ArticleId></ArticleIdList></Reference><Reference><Citation>Haglund K, Di Fiore PP, Dikic I (2003). Distinct monoubiquitin signals in receptor endocytosis. Trends Biochem Sci 28:598&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">14607090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW (2000). Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer&#x2019;s disease beta-secretase. J Biol Chem 275:33729&#x2013;33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin LW, Maezawa I, Vincent I, Bird T (2004). Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. Am J Pathol 164:975&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1614713</ArticleId><ArticleId IdType="pubmed">14982851</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB (2001). Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzmann DJ, Odorizzi G, Emr SD (2002). Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 3:893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">12461556</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Hanni KB, Markesbery WR (2000). Impaired proteasome function in Alzheimer&#x2019;s disease. J Neurochem 75:436&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pubmed">10854289</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleijnen MF, Alarcon RM, Howley PM (2003). The ubiquitin-associated domain of hPLIC-2 interacts with the proteasome. Mol Biol Cell 14:3868&#x2013;3875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC196580</ArticleId><ArticleId IdType="pubmed">12972570</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Squazzo SL (1994). Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 269:17386&#x2013;17389.</Citation><ArticleIdList><ArticleId IdType="pubmed">8021238</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, Level AI (1997). Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci 17:1971&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793763</ArticleId><ArticleId IdType="pubmed">9045726</ArticleId></ArticleIdList></Reference><Reference><Citation>Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C (2004). Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol 165:1465&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618656</ArticleId><ArticleId IdType="pubmed">15509518</ArticleId></ArticleIdList></Reference><Reference><Citation>Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH (2002). Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156:843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173306</ArticleId><ArticleId IdType="pubmed">11864992</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Salon M, Pasquini L, Besio MM, Pasquini JM, Soto E (2003). Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 180:131&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12684027</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuo H, Chevallier J, Mayran N, Le Blanc I, Ferguson C, Faure J, Blanc NS, Matile S, Dubochet J, Sadoul R, Parton RG, Vilbois F, Gruenberg J (2004). Role of LBPA and Alix in multivesicular liposome formation and endosome organization. Science 303:531&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">14739459</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner TA, Lee A, Aicher SA, Rosin DL (1998). Hippocampal alpha2a-adrenergic receptors are located predominantly presynaptically but are also found postsynaptically and in selective astrocytes. J Comp Neurol 395:310&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA (2002). Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9:88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S, Ghosh RN, Maxfield FR (1997). Endocytosis. Physiol Rev 77:759&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">9234965</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA (2005). Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol Aging 26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ, Mook-Jung I (2005). Amyloid peptide attenuates the proteasome activity in neuronal cells. Mech Ageing Dev 126:1292&#x2013;1299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, Miyoshi K, Yamada T, Kikuchi H, Taniwaki T, Murai H, Ikezoe K, Furuya H, Kawarabayashi T, Shoji M, Checler F, Iwaki T, Makifuchi T, Takeda K, Kira J, Tabira T (2005). Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer&#x2019;s disease. FASEB J 19:255&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">15548589</ArticleId></ArticleIdList></Reference><Reference><Citation>Parton RG, Dotti CG (1993). Cell biology of neuronal endocytosis. J Neurosci Res 36:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7693962</ArticleId></ArticleIdList></Reference><Reference><Citation>Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T (2002). Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22:1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pubmed">11880497</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell NS, Wilkinson KD (2005). Deubiquitinating enzyme purification, assay inhibitors, and characterization. Methods Mol Biol 301:207&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15917634</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, Parkinson NJ, Brown JM, Chakrabarti L, Lloyd SL, Hummerich H, Nielsen JE, Hodges JR, Spillantini MG, Thusgaard T, Brandner S, Brun A, Rossor MN, Gade A, Johannsen P, Sorensen SA, Gydesen S, Fisher EM, Collinge J (2005). Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat Genet 37:806&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">16041373</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P (2005). Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorkin A, von Zastrow M (2002). Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 3:600&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154371</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002). Intraneuronal Alzheimer Abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK (2004). Oligomerization of Alzheimer&#x2019;s &#x3b2;-amyloid within processes and synapses of cultured neurons and brain. J Neurosci 24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez G, Akmentin W, Philippidou P, Kuruvilla R, Ginty DD, Halegoua S (2005). Pincher-mediated macroendocytosis underlies retrograde signaling by neurotrophin receptors. J Neurosci 25:5236&#x2013;5247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724820</ArticleId><ArticleId IdType="pubmed">15917464</ArticleId></ArticleIdList></Reference><Reference><Citation>van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neubauer A, Sonnemans MA, Sluijs JA, Koycu S, Ramdjielal RD, Salehi A, Martens GJ, Grosveld FG, Peter J, Burbach H, Hol EM (1998). Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer&#x2019;s and Down patients. Science 279:242&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pubmed">9422699</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999). Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G (2005). Spatial segregation of &#x3b3;-secretase and substrates in distinct membrane domains. J Biol Chem 280:25892&#x2013;25900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201532</ArticleId><ArticleId IdType="pubmed">15886206</ArticleId></ArticleIdList></Reference><Reference><Citation>Weible MW, Hendry IA (2004). What is the importance of multivesicular bodies in retrograde axonal transport in vivo? J Neurobiol 58:230&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">14704955</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki T, Koo EH, Selkoe DJ (1996). Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. J Cell Sci 109:999&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">8743947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, Heavens RP, Dawson GR, Boyce S, Conner MW, Stevens KA, Slunt HH, Sisoda SS, Chen HY, Van Der Ploeg LH (1995). beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81:525&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17553422</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Jun</Month><Day>07</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity.</ArticleTitle><Pagination><StartPage>721</StartPage><EndPage>737</EndPage><MedlinePgn>721-37</MedlinePgn></Pagination><Abstract><AbstractText>Beta-site APP-cleaving enzyme (BACE) is required for production of the Alzheimer's disease (AD)-associated Abeta protein. BACE levels are elevated in AD brain, and increasing evidence reveals BACE as a stress-related protease that is upregulated following cerebral ischemia. However, the molecular mechanism responsible is unknown. We show that increases in BACE and beta-secretase activity are due to posttranslational stabilization following caspase activation. We also found that during cerebral ischemia, levels of GGA3, an adaptor protein involved in BACE trafficking, are reduced, while BACE levels are increased. RNAi silencing of GGA3 also elevated levels of BACE and Abeta. Finally, in AD brain samples, GGA3 protein levels were significantly decreased and inversely correlated with increased levels of BACE. In summary, we have elucidated a GGA3-dependent mechanism regulating BACE levels and beta-secretase activity. This mechanism may explain increased cerebral levels of BACE and Abeta following cerebral ischemia and existing in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tesco</LastName><ForeName>Giuseppina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Genetics and Aging Research Unit, Massachusetts General Hospital, Charlestown, MA 02129, USA. tescog@helix.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Young Ho</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Eugene L</ForeName><Initials>EL</Initials></Author><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>Andrew N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Shinjita</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sena-Esteves</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hiltunen</LastName><ForeName>Mikko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shao-Hua</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Simpkins</LastName><ForeName>James W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 MH060009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025888</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01AG025952</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025952</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033016</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R37MH60009</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1K12MH069281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 MH069281</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C407306">GGA adaptor proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020727">ADP-Ribosylation Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Jun 7;54(5):671-3. doi: 10.1016/j.neuron.2007.05.018.</RefSource><PMID Version="1">17553417</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D020727" MajorTopicYN="N">ADP-Ribosylation Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002545" MajorTopicYN="N">Brain Ischemia</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17553422</ArticleId><ArticleId IdType="mid">NIHMS25291</ArticleId><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.05.012</ArticleId><ArticleId IdType="pii">S0896-6273(07)00346-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe K, Tanzi RE, Kogure K. Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett. 1991;125:172&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">1908958</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasko I, Beer R, Bigl M, Apelt J, Franz G, Rudzki D, Ransmayr G, Kampfl A, Schliebs R. Experimental traumatic brain injury in rats stimulates the expression, production and activity of Alzheimer's disease beta-secretase (BACE-1) J Neural Transm. 2004;111:523&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">15057522</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS. The GGA proteins: adaptors on the move. Nat Rev Mol Cell Biol. 2004;5:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">14708007</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino JS, Traub LM. Signals for sorting of transmembrane proteins to endosomes and lysosomes. Annu Rev Biochem. 2003;72:395&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12651740</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease--promise and challenge. Trends Pharmacol Sci. 2004;25:92&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102495</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113(Pt 11):1857&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">10806097</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999;97:395&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">10319819</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Chang WP, Koelsch G, Tang J. Memapsin 2 (beta-secretase) cytosolic domain binds to the VHS domains of GGA1 and GGA2: implications on the endocytosis mechanism of memapsin 2. FEBS Lett. 2002;524:183&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135764</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Li F, Chang WP, Tang J. GGA proteins mediate the recycling pathway of memapsin 2 (BACE) J Biol Chem 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">15615712</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Zhu G, Koelsch G, Rodgers KK, Zhang XC, Tang J. Biochemical and structural characterization of the interaction of memapsin 2 (beta-secretase) cytosolic domain with the VHS domain of GGA proteins. Biochemistry. 2003;42:12174&#x2013;12180.</Citation><ArticleIdList><ArticleId IdType="pubmed">14567678</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol. 2002;51:783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112088</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y, Mayeux R. Stroke and the risk of Alzheimer disease. Arch Neurol. 2003;60:1707&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676044</ArticleId></ArticleIdList></Reference><Reference><Citation>Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. The Alzheimer's disease beta-secretase. J Biol Chem. 2000;275:33729&#x2013;33737.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN. The role of cerebral ischemia in Alzheimer's disease. Neurobiol Aging. 2000;21:321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867217</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalaria RN, Bhatti SU, Palatinsky EA, Pennington DH, Shelton ER, Chan HW, Perry G, Lust WD. Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain. Neuroreport. 1993;4:211&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453062</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh YH, von Arnim CA, Hyman BT, Tanzi RE, Tesco G. BACE is degraded via the lysosomal pathway. J Biol Chem. 2005;280:32499&#x2013;32504.</Citation><ArticleIdList><ArticleId IdType="pubmed">16033761</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc A. Increased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci. 1995;15:7837&#x2013;7846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577962</ArticleId><ArticleId IdType="pubmed">8613723</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem. 1999;274:23426&#x2013;23436.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438520</ArticleId></ArticleIdList></Reference><Reference><Citation>LeBlanc AC. The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res. 2005;2:389&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">16248844</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2004a;101:3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Namura S, Zhu J, Fink K, Endres M, Srinivasan A, Tomaselli KJ, Yuan J, Moskowitz MA. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci. 1998;18:3659&#x2013;3668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793169</ArticleId><ArticleId IdType="pubmed">9570797</ArticleId></ArticleIdList></Reference><Reference><Citation>Puertollano R, Bonifacino JS. Interactions of GGA3 with the ubiquitin sorting machinery. Nat Cell Biol. 2004;6:244&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">15039775</ArticleId></ArticleIdList></Reference><Reference><Citation>Puertollano R, Randazzo PA, Presley JF, Hartnell LM, Bonifacino JS. The GGAs promote ARF-dependent recruitment of clathrin to the TGN. Cell. 2001;105:93&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">11301005</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing H, Zhou W, Christensen MA, Sun X, Tong Y, Song W. Degradation of BACE by the ubiquitin-proteasome pathway. Faseb J 2004</Citation><ArticleIdList><ArticleId IdType="pubmed">15289451</ArticleId></ArticleIdList></Reference><Reference><Citation>Rippon GA, Tang MX, Lee JH, Lantigua R, Medrano M, Mayeux R. Familial Alzheimer disease in Latinos: interaction between APOE, stroke, and estrogen replacement. Neurology. 2006;66:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639210</ArticleId><ArticleId IdType="pubmed">16401842</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiba T, Kametaka S, Kawasaki M, Shibata M, Waguri S, Uchiyama Y, Wakatsuki S. Insights into the phosphoregulation of beta-secretase sorting signal by the VHS domain of GGA1. Traffic. 2004;5:437&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">15117318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama. 1997;277:813&#x2013;817. see comments.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052711</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, Koh YH, Tanzi RE. Caspase activation increases beta-amyloid generation independently of caspase cleavage of the beta-amyloid precursor protein (APP) J Biol Chem. 2003;278:46074&#x2013;46080.</Citation><ArticleIdList><ArticleId IdType="pubmed">12960154</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Velliquette RA, O'Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. J Neurosci. 2005;25:10874&#x2013;10883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725876</ArticleId><ArticleId IdType="pubmed">16306400</ArticleId></ArticleIdList></Reference><Reference><Citation>von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A, Hyman BT. Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci. 2004;117:5437&#x2013;5445.</Citation><ArticleIdList><ArticleId IdType="pubmed">15466887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahle T, Prager K, Raffler N, Haass C, Famulok M, Walter J. GGA proteins regulate retrograde transport of BACE1 from endosomes to the trans-Golgi network. Mol Cell Neurosci. 2005;29:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15886016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Onyewuchi O, Yang S, Liu R, Simpkins JW. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 2004;1009:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15120577</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature. 1999;402:533&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV. Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets. Adv Drug Deliv Rev. 2002;54:1553&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pubmed">12453672</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21841800</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>477</Volume><Issue>7362</Issue><PubDate><Year>2011</Year><Month>Aug</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>&#x3b1;-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation.</ArticleTitle><Pagination><StartPage>107</StartPage><EndPage>110</EndPage><MedlinePgn>107-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10324</ELocationID><Abstract><AbstractText>Parkinson's disease is the second most common neurodegenerative disorder. Growing evidence indicates a causative role of misfolded forms of the protein &#x3b1;-synuclein in the pathogenesis of Parkinson's disease. Intraneuronal aggregates of &#x3b1;-synuclein occur in Lewy bodies and Lewy neurites, the cytopathological hallmarks of Parkinson's disease and related disorders called synucleinopathies. &#x3b1;-Synuclein has long been defined as a 'natively unfolded' monomer of about 14&#x2009;kDa (ref. 6) that is believed to acquire &#x3b1;-helical secondary structure only upon binding to lipid vesicles. This concept derives from the widespread use of recombinant bacterial expression protocols for in vitro studies, and of overexpression, sample heating and/or denaturing gels for cell culture and tissue studies. In contrast, we report that endogenous &#x3b1;-synuclein isolated and analysed under non-denaturing conditions from neuronal and non-neuronal cell lines, brain tissue and living human cells occurs in large part as a folded tetramer of about 58&#x2009;kDa. Several methods, including analytical ultracentrifugation, scanning transmission electron microscopy and in vitro cell crosslinking confirmed the occurrence of the tetramer. Native, cell-derived &#x3b1;-synuclein showed &#x3b1;-helical structure without lipid addition and had much greater lipid-binding capacity than the recombinant &#x3b1;-synuclein studied heretofore. Whereas recombinantly expressed monomers readily aggregated into amyloid-like fibrils in vitro, native human tetramers underwent little or no amyloid-like aggregation. On the basis of these findings, we propose that destabilization of the helically folded tetramer precedes &#x3b1;-synuclein misfolding and aggregation in Parkinson's disease and other human synucleinopathies, and that small molecules that stabilize the physiological tetramer could reduce &#x3b1;-synuclein pathogenicity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Joanna G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS038375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051318</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS051318</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS038375</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Sep 02;12(10):550. doi: 10.1038/nrn3106.</RefSource><PMID Version="1">21886184</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2011 Nov;26(13):2324. doi: 10.1002/mds.24009.</RefSource><PMID Version="1">22319787</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2013 Jun 13;498(7453):E4-6; discussion E6-7. doi: 10.1038/nature12125.</RefSource><PMID Version="1">23765500</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019556" MajorTopicYN="N">COS Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050356" MajorTopicYN="N">Lipid Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21841800</ArticleId><ArticleId IdType="mid">NIHMS313099</ArticleId><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="doi">10.1038/nature10324</ArticleId><ArticleId IdType="pii">nature10324</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Obeso JA, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med. 2010;16:653&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">20495568</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Dawson VL, Dawson TM. What causes cell death in Parkinson's disease? Annals of Neurology. 2008;64:S3&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4118469</ArticleId><ArticleId IdType="pubmed">19127586</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. The EMBO Journal. 2008;27:336&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="pubmed">18216876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J, et al. Brain {alpha}-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain. 2010;133:172&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">19903734</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PTJ. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35:13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. The Journal of biological chemistry. 1998;273:9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>DeTure M, et al. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions. Brain Res. 2000;853:5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10627302</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:10907&#x2013;10912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504800</ArticleId><ArticleId IdType="pubmed">18669654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittig I, Schagger H. Advantages and limitations of clear-native PAGE. PROTEOMICS. 2005;5:4338&#x2013;4346.</Citation><ArticleIdList><ArticleId IdType="pubmed">16220535</ArticleId></ArticleIdList></Reference><Reference><Citation>Osenkowski P, et al. Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution. Journal of molecular biology. 2009;385:642&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830092</ArticleId><ArticleId IdType="pubmed">19013469</ArticleId></ArticleIdList></Reference><Reference><Citation>Wall JS, Simon MN, Lin BY, Vinogradov SN. Mass mapping of large globin complexes by scanning transmission electron microscopy. Methods Enzymol. 2008;436:487&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">18237650</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyer K. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane. Cell Biochem Biophys. 2007;47:285&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">17652776</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Yang JT, Martinez HM. Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion. Biochemistry. 2002;11:4120&#x2013;4131.</Citation><ArticleIdList><ArticleId IdType="pubmed">4343790</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon R, et al. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:9110&#x2013;9115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC55381</ArticleId><ArticleId IdType="pubmed">11481478</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen PS, Toribara TY, Warner H. Microdetermination of Phosphorus. Analytical Chemistry. 1956;28:1756&#x2013;1758.</Citation></Reference><Reference><Citation>Ko LW, Ko HH, Lin WL, Kulathingal JG, Yen SH. Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol. 2008;67:1084&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768257</ArticleId><ArticleId IdType="pubmed">18957893</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean PJ, Kawamata H, Ribich S, Hyman BT. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. The Journal of biological chemistry. 2000;275:8812&#x2013;8816.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722726</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DP, et al. Formation of a High Affinity Lipid-Binding Intermediate during the Early Aggregation Phase of alpha-Synuclein. Biochemistry. 2008;47:1425&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">18179253</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. The Parkinson disease-associated protein alpha-synuclein is folded in solution. Proceedings of the National Academy of Sciences of the United States of America</Citation></Reference><Reference><Citation>Tsika E, et al. Distinct Region-Specific {alpha}-Synuclein Oligomers in A53T Transgenic Mice: Implications for Neurodegeneration. Journal of Neuroscience. 2010;30:3409&#x2013;3418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844128</ArticleId><ArticleId IdType="pubmed">20203200</ArticleId></ArticleIdList></Reference><Reference><Citation>Klucken J, Outeiro TF, Nguyen P, McLean PJ, Hyman BT. Detection of novel intracellular alpha-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 2006;20:2050&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012257</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintas A, Saraiva MJM, Brito RMM. The Tetrameric Protein Transthyretin Dissociates to a Non-native Monomer in Solution. The Journal of biological chemistry. 1999;274:32943&#x2013;32949.</Citation><ArticleIdList><ArticleId IdType="pubmed">10551861</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current Opinion in Structural Biology. 2010;20:54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830738</ArticleId><ArticleId IdType="pubmed">20133122</ArticleId></ArticleIdList></Reference><Reference><Citation>Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774&#x2013;779.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051203</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19433664</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.</ArticleTitle><Pagination><StartPage>638</StartPage><EndPage>645</EndPage><MedlinePgn>638-45</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2009.55</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cerebrospinal fluid (CSF) levels of Abeta peptide 1-42 (Abeta 42), tau, and phosphorylated tau (ptau) are potential biomarkers of Alzheimer disease.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether Abeta 42, tau, and ptau predict the rate of cognitive change in individuals with very mild dementia of the Alzheimer type (DAT).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective analysis of CSF biomarkers and clinical data.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">An academic Alzheimer disease research center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Research volunteers in a longitudinal study of aging and cognition. Participants (n = 49) had a clinical diagnosis of very mild DAT with a Clinical Dementia Rating (CDR) of 0.5 at the time of lumbar puncture. All the participants had at least 1 follow-up assessment (mean [SD] follow-up, 3.5 [1.8] years).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Baseline CSF levels of Abeta 42, Abeta 40, tau, and ptau at threonine 181 (ptau181) and the rate of dementia progression as measured using the CDR sum of boxes (CDR-SB) score and psychometric performance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of dementia progression was significantly more rapid in individuals with lower baseline CSF Abeta 42 levels, higher tau or ptau181 levels, or high tau: Abeta 42 ratios. For example, the annual change in the CDR-SB score was 1.1 for the lowest 2 tertiles of Abeta 42 values and 0.3 for the highest tertile of Abeta 42 values.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In individuals with very mild DAT, lower CSF Abeta 42 levels, high tau or ptau181 levels, or high tau:Abeta 42 ratios quantitatively predict more rapid progression of cognitive deficits and dementia. Biomarkers of CSF may be useful prognostically and to identify individuals who are more likely to progress for participation in therapeutic clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snider</LastName><ForeName>Barbara J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Campus Box 8111, 660 S Euclid, St Louis, MO 63110, USA. sniderj@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19433664</ArticleId><ArticleId IdType="mid">NIHMS105370</ArticleId><ArticleId IdType="pmc">PMC2759394</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2009.55</ArticleId><ArticleId IdType="pii">66/5/638</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hogervorst E, Bandelow S, Combrinck M, Irani SR, Smith AD. The validity and reliability of 6 sets of clinical criteria to classify Alzheimer's disease and vascular dementia in cases confirmed post-mortem: added value of a decision tree approach. Dement Geriatr Cogn Disord. 2003;16(3):170&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">12826744</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranginwala NA, Hynan LS, Weiner MF, White CL., 3rd. Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry. 2008;16(5):384&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18448850</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Hindley NJ, et al. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Disord. 1998;9(4):219&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9681644</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2(10):605&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Blennow K. CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clin Neurol Neurosurg. 2005;107(3):165&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Linker G, Mirza N, et al. Decreased &#x3b2;-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. Journal of the American Medical Association. 2003;289(16):2094&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A42 in humans. Ann Neurol. 2006;59(3):512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41(7):1006&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2067629</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5(3):228&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, et al. CSF tau/A&#x3b2;42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67(3):467&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol. 1992;31(3):242&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637132</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin EH, Storandt M, Miller JP, et al. A prospective study of cognitive function and onset of dementia in cognitively healthy elders. Arch Neurol. 1998;55(3):395&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520014</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr., Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55(3):326&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58(3):397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324367</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, et al. In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-&#x3b2; Metabolism and Half-Life. J. Neurosci. 2003;23(26):8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer's disease using the CSF A&#x3b2;42/A&#x3b2;40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007;23(5):316&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">17374949</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging. 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">17646035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF &#x3b2;-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9(7):705&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">14699432</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF A&#x3b2;42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64(7):1294&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824371</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59(4):627&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196665</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Andreasen N, et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology. 2005;65(9):1502&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">16275849</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Sleegers K, Cras P, et al. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain. 2007;130(Pt 9):2320&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">17586559</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002;59(7):1034&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370458</ArticleId></ArticleIdList></Reference><Reference><Citation>Barten DM, Guss VL, Corsa JA, et al. Dynamics of &#x3b2;-amyloid reductions in brain, cerebrospinal fluid, and plasma of &#x3b2;-amyloid precursor protein transgenic mice treated with a &#x3b3;-secretase inhibitor. J Pharmacol Exp Ther. 2005;312(2):635&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452193</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Minthon L, et al. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci Lett. 2007;419(1):18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Pedersen M, Lind K, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis. 2007;12(3):255&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057559</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A&#x3b2;1-40, and A&#x3b2;1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol. 1998;44(1):17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9667589</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid &#x3b2;-amyloid1-42 in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56(6):673&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollenhauer B, Bibl M, Trenkwalder C, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm. 2005;112(7):933&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sluimer JD, Bouwman FH, Vrenken H, et al. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. Neurobiol Aging. 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18692273</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Zhu K, Yu K, Miller JP. Statistical Modeling in Biomedical Research: Longitudinal Data Analys. In: Rao DR, Miller JP, Rao DC, editors. Epidemiology and Medical Statistics. 27 vol. Elsevier; Amsterdam, The Netherlands: 2008.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16120771</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>34</Issue><PubDate><Year>2005</Year><Month>Aug</Month><Day>24</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.</ArticleTitle><Pagination><StartPage>7709</StartPage><EndPage>7717</EndPage><MedlinePgn>7709-17</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease (AD) and antecedent factors associated with AD were explored using amyloid imaging and unbiased measures of longitudinal atrophy in combination with reanalysis of previous metabolic and functional studies. In total, data from 764 participants were compared across five in vivo imaging methods. Convergence of effects was seen in posterior cortical regions, including posterior cingulate, retrosplenial, and lateral parietal cortex. These regions were active in default states in young adults and also showed amyloid deposition in older adults with AD. At early stages of AD progression, prominent atrophy and metabolic abnormalities emerged in these posterior cortical regions; atrophy in medial temporal regions was also observed. Event-related functional magnetic resonance imaging studies further revealed that these cortical regions are active during successful memory retrieval in young adults. One possibility is that lifetime cerebral metabolism associated with regionally specific default activity predisposes cortical regions to AD-related changes, including amyloid deposition, metabolic disruption, and atrophy. These cortical regions may be part of a network with the medial temporal lobe whose disruption contributes to memory impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Washington University School of Medicine, St. Louis, Missouri 63105, USA. rbuckner@artsci.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snyder</LastName><ForeName>Abraham Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Benjamin J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>LaRossa</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>Rimmon</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fotenos</LastName><ForeName>Anthony F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Sheline</LastName><ForeName>Yvette I</ForeName><Initials>YI</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>2</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16120771</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pii">25/34/7709</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Watkins GL, Ponto LL, Hichwa RD (1995) Remembering the past: two facets of episodic memory explored with positron emission tomography. Am J Psychiatry 152: 1576-1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">7485619</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel Jr DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM (1998) Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55: 326-335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Black KJ, Snyder AZ, Koller JM, Gado MH, Perlmutter JS (2001a) Template images for nonhuman primate neuroimaging. I. Baboon. NeuroImage 14: 736-743.</Citation><ArticleIdList><ArticleId IdType="pubmed">11506545</ArticleId></ArticleIdList></Reference><Reference><Citation>Black KJ, Koller JM, Snyder AZ, Perlmutter JS (2001b) Template images for nonhuman primate neuroimaging. II. Macaque. NeuroImage 14: 744-748.</Citation><ArticleIdList><ArticleId IdType="pubmed">11506546</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E (1997) Staging of Alzheimer-related cortical destruction. Int Psychogeriatr 9 [Suppl 1]: 257-261.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447446</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL (2004) Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44: 195-208.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450170</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Wheeler ME (2001) The cognitive neuroscience of remembering. Nat Rev Neurosci 2: 624-634.</Citation><ArticleIdList><ArticleId IdType="pubmed">11533730</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Head D, Parker J, Fotenos A, Marcus D, Morris JC, Snyder AZ (2004) A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. NeuroImage 23: 724-738.</Citation><ArticleIdList><ArticleId IdType="pubmed">15488422</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton H, Abend NS, MacLeod AM, Sinclair RJ, Snyder AZ, Raichle ME (1999) Tactile attention tasks enhance activation in somatosensory regions of parietal cortex: a positron emission tomography study. Cereb Cortex 9: 662-674.</Citation><ArticleIdList><ArticleId IdType="pubmed">10554989</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen GE, Rabbitt RD, Miller MI (1996) Deformable templates using large deformation kinematics. IEEE Trans. Image Processing 5: 1435-1447.</Citation><ArticleIdList><ArticleId IdType="pubmed">18290061</ArticleId></ArticleIdList></Reference><Reference><Citation>Christoff K, Ream JM, Gabrieli JDE (2004) Neural basis of spontaneous thought processes. Cortex 40: 623-630.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505972</ArticleId></ArticleIdList></Reference><Reference><Citation>Donaldson DI, Petersen SE, Buckner RL (2001) Dissociating memory retrieval processes using fMRI: evidence that priming does not support recognition memory. Neuron 31: 1047-1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">11580903</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR (1975) &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Snyder AZ, Girton LE, Morris JC, Buckner RL (2005) Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Neurology 64: 1032-1039.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781822</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Rossor MN (1999) Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet 353: 2125.</Citation><ArticleIdList><ArticleId IdType="pubmed">10382699</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN (2001) Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 358: 201-205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeborough PA, Woods RP, Fox NC (1996) Accurate registration of serial 3D MR brain images and its application to visualizing change in neuro-degenerative disorders. J Comput Assist Tomogr 20: 1012-1022.</Citation><ArticleIdList><ArticleId IdType="pubmed">8933812</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE (1983) Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 7: 590-598.</Citation><ArticleIdList><ArticleId IdType="pubmed">6602819</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 16: 4491-4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Menon V (2004) Default-mode activity during a passive sensory task: uncoupled from deactivation but impacting activation. J Cogn Neurosci 16: 1484-1492.</Citation><ArticleIdList><ArticleId IdType="pubmed">15601513</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V (2003) Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA 100: 253-258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V (2004) Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA 101: 4637-4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME (2001) Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci 2: 685-694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Heilman KM, Gonzalez Rothi LJ (1993) Apraxia. In: Clinical neuropsychology, Ed 3 (Heilman KM, Valenstein E, eds), pp 141-163. New York: Oxford UP.</Citation></Reference><Reference><Citation>Henson RN, Rugg MD, Shallice T, Josephs O, Dolan RJ (1999) Recollection and familiarity in recognition memory: an event-related functional magnetic resonance imaging study. J Neurosci 19: 3962-3972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782715</ArticleId><ArticleId IdType="pubmed">10234026</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K (1995) FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord 9: 6-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605624</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron, JC, Holthoff V, Fr&#xf6;lich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, et al. (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 17: 302-316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225: 1168-1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR (1990) Memory-related neural systems in Alzheimer's disease: an anatomic study. Neurology 40: 1721-1730.</Citation><ArticleIdList><ArticleId IdType="pubmed">2234428</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingvar DH (1985) &#x201c;Memory of the future&#x201d;: an essay on the temporal organization of conscious awareness. Hum Neurobiol 4: 127-136.</Citation><ArticleIdList><ArticleId IdType="pubmed">3905726</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R, Amaral DG, Cowan WM (1987) The entorhinal cortex of the monkey. II. Cortical afferents. J Comp Neurol 264: 356-395.</Citation><ArticleIdList><ArticleId IdType="pubmed">2445796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii K, Willoch F, Minoshima S, Drzezga A, Ficaro EP, Cross DJ, Kuhl DE, Schwaiger M (2001) Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 42: 548-557.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack Jr CR, Petersen RC (2000) Structural imaging approaches to Alzheimer's disease. In: Early diagnosis and treatment of Alzheimer's disease (Scinto LFM, Daffner KR, eds), pp 127-148. Totowa, NJ: Human.</Citation></Reference><Reference><Citation>Jack Jr CR, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Cha RH, Tangalos EG, Petersen RC, (2004) Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62: 591-600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730165</ArticleId><ArticleId IdType="pubmed">14981176</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R (2003) APP processing and synaptic function. Neuron 37: 925-937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42: 1097-1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Hyman BT, G&#xf3;mez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS (2002) MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58: 1188-1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA (2001) Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69: 1471-1484.</Citation><ArticleIdList><ArticleId IdType="pubmed">11554609</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Longstr&#xf6;m B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburg Compound-B. Ann Neurol 55: 306-319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Amaral DG (2003) Macaque monkey retrosplenial cortex. II. cortical afferents. J Comp Neurol 466: 48-79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14515240</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi S, Wheeler ME, Donaldson DI, Buckner RL (2000) Neural correlates of episodic retrieval success. NeuroImage 12: 276-286.</Citation><ArticleIdList><ArticleId IdType="pubmed">10944410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kung MP, Hou C, Zhuang ZP, Zhang B, Skovronsky D, Trojanowski JQ, Lee VM, Kung HF (2002) IMPY: an improved thioflavin-T derivative for in vivo labeling of beta-amyloid plaques. Brain Res 956: 202-210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445687</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JSK, Hinrichs AL, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Gogic G, Chan J, Cravchik A, Ross D, Lau K, Kwok S, Chang SY, et al. (2004) Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci USA 101: 15688-15693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524264</ArticleId><ArticleId IdType="pubmed">15507493</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL (2003) Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci USA 100: 14504-14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12: 295-298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazoyer B, Zago L, Mellet E, Bricogne S, Etard O, Houd&#xe9; O, Crivello F, Joliot M, Petit L, Tzourio-Mazoyer N (2001) Cortical networks for working memory and executive functions sustain the conscious resting state in man. Brain Res Bull 54: 287-298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287133</ArticleId></ArticleIdList></Reference><Reference><Citation>McKiernan KA, Kaufman JN, Kucera-Thompson J, Binder JR (2003) A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging. J Cogn Neurosci 15: 394-408.</Citation><ArticleIdList><ArticleId IdType="pubmed">12729491</ArticleId></ArticleIdList></Reference><Reference><Citation>Meguro K, Blaizot X, Kondoh Y, Le Mestric C, Baron JC, Chavoix C (1999) Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain 122: 1519-1531.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430835</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM (1999) Spatial attention and neglect: parietal, frontal, and cingulated contributions to the mental representation and attentional targeting of salient extrapersonal events. Philos Trans R Soc Lond B Biol Sci 354: 1325-1346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1692628</ArticleId><ArticleId IdType="pubmed">10466154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM (2000) A plasticity-based theory of the pathogenesis of Alzheimer's disease. Ann NY Acad Sci 924: 42-52.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193801</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MI (2004) Computational anatomy: shape, growth, and atrophy comparison via diffeomorphisms. NeuroImage 23: 19-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15501089</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD). II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 41: 479-486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43: 2412-2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58: 397-405.</Citation><ArticleIdList><ArticleId IdType="pubmed">11255443</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R, Petrides M, Pandya DN (1999) Architecture and connections of retrosplenial area 30 in the rhesus monkey (Macaca mulatta). Eur J Neurosci 11: 2506-2518.</Citation><ArticleIdList><ArticleId IdType="pubmed">10383640</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18: S1-S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Farber SA, Growdon JH, Wurtman RJ (1993) Release of amyloid &#x3b2;-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci USA 90: 5191-5193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46681</ArticleId><ArticleId IdType="pubmed">8506366</ArticleId></ArticleIdList></Reference><Reference><Citation>Perani D, Cappa SF (2001) Brain imaging in normal aging and dementia. In: Handbook of neuropsychology, Vol 6, Aging and dementia (Boller F, Cappa S, eds), pp 429-452. Amsterdam: Elsevier.</Citation></Reference><Reference><Citation>Pluim JP, Maintz JB, Viergever MA (2000) Image registration by maximization of combined mutual information and gradient information. IEEE Trans Med Imaging 19: 809-814.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055805</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques, and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 12: 295-312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001) A default mode of brain function. Proc Natl Acad Sci USA 98: 676-682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Redwine JM, Kosofsky B, Jacobs RE, Games D, Reilly JF, Morrison JH, Young WG, Bloom FE (2003) Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and sterologic analysis. Proc Natl Acad Sci USA 100: 1381-1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298781</ArticleId><ArticleId IdType="pubmed">12552120</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for epsilon 4 allele for apolipoprotein E. N Engl J Med 334: 752-758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci USA 101: 284-289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC (2002) Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 99: 4703-4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon BJ, Buckner RL (2004) Functional-anatomic correlates of memory retrieval that suggest nontraditional processing roles for multiple distinct regions within posterior parietal cortex. J Neurosci 24: 10084-10092.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730171</ArticleId><ArticleId IdType="pubmed">15537877</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10: 24-35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790632</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Corbetta M, Buckner RL, Fiez JA, Miezin FM, Raichle ME, Petersen SE (1997a) Common blood flow changes across visual tasks: I. Increases in subcortical structures and cerebellum but not in nonvisual cortex. J Cogn Neurosci 9: 624-647.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965121</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Fiez JA, Corbetta M, Buckner RL, Miezin FM, Raichle ME, Petersen SE (1997b) Common blood flow changes across visual tasks: II. Decreases in cerebral cortex. J Cogn Neurosci 9: 648-663.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965122</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowdon DA, Kemper SJ, Mortimer JA, Greiner LH, Wekstein DR, Markesbery WR (1996) Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. J Am Med Assoc 275: 528-532.</Citation><ArticleIdList><ArticleId IdType="pubmed">8606473</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki WA, Amaral DG (1994) Perirhinal and parahippocampal cortices of the macaque monkey: cortical afferents. J Comp Neurol 350: 497-533.</Citation><ArticleIdList><ArticleId IdType="pubmed">7890828</ArticleId></ArticleIdList></Reference><Reference><Citation>Talairach J, Tournoux P (1988) Co-planar stereotaxic atlas of the human brain. Stuttgart, Germany: Thieme Medical Publishers.</Citation></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW (2003) Dynamics of gray matter loss in Alzheimer's disease. J Neurosci 23: 994-1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenstein E, Bowers D, Verfaellie M, Heilman KM, Day A, Watson RT (1987) Retrosplenial amnesia. Brain 110: 1631-1646.</Citation><ArticleIdList><ArticleId IdType="pubmed">3427404</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Essen DC, Drury HA, Dickson J, Harwell J, Hanlon D, Anderson CH (2001) An integrated software suite for surface-based analyses of cerebral cortex. J Am Med Inform Assoc 8: 443-459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC131042</ArticleId><ArticleId IdType="pubmed">11522765</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt BA, Finch DM, Olson CR (1992) Functional heterogeneity in cingulate cortex: the anterior executive and posterior evaluative regions. Cereb Cortex 2: 435-443.</Citation><ArticleIdList><ArticleId IdType="pubmed">1477524</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, Shannon BJ, Kahn I, Buckner RL (2005) Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci, in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054861</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler ME, Buckner RL (2004) Functional-anatomic correlates of remembering and knowing. NeuroImage 21: 1337-1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19211893</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1860</StartPage><EndPage>1873</EndPage><MedlinePgn>1860-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5062-08.2009</ELocationID><Abstract><AbstractText>Recent evidence suggests that some brain areas act as hubs interconnecting distinct, functionally specialized systems. These nexuses are intriguing because of their potential role in integration and also because they may augment metabolic cascades relevant to brain disease. To identify regions of high connectivity in the human cerebral cortex, we applied a computationally efficient approach to map the degree of intrinsic functional connectivity across the brain. Analysis of two separate functional magnetic resonance imaging datasets (each n = 24) demonstrated hubs throughout heteromodal areas of association cortex. Prominent hubs were located within posterior cingulate, lateral temporal, lateral parietal, and medial/lateral prefrontal cortices. Network analysis revealed that many, but not all, hubs were located within regions previously implicated as components of the default network. A third dataset (n = 12) demonstrated that the locations of hubs were present across passive and active task states, suggesting that they reflect a stable property of cortical network architecture. To obtain an accurate reference map, data were combined across 127 participants to yield a consensus estimate of cortical hubs. Using this consensus estimate, we explored whether the topography of hubs could explain the pattern of vulnerability in Alzheimer's disease (AD) because some models suggest that regions of high activity and metabolism accelerate pathology. Positron emission tomography amyloid imaging in AD (n = 10) compared with older controls (n = 29) showed high amyloid-beta deposition in the locations of cortical hubs consistent with the possibility that hubs, while acting as critical way stations for information processing, may also augment the underlying pathological cascade in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Psychology and Center for Brain Science, Harvard University, Cambridge, Massachusetts 02138, USA. randy_buckner@harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sepulcre</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Talukdar</LastName><ForeName>Tanveer</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Krienen</LastName><ForeName>Fenna M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hesheng</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Andrews-Hanna</LastName><ForeName>Jessica R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-021910</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021910</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG-027435-S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19211893</ArticleId><ArticleId IdType="mid">NIHMS93863</ArticleId><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5062-08.2009</ArticleId><ArticleId IdType="pii">29/6/1860</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Achard S, Salvador R, Whitcher B, Suckling J, Bullmore E. A resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. J Neurosci. 2006;26:63&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674299</ArticleId><ArticleId IdType="pubmed">16399673</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen G, McColl R, Barnard H, Ringe WK, Fleckenstein J, Cullum CM. Magnetic resonance imaging of cerebellar-prefrontal and cerebellar-parietal functional connectivity. Neuroimage. 2005;28:39&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16023375</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen NC, O'Leary DS, Cizadlo T, Arndt S, Rezai K, Watkins GL, Ponto LL, Hichwa RD. Remembering the past: two facets of episodic memory explored with positron emission tomography. Am J Psychiatry. 1995;152:1576&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pubmed">7485619</ArticleId></ArticleIdList></Reference><Reference><Citation>Antrobus JS. Information theory and stimulus-independent thought. Br J Psychol. 1968;59:423&#x2013;430.</Citation></Reference><Reference><Citation>Antrobus JS, Singer JL, Greenberg S. Studies in the stream of consciousness: experimental enhancement and suppression of spontaneous cognitive processes. Percept Motor Skills. 1966;23:399&#x2013;417.</Citation></Reference><Reference><Citation>Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, Greenberg SM, Hyman BT, Growdon JH. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64:431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels A, Zeki S. The chronoarchitecture of the cerebral cortex. Philos Trans R Soc Lond B Biol Sci. 2005;360:733&#x2013;750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569482</ArticleId><ArticleId IdType="pubmed">15937010</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DS, Bullmore E. Small-world brain networks. Neuroscientist. 2006;12:512&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">17079517</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder JR, Frost JA, Hammeke TA, Bellgowan PS, Rao SM, Cox RW. Conceptual processing during the conscious resting state a functional MRI study. J Cogn Neurosci. 1999;11:80&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9950716</ArticleId></ArticleIdList></Reference><Reference><Citation>Birn RM, Diamond JB, Smith MA, Bandettini PA. Separating respiratory-variation-related fluctuations from neuronal-activity-related fluctuations in fMRI. Neuroimage. 2006;31:1536&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16632379</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">8524021</ArticleId></ArticleIdList></Reference><Reference><Citation>Brainard DH. The psychophysics toolbox. Spat Vis. 1997;10:433&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">9176952</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-&#x3b2; dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Carroll DC. Self-projection and the brain. Trends Cogn Sci. 2007;11:49&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188554</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Demb JB, Desmond JE, Wagner AD, Vaidya CJ, Glover GH, Gabrieli JD. Semantic encoding and retrieval in the left inferior prefrontal cortex: a functional MRI study of task difficulty and process specificity. J Neurosci. 1995;15:5870&#x2013;5878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577672</ArticleId><ArticleId IdType="pubmed">7666172</ArticleId></ArticleIdList></Reference><Reference><Citation>De Nooy W, Mrvar A, Batageli V. Exploratory network analysis with Pajek. New York: Cambridge UP; 2005.</Citation></Reference><Reference><Citation>D'Esposito M, Zarahn E, Aguirre GK, Shin RK, Auerbach P, Detre JA. The effect of pacing of experimental stimuli on observed functional MRI activity. Neuroimage. 1997;6:113&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">9299385</ArticleId></ArticleIdList></Reference><Reference><Citation>Dosenbach NU, Fair DA, Miezin FM, Cohen AL, Wenger KK, Dosenbach RA, Fox MD, Snyder AZ, Vincent JL, Raichle ME, Schlaggar BL, Petersen SE. Distinct brain networks for adaptive and stable task control in humans. Proc Natl Acad Sci U S A. 2007;104:11073&#x2013;11078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904171</ArticleId><ArticleId IdType="pubmed">17576922</ArticleId></ArticleIdList></Reference><Reference><Citation>Felleman DJ, Van Essen DC. Distributed hierarchical processing in the primate cerebral cortex. Cereb Cortex. 1991;1:1&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">1822724</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman LC. A set of measures of centrality based on betweenness. Sociometry. 1977;1:35&#x2013;41.</Citation></Reference><Reference><Citation>Freeman LC. Centrality in social networks: conceptual clarification. Soc Networks. 1978;1:215&#x2013;239.</Citation></Reference><Reference><Citation>Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P. Spontaneous low-frequency BOLD signal fluctuations: an fMRI investigation of the resting-state default mode of brain function hypothesis. Hum Brain Mapp. 2005;26:15&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871700</ArticleId><ArticleId IdType="pubmed">15852468</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P. How default is the default mode of brain function? Further evidence from intrinsic BOLD signal fluctuations. Neuropsychologia. 2006;44:2836&#x2013;2845.</Citation><ArticleIdList><ArticleId IdType="pubmed">16879844</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default network: evidence from a partial correlation network analysis. Neuroimage. 2008;42:1178&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">18598773</ArticleId></ArticleIdList></Reference><Reference><Citation>Girvan M, Newman MEJ. Community structure in social and biological networks. Proc Natl Acad Sci U S A. 2002;99:7821&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122977</ArticleId><ArticleId IdType="pubmed">12060727</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, Hyman BT, Growdon JH, Johnson KA. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637553</ArticleId><ArticleId IdType="pubmed">18794492</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong G, He Y, Concha L, Lebel C, Gross DW, Evans AC, Beaulieu C. Mapping anatomical connectivity patterns of human cerebral cortex using in vivo diffusion tensor imaging tractography. Cereb Cortex. 2008 doi: 10.1093/cercor/bhn102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhn102</ArticleId><ArticleId IdType="pmc">PMC2722790</ArticleId><ArticleId IdType="pubmed">18567609</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009;19:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimer&#xe0; R, Sales-Pardo M, Amaral LA. Classes of complex networks defined by role-to-role connectivity profiles. Nat Phys. 2007;3:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447920</ArticleId><ArticleId IdType="pubmed">18618010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2:685&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of the human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassabis D, Maguire EA. Deconstructing episodic memory with construction. Trends Cogn Sci. 2007;11:299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548229</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K. FDG PET and differential diagnosis of dementia. Alzheimer Dis Assoc Disord. 1995;9:6&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones EG, Powell TP. An anatomical study of converging sensory pathways within the cerebral cortex of the monkey. Brain. 1970;93:793&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">4992433</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn I, Andrews-Hanna JR, Vincent JL, Snyder AZ, Buckner RL. Distinct cortical anatomy linked to subregions of the medial temporal lobe revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493488</ArticleId><ArticleId IdType="pubmed">18385483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamada K, Kawai S. An algorithm for drawing general undirected graphs. Inf Process Lett. 1989;31:7&#x2013;15.</Citation></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly RM, Strick PL. Cerebellar loops with motor cortex and prefrontal cortex of a nonhuman primate. J Neurosci. 2003;23:8432&#x2013;8444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740694</ArticleId><ArticleId IdType="pubmed">12968006</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Nowotny P, Holmans P, Smemo S, Kauwe JS, Hinrichs AL, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Schrodi S, Leong D, Gogic G, Chan J, Cravchik A, Ross D, Lau K, Kwok S, Chang SY, et al. Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A. 2004;101:15688&#x2013;15693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524264</ArticleId><ArticleId IdType="pubmed">15507493</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(&#x2212;)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384545</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe MJ, Mock BJ, Sorenson JA. Functional connectivity in single and multislice echoplanar imaging using resting-state fluctuations. Neuroimage. 1998;7:119&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558644</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem. 2003;46:2740&#x2013;2754.</Citation><ArticleIdList><ArticleId IdType="pubmed">12801237</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazoyer B, Zago L, Mellet E, Bricogne S, Etard O, Houd&#xe9; O, Crivello F, Joliot M, Petit L, Tzourio-Mazoyer N. Cortical networks for working memory and executive functions sustain the conscious resting state in man. Brain Res Bull. 2001;54:287&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287133</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. From sensation to cognition. Brain. 1998;121:1013&#x2013;1052.</Citation><ArticleIdList><ArticleId IdType="pubmed">9648540</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006a;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Sacco D, Snyder AZ, Couture L, Powers WJ, Hornbeck R, Videen TO, McGee-Minnich L, Perlmutter JS, Mach RH, Morris JC, Raichle ME. Distribution of glycolysis in the resting healthy human brain correlates with distribution of &#x3b2;-amyloid plaques in Alzheimer's disease. Soc Neurosci Abstr. 2006b;32 707.6.</Citation></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K, Birn RM, Handwerker DA, Jones TB, Bandettini PA. The impact of global signal regression on resting state correlations: are anti-correlated networks introduced? Neuroimage. 2009;44:893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750906</ArticleId><ArticleId IdType="pubmed">18976716</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Farber SA, Growdon JH, Wurtman RJ. Release of amyloid-&#x3b2; protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci U S A. 1993;90:5191&#x2013;5193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46681</ArticleId><ArticleId IdType="pubmed">8506366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandya DN, Kuypers HG. Cortico-cortico connections in the rhesus monkey. Brain Res. 1969;13:13&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">4185124</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvador R, Mart&#xed;nez A, Pomarol-Clotet E, Gomar J, Vila F, Sarr&#xf3; S, Capdevila A, Bullmore E. A simple view of the brain through a frequency-specific functional connectivity measure. Neuroimage. 2008;39:279&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">17919927</ArticleId></ArticleIdList></Reference><Reference><Citation>Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99:4703&#x2013;4707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123711</ArticleId><ArticleId IdType="pubmed">11930016</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacter DL, Addis DR, Buckner RL. Remembering the past to imagine the future: the prospective brain. Nat Rev Neurosci. 2007;8:657&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">17700624</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. The ups and downs of Abeta. Nat Med. 2006;12:758&#x2013;759. discussion 759.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829932</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon BJ, Snyder AZ, Vincent JL, Buckner RL. Spontaneous correlations and the default network: effects of task performance. Soc Neurosci Abstr. 2006;32 119.5.</Citation></Reference><Reference><Citation>Shulman GL, Fiez JA, Corbetta M, Buckner RL, Miezin FM, Raichle ME, Petersen SE. Common blood flow changes across visual tasks. II. Decreases in cerebral cortex. J Cogn Neurosci. 1997;9:648&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, Edelman GM. Theoretical neuroanatomy: relating anatomical and functional connectivity in graphs and cortical connection matricies. Cereb Cortex. 2000;10:127&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Chialvo DR, Kaiser M, Hilgetag CC. Organization, development and function of complex brain networks. Trends Cogn Sci. 2004;8:418&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pubmed">15350243</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Honey CJ, K&#xf6;tter R. Identification and classification of hubs in brain networks. PLoS ONE. 2007;2:e1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2013941</ArticleId><ArticleId IdType="pubmed">17940613</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreng RN, Mar RA, Kim AS. The common neural basis of autobiographical memory, prospection, navigation, theory of mind and the default mode: a quantitative meta-analysis. J Cogn Neurosci. 2008 doi: 10.1162/jocn.2008.21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/jocn.2008.21029</ArticleId><ArticleId IdType="pubmed">18510452</ArticleId></ArticleIdList></Reference><Reference><Citation>St George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Alzheimer's disease? Lancet. 2008;372:180&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640437</ArticleId></ArticleIdList></Reference><Reference><Citation>Svoboda E, McKinnon MC, Levine B. The functional neuroanatomy of autobiographical memory: a meta-analysis. Neuropsychologia. 2006;44:2189&#x2013;2208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995661</ArticleId><ArticleId IdType="pubmed">16806314</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer SS, Doddrell DM, Toga AW. Dynamics of gray matter loss in Alzheimer's disease. J Neurosci. 2003;23:994&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741905</ArticleId><ArticleId IdType="pubmed">12574429</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerleider LG, Mishkin M. Two cortical visual systems. In: Ingle DJ, Goodale MA, Mansfield RJW, editors. Analysis of visual behavior. Cambridge, MA: MIT; 1982. pp. 549&#x2013;586.</Citation></Reference><Reference><Citation>Van Essen DC. A population-average, landmark- and surface-based (PALS) atlas of human cerebral cortex. Neuroimage. 2005;28:635&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16172003</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Patel GH, Fox MD, Snyder AZ, Baker JT, Van Essen DC, Zempel JM, Snyder LH, Corbetta M, Raichle ME. Intrinsic functional architecture in the anaesthetized monkey brain. Nature. 2007;447:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476267</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Kahn I, Snyder AZ, Raichle ME, Buckner RL. Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:3328&#x2013;3342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604839</ArticleId><ArticleId IdType="pubmed">18799601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, Schacter DL, Rotte M, Koutstaal W, Maril A, Dale AM, Rosen BR, Buckner RL. Building memories: remembering and forgetting of verbal experiences as predicted by brain activity. Science. 1998;281:1188&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9712582</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasserman S, Faust K. Social network analysis: methods and applications. New York: Cambridge UP; 1994.</Citation></Reference><Reference><Citation>Watts DJ, Strogatz SH. Collective dynamics of &#x201c;small-world&#x201d; networks. Nature. 1998;393:440&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">9623998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise RG, Ide K, Poulin MJ, Tracey I. Resting fluctuations in arterial carbon dioxide induce significant low frequency variations in BOLD signal. Neuroimage. 2004;21:1652&#x2013;1664.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao F, Zhao T, Zhou L, Wu Q, Hu X. BOLD study of stimulation-induced neural activity and resting-state connectivity in medetomide-sedated rat. Neuroimage. 2008;39:248&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2137163</ArticleId><ArticleId IdType="pubmed">17904868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19376066</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Neurodegenerative diseases target large-scale human brain networks.</ArticleTitle><Pagination><StartPage>42</StartPage><EndPage>52</EndPage><MedlinePgn>42-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2009.03.024</ELocationID><Abstract><AbstractText>During development, the healthy human brain constructs a host of large-scale, distributed, function-critical neural networks. Neurodegenerative diseases have been thought to target these systems, but this hypothesis has not been systematically tested in living humans. We used network-sensitive neuroimaging methods to show that five different neurodegenerative syndromes cause circumscribed atrophy within five distinct, healthy, human intrinsic functional connectivity networks. We further discovered a direct link between intrinsic connectivity and gray matter structure. Across healthy individuals, nodes within each functional network exhibited tightly correlated gray matter volumes. The findings suggest that human neural networks can be defined by synchronous baseline activity, a unified corticotrophic fate, and selective vulnerability to neurodegenerative illness. Future studies may clarify how these complex systems are assembled during development and undermined by disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Memory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA. wseeley@memory.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crawford</LastName><ForeName>Richard K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Greicius</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS048302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23NS048302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG027086</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG19724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG1657303-75271</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2009 Apr 16;62(1):1-3. doi: 10.1016/j.neuron.2009.04.001.</RefSource><PMID Version="1">19376059</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19376066</ArticleId><ArticleId IdType="mid">NIHMS112073</ArticleId><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2009.03.024</ArticleId><ArticleId IdType="pii">S0896-6273(09)00249-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity using independent component analysis. Philos Trans R Soc Lond B Biol Sci. 2005;360:1001&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1854918</ArticleId><ArticleId IdType="pubmed">16087444</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi G, Poo M. Distributed synaptic modification in neural networks induced by patterned stimulation. Nature. 1999;401:792&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">10548104</ArticleId></ArticleIdList></Reference><Reference><Citation>Boccardi M, Sabattoli F, Laakso MP, Testa C, Rossi R, Beltramello A, Soininen H, Frisoni GB. Frontotemporal dementia as a neural system disease. Neurobiol Aging. 2005;26:37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">15585344</ArticleId></ArticleIdList></Reference><Reference><Citation>Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF, Miller BL, Weiner MW, Rosen HJ. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol. 2006;63:81&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401739</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambati SM, Rankin KP, Narvid J, Seeley WW, Dean D, Rosen HJ, Miller BL, Ashburner J, Gorno-Tempini ML. Atrophy progression in semantic dementia with asymmetric temporal involvement: A tensor-based morphometry study. Neurobiol Aging 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643844</ArticleId><ArticleId IdType="pubmed">17604879</ArticleId></ArticleIdList></Reference><Reference><Citation>Brett M, Anton JL, Valabregue R, Poline JB. Region of interest analysis using an SPM toolbox [abstract]. Paper presented at: 8th International Conference on Functional Mapping of the Human Brain; Sendai, Japan. 2002.</Citation></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A. 2006;103:13848&#x2013;13853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564249</ArticleId><ArticleId IdType="pubmed">16945915</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca M, Beckmann CF, De Stefano N, Matthews PM, Smith SM. fMRI resting state networks define distinct modes of long-distance interactions in the human brain. Neuroimage. 2006;29:1359&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pubmed">16260155</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, Sperling RA. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Fair DA, Cohen AL, Dosenbach NU, Church JA, Miezin FM, Barch DM, Raichle ME, Petersen SE, Schlaggar BL. The maturing architecture of the brain's default network. Proc Natl Acad Sci U S A. 2008;105:4028&#x2013;4032.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268790</ArticleId><ArticleId IdType="pubmed">18322013</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">17704812</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Raichle ME. Intrinsic fluctuations within cortical systems account for intertrial variability in human behavior. Neuron. 2007;56:171&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17920023</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P. Spontaneous low-frequency BOLD signal fluctuations: an fMRI investigation of the resting-state default mode of brain function hypothesis. Hum Brain Mapp. 2005;26:15&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871700</ArticleId><ArticleId IdType="pubmed">15852468</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P. How default is the default mode of brain function? Further evidence from intrinsic BOLD signal fluctuations. Neuropsychologia. 2006;44:2836&#x2013;2845.</Citation><ArticleIdList><ArticleId IdType="pubmed">16879844</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type tau fibrils specified by templated conformation change. J Biol Chem 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Geschwind D, Robidoux J, Alarcon M, Miller B, Wilhelmsen K, Cummings J, Nasreddine Z. Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia. Ann Neurol. 2001;50:741&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">11761471</ArticleId></ArticleIdList></Reference><Reference><Citation>Glover GH, Lai S. Self-navigated spiral fMRI: interleaved versus single-shot. Magn Reson Med. 1998;39:361&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9498591</ArticleId></ArticleIdList></Reference><Reference><Citation>Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage. 2001;14:21&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">11525331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, Johnson JK, Weiner MW, Miller BL. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55:335&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2362399</ArticleId><ArticleId IdType="pubmed">14991811</ArticleId></ArticleIdList></Reference><Reference><Citation>Graveland GA, Williams RS, DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science. 1985;227:770&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">3155875</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-State Functional Connectivity Reflects Structural Connectivity in the Default Mode Network. Cereb Cortex 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Chen ZJ, Evans AC. Small-world anatomical networks in the human brain revealed by cortical thickness from MRI. Cereb Cortex. 2007;17:2407&#x2013;2419.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesselmann G, Kell CA, Eger E, Kleinschmidt A. Spontaneous local variations in ongoing neural activity bias perceptual decisions. Proc Natl Acad Sci U S A. 2008;105:10984&#x2013;10989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2504783</ArticleId><ArticleId IdType="pubmed">18664576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hof PR, Vogt BA, Bouras C, Morrison JH. Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res. 1997;37:3609&#x2013;3625.</Citation><ArticleIdList><ArticleId IdType="pubmed">9425534</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Damasio AR, Van Hoesen GW, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;298:83&#x2013;95.</Citation></Reference><Reference><Citation>Johnson JK, Diehl J, Mendez MF, Neuhaus J, Shapira JS, Forman M, Chute DJ, Roberson ED, Pace-Savitsky C, Neumann M, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005;62:925&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">15956163</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129:1385&#x2013;1398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748312</ArticleId><ArticleId IdType="pubmed">16613895</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Dickson DW, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Jack CR., Jr Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging. 2008;29:280&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702857</ArticleId><ArticleId IdType="pubmed">17097770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassubek J, Unrath A, Huppertz HJ, Lule D, Ethofer T, Sperfeld AD, Ludolph AC. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">16319024</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz LC, Shatz CJ. Synaptic activity and the construction of cortical circuits. Science. 1996;274:1133&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">8895456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly AM, Di Martino A, Uddin LQ, Shehzad Z, Gee DG, Reiss PT, Margulies DS, Castellanos FX, Milham MP. Development of Anterior Cingulate Functional Connectivity from Late Childhood to Early Adulthood. Cereb Cortex 2008</Citation><ArticleIdList><ArticleId IdType="pubmed">18653667</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Adalsteinsson E, Glover GH, Spielman S. SVD regularization algorithm for improved high-order shimming. Denver: 2000.</Citation></Reference><Reference><Citation>Lerch JP, Worsley K, Shaw WP, Greenstein DK, Lenroot RK, Giedd J, Evans AC. Mapping anatomical correlations across cerebral cortex (MACACC) using cortical thickness from MRI. Neuroimage. 2006;31:993&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">16624590</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Miller BL, Kramer JH, Rankin K, Wyss-Coray C, Gearhart R, Phengrasamy L, Weiner M, Rosen HJ. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology. 2004;62:742&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367136</ArticleId><ArticleId IdType="pubmed">15007124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe MJ, Mock BJ, Sorenson JA. Functional connectivity in single and multislice echoplanar imaging using resting-state fluctuations. Neuroimage. 1998;7:119&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558644</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire EA, Gadian DG, Johnsrude IS, Good CD, Ashburner J, Frackowiak RS, Frith CD. Navigation-related structural change in the hippocampi of taxi drivers. Proc Natl Acad Sci U S A. 2000;97:4398&#x2013;4403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18253</ArticleId><ArticleId IdType="pubmed">10716738</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A, Friston KJ, Frackowiak RS, Price CJ. Structural covariance in the human cortex. J Neurosci. 2005;25:8303&#x2013;8310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725541</ArticleId><ArticleId IdType="pubmed">16148238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM, Mufson EJ. Insula of the old world monkey. I. Architectonics in the insulo-orbito-temporal component of the paralimbic brain. J Comp Neurol. 1982;212:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">7174905</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojemann JG, Akbudak E, Snyder AZ, McKinstry RC, Raichle ME, Conturo TE. Anatomic localization and quantitative analysis of gradient refocused echo-planar fMRI susceptibility artifacts. Neuroimage. 1997;6:156&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">9344820</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Poline JB, Worsley KJ, Evans AC, Friston KJ. Combining spatial extent and peak intensity to test for activations in functional imaging. Neuroimage. 1997;5:83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9345540</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruthazer ES, Cline HT. Insights into activity-dependent map formation from the retinotectal system: a middle-of-the-brain perspective. J Neurobiol. 2004;59:134&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">15007832</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott JR, Davies D, Fraser H. Scrapie in the central nervous system: neuroanatomical spread of infection and Sinc control of pathogenesis. J Gen Virol. 1992;73(Pt 7):1637&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pubmed">1629695</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW. Selective functional, regional, and neuronal vulnerability in frontotemporal dementia. Curr Opin Neurol. 2008;21:701&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909835</ArticleId><ArticleId IdType="pubmed">18989116</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Bauer AM, Miller BL, Gorno-Tempini ML, Kramer JH, Weiner M, Rosen HJ. The natural history of temporal variant frontotemporal dementia. Neurology. 2005;64:1384&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2376750</ArticleId><ArticleId IdType="pubmed">15851728</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Carlin DA, Allman JM, Macedo MN, Bush C, Miller BL, Dearmond SJ. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol. 2006;60:660&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187353</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford R, Rascovsky K, Kramer JH, Weiner M, Miller BL, Gorno-Tempini ML. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol. 2008a;65:249&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544627</ArticleId><ArticleId IdType="pubmed">18268196</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Matthews BR, Crawford RK, Gorno-Tempini ML, Foti D, Mackenzie IR, Miller BL. Unravelling Bolero: progressive aphasia, transmodal creativity and the right posterior neocortex. Brain. 2008b;131:39&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057074</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, Reiss AL, Greicius MD. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27:2349&#x2013;2356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680293</ArticleId><ArticleId IdType="pubmed">17329432</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Senjem ML, Gunter JL, Shiung MM, Petersen RC, Jack CR., Jr Comparison of different methodological implementations of voxel-based morphometry in neurodegenerative disease. Neuroimage. 2005;26:600&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739382</ArticleId><ArticleId IdType="pubmed">15907317</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P, Lerch JP, Pruessner JC, Taylor KN, Rose AB, Greenstein D, Clasen L, Evans A, Rapoport JL, Giedd JN. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007;6:494&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">17509484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, Drzezga A, Forstl H, Kurz A, Zimmer C, Wohlschlager AM. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, Kotter R. The human connectome: a structural description of the human brain. PLoS Comput Biol. 2005;1:e42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239902</ArticleId><ArticleId IdType="pubmed">16201007</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark DE, Margulies DS, Shehzad ZE, Reiss P, Kelly AM, Uddin LQ, Gee DG, Roy AK, Banich MT, Castellanos FX, Milham MP. Regional variation in interhemispheric coordination of intrinsic hemodynamic fluctuations. J Neurosci. 2008;28:13754&#x2013;13764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4113425</ArticleId><ArticleId IdType="pubmed">19091966</ArticleId></ArticleIdList></Reference><Reference><Citation>Supekar K, Menon V, Rubin D, Musen M, Greicius MD. Network analysis of intrinsic functional brain connectivity in Alzheimer's disease. PLoS Comput Biol. 2008;4:e1000100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2435273</ArticleId><ArticleId IdType="pubmed">18584043</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel M, Mandl R, Hulshoff Pol H. Normalized cut group clustering of resting-state FMRI data. PLoS ONE. 2008;3:e2001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2291558</ArticleId><ArticleId IdType="pubmed">18431486</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Kahn I, Snyder AZ, Raichle ME, Buckner RL. Evidence for a frontoparietal control system revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:3328&#x2013;3342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604839</ArticleId><ArticleId IdType="pubmed">18799601</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Patel GH, Fox MD, Snyder AZ, Baker JT, Van Essen DC, Zempel JM, Snyder LH, Corbetta M, Raichle ME. Intrinsic functional architecture in the anaesthetized monkey brain. Nature. 2007;447:83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">17476267</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16364896</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo.</ArticleTitle><Pagination><StartPage>913</StartPage><EndPage>922</EndPage><MedlinePgn>913-22</MedlinePgn></Pagination><Abstract><AbstractText>Aggregation of the amyloid-beta (Abeta) peptide in the extracellular space of the brain is central to Alzheimer's disease pathogenesis. Abeta aggregation is concentration dependent and brain region specific. Utilizing in vivo microdialysis concurrently with field potential recordings, we demonstrate that Abeta levels in the brain interstitial fluid are dynamically and directly influenced by synaptic activity on a timescale of minutes to hours. Using an acute brain slice model, we show that the rapid effects of synaptic activity on Abeta levels are primarily related to synaptic vesicle exocytosis. These results suggest that synaptic activity may modulate a neurodegenerative disease process, in this case by influencing Abeta metabolism and ultimately region-specific Abeta deposition. The findings also have important implications for treatment development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kelvin A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Sloviter</LastName><ForeName>Robert S</ForeName><Initials>RS</Initials></Author><Author ValidYN="Y"><LastName>Bales</LastName><ForeName>Kelly R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>May</LastName><ForeName>Patrick C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Schoepp</LastName><ForeName>Darryle D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Steven M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Mennerick</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG11355</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA70261</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2005 Dec 22;48(6):873-5. doi: 10.1016/j.neuron.2005.12.005.</RefSource><PMID Version="1">16364890</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005089" MajorTopicYN="N">Exocytosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009924" MajorTopicYN="N">Organ Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019580" MajorTopicYN="N">Perforant Pathway</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pii">S0896-6273(05)00939-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19282288</PMID><DateCompleted><Year>2009</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>284</Volume><Issue>19</Issue><PubDate><Year>2009</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Propagation of tau misfolding from the outside to the inside of a cell.</ArticleTitle><Pagination><StartPage>12845</StartPage><EndPage>12852</EndPage><MedlinePgn>12845-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M808759200</ELocationID><Abstract><AbstractText>Tauopathies are neurodegenerative diseases characterized by aggregation of the microtubule-associated protein Tau in neurons and glia. Although Tau is normally considered an intracellular protein, Tau aggregates are observed in the extracellular space, and Tau peptide is readily detected in the cerebrospinal fluid of patients. Tau aggregation occurs in many diseases, including Alzheimer disease and frontotemporal dementia. Tau pathology begins in discrete, disease-specific regions but eventually involves much larger areas of the brain. It is unknown how this propagation of Tau misfolding occurs. We hypothesize that extracellular Tau aggregates can transmit a misfolded state from the outside to the inside of a cell, similar to prions. Here we show that extracellular Tau aggregates, but not monomer, are taken up by cultured cells. Internalized Tau aggregates displace tubulin, co-localize with dextran, a marker of fluid-phase endocytosis, and induce fibrillization of intracellular full-length Tau. These intracellular fibrils are competent to seed fibril formation of recombinant Tau monomer in vitro. Finally, we observed that newly aggregated intracellular Tau transfers between co-cultured cells. Our data indicate that Tau aggregates can propagate a fibrillar, misfolded state from the outside to the inside of a cell. This may have important implications for understanding how protein misfolding spreads through the brains of tauopathy patients, and it is potentially relevant to myriad neurodegenerative diseases associated with protein misfolding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Bess</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacks</LastName><ForeName>Rachel L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS50284-03</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003911">Dextrans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003911" MajorTopicYN="N">Dextrans</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042541" MajorTopicYN="N">Intracellular Space</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018625" MajorTopicYN="N">Microscopy, Atomic Force</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="Y">Protein Folding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>5</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19282288</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pii">S0021-9258(20)58284-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee, V. M., Goedert, M., and Trojanowski, J. Q. (2001) Annu. Rev. Neurosci. 24 1121-1159</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., Hackett, J., Adamson, J., Lincoln, S., Dickson, D., Davies, P., Petersen, R. C., Stevens, M., de Graaff, E., Wauters, E., van Baren, J., Hillebrand, M., Joosse, M., Kwon, J. M., Nowotny, P., Che, L. K., Norton, J., Morris, J. C., Reed, L. A., Trojanowski, J., Basun, H., Lannfelt, L., Neystat, M., Fahn, S., Dark, F., Tannenberg, T., Dodd, P. R., Hayward, N., Kwok, J. B., Schofield, P. R., Andreadis, A., Snowden, J., Craufurd, D., Neary, D., Owen, F., Oostra, B. A., Hardy, J., Goate, A., van Swieten, J., Mann, D., Lynch, T., and Heutink, P. (1998) Nature 393 702-705</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., and Schellenberg, G. D. (1998) Ann. Neurol. 43 815-825</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., and Ghetti, B. (1998) Proc. Natl. Acad. Sci. U. S. A. 95 7737-7741</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, W., Miller, B. L., Kramer, J. H., Rankin, K., Wyss-Coray, C., Gearhart, R., Phengrasamy, L., Weiner, M., and Rosen, H. J. (2004) Neurology 62 742-748</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367136</ArticleId><ArticleId IdType="pubmed">15007124</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H., and Braak, E. (1991) Acta Neuropathol. 82 239-259</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak, H., and Braak, E. (1997) Neurobiol. Aging 18 351-357</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte, A., David, J. P., Sergeant, N., Buee, L., Wattez, A., Vermersch, P., Ghozali, F., Fallet-Bianco, C., Pasquier, F., Lebert, F., Petit, H., and Di Menza, C. (1999) Neurology 52 1158-1165</Citation><ArticleIdList><ArticleId IdType="pubmed">10214737</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold, S. E., Hyman, B. T., Flory, J., Damasio, A. R., and Van Hoesen, G. W. (1991) Cereb. Cortex 1 103-116</Citation><ArticleIdList><ArticleId IdType="pubmed">1822725</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant, N., Wattez, A., and Delacourte, A. (1999) J. Neurochem. 72 1243-1249</Citation><ArticleIdList><ArticleId IdType="pubmed">10037497</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G. M., Cooper, N. R., Eikelenboom, P., Emmerling, M., Fiebich, B. L., Finch, C. E., Frautschy, S., Griffin, W. S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I. R., McGeer, P. L., O'Banion, M. K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F. L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Neurobiol. Aging 21 383-421</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte, A. (2005) Polish Acad. Sci. 43 244-257</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Ramos, A., Diaz-Hernandez, M., Cuadros, R., Hernandez, F., and Avila, J. (2006) FEBS Lett. 580 4842-4850</Citation><ArticleIdList><ArticleId IdType="pubmed">16914144</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Ramos, A., Diaz-Hernandez, M., Rubio, A., Miras-Portugal, M. T., and Avila, J. (2008) Mol. Cell. Neurosci. 37 673-681</Citation><ArticleIdList><ArticleId IdType="pubmed">18272392</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni, A. A., Boutajangout, A., Quartermain, D., and Sigurdsson, E. M. (2007) J. Neurosci. 27 9115-9129</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., and Kirschner, M. W. (1975) Proc. Natl. Acad. Sci. U. S. A. 72 1858-1862</Citation><ArticleIdList><ArticleId IdType="pmc">PMC432646</ArticleId><ArticleId IdType="pubmed">1057175</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandermeeren, M., Mercken, M., Vanmechelen, E., Six, J., van de Voorde, A., Martin, J. J., and Cras, P. (1993) J. Neurochem. 61 1828-1834</Citation><ArticleIdList><ArticleId IdType="pubmed">8228996</ArticleId></ArticleIdList></Reference><Reference><Citation>Endoh, R., Ogawara, M., Iwatsubo, T., Nakano, I., and Mori, H. (1993) Brain Res. 601 164-172</Citation><ArticleIdList><ArticleId IdType="pubmed">8431763</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert, M., and Jakes, R. (1990) EMBO J. 9 4225-4230</Citation><ArticleIdList><ArticleId IdType="pmc">PMC552204</ArticleId><ArticleId IdType="pubmed">2124967</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg, S. G., and Davies, P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87 5827-5831</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder, E. F., Snyder, E. Y., and Cepko, C. L. (1990) J. Neurobiol. 21 356-375</Citation><ArticleIdList><ArticleId IdType="pubmed">2307979</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek, B., Biernat, J., Baumann, K., Mandelkow, E. M., and Mandelkow, E. (1995) Mol. Biol. Cell 6 1887-1902</Citation><ArticleIdList><ArticleId IdType="pmc">PMC366657</ArticleId><ArticleId IdType="pubmed">8590813</ArticleId></ArticleIdList></Reference><Reference><Citation>King, M. E., Kan, H. M., Baas, P. W., Erisir, A., Glabe, C. G., and Bloom, G. S. (2006) J. Cell Biol. 175 541-546</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064590</ArticleId><ArticleId IdType="pubmed">17101697</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanu, N., Imokawa, Y., Drechsel, D. N., Williamson, R. A., Birkett, C. R., Bostock, C. J., and Brockes, J. P. (2002) Curr. Biol. 12 523-530</Citation><ArticleIdList><ArticleId IdType="pubmed">11937020</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, W., Dunlap, J. R., Andrews, R. B., and Wetzel, R. (2002) Hum. Mol. Genet. 11 2905-2917</Citation><ArticleIdList><ArticleId IdType="pubmed">12393802</ArticleId></ArticleIdList></Reference><Reference><Citation>Magalhaes, A. C., Baron, G. S., Lee, K. S., Steele-Mortimer, O., Dorward, D., Prado, M. A., and Caughey, B. (2005) J. Neurosci. 25 5207-5216</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724812</ArticleId><ArticleId IdType="pubmed">15917460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, P. H., Lauckner, J. E., Kachirskaia, I., Heuser, J. E., Melki, R., and Kopito, R. R. (2009) Nat. Cell Biol. 11 219-225</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757079</ArticleId><ArticleId IdType="pubmed">19151706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T. M., Milton, S. C., Hall, J. E., and Glabe, C. G. (2004) J. Biol. Chem. 279 46363-46366</Citation><ArticleIdList><ArticleId IdType="pubmed">15385542</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedhoff, P., von Bergen, M., Mandelkow, E. M., Davies, P., and Mandelkow, E. (1998) Proc. Natl. Acad. Sci. U. S. A. 95 15712-15717</Citation><ArticleIdList><ArticleId IdType="pmc">PMC28109</ArticleId><ArticleId IdType="pubmed">9861035</ArticleId></ArticleIdList></Reference><Reference><Citation>DePace, A. H., and Weissman, J. S. (2002) Nat. Struct. Biol. 9 389-396</Citation><ArticleIdList><ArticleId IdType="pubmed">11938354</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevrier, B., Vilette, D., Archer, F., Loew, D., Faigle, W., Vidal, M., Laude, H., and Raposo, G. (2004) Proc. Natl. Acad. Sci. U. S. A. 101 9683-9688</Citation><ArticleIdList><ArticleId IdType="pmc">PMC470735</ArticleId><ArticleId IdType="pubmed">15210972</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost, B., Ollesch, J., Wille, H., and Diamond, M. I. (2009) J. Biol. Chem. 284 3546-3551</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15748850</PMID><DateCompleted><Year>2005</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>5</Issue><PubDate><Year>2005</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.</ArticleTitle><Pagination><StartPage>753</StartPage><EndPage>764</EndPage><MedlinePgn>753-64</MedlinePgn></Pagination><Abstract><AbstractText>Fragile X syndrome is a leading heritable cause of mental retardation that results from the loss of FMR1 gene function. A Drosophila model for Fragile X syndrome, based on the loss of dfmr1 activity, exhibits phenotypes that bear similarity to Fragile X-related symptoms. Herein, we demonstrate that treatment with metabotropic glutamate receptor (mGluR) antagonists or lithium can rescue courtship and mushroom body defects observed in these flies. Furthermore, we demonstrate that dfmr1 mutants display cognitive deficits in experience-dependent modification of courtship behavior, and treatment with mGluR antagonists or lithium restores these memory defects. These findings implicate enhanced mGluR signaling as the underlying cause of the cognitive, as well as some of the behavioral and neuronal, phenotypes observed in the Drosophila Fragile X model. They also raise the possibility that compounds having similar effects on metabotropic glutamate receptors may ameliorate cognitive and behavioral defects observed in Fragile X patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McBride</LastName><ForeName>Sean M J</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Section of Molecular Cardiology, Department of Medicine, Medical Scientist Training Program, Albert Einstein College of Medicine, Bronx, NY 10461, USA. smcbride@aecom.yu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Catherine H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Liebelt</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Braunstein</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ferreiro</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sehgal</LastName><ForeName>Amita</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Siwicki</LastName><ForeName>Kathleen K</ForeName><Initials>KK</Initials></Author><Author ValidYN="Y"><LastName>Dockendorff</LastName><ForeName>Thomas C</ForeName><Initials>TC</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hanh T</ForeName><Initials>HT</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Thomas V</ForeName><Initials>TV</Initials></Author><Author ValidYN="Y"><LastName>Jongens</LastName><ForeName>Thomas A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2005 Mar 3;45(5):642-4. doi: 10.1016/j.neuron.2005.02.021.</RefSource><PMID Version="1">15748838</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003380" MajorTopicYN="Y">Courtship</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005600" MajorTopicYN="N">Fragile X Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024521" MajorTopicYN="N">Mushroom Bodies</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>4</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15748850</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2005.01.038</ArticleId><ArticleId IdType="pii">S0896-6273(05)00076-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20231471</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>14</Issue><PubDate><Year>2010</Year><Month>Apr</Month><Day>06</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6498</StartPage><EndPage>6503</EndPage><MedlinePgn>6498-503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1001422107</ELocationID><Abstract><AbstractText>Our previous analyses showed that allopregnanolone (APalpha) significantly increased proliferation of rodent and human neural progenitor cells in vitro. In this study, we investigated the efficacy of APalpha to promote neurogenesis in the hippocampal subgranular zone (SGZ), to reverse learning and memory deficits in 3-month-old male triple transgenic mouse model of Alzheimer's (3xTgAD) and the correlation between APalpha-induced neural progenitor cell survival and memory function in 3xTgAD mice. Neural progenitor cell proliferation was determined by unbiased stereological analysis of BrdU incorporation and survival determined by FACS for BrdU+ cells. Learning and memory function was assessed using the hippocampal-dependent trace eye-blink conditioning paradigm. At 3 months, basal level of BrdU+ cells in the SGZ of 3xTgAD mice was significantly lower relative to non-Tg mice, despite the lack of evident AD pathology. APalpha significantly increased, in a dose-dependent manner, BrdU+ cells in SGZ in 3xTgAD mice and restored SGZ proliferation to normal magnitude. As with the deficit in proliferation, 3xTgAD mice exhibited deficits in learning and memory. APalpha reversed the cognitive deficits to restore learning and memory performance to the level of normal non-Tg mice. In 3xTgAD mice, APalpha-induced survival of neural progenitors was significantly correlated with APalpha-induced memory performance. These findings suggest that early neurogenic deficits, which were evident before immunodetectable Abeta, may contribute to the cognitive phenotype of AD, and that APalpha could serve as a regenerative therapeutic to prevent or delay neurogenic and cognitive deficits associated with mild cognitive impairment and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun Ming</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern [corrected] California, Los Angeles, CA 90089, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Chanpreet</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Lifei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>Ronald W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shuhua</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Eun Ji</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Brinton</LastName><ForeName>Roberta Diaz</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 AG031115</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG02657</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG031115</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>BXO86P3XXW</RegistryNumber><NameOfSubstance UI="D011280">Pregnanolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11145</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="N">Neurogenesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011280" MajorTopicYN="N">Pregnanolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013234" MajorTopicYN="N">Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20231471</ArticleId><ArticleId IdType="pmc">PMC2851948</ArticleId><ArticleId IdType="doi">10.1073/pnas.1001422107</ArticleId><ArticleId IdType="pii">1001422107</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci. 2005;25:4706&#x2013;4718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724768</ArticleId><ArticleId IdType="pubmed">15888646</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD. The neurosteroid 3 alpha-hydroxy-5 alpha-pregnan-20-one induces cytoarchitectural regression in cultured fetal hippocampal neurons. J Neurosci. 1994;14:2763&#x2013;2774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577501</ArticleId><ArticleId IdType="pubmed">7910201</ArticleId></ArticleIdList></Reference><Reference><Citation>Baulieu EE, Robel P. Neurosteroids: a new brain function? J Steroid Biochem Mol Biol. 1990;37:395&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">2257243</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellon SH, Griffin LD. Neurosteroids: Biochemistry and clinical significance. Trends Endocrinol Metab. 2002;13:35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11750861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gago N, et al. 3alpha,5alpha-Tetrahydroprogesterone (allopregnanolone) and gamma-aminobutyric acid: Autocrine/paracrine interactions in the control of neonatal PSA-NCAM+ progenitor proliferation. J Neurosci Res. 2004;78:770&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">15523635</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N, et al. Neurons born in the adult dentate gyrus form functional synapses with target cells. Nat Neurosci. 2008;11:901&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572641</ArticleId><ArticleId IdType="pubmed">18622400</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessberger S, Gage FH. Fate plasticity of adult hippocampal progenitors: Biological relevance and therapeutic use. Trends Pharmacol Sci. 2009;30:61&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2752320</ArticleId><ArticleId IdType="pubmed">19135265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn HG, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: Age-related decrease of neuronal progenitor proliferation. J Neurosci. 1996;16:2027&#x2013;2033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578509</ArticleId><ArticleId IdType="pubmed">8604047</ArticleId></ArticleIdList></Reference><Reference><Citation>Genazzani AR, et al. Circulating levels of allopregnanolone in humans: Gender, age, and endocrine influences. J Clin Endocrinol Metab. 1998;83:2099&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9626145</ArticleId></ArticleIdList></Reference><Reference><Citation>Weill-Engerer S, et al. Neurosteroid quantification in human brain regions: Comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab. 2002;87:5138&#x2013;5143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12414884</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx CE, et al. The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. Biol Psychiatry. 2006;60:1287&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattiangady B, Shetty AK. Aging does not alter the number or phenotype of putative stem/progenitor cells in the neurogenic region of the hippocampus. Neurobiol Aging. 2008;29:129&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612500</ArticleId><ArticleId IdType="pubmed">17092610</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetty AK, Hattiangady B, Shetty GA. Stem/progenitor cell proliferation factors FGF-2, IGF-1, and VEGF exhibit early decline during the course of aging in the hippocampus: Role of astrocytes. Glia. 2005;51:173&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">15800930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauber ME, Lichtensteiger W. Ontogeny of 5 alpha-reductase (type 1) messenger ribonucleic acid expression in rat brain: Early presence in germinal zones. Endocrinology. 1996;137:2718&#x2013;2730.</Citation><ArticleIdList><ArticleId IdType="pubmed">8770891</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci. 2007;8:499&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pubmed">17551515</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, et al. Neurogenesis in the adult is involved in the formation of trace memories. Nature. 2001;410:372&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268214</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson RF, Kim JJ. Memory systems in the brain and localization of a memory. Proc Natl Acad Sci USA. 1996;93:13438&#x2013;13444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33628</ArticleId><ArticleId IdType="pubmed">8942954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Gast D, Kronenberg G, Yamaguchi M, Gage FH. Early determination and long-term persistence of adult-generated new neurons in the hippocampus of mice. Development. 2003;130:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">12466205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JJ, et al. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One. 2008;3:e2935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2492828</ArticleId><ArticleId IdType="pubmed">18698410</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ. Memory traces of trace memories: Neurogenesis, synaptogenesis and awareness. Trends Neurosci. 2004;27:250&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3363970</ArticleId><ArticleId IdType="pubmed">15111006</ArticleId></ArticleIdList></Reference><Reference><Citation>Aimone JB, Wiles J, Gage FH. Computational influence of adult neurogenesis on memory encoding. Neuron. 2009;61:187&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670434</ArticleId><ArticleId IdType="pubmed">19186162</ArticleId></ArticleIdList></Reference><Reference><Citation>Donovan MH, et al. Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's disease. J Comp Neurol. 2006;495:70&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">16432899</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, et al. Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease. J Neurochem. 2002;83:1509&#x2013;1524.</Citation><ArticleIdList><ArticleId IdType="pubmed">12472904</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng R, et al. Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced clearance of hippocampal memory traces. Neuron. 2001;32:911&#x2013;926.</Citation><ArticleIdList><ArticleId IdType="pubmed">11738035</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen PH, et al. The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the hippocampus of adult mice. Exp Neurol. 2004;188:224&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">15246822</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki TR, et al. Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci. 2007;27:11925&#x2013;11933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673368</ArticleId><ArticleId IdType="pubmed">17978032</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wang JM, Irwin RW, Chen S, Brinton RD. Washington, DC: Society for Neuroscience Program No. 554.8; 2008. Neuroscience. November 15-19, 2008.</Citation></Reference><Reference><Citation>Lustbader JW, et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087549</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SY, He XY, Schulz H. Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase. Trends Endocrinol Metab. 2005;16:167&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">15860413</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma K, et al. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J. 2005;19:597&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665036</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD, et al. Progesterone receptors: Form and function in brain. Front Neuroendocrinol. 2008;29:313&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2398769</ArticleId><ArticleId IdType="pubmed">18374402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JM, Irwin RW, Liu L, Chen S, Brinton RD. Regeneration in a degenerating brain: Potential of allopregnanolone as a neuroregenerative agent. Curr Alzheimer Res. 2007;4:510&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3182411</ArticleId><ArticleId IdType="pubmed">18220513</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K, Yang Y. Cell cycle regulation in the postmitotic neuron: Oxymoron or new biology? Nat Rev Neurosci. 2007;8:368&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">17453017</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel NH, et al. Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci. 2008;28:10786&#x2013;10793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680286</ArticleId><ArticleId IdType="pubmed">18945886</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes JP, Blurton-Jones M, Yamasaki TR, Agostinho P, LaFerla FM. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J Alzheimers Dis. 2009;16:541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">19276549</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JM, Brinton RD. Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. BMC Neurosci. 2008;9(Suppl 2):S1&#x2013;S10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2604895</ArticleId><ArticleId IdType="pubmed">19090984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagasia R, et al. GABA-cAMP response element-binding protein signaling regulates maturation and survival of newly generated neurons in the adult hippocampus. J Neurosci. 2009;29:7966&#x2013;7977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776747</ArticleId><ArticleId IdType="pubmed">19553437</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuner B, et al. Learning enhances the survival of new neurons beyond the time when the hippocampus is required for memory. J Neurosci. 2004;24:7477&#x2013;7481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279157</ArticleId><ArticleId IdType="pubmed">15329394</ArticleId></ArticleIdList></Reference><Reference><Citation>Waddell J, Shors TJ. Neurogenesis, learning and associative strength. Eur J Neurosci. 2008;27:3020&#x2013;3028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289543</ArticleId><ArticleId IdType="pubmed">18588540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15071107</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>14</Issue><PubDate><Year>2004</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain.</ArticleTitle><Pagination><StartPage>3592</StartPage><EndPage>3599</EndPage><MedlinePgn>3592-9</MedlinePgn></Pagination><Abstract><AbstractText>Multiple lines of evidence implicate beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD), but the mechanisms whereby Abeta is involved remain unclear. Addition of Abeta to the extracellular space can be neurotoxic. Intraneuronal Abeta42 accumulation is also associated with neurodegeneration. We reported previously that in Tg2576 amyloid precursor protein mutant transgenic mice, brain Abeta42 localized by immunoelectron microscopy to, and accumulated with aging in, the outer membranes of multivesicular bodies, especially in neuronal processes and synaptic compartments. We now demonstrate that primary neurons from Tg2576 mice recapitulate the in vivo localization and accumulation of Abeta42 with time in culture. Furthermore, we demonstrate that Abeta42 aggregates into oligomers within endosomal vesicles and along microtubules of neuronal processes, both in Tg2576 neurons with time in culture and in Tg2576 and human AD brain. These Abeta42 oligomer accumulations are associated with pathological alterations within processes and synaptic compartments in Tg2576 mouse and human AD brains.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Reisuke H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Claudia G</ForeName><Initials>CG</Initials></Author><Author ValidYN="Y"><LastName>Kearney</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Fangmin</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Milner</LastName><ForeName>Teresa A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>Gunnar K</ForeName><Initials>GK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS045677</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 HL018974</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL18974</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS02037</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS045677</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015388" MajorTopicYN="N">Organelles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15071107</ArticleId><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5167-03.2004</ArticleId><ArticleId IdType="pii">24/14/3592</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Busciglio J, Pelsman A, Wong C, Pigino G, Yuan ML, Mori H, Yankner BA (2002) Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33: 677&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">11879646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA (2000) Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol 157: 277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J, Aoki C, Pickel VM (1990) Optimization of differential immunogold-silver and peroxidase labeling with maintenance of ultrastructure in brain sections before plastic embedding. J Neurosci Methods 33: 113&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845158</ArticleId><ArticleId IdType="pubmed">1977960</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2: 271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH (2001) Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38: 120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Echeverria V, Cuello AC (2002) Intracellular A-beta amyloid: a sign for worse things to come? Mol Neurobiol 26: 299&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD (2003) Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci 6: 231&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury Jr PT, Fink AL, Teplow DB (2000) An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid 7: 166&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">11019857</ArticleId></ArticleIdList></Reference><Reference><Citation>Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA (1998) Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 4: 827&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662375</ArticleId></ArticleIdList></Reference><Reference><Citation>Glabe C (2001) Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease. J Mol Neurosci 17: 137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816787</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE (2003) Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 111: 11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC151845</ArticleId><ArticleId IdType="pubmed">12511580</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156: 15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC (2001) Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med 125: 489&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">11260621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4: 97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427614</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT (1997) APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">9291938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS (2001) Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 414: 643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">11740561</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzmann DJ, Odorizzi G, Emr SD (2002) Receptor downregulation and multivesicular-body sorting. Nat Rev Mol Cell Biol 3: 893&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">12461556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001) Age-dependent changes in brain, CSF, and plasma amyloid (&#x3b2;) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkitadze MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 69: 567&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210822</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41: 345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176077</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Stang E, Fang KS, de Moerloose P, Parton RG, Gruenberg J (1998) A lipid associated with the antiphospholipid syndrome regulates endosome structure and function. Nature 392: 193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">9515966</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Tinkle BT, Bieberich CJ, Haudenschild CC, Jay G (1995) The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 9: 21&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">7704018</ArticleId></ArticleIdList></Reference><Reference><Citation>Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, Madshus IH (2002) Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156: 843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173306</ArticleId><ArticleId IdType="pubmed">11864992</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E (2001) Recent advances in the understanding of the role of synaptic proteins in Alzheimer's disease and other neurodegenerative disorders. J Alzheimers Dis 3: 121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214081</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner TA, Lee A, Aicher SA, Rosin DL (1998) Hippocampal alpha2a-adrenergic receptors are located predominantly presynaptically but are also found postsynaptically and in selective astrocytes. J Comp Neurol 395: 310&#x2013;327.</Citation><ArticleIdList><ArticleId IdType="pubmed">9596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Mobius W, van Donselaar E, Ohno-Iwashita Y, Shimada Y, Heijnen HFG, Slot JW, Geuze HJ (2003) Recycling compartments and the internal vesicles of multivesicular bodies harbor most of the cholesterol found in the endocytic pathway. Traffic 4: 222&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">12694561</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274: 6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguchi H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA (2002) Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9: 88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440481</ArticleId></ArticleIdList></Reference><Reference><Citation>Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571&#x2013;1577.</Citation><ArticleIdList><ArticleId IdType="pubmed">10735393</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles. Intracellular abeta and synaptic dysfunction. Neuron 39: 409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Palay SL, Webster Hd (1991) The fine structure of nervous system. Oxford: Oxford UP.</Citation></Reference><Reference><Citation>Pratico D, Uryu K, Leight S, Trojanoswki JQ, Lee VM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21: 4183&#x2013;4187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762743</ArticleId><ArticleId IdType="pubmed">11404403</ArticleId></ArticleIdList></Reference><Reference><Citation>Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R, Hartmann T (2002) Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. J Neurosci 22: 1679&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758870</ArticleId><ArticleId IdType="pubmed">11880497</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE (2003) Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14: 133&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678674</ArticleId></ArticleIdList></Reference><Reference><Citation>Skovronsky DM, Doms RW, Lee VM (1998) Detection of a novel intraneuronal pool of insoluble amyloid beta protein that accumulates with time in culture. J Cell Biol 141: 1031&#x2013;1039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132781</ArticleId><ArticleId IdType="pubmed">9585420</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabira T, Chui DH, Kuroda S (2002) Significance of intracellular Abeta42 accumulation in Alzheimer's disease. Front Biosci 7: a44&#x2013;a49.</Citation><ArticleIdList><ArticleId IdType="pubmed">11897569</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer A&#x3b2;42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ (2000) The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39: 10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA (2001) Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 306: 116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AJ, Knauer M, Burdick DA, Glabe C (1995) Intracellular A&#x3b2;1&#x2013;42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. J Biol Chem 270: 14786&#x2013;14792.</Citation><ArticleIdList><ArticleId IdType="pubmed">7782344</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Dawes LR, Fisher S, Villa-Komaroff L, Oster-Granite ML, Neve RL (1989) Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science 245: 417&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">2474201</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, McLaughlin R, Goodyer C, LeBlanc A (2002) Selective cytotoxicity of intracellular amyloid &#x3b2; peptide 1&#x2013;42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156: 519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173346</ArticleId><ArticleId IdType="pubmed">11815632</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20049742</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1757-4684</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>8-9</Issue><PubDate><Year>2009</Year><Month>Nov</Month></PubDate></JournalIssue><Title>EMBO molecular medicine</Title><ISOAbbreviation>EMBO Mol Med</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>371</StartPage><EndPage>380</EndPage><MedlinePgn>371-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/emmm.200900048</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) pathology is estimated to develop many years before detectable cognitive decline. Fluid and imaging biomarkers may identify people in early symptomatic and even preclinical stages, possibly when potential treatments can best preserve cognitive function. We previously reported that cerebrospinal fluid (CSF) levels of amyloid-beta(42) (Abeta(42)) serve as an excellent marker for brain amyloid as detected by the amyloid tracer, Pittsburgh compound B (PIB). Using data from 189 cognitively normal participants, we now report a positive linear relationship between CSF tau/ptau(181) (primary constituents of neurofibrillary tangles) with the amount of cortical amyloid. We observe a strong inverse relationship of cortical PIB binding with CSF Abeta(42) but not for plasma Abeta species. Some individuals have low CSF Abeta(42) but no cortical PIB binding. Together, these data suggest that changes in brain Abeta(42) metabolism and amyloid formation are early pathogenic events in AD, and that significant disruptions in CSF tau metabolism likely occur after Abeta(42) initially aggregates and increases as amyloid accumulates. These findings have important implications for preclinical AD diagnosis and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA. fagana@neuro.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Aarti R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Aldea</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Mach</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>EMBO Mol Med</MedlineTA><NlmUniqueID>101487380</NlmUniqueID><ISSNLinking>1757-4676</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002525" MajorTopicYN="N">Cerebellar Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20049742</ArticleId><ArticleId IdType="mid">NIHMS167617</ArticleId><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="doi">10.1002/emmm.200900048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N, Ziolko S, James J, Snitz B, Houck P, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage S. An analysis of certain psychological tests used in the evaluation of brain injury. Psych Mono. 1946;60:1&#x2013;48.</Citation></Reference><Reference><Citation>Bakkour A, Morris J, Dickerson B. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72:1048&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677470</ArticleId><ArticleId IdType="pubmed">19109536</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease&#x2014;relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Meyer GD, Hansson O, Minthon L, Wallin A, Zetterberg H, Lewczuk P, Vanderstichele H, Vanmechelen E, Kornhuber J, et al. Evolution of Abeta42 and Abeta40 Levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging. 2009;13:205&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19262954</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns N, Ikonomovic M, Benzinger T, Storandt M, Fagan A, Shah A, Reinwald L, Carter D, Felton A, Holtzman D, et al. PiB-PET detection of cerebral A&#x3b2; may lag clinical, cognitive, and CSF markers of Alzheimer's disease: a case report. Arch Neurol. 2009 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J, May P, O'Dell M, Taylor J, Parsadanian M, Cramer J, Audia J, Nissen J, Bales K, Paul S, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig-Schapiro R, Fagan A, Holtzman D. Biomarkers of Alzheimer's disease. Neurobiol Dis. 2008;35:128&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747727</ArticleId><ArticleId IdType="pubmed">19010417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson B, Bakkour A, Salat D, Feczko E, Pacheco J, Greve D, Grodstein F, Wright C, Blacker D, Rosas H, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Head D, Shah A, Marcus D, Mintun M, Morris J, Holtzman D. Decreased cerebrospinal fluid A&#x3b2;42 correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:175&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, LaRossa G, Spinner M, Klunk W, Mathis C, et al. Inverse relation between in vivo amyloid imaging load and CSF A&#x3b2;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D. Cerebrospinal fluid tau/A&#x3b2;42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tennis M, Locascio J, Hyman B, Growdon J, Irizarry M. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003;60:958&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pubmed">12873852</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price J, McKeel D, Morris J, Growdon J, Hyman B. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodglass H, Kaplan E. Boston Naming Test scoring booklet. Philadelphia: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Gotz J, Chen F, Dorpe JV, Nitsch R. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford N, Crook J, Lucas J, Boeve B, Knopman D, Ivnik R, Smith G, Younkin L, Petersen R, Younkin S. Association of low plasma A&#x3b2;42/A&#x3b2;40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353377</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;3:900&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2008 in press, doi:  10.1016/j.neurobiolaging.2008.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.03.027</ArticleId><ArticleId IdType="pubmed">18486992</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C, Lowe V, Weigand S, Wiste H, Senjem M, Knopman D, Shiung M, Gunter J, Boeve B, Kemp B, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, Bergstr&#xf6;m M, Savitcheva I, Huang G-F, Estrada S, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lachno D, Vanderstichele H, Groote GD, Kostanjevecki V, Meyer GD, Siemers E, Willey M, Bourdage J, Konrad R, Dean R. The influence of matrix type, diurnal rhythm and sample collection and processing on the measurement of plasma beta-amyloid isoforms using the Inno-Bia Plasma Abeta Forms Multiplex Assay. J Nutr Health Aging. 2009;13:220&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pubmed">19262957</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, B&#xfc;rger K, Hampel H, Fr&#xf6;lich L, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp Neurol. 2009 (in press), PMID:19664622.</Citation><ArticleIdList><ArticleId IdType="pubmed">19664622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson D, Lin W, Chisholm L, A AAC, Jones G, Yen S, Sahara N, Skipper L, Yager D, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, Kaye J, Raskind M, Zhang J, Peskind E, et al. CSF tau/A&#x3b2;42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Logan J, Fowler J, Volkow N, Wang G, Ding Y, Alexoff D. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">8784228</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D. Neuropathologic substrate of Mild Cognitive Impairment. Arch Neurol. 2006;63:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, Van der Flier WM, Blankenstein M, Ewers M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Pirttila T. Increased cerebrospinal fluid Abeta38/Abeta42 ratio in Alzheimer's disease. Neurodegener Dis. 2005;2:242&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909004</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun M, LaRossa G, Sheline Y, Dence C, Lee S-Y, Mach R, Klunk W, Mathis C, DeKosky S, Morris J. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, McKeel D, Fulling K, Torack R, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">3415196</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Roe C, Grant E, Head D, Storandt M, Goate A, Fagan A, Holtzman D, Mintun M. PIB imaging predicts progression from cognitively normal to symptomatic Alzheimer's disease. Arch Neurol. 2009 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Kitazawa M, Tseng B, LaFerla F. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003a;24:1063&#x2013;1070.</Citation><ArticleIdList><ArticleId IdType="pubmed">14643377</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd J, Murphy M, Golde T, Kayed R, Metherate R, Mattson M, Akbari Y, LaFerla F. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular A&#xdf; and synaptic dysfunction. Neuron. 2003b;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol. 2001;58:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafii M, Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2649159</ArticleId><ArticleId IdType="pubmed">19228370</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Mintzer J, Weiner M, Cummings J. Disease-modifying therapies in Alzheimer's disease. Alzheimers Dement. 2008;4:65&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631951</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom N, Mulder C, Kamp GV, Mehta S, Scheltens P, Blankenstein M, Mehta P. Amyloid &#x3b2; 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol. 2005;58:139&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">15984010</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Tang M, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA. 2008;105:14052&#x2013;14057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544577</ArticleId><ArticleId IdType="pubmed">18779561</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider B, Fagan A, Roe C, Shah A, Grant E, Xiong C, Morris J, Holtzman D. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009;66:638&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759394</ArticleId><ArticleId IdType="pubmed">19433664</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Mirza N, Putnam K, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, et al. Cerebrospinal fluid beta-amyloid -42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry. 2004;56:670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522251</ArticleId></ArticleIdList></Reference><Reference><Citation>Welge V, Fiege O, Lewczul P, Mollenhauer B, Esselmann H, Klafki H-W, Wolf S, Trenkwalder C, Otto M, Kornhuber J, et al. Combined CSF tau, p-tau181 and amyloid-&#x3b2; 38/40/42 for diagnosing Alzheimer's disease. J Neural Transm. 2009;116:203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">19142572</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19188609</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>106</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.</ArticleTitle><Pagination><StartPage>1971</StartPage><EndPage>1976</EndPage><MedlinePgn>1971-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0809158106</ELocationID><Abstract><AbstractText>Synapse deterioration underlying severe memory loss in early Alzheimer's disease (AD) is thought to be caused by soluble amyloid beta (Abeta) oligomers. Mechanistically, soluble Abeta oligomers, also referred to as Abeta-derived diffusible ligands (ADDLs), act as highly specific pathogenic ligands, binding to sites localized at particular synapses. This binding triggers oxidative stress, loss of synaptic spines, and ectopic redistribution of receptors critical to plasticity and memory. We report here the existence of a protective mechanism that naturally shields synapses against ADDL-induced deterioration. Synapse pathology was investigated in mature cultures of hippocampal neurons. Before spine loss, ADDLs caused major downregulation of plasma membrane insulin receptors (IRs), via a mechanism sensitive to calcium calmodulin-dependent kinase II (CaMKII) and casein kinase II (CK2) inhibition. Most significantly, this loss of surface IRs, and ADDL-induced oxidative stress and synaptic spine deterioration, could be completely prevented by insulin. At submaximal insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes. The mechanism of insulin protection entailed a marked reduction in pathogenic ADDL binding. Surprisingly, insulin failed to block ADDL binding when IR tyrosine kinase activity was inhibited; in fact, a significant increase in binding was caused by IR inhibition. The protective role of insulin thus derives from IR signaling-dependent downregulation of ADDL binding sites rather than ligand competition. The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208, USA. felice@bioqmed.ufrj.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Marcelo N N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Bomfim</LastName><ForeName>Theresa R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Decker</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Velasco</LastName><ForeName>Pauline T</ForeName><Initials>PT</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Mary P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Viola</LastName><ForeName>Kirsten L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei-Qin</ForeName><Initials>WQ</Initials></Author><Author ValidYN="Y"><LastName>Ferreira</LastName><ForeName>Sergio T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG18877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG22547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance></Chemical><Chemical><RegistryNumber>05V02F2KDG</RegistryNumber><NameOfSubstance UI="D000077154">Rosiglitazone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011972">Receptor, Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Proc Natl Acad Sci U S A. 2009 May 5;106(18):7678</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Sci Signal. 2009 Jun 09;2(74):pe36. doi: 10.1126/scisignal.274pe36.</RefSource><PMID Version="1">19509405</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011972" MajorTopicYN="N">Receptor, Insulin</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077154" MajorTopicYN="N">Rosiglitazone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>2</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>2</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19188609</ArticleId><ArticleId IdType="pmc">PMC2634809</ArticleId><ArticleId IdType="doi">10.1073/pnas.0809158106</ArticleId><ArticleId IdType="pii">0809158106</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gong Y, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA. 2003;100:10417&#x2013;10422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Pathways towards and away from Alzheimer's disease. Nature. 2004;430:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheibel ME, Lindsay RD, Tomiyasu U, Scheibel AB. Progressive dendritic changes in aging human cortex. Exp Neurol. 1975:47392&#x2013;47403.</Citation><ArticleIdList><ArticleId IdType="pubmed">48474</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Krafft GA, Finch CE. Targeting small A beta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 2001;24:219&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">11250006</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8:101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira ST, Vieira MN, De Felice FG. Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life. 2007;59:332&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">17505973</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, et al. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008;22:246&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">17720802</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL, Stine WB, Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging. 2004;25:569&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A beta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24:10191&#x2013;10200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging. 2008;29:1334&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3142933</ArticleId><ArticleId IdType="pubmed">17403556</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice FG, et al. A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282:11590&#x2013;11601.</Citation><ArticleIdList><ArticleId IdType="pubmed">17308309</ArticleId></ArticleIdList></Reference><Reference><Citation>Roselli F, et al. Soluble beta-amyloid1&#x2013;40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005;25:11061&#x2013;11070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725651</ArticleId><ArticleId IdType="pubmed">16319306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, et al. A beta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, et al. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005;8:1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, et al. AMPAR removal underlies A beta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou DG, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA. 2005;102:2273&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC548981</ArticleId><ArticleId IdType="pubmed">15695586</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, et al. Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat Med. 2005;11:556&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">15834427</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin NR, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging. 2008 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">18294736</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem. 1999;274:34893&#x2013;34902.</Citation><ArticleIdList><ArticleId IdType="pubmed">10574963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 2001;177:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11377828</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson GS, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen WA, et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol. 2006;199:265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">16515786</ArticleId></ArticleIdList></Reference><Reference><Citation>Reger MA, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008;70:440&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942819</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430239</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho L, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J. 2004;18:902&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">15033922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Lu H, Lewis TL, Li L. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2007;282:36275&#x2013;36282.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942401</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump FT, Dillman KS, Craig AM. cAMP-dependent protein kinase mediates activity-regulated synaptic targeting of NMDA receptors. J Neurosci. 2001;21:5079&#x2013;5088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762832</ArticleId><ArticleId IdType="pubmed">11438583</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyer C, Schikorski T, Stevens CF. Comparison of hippocampal dendritic spines in culture and in brain. J Neurosci. 1998;18:5294&#x2013;5300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793498</ArticleId><ArticleId IdType="pubmed">9651212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol. 2007;42:10&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">17049785</ArticleId></ArticleIdList></Reference><Reference><Citation>Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes. 2006;55:3320&#x2013;3325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851885</ArticleId><ArticleId IdType="pubmed">17130475</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xfc;nblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. 2007;101:757&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">17448147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung HJ, Huang YH, Lau LF, Huganir RL. Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. 2004;i24:10248&#x2013;10259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730169</ArticleId><ArticleId IdType="pubmed">15537897</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedict C, et al. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology. 2007b;32:239&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">16936707</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Mehta T, Selkoe DJ. Soluble A beta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007;282:33305&#x2013;33312.</Citation><ArticleIdList><ArticleId IdType="pubmed">17855343</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CC, Kuo YM, Huang CC, Hsu KS. Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging. 2007 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">17692997</ArticleId></ArticleIdList></Reference><Reference><Citation>Risner ME, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6:246&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">16446752</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Monoclonal antibodies that target pathological assemblies of A beta. J Neurochem. 2007;100:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17116235</ArticleId></ArticleIdList></Reference><Reference><Citation>Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA. 2001;98:3561&#x2013;3566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30692</ArticleId><ArticleId IdType="pubmed">11248117</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, You JL, Lee CC, Hsu KS. Insulin induces a novel form of postsynaptic mossy fiber long-term depression in the hippocampus. Mol Cell Neurosci. 2003;24:831&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14664829</ArticleId></ArticleIdList></Reference><Reference><Citation>Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci. 2000;23:542&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074263</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 2008;21:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">9786340</ArticleId></ArticleIdList></Reference><Reference><Citation>Moloney AM, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. 2008 [Epub ahead of print]</Citation><ArticleIdList><ArticleId IdType="pubmed">18479783</ArticleId></ArticleIdList></Reference><Reference><Citation>Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res. 2007;4:159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CM, et al. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006;29:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">16443885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12925848</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>9</Issue><PubDate><Year>2003</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.</ArticleTitle><Pagination><StartPage>1173</StartPage><EndPage>1179</EndPage><MedlinePgn>1173-9</MedlinePgn></Pagination><Abstract><AbstractText>Glucagon-like peptide-1 (GLP-1) is a gut peptide that, together with its receptor, GLP-1R, is expressed in the brain. Here we show that intracerebroventricular (i.c.v.) GLP-1 and [Ser(2)]exendin(1-9) (HSEGTFTSD; homologous to a conserved domain in the glucagon/GLP-1 family) enhance associative and spatial learning through GLP-1R. [Ser(2)]exendin(1-9), but not GLP-1, is also active when administered peripherally. GLP-1R-deficient mice have a phenotype characterized by a learning deficit that is restored after hippocampal Glp1r gene transfer. In addition, rats overexpressing GLP-1R in the hippocampus show improved learning and memory. GLP-1R-deficient mice also have enhanced seizure severity and neuronal injury after kainate administration, with an intermediate phenotype in heterozygotes and phenotypic correction after Glp1r gene transfer in hippocampal somatic cells. Systemic administration of [Ser(2)]exendin(1-9) in wild-type animals prevents kainate-induced apoptosis of hippocampal neurons. Brain GLP-1R represents a promising new target for both cognitive-enhancing and neuroprotective agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>During</LastName><ForeName>Matthew J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Medicine and Pathology, University of Auckland, Private Bag 92019, Auckland 86716, New Zealand. m.during@auckland.ac.nz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Zuzga</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Francis</LastName><ForeName>Jeremy S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Fitzsimons</LastName><ForeName>Helen L</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Jiao</LastName><ForeName>Xiangyang</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Bland</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Klugmann</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Banks</LastName><ForeName>William A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Drucker</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Haile</LastName><ForeName>Colin N</ForeName><Initials>CN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593834">Glp1r protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000593835">Glp1r protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000067757">Glucagon-Like Peptide-1 Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018027">Receptors, Glucagon</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478740">exendin (1-9), Ser(2)-</NameOfSubstance></Chemical><Chemical><RegistryNumber>89750-14-1</RegistryNumber><NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-92-5</RegistryNumber><NameOfSubstance UI="D005934">Glucagon</NameOfSubstance></Chemical><Chemical><RegistryNumber>SIV03811UC</RegistryNumber><NameOfSubstance UI="D007608">Kainic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2003 Sep;9(9):1113-5. doi: 10.1038/nm0903-1113.</RefSource><PMID Version="1">12949521</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005934" MajorTopicYN="N">Glucagon</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067757" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007608" MajorTopicYN="N">Kainic Acid</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="N">Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018027" MajorTopicYN="N">Receptors, Glucagon</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017386" MajorTopicYN="N">Sequence Homology, Amino Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12925848</ArticleId><ArticleId IdType="doi">10.1038/nm919</ArticleId><ArticleId IdType="pii">nm919</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17720802</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-6860</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Jan</Month></PubDate></JournalIssue><Title>FASEB journal : official publication of the Federation of American Societies for Experimental Biology</Title><ISOAbbreviation>FASEB J</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta oligomers induce impairment of neuronal insulin receptors.</ArticleTitle><Pagination><StartPage>246</StartPage><EndPage>260</EndPage><MedlinePgn>246-60</MedlinePgn></Pagination><Abstract><AbstractText>Recent studies have indicated an association between Alzheimer's disease (AD) and central nervous system (CNS) insulin resistance. However, the cellular mechanisms underlying the link between these two pathologies have not been elucidated. Here we show that signal transduction by neuronal insulin receptors (IR) is strikingly sensitive to disruption by soluble Abeta oligomers (also known as ADDLs). ADDLs are known to accumulate in AD brain and have recently been implicated as primary candidates for initiating deterioration of synapse function, composition, and structure. Using mature cultures of hippocampal neurons, a preferred model for studies of synaptic cell biology, we found that ADDLs caused a rapid and substantial loss of neuronal surface IRs specifically on dendrites bound by ADDLs. Removal of dendritic IRs was associated with increased receptor immunoreactivity in the cell body, indicating redistribution of the receptors. The neuronal response to insulin, measured by evoked IR tyrosine autophosphorylation, was greatly inhibited by ADDLs. Inhibition also was seen with added glutamate or potassium-induced depolarization. The effects on IR function were completely blocked by NMDA receptor antagonists, tetrodotoxin, and calcium chelator BAPTA-AM. Downstream from the IR, ADDLs induced a phosphorylation of Akt at serine473, a modification associated with neurodegenerative and insulin resistance diseases. These results identify novel factors that affect neuronal IR signaling and suggest that insulin resistance in AD brain is a response to ADDLs, which disrupt insulin signaling and may cause a brain-specific form of diabetes as part of an overall pathogenic impact on CNS synapses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Wei-Qin</ForeName><Initials>WQ</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Physiology, Northwestern University, 2205 Tech Dr., Hogan 5-110, Evanston, IL 60280, USA. w-zhao@northwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Felice</LastName><ForeName>Fernanda G</ForeName><Initials>FG</Initials></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Mary P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Quon</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Krafft</LastName><ForeName>Grant A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>William L</ForeName><Initials>WL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG18877</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FASEB J</MedlineTA><NlmUniqueID>8804484</NlmUniqueID><ISSNLinking>0892-6638</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001704">Biopolymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007328">Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011972">Receptor, Insulin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001704" MajorTopicYN="N">Biopolymers</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007328" MajorTopicYN="N">Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011972" MajorTopicYN="N">Receptor, Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17720802</ArticleId><ArticleId IdType="doi">10.1096/fj.06-7703com</ArticleId><ArticleId IdType="pii">fj.06-7703com</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">12907804</PMID><DateCompleted><Year>2003</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>301</Volume><Issue>5634</Issue><PubDate><Year>2003</Year><Month>Aug</Month><Day>08</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.</ArticleTitle><Pagination><StartPage>839</StartPage><EndPage>842</EndPage><MedlinePgn>839-42</MedlinePgn></Pagination><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive, lethal neuromuscular disease that is associated with the degeneration of spinal and brainstem motor neurons, leading to atrophy of limb, axial, and respiratory muscles. The cause of ALS is unknown, and there is no effective therapy. Neurotrophic factors are candidates for therapeutic evaluation in ALS. Although chronic delivery of molecules to the central nervous system has proven difficult, we recently discovered that adeno-associated virus can be retrogradely transported efficiently from muscle to motor neurons of the spinal cord. We report that insulin-like growth factor 1 prolongs life and delays disease progression, even when delivered at the time of overt disease symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kaspar</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llad&#xf3;</LastName><ForeName>Jer&#xf2;nia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sherkat</LastName><ForeName>Nushin</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG12992</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG21876</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS33958</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495040">Gdnf protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051100">Glial Cell Line-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011518">Proto-Oncogene Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>67763-96-6</RegistryNumber><NameOfSubstance UI="D007334">Insulin-Like Growth Factor I</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C506434">Casp9 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D053453">Caspase 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053453" MajorTopicYN="N">Caspase 9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="Y">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="Y">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051100" MajorTopicYN="N">Glial Cell Line-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007334" MajorTopicYN="N">Insulin-Like Growth Factor I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="Y">Protein Serine-Threonine Kinases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011518" MajorTopicYN="N">Proto-Oncogene Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>8</Month><Day>23</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12907804</ArticleId><ArticleId IdType="doi">10.1126/science.1086137</ArticleId><ArticleId IdType="pii">301/5634/839</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19640477</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><Issue>2</Issue><PubDate><Year>2009</Year><Month>Jul</Month><Day>30</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Amyloid deposition is associated with impaired default network function in older persons without dementia.</ArticleTitle><Pagination><StartPage>178</StartPage><EndPage>188</EndPage><MedlinePgn>178-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2009.07.003</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) has been associated with functional alterations in a distributed network of brain regions linked to memory function, with a recent focus on the cortical regions collectively known as the default network. Posterior components of the default network, including the precuneus and posterior cingulate, are particularly vulnerable to early deposition of amyloid beta-protein, one of the hallmark pathologies of AD. In this study, we use in vivo amyloid imaging to demonstrate that high levels of amyloid deposition are associated with aberrant default network functional magnetic resonance imaging (fMRI) activity in asymptomatic and minimally impaired older individuals, similar to the pattern of dysfunction reported in AD patients. These findings suggest that amyloid pathology is linked to neural dysfunction in brain regions supporting memory function and provide support for the hypothesis that cognitively intact older individuals with evidence of amyloid pathology may be in early stages of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. reisa@rics.bwh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laviolette</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Pihlajamaki</LastName><ForeName>Maija</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Randy L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG021910</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034556</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2009 Jul 30;63(2):141-3. doi: 10.1016/j.neuron.2009.07.008.</RefSource><PMID Version="1">19640471</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="Y">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosures</b>: Dr. Keith Johnson has consulted for GE Healthcare, who holds the commercial licensing and distribution rights for PiB PET imaging.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19640477</ArticleId><ArticleId IdType="mid">NIHMS133248</ArticleId><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2009.07.003</ArticleId><ArticleId IdType="pii">S0896-6273(09)00505-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Addis DR, McIntosh AR, Moscovitch M, Crawley AP, McAndrews MP. Characterizing spatial and temporal features of autobiographical memory retrieval networks: a partial least squares approach. Neuroimage. 2004;23:1460&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pubmed">15589110</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, Buckner RL. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42:1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Zhang Z, Yu H, Shi Y, Yuan Y, Zhu W, Zhang X, Qian Y. Default-mode network activity distinguishes amnestic type mild cognitive impairment from healthy aging: a combined structural and resting-state functional MRI study. Neurosci Lett. 2008;438:111&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">18455308</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig S, Wilcock GK, Love S. Loss of perineuronal net N-acetylgalactosamine in Alzheimer's disease. Acta Neuropathol. 2005;110:393&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">16133543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D, Schneider J, Arvanitakis Z, Kelly J, Aggarwal N, Shah R, Wilson R. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005;64:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: Anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen F, Liu H, Hedden T, Andrews-Hanna J, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: Mapping, assessment of stability, and relation to Alzheimer's disease. Journal of Neuroscience. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Chua EF, Schacter DL, Rand-Giovannetti E, Sperling RA. Understanding metamemory: neural correlates of the cognitive process and subjective level of confidence in recognition memory. Neuroimage. 2006;29:1150&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16303318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Prince SE, Cabeza R. When less means more: deactivations during encoding that predict subsequent memory. Neuroimage. 2004;23:921&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">15528092</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Veltman DJ, Rombouts SA, Raaijmakers JG, Jonker C. Neuroanatomical correlates of episodic encoding and retrieval in young and elderly subjects. Brain. 2003;126:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">12477696</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat D, Greve D, Chua E, Rand-Giovannetti E, Rentz D, Bertram L, Mullin K, Tanzi R, Blacker D, et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN, Dale AM, Stern CE, Blacker D, Albert MS, Sperling RA. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Duverne S, Motamedinia S, Rugg MD. The Relationship between Aging, Performance, and the Neural Correlates of Successful Memory Encoding. Cereb Cortex 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637304</ArticleId><ArticleId IdType="pubmed">18653664</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol. 2008;65:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195148</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson P, Marrelec G. The precuneus/posterior cingulate cortex plays a pivotal role in the default mode network: Evidence from a partial correlation network analysis. Neuroimage. 2008;42:1178&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">18598773</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire L, Mangin JF. Motion correction algorithms may create spurious brain activations in the absence of subject motion. Neuroimage. 2001;14:709&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">11506543</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71:903&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637553</ArticleId><ArticleId IdType="pubmed">18794492</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009;19:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Marzloff K, Wenniger JJ, Dawson TM, Bredt DS, Snyder SH. Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Ann Neurol. 1992;32:818&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">1281971</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;225:1168&#x2013;1170.</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol. 2006;59:673&#x2013;681.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470518</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging. 2000;21:289&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867213</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Jones K, Holman BL, Becker JA, Spiers PA, Satlin A, Albert MS. Preclinical prediction of Alzheimer's disease using SPECT. Neurology. 1998;50:1563&#x2013;1571.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633695</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology. 2005;234:851&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851934</ArticleId><ArticleId IdType="pubmed">15734937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher TT, Weis S, Freymann K, Erb M, Jessen F, Grodd W, Heun R, Leube DT. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J Neurol Neurosurg Psychiatry. 2007;78:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117738</ArticleId><ArticleId IdType="pubmed">17287238</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002;12:295&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">11814781</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, Pihlajamaki M, Sperling RA. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A. 2008a;105:2181&#x2013;2186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538895</ArticleId><ArticleId IdType="pubmed">18238903</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry 2007</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry. 2008b;79:630&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Episodic memory loss is related to hippocampal-mediated {beta}-amyloid deposition in elderly subjects. Brain 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Jr, Rubin EH, Price JL, Grant EA, Berg L. Cerebral amyloid deposition and diffuse plaques in &#x201c;normal&#x201d; aging: Evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Otten LJ, Rugg MD. Task-dependency of the neural correlates of episodic encoding as measured by fMRI. Cereb Cortex. 2001;11:1150&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">11709486</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson J, Lind J, Larsson A, Ingvar M, Sleegers K, Van Broeckhoven C, Adolfsson R, Nilsson LG, Nyberg L. Altered deactivation in individuals with genetic risk for Alzheimer's disease. Neuropsychologia. 2008;46:1679&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">18346764</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985&#x2013;1992.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Prince SE, Wang L, Hellegers C, Doraiswamy PM. Prognostic value of posteromedial cortex deactivation in mild cognitive impairment. PLoS ONE. 2007;2:e1104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040216</ArticleId><ArticleId IdType="pubmed">17971867</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlajamaki M, Depeau KM, Blacker D, Sperling RA. Impaired Medial Temporal Repetition Suppression is Related to Failure of Parietal Deactivation in Alzheimer Disease. Am J Geriatr Psychiatry. 2008;16:283&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2602949</ArticleId><ArticleId IdType="pubmed">18378553</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihlajamaki M, O'Keefe K, Bertram L, Tanzi R, Dickerson B, Blacker D, Albert M, Sperling R. Evidence of altered posteromedial cortical fMRI activity in subjects at risk for Alzheimer disease. Alzheimer Dis Assoc Disord in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837131</ArticleId><ArticleId IdType="pubmed">19571734</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E varepsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman GL, Fiez JA, Corbetta M, Buckner RL, Miezin FM, Raichle ME, Petersen SE. Common blood flow changes across visual tasks:Decreases in cerebral cortex. J Cogn Neurosci. 1997;9:648&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">23965122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sojkova J, Beason-Held L, Zhou Y, An Y, Kraut MA, Ye W, Ferrucci L, Mathis CA, Klunk WE, Wong DF, Resnick SM. Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med. 2008;49:1465&#x2013;1471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570023</ArticleId><ArticleId IdType="pubmed">18703614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, Muhlau M, Calhoun VD, Eichele T, Laer L, Drzezga A, Forstl H, Kurz A, Zimmer C, Wohlschlager AM. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Chua E, Cocchiarella A, Rand-Giovannetti E, Poldrack R, Schacter DL, Albert M. Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation. Neuroimage. 2003;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230827</ArticleId><ArticleId IdType="pubmed">14568509</ArticleId></ArticleIdList></Reference><Reference><Citation>Svoboda E, McKinnon MC, Levine B. The functional neuroanatomy of autobiographical memory: a meta-analysis. Neuropsychologia. 2006;44:2189&#x2013;2208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995661</ArticleId><ArticleId IdType="pubmed">16806314</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vul E, Harris C, Winkielman P, Pashler H. Puzzlingly High Correlations in fMRI Studies of Emotion, Personality, and Social Cognition. Perspectives on Psychological Science in press.</Citation><ArticleIdList><ArticleId IdType="pubmed">26158964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AD, Shannon BJ, Kahn I, Buckner RL. Parietal lobe contributions to episodic memory retrieval. Trends Cogn Sci. 2005;9:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054861</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler ME, Buckner RL. Functional-anatomic correlates of remembering and knowing. Neuroimage. 2004;21:1337&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">15050559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17576410</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1465-7392</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>7</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature cell biology</Title><ISOAbbreviation>Nat Cell Biol</ISOAbbreviation></Journal><ArticleTitle>BACE1 regulates voltage-gated sodium channels and neuronal activity.</ArticleTitle><Pagination><StartPage>755</StartPage><EndPage>764</EndPage><MedlinePgn>755-64</MedlinePgn></Pagination><Abstract><AbstractText>BACE1 activity is significantly increased in the brains of Alzheimer's disease patients, potentially contributing to neurodegeneration. The voltage-gated sodium channel (Na(v)1) beta2-subunit (beta2), a type I membrane protein that covalently binds to Na(v)1 alpha-subunits, is a substrate for BACE1 and gamma-secretase. Here, we find that BACE1-gamma-secretase cleavages release the intracellular domain of beta2, which increases mRNA and protein levels of the pore-forming Na(v)1.1 alpha-subunit in neuroblastoma cells. Similarly, endogenous beta2 processing and Na(v)1.1 protein levels are elevated in brains of BACE1-transgenic mice and Alzheimer's disease patients with high BACE1 levels. However, Na(v)1.1 is retained inside the cells and cell surface expression of the Na(v)1 alpha-subunits and sodium current densities are markedly reduced in both neuroblastoma cells and adult hippocampal neurons from BACE1-transgenic mice. BACE1, by cleaving beta2, thus regulates Na(v)1 alpha-subunit levels and controls cell-surface sodium current densities. BACE1 inhibitors may normalize membrane excitability in Alzheimer's disease patients with elevated BACE1 activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Doo Yeon</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Neurobiology of Disease Laboratory, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carey</LastName><ForeName>Bryce W</ForeName><Initials>BW</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haibin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ingano</LastName><ForeName>Laura A M</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Binshtok</LastName><ForeName>Alexander M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Wertz</LastName><ForeName>Mary H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Pettingell</LastName><ForeName>Warren H</ForeName><Initials>WH</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Woolf</LastName><ForeName>Clifford J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Dora M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG014713</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Cell Biol</MedlineTA><NlmUniqueID>100890575</NlmUniqueID><ISSNLinking>1465-7392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062550">NAV1.1 Voltage-Gated Sodium Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D021122">Protein Subunits</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568242">SCN1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568249">Scn1a protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568250">Scn1a protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015222">Sodium Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015640" MajorTopicYN="N">Ion Channel Gating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062550" MajorTopicYN="N">NAV1.1 Voltage-Gated Sodium Channel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021122" MajorTopicYN="N">Protein Subunits</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015222" MajorTopicYN="N">Sodium Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17576410</ArticleId><ArticleId IdType="mid">NIHMS125188</ArticleId><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="doi">10.1038/ncb1602</ArticleId><ArticleId IdType="pii">ncb1602</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr. Opin. Neurol. 2002;15:445&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">12151841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003;20:791&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">12964886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, Rocca WA. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46:727&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer&#x2019;s disease. Neurology. 1986;36:1226&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">3092131</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer&#x2019;s disease associated with mutations of the presenilin-1 gene. J. Neurol. 2006;253:139&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267640</ArticleId></ArticleIdList></Reference><Reference><Citation>Isom LL. Sodium channel &#x3b2; subunits: anything but auxiliary. Neuroscientist. 2001;7:42&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11486343</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA. Molecular mechanisms of gating and drug block of sodium channels. Novartis Found. Symp. 2002;241:206&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771647</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000;26:13&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798388</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra JD, Kazen-Gillespie K, Hortsch M, Isom LL. Sodium channel &#x3b2; subunits mediate homophilic cell adhesion and recruit ankyrin to points of cell-cell contact. J. Biol. Chem. 2000;275:11383&#x2013;11388.</Citation><ArticleIdList><ArticleId IdType="pubmed">10753953</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis TH, Chen C, Isom LL. Sodium channel &#x3b2; 1 subunits promote neurite outgrowth in cerebellar granule neurons. J. Biol. Chem. 2004;279:51424&#x2013;51432.</Citation><ArticleIdList><ArticleId IdType="pubmed">15452131</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, et al. Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel &#x3b2;2-subunits. Proc. Natl Acad. Sci. USA. 2002;99:17072&#x2013;17077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC139271</ArticleId><ArticleId IdType="pubmed">12481039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Santiago LF, et al. Sodium channel &#x3b2;2 subunits regulate tetrodotoxin-sensitive sodium channels in small dorsal root ganglion neurons and modulate the response to pain. J. Neurosci. 2006;26:7984&#x2013;7994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674206</ArticleId><ArticleId IdType="pubmed">16870743</ArticleId></ArticleIdList></Reference><Reference><Citation>Catterall WA. Molecular properties of voltage-sensitive sodium channels. Annu. Rev. Biochem. 1986;55:953&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">2427018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai HC, Jan LY. The distribution and targeting of neuronal voltage-gated ion channels. Nature Rev. Neurosci. 2006;7:548&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">16791144</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, et al. &#x3b2;-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, et al. Purification and cloning of amyloid precursor protein &#x3b2;-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. &#x3b2;-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. &#x3b1;- and &#x3b2;-secretase: profound changes in Alzheimer&#x2019;s disease. Biochem. Biophys. Res. Commun. 2002;299:373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">12445809</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, et al. Elevated &#x3b2;-secretase expression and enzymatic activity detected in sporadic Alzheimer&#x2019;s disease. Nature Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-&#x3b2; amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitazume S, et al. Characterization of &#x3b1; 2,6-sialyltransferase cleavage by Alzheimer&#x2019;s &#x3b2;-secretase (BACE1) J. Biol. Chem. 2003;278:14865&#x2013;14871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12473667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, et al. The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. 2003;278:48713&#x2013;48719.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507929</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, et al. Control of peripheral nerve myelination by the &#x3b2;-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/&#x3b3;-secretase-mediated cleavage of the voltage-gated sodium channel &#x3b2;2-subunit regulates cell adhesion and migration. J. Biol. Chem. 2005;280:23251&#x2013;23261.</Citation><ArticleIdList><ArticleId IdType="pubmed">15833746</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, et al. &#x3b2; subunits of voltage-gated sodium channels are novel substrates of &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE1) and &#x3b3;-secretase. J. Biol. Chem. 2005;280:23009&#x2013;23017.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo EH, Kopan R. Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nature Med. 2004;10:S26&#x2013;S33.</Citation><ArticleIdList><ArticleId IdType="pubmed">15272268</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, Rhodes KJ, Bekele-Arcuri Z, Trimmer JS. Type I and type II Na(+) channel &#x3b1;-subunit polypeptides exhibit distinct spatial and temporal patterning, and association with auxiliary subunits in rat brain. J. Comp. Neurol. 1999;412:342&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">10441760</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker WR, et al. Distribution of voltage-gated sodium channel &#x3b1;-subunit and &#x3b2;-subunit mRNAs in human hippocampal formation, cortex, and cerebellum. J. Comp. Neurol. 2000;422:123&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">10842222</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker WR, et al. Changes in the mRNAs encoding voltage-gated sodium channel types II and III in human epileptic hippocampus. Neuroscience. 2001;106:275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">11566500</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisler MH, Kearney J, Ottman R, Escayg A. Identification of epilepsy genes in human and mouse. Annu. Rev. Genet. 2001;35:567&#x2013;588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765248</ArticleId><ArticleId IdType="pubmed">11700294</ArticleId></ArticleIdList></Reference><Reference><Citation>Dib-Hajj SD, Hinson AW, Black JA, Waxman SG. Sodium channel mRNA in the B104 neuroblastoma cell line. FEBS Lett. 1996;384:78&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">8797808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang WP, et al. In vivo inhibition of Abeta production by memapsin 2 (&#x3b2;-secretase) inhibitors. J. Neurochem. 2004;89:1409&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15189343</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertin M, et al. Upregulation of the voltage-gated sodium channel &#x3b2;2 subunit in neuropathic pain models: characterization of expression in injured and non-injured primary sensory neurons. J. Neurosci. 2005;25:10970&#x2013;10980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725885</ArticleId><ArticleId IdType="pubmed">16306410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, et al. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J. Cell Biol. 2005;168:291&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171598</ArticleId><ArticleId IdType="pubmed">15642747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt JW, Catterall WA. Biosynthesis and processing of the &#x3b1; subunit of the voltage-sensitive sodium channel in rat brain neurons. Cell. 1986;46:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">2425982</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas-Crusells J, Vieira A, Saarma M, Rivera C. A novel method for monitoring surface membrane trafficking on hippocampal acute slice preparation. J. Neurosci. Methods. 2003;125:159&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">12763242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmer T, Benndorf K. The human heart and rat brain IIA Na+ channels interact with different molecular regions of the &#x3b2;1 subunit. J. Gen. Physiol. 2002;120:887&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2229568</ArticleId><ArticleId IdType="pubmed">12451056</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Yi J, Hu N, George AL, Jr., Murray KT. Activation of protein kinase A modulates trafficking of the human cardiac sodium channel in Xenopus oocytes. Circ. Res. 2000;87:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">10884369</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SM, et al. BACE1 (&#x3b2;-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. 2003;24:646&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pubmed">14664815</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, et al. High &#x3b2;-secretase activity elicits neurodegeneration in transgenic mice despite reductions in amyloid-&#x3b2; levels: implications for the treatment of Alzheimer disease. J. Biol. Chem. 2005;280:32957&#x2013;32967.</Citation><ArticleIdList><ArticleId IdType="pubmed">16027115</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, et al. Bace1 modulates myelination in the central and peripheral nervous system. Nature Neurosci. 2006;9:1520&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">17099708</ArticleId></ArticleIdList></Reference><Reference><Citation>Spampanato J, Escayg A, Meisler MH, Goldin AL. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. J. Neurosci. 2001;21:7481&#x2013;7490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762922</ArticleId><ArticleId IdType="pubmed">11567038</ArticleId></ArticleIdList></Reference><Reference><Citation>Claes L, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am. J. Hum. Genet. 2001;68:1327&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1226119</ArticleId><ArticleId IdType="pubmed">11359211</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Catanzaro P, Doss RC, ARquello R, Frey WH., 2nd Seizures in Alzheimer&#x2019;s disease: clinicopathologic study. J. Geriatr. Psychiatry. Neurol. 1994;7:230&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17785178</PMID><DateCompleted><Year>2007</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0896-6273</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>5</Issue><PubDate><Year>2007</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>697</StartPage><EndPage>711</EndPage><MedlinePgn>697-711</MedlinePgn></Pagination><Abstract><AbstractText>Neural network dysfunction may play an important role in Alzheimer's disease (AD). Neuronal circuits vulnerable to AD are also affected in human amyloid precursor protein (hAPP) transgenic mice. hAPP mice with high levels of amyloid-beta peptides in the brain develop AD-like abnormalities, including cognitive deficits and depletions of calcium-related proteins in the dentate gyrus, a region critically involved in learning and memory. Here, we report that hAPP mice have spontaneous nonconvulsive seizure activity in cortical and hippocampal networks, which is associated with GABAergic sprouting, enhanced synaptic inhibition, and synaptic plasticity deficits in the dentate gyrus. Many Abeta-induced neuronal alterations could be simulated in nontransgenic mice by excitotoxin challenge and prevented in hAPP mice by blocking overexcitation. Aberrant increases in network excitability and compensatory inhibitory mechanisms in the hippocampus may contribute to Abeta-induced neurological deficits in hAPP mice and, possibly, also in humans with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palop</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA. jpalop@gladstone.ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Roberson</LastName><ForeName>Erik D</ForeName><Initials>ED</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Thwin</LastName><ForeName>Myo T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Bien-Ly</LastName><ForeName>Nga</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jong</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn O</ForeName><Initials>KO</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials></Author><Author ValidYN="Y"><LastName>Kreitzer</LastName><ForeName>Anatol</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Finkbeiner</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Noebels</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS29709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039074</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS029709</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS39074</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD024064</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041787</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS054811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011385</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS54811</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009498">Neurotoxins</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2007 Sep 6;55(5):677-8. doi: 10.1016/j.neuron.2007.08.014.</RefSource><PMID Version="1">17785172</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019579" MajorTopicYN="N">Neocortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009498" MajorTopicYN="N">Neurotoxins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>11</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17785178</ArticleId><ArticleId IdType="mid">NIHMS1553440</ArticleId><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2007.07.025</ArticleId><ArticleId IdType="pii">S0896-6273(07)00570-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, and Gouras GK (2005). &#x3b2;-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20, 187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, and Stern Y (2006). Incidence and predictors of seizures in patients with Alzheimer&#x2019;s disease. Epilepsia 47, 867&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakst I, Avendano C, Morrison JH, and Amaral DG (1986). An experimental analysis of the origins of somatostatin-like immunoreactivity in the dentate gyrus of the rat. J Neurosci 6, 1452&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568547</ArticleId><ArticleId IdType="pubmed">2872280</ArticleId></ArticleIdList></Reference><Reference><Citation>Baraban SC, Hollopeter G, Erickson JC, Schwartzkroin PA, and Palmiter RD (1997). Knock-out mice reveal a critical antiepileptic role for neuropeptide Y. J Neurosci 17, 8927&#x2013;8936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573608</ArticleId><ArticleId IdType="pubmed">9364040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijak M (1995). Inhibitory effect of neuropeptide y on epileptiform activity in the frontal cortex and hippocampus in vitro. Pol J Pharmacol 47, 461&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">8868141</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, de Leon MJ, and Zetterberg H (2006). Alzheimer&#x2019;s disease. Lancet 368, 387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess N, Maguire EA, and O&#x2019;Keefe J (2002). The human hippocampus and spatial and episodic memory. Neuron 35, 625&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194864</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrejo L, Guyant-Mar&#xe9;chal L, Laquerri&#xe9;re A, Vercelletto M, De La Fourni&#xe9;re F, Thomas-Ant&#xe9;rion C, Verny C, Letournel F, Pasquier F, Vital A , et al. (2006). Phenotype associated with APP duplication in five families. Brain 129, 2966&#x2013;2976.</Citation><ArticleIdList><ArticleId IdType="pubmed">16959815</ArticleId></ArticleIdList></Reference><Reference><Citation>Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TVP, Hyman BT , et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2, 271&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng I, Palop J, Esposito L, Bien-Ly N, Yan F, and Mucke L (2004). Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 10, 1190&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pubmed">15502844</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng I, Scearce-Levie K, Legleiter J, Palop J, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe K, Muchowski P, and Mucke L (2007). Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem, In press.</Citation><ArticleIdList><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Puoliv&#xe4;li J, Massaro C, Bien-Ly N, Gerstein H, Scearce-Levie K, Masliah E, and Mucke L (2005). Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer&#x2019;s disease. J Neurosci 25, 9694&#x2013;9703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725734</ArticleId><ArticleId IdType="pubmed">16237174</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J, Palop JJ, Yu G-Q, Kojima N, Masliah E, and Mucke L (2004). Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24, 4692&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729387</ArticleId><ArticleId IdType="pubmed">15140940</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobos I, Calcagnotto ME, Vilaythong AJ, Thwin MT, Noebels JL, Baraban SC, and Rubenstein JL (2005). Mice lacking Dlx1 show subtype-specific loss of interneurons, reduced inhibition and epilepsy. Nat Neurosci 8, 1059&#x2013;1068.</Citation><ArticleIdList><ArticleId IdType="pubmed">16007083</ArticleId></ArticleIdList></Reference><Reference><Citation>Colmers WF, Lukowiak K, and Pittman QJ (1987). Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J Physiol 383, 285&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183070</ArticleId><ArticleId IdType="pubmed">2821236</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, and Vitek MP (2001). Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci 114, 1179&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11228161</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lanerolle NC, Kim JH, Robbins RJ, and Spencer DD (1989). Hippocampal interneuron loss and plasticity in human temporal lobe epilepsy. Brain Res 495, 387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">2569920</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Vecchio RA, Gold LH, Novick SJ, Wong G, and Hyde LA (2004). Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett 367, 164&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">15331144</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Danner S, Frey P, Sommer B, Staufenbiel M, Wiederhold KH, and Hokfelt T (2003). Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing &#x3b2;-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis 14, 579&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">14678773</ArticleId></ArticleIdList></Reference><Reference><Citation>Diez M, Koistinaho J, Kahn K, Games D, and H&#xf6;kfelt T (2000). Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein - Initial observations. Neuroscience 100, 259&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">11008166</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards-Lee T, Ringman JM, Chung J, Werner J, Morgan A, St George Hyslop P, Thompson P, Dutton R, Mlikotic A, Rogaeva E, and Hardy J (2005). An African American family with early-onset Alzheimer disease and an APP (T714I) mutation. Neurology 64, 377&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668448</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, Smith D, Reynolds DS, Davies CH, Collingridge GL, and Seabrook GR (2001). Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 21, 4691&#x2013;4698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762352</ArticleId><ArticleId IdType="pubmed">11425896</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, and Bontempi B (2005). The organization of recent and remote memories. Nat Rev Neurosci 6, 119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Freund TF, and Buzs&#xe1;ki G (1996). Interneurons of the hippocampus. Hippocampus 6, 347&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">8915675</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F , et al. (1995). Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature 373, 523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Gariboldi M, Conti M, Cavaleri D, Samanin R, and Vezzani A (1998). Anticonvulsant properties of BIBP3226, a non-peptide selective antagonist at neuropeptide Y Y1 receptors. Eur J Neurosci 10, 757&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">9749738</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, and Wong CW (1984). Alzheimer&#x2019;s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW Jr., Morris JC, Growdon JH, and Hyman BT (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci 16, 4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, and Chen F (2004). Transgenic animal models of Alzheimer&#x2019;s disease and related disorders: Histopathology, behavior and therapy. Mol Psychiatry 9, 664&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">15052274</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzowski JF, Lyford GL, Stevenson GD, Houston FP, McGaugh JL, Worley PF, and Barnes CA (2000). Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci 20, 3993&#x2013;4001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772617</ArticleId><ArticleId IdType="pubmed">10818134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser WA, Morris ML, Heston LL, and Anderson VE (1986). Seizures and myoclonus in patients with Alzheimer&#x2019;s disease. Neurology 36, 1226&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">3092131</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Yamada K, and Nabeshima T (2002). A role of Fos expression in the CA3 region of the hippocampus in spatial memory formation in rats. Neuropsychopharmacology 26, 259&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesdorffer DC, Hauser WA, Annegers JF, Kokmen E, and Rocca WA (1996). Dementia and adult-onset unprovoked seizures. Neurology 46, 727&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618673</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia A, Masliah E, McConlogue L, Yu G, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, and Mucke L (1999). Plaque-independent disruption of neural circuits in Alzheimer&#x2019;s disease mouse models. Proc Natl Acad Sci USA 96, 3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, and Malinow R (2006). AMPAR Removal Underlies A&#x3b2;-Induced Synaptic Depression and Dendritic Spine Loss. Neuron 52, 831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, and Malinow R (2003). APP processing and synaptic function. Neuron 37, 925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Klapstein GJ, and Colmers WF (1993). On the sites of presynaptic inhibition by neuropeptide Y in rat hippocampus in vitro. Hippocampus 3, 103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">8395947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, and Mobley WC (2004). Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 24, 8153&#x2013;8160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729789</ArticleId><ArticleId IdType="pubmed">15371516</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi DT, and Chen KS (2005). Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer&#x2019;s Disease. Genes Brain and Behav 4, 173&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810905</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi M, and Buckmaster PS (2003). Reduced inhibition of dentate granule cells in a model of temporal lobe epilepsy. J Neurosci 23, 2440&#x2013;2452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741996</ArticleId><ArticleId IdType="pubmed">12657704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopniczky Z, Dobo E, Borbely S, Vilagi I, Detari L, Krisztin-Peva B, Bagosi A, Molnar E, and Mihaly A (2005). Lateral entorhinal cortex lesions rearrange afferents, glutamate receptors, increase seizure latency and suppress seizure-induced c-fos expression in the hippocampus of adult rat. J Neurochem 95, 111&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16181416</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, and Doran M (2006). Clinical phenotypic heterogeneity of Alzheimer&#x2019;s disease associated with mutations of the presenilin-1 gene. J Neurol 253, 139&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">16267640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KW, Lee SH, Kim H, Song JS, Yang SD, Paik SG, and Han PL (2004). Progressive cognitive impairment and anxiety induction in the absence of plaque deposition in C57BL/6 inbred mice expressing transgenic amyloid precursor protein. J Neurosci Res 76, 572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">15114629</ArticleId></ArticleIdList></Reference><Reference><Citation>Link W, Koniezko U, Kauselmann G, Krug M, Schwanke B, Frey U, and Kuhl D (1995). Somatodendritic exprsesion of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci USA 92, 5734&#x2013;5738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC41771</ArticleId><ArticleId IdType="pubmed">7777577</ArticleId></ArticleIdList></Reference><Reference><Citation>Loscher W, Honack D, Fassbender CP, and Nolting B (1991). The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res 8, 171&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1907909</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozsadi DA, and Larner AJ (2006). Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer&#x2019;s disease. Dement Geriatr Cogn Disord 22, 121&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">16733353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, Gilbert DJ, Jenkins NA, Lanahan AA, and Worley PF (1995). Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 14, 433&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857651</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcon G, Giaccone G, Cupidi C, Balestrieri M, Beltrami CA, Finato N, Bergonzi P, Sorbi S, Bugiani O, and Tagliavini F (2004). Neuropathological and clinical phenotype of an Italian Alzheimer family with M239V mutation of presenilin 2 gene. J Neuropathol Exp Neurol 63, 199&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">15055444</ArticleId></ArticleIdList></Reference><Reference><Citation>Mark RJ, Ashford JW, Goodman Y, and Mattson MP (1995). Anticonvulsants attenuate amyloid &#x3b2;-peptide neurotoxicity, Ca2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 16, 187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">7777136</ArticleId></ArticleIdList></Reference><Reference><Citation>Marksteiner J, Ortler M, Bellmann R, and Sperk G (1990). Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat. Neurosci Lett 112, 143&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">2359514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathern GW, Babb TL, Pretorius JK, and Leite JP (1995). Reactive synaptogenesis and neuron densities for neuropeptide Y, somatostatin, and glutamate decarboxylase immunoreactivity in the epileptogenic human fascia dentata. J Neurosci 15, 3990&#x2013;4004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578224</ArticleId><ArticleId IdType="pubmed">7751960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Barger SW, Cheng B, Lieberburg I, Smith-Swintosky VL, and Rydel RE (1993). &#x3b2;-amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer&#x2019;s disease. TINS 16, 409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">7504356</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez M, and Lim G (2003). Seizures in elderly patients with dementia: Epidemiology and management. Drugs Aging 20, 791&#x2013;803.</Citation><ArticleIdList><ArticleId IdType="pubmed">12964886</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez MF, Catanzaro P, Doss RC, R AR, and Frey WH 2nd (1994). Seizures in Alzheimer&#x2019;s disease: Clinicopathologic study. J Geriatr Psychiatry Neurol 7, 230&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">7826492</ArticleId></ArticleIdList></Reference><Reference><Citation>Molinari S, Battini R, Ferrari S, Pozzi L, Killcross AS, Robbins TW, Jouvenceau A, Billard J-M, Dutar P, Lamour Y , et al. (1996). Deficits in memory and hippocampal long-term potentiation in mice with reduced calbindin D28K expression. Proc Natl Acad Sci USA 93, 8028&#x2013;8033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC38869</ArticleId><ArticleId IdType="pubmed">8755597</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, and O&#x2019;Keefe J (1982). Place navigation impaired in rats with hippocampal lesions. Nature 297, 681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, and McConlogue L (2000). High-level neuronal expression of A&#x3b2;1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 20, 4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadler JV (2003). The recurrent mossy fiber pathway of the epileptic brain. Neurochem Res 28, 1649&#x2013;1658.</Citation><ArticleIdList><ArticleId IdType="pubmed">14584819</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xe4;gerl UV, Mody I, Jeub M, Lie AA, Elger CE, and Beck H (2000). Surviving granule cells of the sclerotic human hippocampus have reduced Ca2+ influx because of a loss of calbindin-D28K in temporal lobe epilepsy. J Neurosci 20, 1831&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772910</ArticleId><ArticleId IdType="pubmed">10684884</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keefe J, Nadel L, Keightley S, and Kill D (1975). Fornix lesions selectively abolish place learning in the rat. Exp Neurol 48, 152&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">1093867</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney JW (1995). NMDA receptor hypofunction, excitotoxicity, and Alzheimer&#x2019;s disease. NeurobiolAging 16, 459&#x2013;461.</Citation></Reference><Reference><Citation>Palop JJ, Chin J, Bien-Ly N, Massaro C, Yeung BZ, Yu G-Q, and Mucke L (2005). Vulnerability of dentate granule cells to disruption of Arc expression in human amyloid precursor protein transgenic mice. J Neurosci 25, 9686&#x2013;9693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725729</ArticleId><ArticleId IdType="pubmed">16237173</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, and Mucke L (2006). A network dysfunction perspective on neurodegenerative diseases. Nature 443, 768&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">17051202</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, and Mucke L (2003). Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc Natl Acad Sci USA 100, 9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Z, and Houser CR (2005). Temporal patterns of fos expression in the dentate gyrus after spontaneous seizures in a mouse model of temporal lobe epilepsy. J Neurosci 25, 7210&#x2013;7220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725230</ArticleId><ArticleId IdType="pubmed">16079403</ArticleId></ArticleIdList></Reference><Reference><Citation>Plath N, Ohana O, Dammermann B, Errington ML, Schmitz D, Gross C, Mao X, Engelsberg A, Mahlke C, Welzl H, et al. (2006). Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron 52, 437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088210</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian J, Colmers WF, and Saggau P (1997). Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: Modulation of presynaptic Ca2+ entry. J Neurosci 17, 8169&#x2013;8177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573734</ArticleId><ArticleId IdType="pubmed">9334392</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine RJ (1972). Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32, 281&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Richichi C, Lin EJ, Stefanin D, Colella D, Ravizza T, Grignaschi G, Veglianese P, Sperk G, During MJ, and Vezzani A (2004). Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J Neurosci 24, 3051&#x2013;3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729841</ArticleId><ArticleId IdType="pubmed">15044544</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu G-Q, and Mucke L (2007). Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science 316, 750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman SM, and Olney JW (1995). Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci 18, 57&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">7537407</ArticleId></ArticleIdList></Reference><Reference><Citation>Salter MW, and Kalia LV (2004). Src kinases: A hub for NMDA receptor regulation. Nat Rev Neurosci 5, 317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034556</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzer C, Kofler N, and Sperk G (1998). Up-regulation of neuropeptide Y-Y2 receptors in an animal model of temporal lobe epilepsy. Mol Pharmacol 53, 6&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443927</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, and Sabatini BL (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao LR, and Dudek FE (2005). Changes in mIPSCs and sIPSCs after kainate treatment: evidence for loss of inhibitory input to dentate granule cells and possible compensatory responses. J Neurophysiol 94, 952&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pubmed">15772233</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, and Masliah E (2005). Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 8, 1343&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">16136043</ArticleId></ArticleIdList></Reference><Reference><Citation>Smialowska M, Bijak M, Sopala M, and Tokarski K (1996). Inhibitory effect of NPY on the picrotoxin-induced activity in the hippocampus: a behavioural and electrophysiological study. Neuropeptides 30, 7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">8868293</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW Jr., and Morris JC (2005). Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol 62, 1821&#x2013;1830.</Citation><ArticleIdList><ArticleId IdType="pubmed">16344340</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, and Greengard P (2005). Regulation of NMDA receptor trafficking by amyloid-&#x3b2;. Nat Neurosci 8, 1051&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">16025111</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi R, and Bertram L (2005). Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: A genetic perspective. Cell 120, 545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonder N, Kragh J, Bolwig T, and Zimmer J (1994a). Transient decrease in calbindin immunoreactivity of the rat fascia dentata granule cells after repeated electroconvulsive shocks. Hippocampus 4, 79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8061754</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonder N, Kragh J, Finsen BR, Bolwig TG, and Zimmer J (1994b). Kindling induces transient changes in neuronal expression of somatostatin, neuropeptide Y, and calbindin in adult rat hippocampus and fascia dentata. Epilepsia 35, 1299&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">7988524</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu B, Jiao Y, Herzog H, and Nadler JV (2006). Neuropeptide Y regulates recurrent mossy fiber synaptic transmission less effectively in mice than in rats: Correlation with Y2 receptor plasticity. Neuroscience 143, 1085&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">17027162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzingounis AV, and Nicoll RA (2006). Arc/Arg3.1: Linking gene expression to synaptic plasticity and memory. Neuron 52, 403&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088207</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzani A, and Sperk G (2004). Overexpression of NPY and Y2 receptors in epileptic brain tissue: An endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides 38, 245&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">15337376</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezzani A, Sperk G, and Colmers WF (1999). Neuropeptide Y: Emerging evidence for a functional role in seizure modulation. Trends Neurosci 22, 25&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">10088996</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, and Selkoe DJ (2002). Naturally secreted oligomers of amyloid &#x3b2; protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, and Selkoe DJ (2004). Deciphering the molecular basis of memory failure in Alzheimer&#x2019;s disease. Neuron 44, 181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21525299</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>17</Issue><PubDate><Year>2011</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>6587</StartPage><EndPage>6594</EndPage><MedlinePgn>6587-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0529-11.2011</ELocationID><Abstract><AbstractText>Type 2 diabetes is a risk factor for Alzheimer's disease, most likely linked to an impairment of insulin signaling in the brain. The incretin hormone glucagon-like peptide-1 (GLP-1) facilitates insulin signaling, and novel long-lasting GLP-1 analogs, such as liraglutide, are on the market as diabetes therapeutics. GLP-1 has been shown to have neuroprotective properties in vitro and in vivo. Here we tested the effects of peripherally injected liraglutide in an Alzheimer mouse model, APP(swe)/PS1(&#x394;E9) (APP/PS1). Liraglutide was shown to cross the blood-brain barrier in an acute study. Liraglutide was injected for 8 weeks at 25 nmol/kg body weight i.p. once daily in 7-month-old APP/PS1 and wild-type littermate controls. In APP/PS1 mice, liraglutide prevented memory impairments in object recognition and water maze tasks, and prevented synapse loss and deterioration of synaptic plasticity in the hippocampus, commonly observed in this model. Overall &#x3b2;-amyloid plaque count in the cortex and dense-core plaque numbers were reduced by 40-50%, while levels of soluble amyloid oligomers were reduced by 25%. The inflammation response as measured by activated microglia numbers was halved in liraglutide-treated APP/PS1 mice. Numbers of young neurons in the dentate gyrus were increased in APP/PS1 mice with treatment. Liraglutide treatment had little effect on littermate control mice, whose behavior was comparable to wild-type saline controls; however, synaptic plasticity was enhanced in the drug group. Our results show that liraglutide prevents key neurodegenerative developments found in Alzheimer's disease, suggesting that GLP-1 analogs represent a novel treatment strategy for Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McClean</LastName><ForeName>Paula L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, Northern Ireland, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parthsarathy</LastName><ForeName>Vadivel</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Faivre</LastName><ForeName>Emilie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>H&#xf6;lscher</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016708">Synaptophysin</NameOfSubstance></Chemical><Chemical><RegistryNumber>839I73S42A</RegistryNumber><NameOfSubstance UI="D000069450">Liraglutide</NameOfSubstance></Chemical><Chemical><RegistryNumber>89750-14-1</RegistryNumber><NameOfSubstance UI="D052216">Glucagon-Like Peptide 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052216" MajorTopicYN="N">Glucagon-Like Peptide 1</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069450" MajorTopicYN="N">Liraglutide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016708" MajorTopicYN="N">Synaptophysin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21525299</ArticleId><ArticleId IdType="pmc">PMC6622662</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0529-11.2011</ArticleId><ArticleId IdType="pii">31/17/6587</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbas T, Faivre E, H&#xf6;lscher C. Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res. 2009;205:265&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19573562</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002;1:279&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849425</ArticleId></ArticleIdList></Reference><Reference><Citation>Blurton-Jones M, Kitazawa M, Martinez-Coria H, Castello NA, M&#xfc;ller FJ, Loring JF, Yamasaki TR, Poon WW, Green KN, LaFerla FM. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A. 2009;106:13594&#x2013;13599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715325</ArticleId><ArticleId IdType="pubmed">19633196</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold KH, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradbury J. Hope for AD with NGF gene-therapy trial. Lancet Neurol. 2005;4:335.</Citation><ArticleIdList><ArticleId IdType="pubmed">15931729</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarris HJ, Nurcombe V, Small DH, Beyreuther K, Masters CL. Secretion of nerve growth factor from septum stimulates neurite outgrowth and release of the amyloid protein precursor of Alzheimer's disease from hippocampal explants. J Neurosci Res. 1994;38:248&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">7932862</ArticleId></ArticleIdList></Reference><Reference><Citation>Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res. 2009;6:158&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">19355851</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">17430239</ArticleId></ArticleIdList></Reference><Reference><Citation>During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925848</ArticleId></ArticleIdList></Reference><Reference><Citation>Gengler S, Hamilton A, H&#xf6;lscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One. 2010a;5:e9764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842299</ArticleId><ArticleId IdType="pubmed">20339537</ArticleId></ArticleIdList></Reference><Reference><Citation>Gengler S, McClean P, McCurtin R, Gault V, Holscher C. Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol Aging. 2010b doi: 10.1016/j.neurobiolaging.2010.1002.1014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.1002.1014</ArticleId><ArticleId IdType="pubmed">20359773</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg DA, Jin K. Neurodegeneration and neurogenesis: focus on Alzheimer's disease. Curr Alzheimer Res. 2006;3:25&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472199</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton A, Patterson S, Porter D, Gault VA, Holscher C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J Neurosci Res. 2011;89:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">21312223</ArticleId></ArticleIdList></Reference><Reference><Citation>Heese K, Low JW, Inoue N. Nerve growth factor, neural stem cells and Alzheimer's disease. Neurosignals. 2006;15:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16825799</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C. Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci. 2005;16:181&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16323560</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher C. Incretin Analogues that have been Developed to Treat Type 2 Diabetes Hold Promise as a Novel Treatment Strategy for Alzheimer's Disease. Recent Pat CNS Drug Discov. 2010;5:109&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">20337586</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;lscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: New hopes for novel treatments of Alzheimer's disease? Neurobiol Aging. 2010;31:1495&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490:115&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">15094078</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55:352&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">16720054</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17:157&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18:7&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Mufson EJ, Fox N, Martel L, Emerich DF. Cellular delivery of NGF does not alter the expression of beta-amyloid immunoreactivity in young or aged nonhuman primates. Exp Neurol. 1997;145:586&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">9217095</ArticleId></ArticleIdList></Reference><Reference><Citation>Korecka JA, Verhaagen J, Hol EM. Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease. Regen Med. 2007;2:425&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">17635050</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM, Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol Med. 2005;11:170&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">15823755</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">19444259</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2009;15:331&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838375</ArticleId><ArticleId IdType="pubmed">19198615</ArticleId></ArticleIdList></Reference><Reference><Citation>Paresce DM, Chung H, Maxfield FR. Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem. 1997;272:29390&#x2013;29397.</Citation><ArticleIdList><ArticleId IdType="pubmed">9361021</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res. 2003;72:603&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">12749025</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry T, Holloway HW, Weerasuriya A, Mouton PR, Duffy K, Mattison JA, Greig NH. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol. 2007;203:293&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850958</ArticleId><ArticleId IdType="pubmed">17125767</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Herbr&#xfc;ggen O, Braun A, Rochlitzer S, Jockers-Scher&#xfc;bl MC, Hellweg R. Neurotrophic factors&#x2014;a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Curr Med Chem. 2007;14:2318&#x2013;2329.</Citation><ArticleIdList><ArticleId IdType="pubmed">17896980</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572:477&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779683</ArticleId><ArticleId IdType="pubmed">16469784</ArticleId></ArticleIdList></Reference><Reference><Citation>Vella A, Shah P, Reed AS, Adkins AS, Basu R, Rizza RA. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia. 2002;45:1410&#x2013;1415.</Citation><ArticleIdList><ArticleId IdType="pubmed">12378382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc. 2006;1:1591&#x2013;1595.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406451</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11981560</PMID><DateCompleted><Year>2002</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1087-0156</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>5</Issue><PubDate><Year>2002</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature biotechnology</Title><ISOAbbreviation>Nat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Protein detection using proximity-dependent DNA ligation assays.</ArticleTitle><Pagination><StartPage>473</StartPage><EndPage>477</EndPage><MedlinePgn>473-7</MedlinePgn></Pagination><Abstract><AbstractText>The advent of in vitro DNA amplification has enabled rapid acquisition of genomic information. We present here an analogous technique for protein detection, in which the coordinated and proximal binding of a target protein by two DNA aptamers promotes ligation of oligonucleotides linked to each aptamer affinity probe. The ligation of two such proximity probes gives rise to an amplifiable DNA sequence that reflects the identity and amount of the target protein. This proximity ligation assay detects zeptomole (40 x 10(-21) mol) amounts of the cytokine platelet-derived growth factor (PDGF) without washes or separations, and the mechanism can be generalized to other forms of protein analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fredriksson</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Beijer Laboratory, Department of Genetics and Pathology, Rudbeck Laboratory, Se-75185 Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gullberg</LastName><ForeName>Mats</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Jarvius</LastName><ForeName>Jonas</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Charlotta</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pietras</LastName><ForeName>Kristian</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>G&#xfa;stafsd&#xf3;ttir</LastName><ForeName>Sigr&#xfa;n Margr&#xe9;t</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Ostman</LastName><ForeName>Arne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Landegren</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Biotechnol</MedlineTA><NlmUniqueID>9604648</NlmUniqueID><ISSNLinking>1087-0156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010982">Platelet-Derived Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020574">Proto-Oncogene Proteins c-sis</NameOfSubstance></Chemical><Chemical><RegistryNumber>1B56C968OA</RegistryNumber><NameOfSubstance UI="D000077214">Becaplermin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.5</RegistryNumber><NameOfSubstance UI="D013917">Thrombin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Biotechnol. 2002 May;20(5):448-9. doi: 10.1038/nbt0502-448.</RefSource><PMID Version="1">11981554</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077214" MajorTopicYN="N">Becaplermin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002624" MajorTopicYN="N">Chemistry, Clinical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010982" MajorTopicYN="N">Platelet-Derived Growth Factor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020574" MajorTopicYN="N">Proto-Oncogene Proteins c-sis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013917" MajorTopicYN="N">Thrombin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>9</Month><Day>6</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11981560</ArticleId><ArticleId IdType="doi">10.1038/nbt0502-473</ArticleId><ArticleId IdType="pii">nbt0502-473</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21644996</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.</ArticleTitle><Pagination><StartPage>658</StartPage><EndPage>667</EndPage><MedlinePgn>658-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1471-4159.2011.07337.x</ELocationID><Abstract><AbstractText>Targeting hyperphosphorylated tau by immunotherapy is emerging as a promising approach to treat tauopathies such as Alzheimer's disease and frontotemporal dementia. We have previously reported that active tau immunization clears tau aggregates from the brain and attenuates or prevents functional impairments in two different tangle mouse models. Here, we assessed the efficacy of passive immunization with the PHF1 antibody, which targets a phospho-epitope within one of our active immunogens. Homozygous female tangle mice (JNPL3, 2-3 months) were injected intraperitoneally once per week with PHF1 or pooled mouse IgG (250 &#x3bc;g/125 &#x3bc;L; n = 10 per group) for a total of 13 injections. Their behavior was assessed at 5-6 months of age and brain tissue was subsequently harvested for analyses of treatment efficacy. The treated mice performed better than controls on the traverse beam task (p &lt; 0.03), and had 58% less tau pathology in the dentate gyrus of the hippocampus (p = 0.02). As assessed by western blots, the antibody therapy reduced the levels of insoluble pathological tau by 14-27% (PHF1, p &lt; 0.05; PHF1/total tau, p &lt; 0.0001) and 34-45% (CP13 or CP13/total tau, p &lt; 0.05). Levels of soluble tau and sarkosyl soluble tau were unchanged, compared with controls, as well as total tau levels in all the fractions. Plasma levels of PHF1 correlated inversely with tau pathology in the brainstem (p &lt; 0.01), with a strong trend in the motor cortex (p &lt; 0.06) as well as with insoluble total tau levels (p &lt; 0.02), indicating that higher dose of antibodies may have a greater therapeutic effect. Significant correlation was also observed between performance on the traverse beam task and PHF1 immunoreactivity in the dentate gyrus (p &lt; 0.05) as well as with insoluble PHF1/total tau ratio on western blots (p &lt; 0.04). These results show that passive immunization with tau antibodies can decrease tau pathology and functional impairments in the JNPL3 model. Future studies will determine the feasibility of this approach with other monoclonals and in different tangle models in which thorough cognitive assessment can be performed.</AbstractText><CopyrightInformation>&#xa9; 2011 The Authors. Journal of Neurochemistry &#xa9; 2011 International Society for Neurochemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boutajangout</LastName><ForeName>Allal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingadottir</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sigurdsson</LastName><ForeName>Einar M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG020197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH38623</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG020197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH038623</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH038623</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032611</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018891" MajorTopicYN="N">Dentate Gyrus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004856" MajorTopicYN="N">Postural Balance</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest</b>. Patent on tau immunotherapy pending.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21644996</ArticleId><ArticleId IdType="mid">NIHMS379565</ArticleId><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07337.x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM. Vaccination of Alzheimer&#x2019;s model mice with A&#x3b2; derivative in alum adjuvant reduces A&#x3b2; burden without microhemorrhages. Eur J Neurosci. 2006;24:2530&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1779823</ArticleId><ArticleId IdType="pubmed">17100841</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT. Non-Fc-mediated mechanisms are involved in clearance of amyloid-&#x3b2; in vivo by immunotherapy. J Neurosci. 2002;22:7873&#x2013;7878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758112</ArticleId><ArticleId IdType="pubmed">12223540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid &#x3b2;-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendiske J, Bahr BA. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis &#x2013; An approach for slowing Alzheimer disease? J Neuropathol Exp Neurol. 2003;62:451&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">12769185</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Ravikumar B, Menzies FM, et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet. 2006;15:433&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pubmed">16368705</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224:472&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Leroy K, Touchet N, Authelet M, Blanchard V, Tremp G, Pradier L, Brion JP. Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1. Neurosci Lett. 2002;318:29&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11786218</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Authelet M, Blanchard V, Touchet N, Tremp G, Pradier L, Brion JP. Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer&#x2019;s disease mutants of APP and presenilin-1. Neurobiol Dis. 2004;15:47&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">14751770</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive tau immunotherapy diminishes functional decline and clears tau aggregates in a mouse model of tauopathy. Alzheimers &amp; Dement. 2010a;6:S578.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010b;30:16559&#x2013;16566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135981</ArticleId><ArticleId IdType="pubmed">21147995</ArticleId></ArticleIdList></Reference><Reference><Citation>Brion JP, Hanger DP, Bruce MT, Couck AM, Flamentdurand J, Anderton BH. Tau in Alzheimer neurofibrillary tangles &#x2013; N-terminal and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site. Biochem J. 1991;273:127&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1150212</ArticleId><ArticleId IdType="pubmed">1899184</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-&#x3b2; immunization effectively reduces amyloid deposition in FcR&#x3b3;&#x2212;/ &#x2212; knock-out mice. J Neurosci. 2003;23:8532&#x2013;8538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740360</ArticleId><ArticleId IdType="pubmed">13679422</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A&#x3b2; antibody alters CNS and plasma A&#x3b2; clearance and decreases brain A&#x3b2; burden in a mouse model of Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F &#x3b2;-amyloid precursor protein. Behav Neurosci. 1999;113:982&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">10571480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-&#x3b2; immunization in Alzheimer&#x2019;s disease. Brain Pathol. 2004;14:11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095815</ArticleId><ArticleId IdType="pubmed">14997933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher Y, Nemirovsky A, Baron R, Monsonego A. T cells specifically targeted to amyloid plaques enhance plaque clearance in a mouse model of Alzheimer&#x2019;s disease. PLoS One. 2010;5:e10830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877087</ArticleId><ArticleId IdType="pubmed">20520819</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Koller M, Black RS, et al. Clinical effects of A&#x3b2; immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883316</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87:5827&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P, Schein JD, Binder LI. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem. 1992;267:564&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">1370450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C, DeTure M, Ko LW. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wildtype tau expression. Eur J Neurosci. 2008;27:1119&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">18294209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock C, Konietzko U, Streffer JR, et al. Antibodies against &#x3b2;-amyloid slow cognitive decline in Alzheimer&#x2019;s disease. Neuron. 2003;38:547&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">12765607</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes C, Boche D, Wilkinson D, et al. Long-term effects of A&#x3b2; (42) immunisation in Alzheimer&#x2019;s disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Akiyama H, Arai T, Kondo H, Haga C, Iritani S, Tsuchiya K. Alz-50/Gallyas-positive lysosome-like intraneuronal granules in Alzheimer&#x2019;s disease and control brains. Neurosci Lett. 1998;258:113&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875540</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, et al. A&#x3b2; peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer&#x2019;s disease. Nature. 2000;408:979&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493&#x2013;507.</Citation><ArticleIdList><ArticleId IdType="pubmed">20608753</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer&#x2019;s disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy PK, Deng Y, Mathews PM, Sigurdsson EM. Mechanistic studies of antibody mediated clearance of tau aggregates using an ex vivo brain slice model. Alzheimers &amp; Dement. 2010;6:S276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198029</ArticleId><ArticleId IdType="pubmed">22025915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, LaFrancois J, et al. Evidence for peripheral clearance of cerebral A&#x3b2; protein following chronic, active A&#x3b2; immunization in PSAPP mice. Neurobiol Dis. 2003;14:10&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">13678662</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and tau filaments in forebrain. Mol Cell Neurosci. 2001;18:702&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">11749044</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. J Neurocytol. 2003;32:1091&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044841</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D. A&#x3b2; vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005a;64:129&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">15642916</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Adame A, et al. Effects of asynuclein immunization in a mouse model of Parkinson&#x2019;s disease. Neuron. 2005b;46:857&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeker ML, Meeker RB, Hayward JN. Accumulation of circulating endogenous and exogenous immunoglobulins by hypothalamic magnocellular neurons. Brain Res. 1987;423:45&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">3676819</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, et al. A&#x3b2; peptide vaccination prevents memory loss in an animal model of Alzheimer&#x2019;s disease. Nature. 2000;408:982&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-&#x3b2; peptide: a case report. Nat Med. 2003;9:448&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640446</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Barton E, Boche D, et al. A&#x3b2; species removal after A&#x3b2;42 immunization. J Neuropathol Exp Neurol. 2006;65:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086100</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after A&#x3b2;42 immunization. Neurology. 2003;61:46&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12847155</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr, Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D. Amyloid-&#x3b2; immunotherapy for Alzheimer&#x2019;s disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">12360327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-&#x3b2; attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Shechter R. Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol. 2010;6:405&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">20531383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Immunotherapy for conformational diseases. Curr Pharm Des. 2006;12:2569&#x2013;2585.</Citation><ArticleIdList><ArticleId IdType="pubmed">16842179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau-focused immunotherapy for Alzheimer&#x2019;s disease and related tauopathies. Curr Alzheimer Res. 2009;6:446&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891148</ArticleId><ArticleId IdType="pubmed">19874269</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM. Local and distant histopathological effects of unilateral amyloid-&#x3b2; 25&#x2013;35 injections into the amygdala of young F344 rats. Neurobiol Aging. 1996;17:893&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T. Immunization with a non-toxic/non-fibrillar amyloid-&#x3b2; homologous peptide reduces Alzheimer&#x2019;s disease associated pathology in transgenic mice. Am J Pathol. 2001;159:439&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850561</ArticleId><ArticleId IdType="pubmed">11485902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson E, Wisniewski T, Frangione B. Infectivity of amyloid diseases. Trends Mol Med. 2002;8:411.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223307</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM, Knudsen E, Asuni A, Fitzer-Attas C, Sage D, Quartermain D, Goni F, Frangione B, Wisniewski T. An attenuated immune response is sufficient to enhance cognition in an Alzheimer&#x2019;s disease mouse model immunized with amyloid&#x3b2; derivatives. J Neurosci. 2004;24:6277&#x2013;6282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729550</ArticleId><ArticleId IdType="pubmed">15254082</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer &#x3b2;-amyloid by site-directed mAb. Proc Natl Acad Sci USA. 1997;94:4109&#x2013;4112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC20576</ArticleId><ArticleId IdType="pubmed">9108113</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Magrane J, Takahashi RH, Li F, Lin MT, Almeida CG, Gouras GK. Internalized antibodies to the A&#x3b2; domain of APP reduce neuronal A&#x3b2; and protect against synaptic alterations. J Biol Chem. 2007;282:18895&#x2013;18906.</Citation><ArticleIdList><ArticleId IdType="pubmed">17468102</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, Cuervo AM, Mandelkow E. Tau fragmentation, aggregation and clearance: The dual role of lysosomal processing. Hum Mol Genet. 2009;18:4153&#x2013;4170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758146</ArticleId><ArticleId IdType="pubmed">19654187</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21841002</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>286</Volume><Issue>39</Issue><PubDate><Year>2011</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.</ArticleTitle><Pagination><StartPage>34457</StartPage><EndPage>34467</EndPage><MedlinePgn>34457-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M111.229633</ELocationID><Abstract><AbstractText>The microtubule-associated protein Tau plays a critical role in the pathogenesis of Alzheimer disease and several related disorders (tauopathies). In the disease Tau aggregates and becomes hyperphosphorylated forming paired helical and straight filaments, which can further condense into higher order neurofibrillary tangles in neurons. The development of this pathology is consistently associated with progressive neuronal loss and cognitive decline. The identification of tractable therapeutic targets in this pathway has been challenging, and consequently very few clinical studies addressing Tau pathology are underway. Recent active immunization studies have raised the possibility of modulating Tau pathology by activating the immune system. Here we report for the first time on passive immunotherapy for Tau in two well established transgenic models of Tau pathogenesis. We show that peripheral administration of two antibodies against pathological Tau forms significantly reduces biochemical Tau pathology in the JNPL3 mouse model. We further demonstrate that peripheral administration of the same antibodies in the more rapidly progressive P301S tauopathy model not only reduces Tau pathology quantitated by biochemical assays and immunohistochemistry, but also significantly delays the onset of motor function decline and weight loss. This is accompanied by a reduction in neurospheroids, providing direct evidence of reduced neurodegeneration. Thus, passive immunotherapy is effective at preventing the buildup of intracellular Tau pathology, neurospheroids, and associated symptoms, although the exact mechanism remains uncertain. Tau immunotherapy should therefore be considered as a therapeutic approach for the treatment of Alzheimer disease and other tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Xiyun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Su</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Tracey K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Kinley</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cella</LastName><ForeName>Claire V</ForeName><Initials>CV</Initials></Author><Author ValidYN="Y"><LastName>Sims</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Buckner</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Hanmer</LastName><ForeName>Jenna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Hutton</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Citron</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG022102</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="N">Mutation, Missense</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21841002</ArticleId><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="doi">10.1074/jbc.M111.229633</ArticleId><ArticleId IdType="pii">S0021-9258(20)73988-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brody D. L., Holtzman D. M. (2008) Annu. Rev. Neurosci. 31, 175&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561172</ArticleId><ArticleId IdType="pubmed">18352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal D. R., Holzer M., R&#xfc;b U., Waldmann G., G&#xfc;nzel S., Zedlick D., Schober R. (2000) Exp. Neurol. 163, 98&#x2013;110</Citation><ArticleIdList><ArticleId IdType="pubmed">10785448</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M., Lendon C. L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R. C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J. M., Nowotny P., Che L. K., Norton J., Morris J. C., Reed L. A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P. R., Hayward N., Kwok J. B., Schofield P. R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B. A., Hardy J., Goate A., van Swieten J., Mann D., Lynch T., Heutink P. (1998) Nature 393, 702&#x2013;705</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Klug A., Crowther R. (2006) J. Alzheimers Dis. 9, 195&#x2013;207</Citation><ArticleIdList><ArticleId IdType="pubmed">16914859</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni A. A., Boutajangout A., Quartermain D., Sigurdsson E. M. (2007) J. Neurosci. 27, 9115&#x2013;9129</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. (2010) Exp. Neurol. 224, 472&#x2013;485</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A., Quartermain D., Sigurdsson E. M. (2010) J. Neuosci. 30, 16559&#x2013;16566</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135981</ArticleId><ArticleId IdType="pubmed">21147995</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K., Lewis J., Spires T., Paulson J., Kotilinek L., Ingelsson M., Guimares A., DeTure M., Ramsden M., McGowan E., Forster C., Yue M., Orne J., Janus C., Mariash A., Kuskowski M., Hyman B., Hutton M., Ashe K. H. (2005) Science 309, 476&#x2013;481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L., Jr., Feiner L., Lang E., Szendrei G. I., Goedert M., Lee V. M. (1994) J. Neurosci. Res. 39, 669&#x2013;673</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha G. A., Weaver C., Lane E., Vianna C., Kress Y., Rockwood J., Davies P. (1999) J. Neurosci. 19, 7486&#x2013;7494</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg S. G., Davies P. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 5827&#x2013;5831</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamori H., Khatoon S., Grundke-Iqbal I., Blennow K., Ewers M., Hampel H., Iqbal K. (2007) Neurosci. Lett. 418, 186&#x2013;189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950789</ArticleId><ArticleId IdType="pubmed">17400380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay M. A., Acker C. M., Davies P. (2010) J. Alzheimers Dis. 19, 721&#x2013;733</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949685</ArticleId><ArticleId IdType="pubmed">20110615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., McGowan E., Rockwood J., Melrose H., Nacharaju P., Van Slegtenhorst M., Gwinn-Hardy K., Murphy M. P., Baker M., Yu X., Duff K., Hardy J., Corral A., Lin W. L., Yen S. H., Dickson D. W., Davies P., Hutton M. (2000) Nat. Genet. 25, 402&#x2013;405</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahara N., Lewis J., DeTure M., McGowan E., Dickson D. W., Hutton M., Yen S. H. (2002) J. Neurochem. 83, 1498&#x2013;1508</Citation><ArticleIdList><ArticleId IdType="pubmed">12472903</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z., Roder H., Hanna A., Carlson A., Rangachari V., Yue M., Wszolek Z., Ashe K., Knight J., Dickson D., Andorfer C., Rosenberry T. L., Lewis J., Hutton M., Janus C. (2007) J. Neurosci. 27, 3650&#x2013;3662</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M., Jakes R., Vanmechelen E. (1995) Neurosci. Lett. 189, 167&#x2013;179</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Corre S., Klafki H. W., Plesnila N., H&#xfc;binger G., Obermeier A., Sahag&#xfa;n H., Monse B., Seneci P., Lewis J., Eriksen J., Zehr C., Yue M., McGowan E., Dickson D. W., Hutton M., Roder H. M. (2006) Proc. Natl. Acad. Sci. U.S.A. 103, 9673&#x2013;9678</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480465</ArticleId><ArticleId IdType="pubmed">16769887</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen B., Ingram E., Takao M., Smith M. J., Jakes R., Virdee K., Yoshida H., Holzer M., Craxton M., Emson P. C., Atzori C., Migheli A., Crowther R. A., Ghetti B., Spillantini M. G., Goedert M. (2002) J. Neurosci. 22, 9340&#x2013;9351</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758022</ArticleId><ArticleId IdType="pubmed">12417659</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds M. R., Reyes J. F., Fu Y., Bigio E. H., Guillozet-Bongaarts A. L., Berry R. W., Binder L. I. (2006) J. Neuosci. 26, 10636&#x2013;10645</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674733</ArticleId><ArticleId IdType="pubmed">17050703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., Abramsky O. (2006) Arch. Neurol. 63, 1459&#x2013;1467</Citation><ArticleIdList><ArticleId IdType="pubmed">17030663</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F., Cannon C., Barbour R., Burke R. L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. (2000) Nat. Med. 6, 916&#x2013;919</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock D. M., DiCarlo G., Henderson D., Jackson J., Clarke K., Ugen K. E., Gordon M. N., Morgan D. (2003) J. Neurosci. 23, 3745&#x2013;3751</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E. J., Keir G. (1990) Ann. Clin. Biochem. 27, 425&#x2013;435</Citation><ArticleIdList><ArticleId IdType="pubmed">1704202</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R. L., Diamond M. I. (2009) J. Biol. Chem. 284, 12845&#x2013;12852</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Bolmont T., Crowther R. A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A. K., Beibel M., Staufenbiel M., Jucker M., Goedert M., Tolnay M. (2009) Nat. Cell Biol. 11, 909&#x2013;913</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2949367</PMID><DateCompleted><Year>1987</Year><Month>03</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>235</Volume><Issue>4791</Issue><PubDate><Year>1987</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>884</EndPage><MedlinePgn>880-4</MedlinePgn></Pagination><Abstract><AbstractText>The amyloid beta protein has been identified as an important component of both cerebrovascular amyloid and amyloid plaques of Alzheimer's disease and Down syndrome. A complementary DNA for the beta protein suggests that it derives from a larger protein expressed in a variety of tissues. Overexpression of the gene in brain tissue from fetuses with Down syndrome (trisomy 21) can be explained by dosage since the locus encoding the beta protein maps to chromosome 21. Regional localization of this gene by both physical and genetic mapping places it in the vicinity of the genetic defect causing the inherited form of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Gusella</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Bruns</LastName><ForeName>G A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>St George-Hyslop</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Van Keuren</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Pagan</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kurnit</LastName><ForeName>D M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Neve</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>M15532</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="N"><Grant><GrantID>AG00029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD10658</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD20118</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="Y">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>2</Month><Day>20</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2949367</ArticleId><ArticleId IdType="doi">10.1126/science.2949367</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2881207</PMID><DateCompleted><Year>1987</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-0836</ISSN><JournalIssue CitedMedium="Print"><Volume>325</Volume><Issue>6106</Issue><PubDate><MedlineDate>1987 Feb 19-25</MedlineDate></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor.</ArticleTitle><Pagination><StartPage>733</StartPage><EndPage>736</EndPage><MedlinePgn>733-6</MedlinePgn></Pagination><Abstract><AbstractText>Alzheimer's disease is characterized by a widespread functional disturbance of the human brain. Fibrillar amyloid proteins are deposited inside neurons as neurofibrillary tangles and extracellularly as amyloid plaque cores and in blood vessels. The major protein subunit (A4) of the amyloid fibril of tangles, plaques and blood vessel deposits is an insoluble, highly aggregating small polypeptide of relative molecular mass 4,500. The same polypeptide is also deposited in the brains of aged individuals with trisomy 21 (Down's syndrome). We have argued previously that the A4 protein is of neuronal origin and is the cleavage product of a larger precursor protein. To identify this precursor, we have now isolated and sequenced an apparently full-length complementary DNA clone coding for the A4 polypeptide. The predicted precursor consists of 695 residues and contains features characteristic of glycosylated cell-surface receptors. This sequence, together with the localization of its gene on chromosome 21, suggests that the cerebral amyloid deposited in Alzheimer's disease and aged Down's syndrome is caused by aberrant catabolism of a cell-surface receptor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Lemaire</LastName><ForeName>H G</ForeName><Initials>HG</Initials></Author><Author ValidYN="Y"><LastName>Unterbeck</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Salbaum</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Grzeschik</LastName><ForeName>K H</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Multhaup</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Beyreuther</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;ller-Hill</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>Y00264</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="N">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009454" MajorTopicYN="N">Neurofibrils</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009693" MajorTopicYN="N">Nucleic Acid Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011499" MajorTopicYN="N">Protein Processing, Post-Translational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>2</Month><Day>19</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>2</Month><Day>19</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2881207</ArticleId><ArticleId IdType="doi">10.1038/325733a0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">2880184</PMID><DateCompleted><Year>1987</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>8529</Issue><PubDate><Year>1987</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Chromosome 21q21 sublocalisation of gene encoding beta-amyloid peptide in cerebral vessels and neuritic (senile) plaques of people with Alzheimer disease and Down syndrome.</ArticleTitle><Pagination><StartPage>384</StartPage><EndPage>385</EndPage><MedlinePgn>384-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robakis</LastName><ForeName>N K</ForeName><Initials>NK</Initials></Author><Author ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>H M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>E C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Devine-Gage</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>X L</ForeName><Initials>XL</Initials></Author><Author ValidYN="Y"><LastName>Ramakrishna</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Silverman</LastName><ForeName>W P</ForeName><Initials>WP</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>W T</ForeName><Initials>WT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001923" MajorTopicYN="N">Brain Chemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002874" MajorTopicYN="N">Chromosome Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="Y">Chromosomes, Human, Pair 21</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>2</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>2</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2880184</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(87)91754-5</ArticleId><ArticleId IdType="pii">S0140-6736(87)91754-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8574969</PMID><DateCompleted><Year>1996</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-8956</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>2</Issue><PubDate><Year>1996</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Alzheimer-associated presenilins 1 and 2: neuronal expression in brain and localization to intracellular membranes in mammalian cells.</ArticleTitle><Pagination><StartPage>224</StartPage><EndPage>229</EndPage><MedlinePgn>224-9</MedlinePgn></Pagination><Abstract><AbstractText>Mutations in two recently identified genes appear to cause the majority of early-onset familial Alzheimer's disease (FAD). These two novel genes, presenilin 1 (PS1) and presenilin 2 (PS2) are members of an evolutionarily conserved gene family. The normal biological role(s) of the presenilins and the mechanism(s) by which the FAD-associated mutations exert their effect remain unknown. Employing in situ hybridization, we demonstrate that the expression patterns of PS1 and PS2 in the brain are extremely similar to each other and that messages for both are primarily detectable in neuronal populations. Immunochemical analyses indicate that PS1 and PS2 are similar in size and localized to similar intracellular compartments (endoplasmic reticulum and Golgi complex). FAD-associated mutations in PS1 and PS2 do not significantly modify either their migration patterns on SDS-polyacrylamide gel electrophoresis or their overall subcellular localization, although subtle differences in perinuclear staining were noted for mutant PS1.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Genetics and Aging Unit, Massachusetts General Hospital-East, Harvard Medical School, Charlestown 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fausett</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Page</LastName><ForeName>K J</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>T W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Moir</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Merriam</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Hollister</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Hallmark</LastName><ForeName>O G</ForeName><Initials>OG</Initials></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Felsenstein</LastName><ForeName>K M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>B T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Wasco</LastName><ForeName>W</ForeName><Initials>W</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508861">PSEN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000607793">Psen1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000607794">Psen2 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015347">RNA Probes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002451" MajorTopicYN="N">Cell Compartmentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015347" MajorTopicYN="N">RNA Probes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8574969</ArticleId><ArticleId IdType="doi">10.1038/nm0296-224</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">8346443</PMID><DateCompleted><Year>1993</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0036-8075</ISSN><JournalIssue CitedMedium="Print"><Volume>261</Volume><Issue>5123</Issue><PubDate><Year>1993</Year><Month>Aug</Month><Day>13</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.</ArticleTitle><Pagination><StartPage>921</StartPage><EndPage>923</EndPage><MedlinePgn>921-3</MedlinePgn></Pagination><Abstract><AbstractText>The apolipoprotein E type 4 allele (APOE-epsilon 4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon 4 alleles in 42 families with late onset AD. Thus APOE-epsilon 4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon 4 was virtually sufficient to cause AD by age 80.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Corder</LastName><ForeName>E H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>A M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Strittmatter</LastName><ForeName>W J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Schmechel</LastName><ForeName>D E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Gaskell</LastName><ForeName>P C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Roses</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Haines</LastName><ForeName>J L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Pericak-Vance</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Science. 1993 Aug 13;261(5123):828-9. doi: 10.1126/science.8346434.</RefSource><PMID Version="1">8346434</PMID></CommentsCorrections></CommentsCorrectionsList><GeneSymbolList><GeneSymbol>APOE-&amp;egr;4</GeneSymbol></GeneSymbolList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="Y">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId><ArticleId IdType="doi">10.1126/science.8346443</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18434550</PMID><DateCompleted><Year>2008</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>17</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>29</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression.</ArticleTitle><Pagination><StartPage>6415</StartPage><EndPage>6420</EndPage><MedlinePgn>6415-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0710263105</ELocationID><Abstract><AbstractText>Although the role of APP and PSEN genes in genetic Alzheimer's disease (AD) cases is well established, fairly little is known about the molecular mechanisms affecting Abeta generation in sporadic AD. Deficiency in Abeta clearance is certainly a possibility, but increased expression of proteins like APP or BACE1/beta-secretase may also be associated with the disease. We therefore investigated changes in microRNA (miRNA) expression profiles of sporadic AD patients and found that several miRNAs potentially involved in the regulation of APP and BACE1 expression appeared to be decreased in diseased brain. We show here that miR-29a, -29b-1, and -9 can regulate BACE1 expression in vitro. The miR-29a/b-1 cluster was significantly (and AD-dementia-specific) decreased in AD patients displaying abnormally high BACE1 protein. Similar correlations between expression of this cluster and BACE1 were found during brain development and in primary neuronal cultures. Finally, we provide evidence for a potential causal relationship between miR-29a/b-1 expression and Abeta generation in a cell culture model. We propose that loss of specific miRNAs can contribute to increased BACE1 and Abeta levels in sporadic AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>S&#xe9;bastien S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Center for Human Genetics, Katholieke Universiteit Leuven and Department of Molecular and Developmental Genetics, VIB, Herestraat 49 bus 602, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horr&#xe9;</LastName><ForeName>Katrien</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nicola&#xef;</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Papadopoulou</LastName><ForeName>Aikaterini S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Mandemakers</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Silahtaroglu</LastName><ForeName>Asli N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Kauppinen</LastName><ForeName>Sakari</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Delacourte</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>5</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18434550</ArticleId><ArticleId IdType="pmc">PMC2359789</ArticleId><ArticleId IdType="doi">10.1073/pnas.0710263105</ArticleId><ArticleId IdType="pii">0710263105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rovelet-Lecrux A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38:24&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">16369530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaev EI, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature. 1995;376:775&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">7651536</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W, De Strooper B. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol. 2002;18:25&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, et al. Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun A, Koelsch G, Tang J, Bing G. Localization of beta-secretase memapsin 2 in the brain of Alzheimer's patients and normal aged controls. Exp Neurol. 2002;175:10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12009756</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, et al. Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol. 2002;51:783&#x2013;786.</Citation><ArticleIdList><ArticleId IdType="pubmed">12112088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J Neurosci. 2007;27:3639&#x2013;3649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesco G, et al. Depletion of GGA3 Stabilizes BACE and Enhances beta-Secretase Activity. Neuron. 2007;54:721&#x2013;737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1973166</ArticleId><ArticleId IdType="pubmed">17553422</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA. 2004;101:3632&#x2013;3637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Miska EA, et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 2004;5:R68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC522875</ArticleId><ArticleId IdType="pubmed">15345052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sempere LF, et al. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004;5:R13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395763</ArticleId><ArticleId IdType="pubmed">15003116</ArticleId></ArticleIdList></Reference><Reference><Citation>Barad O, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res. 2004;14:2486&#x2013;2494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534673</ArticleId><ArticleId IdType="pubmed">15574827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hohjoh H, Fukushima T. Expression profile analysis of microRNA (miRNA) in mouse central nervous system using a new miRNA detection system that examines hybridization signals at every step of washing. Gene. 2007;391:39&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17229533</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehler MF, Mattick JS. Non-coding RNAs in the nervous system. J Physiol. 2006;575:333&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1819441</ArticleId><ArticleId IdType="pubmed">16809366</ArticleId></ArticleIdList></Reference><Reference><Citation>Schratt GM, et al. A brain-specific microRNA regulates dendritic spine development. Nature. 2006;439:283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16421561</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, De Strooper B. Molecular biology. miRNAs in neurodegeneration. Science. 2007;317:1179&#x2013;1180.</Citation><ArticleIdList><ArticleId IdType="pubmed">17761871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilen J, et al. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell. 2006;24:157&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">17018300</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer A, et al. Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med. 2007;204:1553&#x2013;1558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2118654</ArticleId><ArticleId IdType="pubmed">17606634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007;317:1220&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782470</ArticleId><ArticleId IdType="pubmed">17761882</ArticleId></ArticleIdList></Reference><Reference><Citation>Abel S, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol. 2004;172:6362&#x2013;6372.</Citation><ArticleIdList><ArticleId IdType="pubmed">15128827</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may down-regulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 2004;1:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">17179747</ArticleId></ArticleIdList></Reference><Reference><Citation>Best JD, et al. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b, d]azepin-7-yl]-l-alaninamide] J Pharmacol Exp Ther. 2005;313:902&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pubmed">15743924</ArticleId></ArticleIdList></Reference><Reference><Citation>Grun D, et al. microRNA target predictions across seven Drosophila species and comparison to mammalian targets. PLoS Comput Biol. 2005;1:e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1183519</ArticleId><ArticleId IdType="pubmed">16103902</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004;32:D109&#x2013;D111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308757</ArticleId><ArticleId IdType="pubmed">14681370</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science. 2007;315:97&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">17204650</ArticleId></ArticleIdList></Reference><Reference><Citation>Willem M, et al. Control of peripheral nerve myelination by the beta-secretase BACE1. Science. 2006;314:664&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990514</ArticleId></ArticleIdList></Reference><Reference><Citation>Smirnova L, et al. Regulation of miRNA expression during neural cell specification. Eur J Neurosci. 2005;21:1469&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845075</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird FM, et al. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci. 2005;25:11693&#x2013;11709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2564291</ArticleId><ArticleId IdType="pubmed">16354928</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers JW, et al. Processing of beta-secretase by furin and other members of the proprotein convertase family. J Biol Chem. 2001;276:4211&#x2013;4217.</Citation><ArticleIdList><ArticleId IdType="pubmed">11071887</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez D, et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem. 2005;280:30797&#x2013;30806.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987683</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, Sastre M, Bourne K, Lichtenthaler SF. Transcriptional and translational regulation of BACE1 expression&#x2212;implications for Alzheimer's disease. Prog Neurobiol. 2006;79:95&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">16904810</ArticleId></ArticleIdList></Reference><Reference><Citation>Sastre M, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci USA. 2006;103:443&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1326151</ArticleId><ArticleId IdType="pubmed">16407166</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartlage-Rubsamen M, et al. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia. 2003;41:169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">12509807</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacchetti D, et al. BACE1 Expression and Activity: Relevance in Alzheimer's Disease. Neurodegener Dis. 2007;4:117&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">17596706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto M, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol. 2007;170:680&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1851864</ArticleId><ArticleId IdType="pubmed">17255335</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuba G, et al. Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;19:171&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">15677864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossner S, et al. Neuronal and glial beta-secretase (BACE) protein expression in transgenic Tg2576 mice with amyloid plaque pathology. J Neurosci Res. 2001;64:437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">11391698</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehm M, Slack F. A developmental timing microRNA and its target regulate life span in C. elegans. Science. 2005;310:1954&#x2013;1957.</Citation><ArticleIdList><ArticleId IdType="pubmed">16373574</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbri M, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA. 2007;104:15805&#x2013;15810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2000384</ArticleId><ArticleId IdType="pubmed">17890317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP. Methylation and acetylation in nervous system development and neurodegenerative disorders. Ageing Res Rev. 2003;2:329&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">12726778</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa R, Zhou F, Li C, Slack FJ. The expression of the Alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in Caenorhabditis elegans. Dev Biol. 2008;315:418&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2307910</ArticleId><ArticleId IdType="pubmed">18262516</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport. 2007;18:297&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17314675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, et al. Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 2006;7:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1500829</ArticleId><ArticleId IdType="pubmed">16729020</ArticleId></ArticleIdList></Reference><Reference><Citation>Esselens C, et al. Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol. 2004;166:1041&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172014</ArticleId><ArticleId IdType="pubmed">15452145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert SS, et al. Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. Neurobiol Dis. 2004;17:260&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474363</ArticleId></ArticleIdList></Reference><Reference><Citation>Silahtaroglu AN, et al. Detection of microRNAs in frozen tissue sections by fluorescence in situ hybridization using locked nucleic acid probes and tyramide signal amplification. Nat Protoc. 2007;2:2520&#x2013;2528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17947994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang WX, et al. The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci. 2008;28:1213&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837363</ArticleId><ArticleId IdType="pubmed">18234899</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21514250</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>263</StartPage><EndPage>269</EndPage><MedlinePgn>263-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2011.03.005</ELocationID><Abstract><AbstractText>The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011. Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McKhann</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. guy.mckhann@jhu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Koroshetz</LastName><ForeName>Walter J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Manly</LastName><ForeName>Jennifer J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Mohs</LastName><ForeName>Richard C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Thies</LastName><ForeName>Bill</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Phelps</LastName><ForeName>Creighton H</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016447">Consensus Development Conference, NIH</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054561" MajorTopicYN="N">National Institute on Aging (U.S.)</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21514250</ArticleId><ArticleId IdType="mid">NIHMS363310</ArticleId><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2011.03.005</ArticleId><ArticleId IdType="pii">S1552-5260(11)00101-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, DeKosky ST, Cummings JL, Chuit H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review) Neurology. 2001;56:1143&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11342678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:257&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Towards defining the preclinical stagse of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, Emre M, O&#x2019;Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8094895</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Kipps CM, Johnson JK, Seeley WW, Mendez MF, et al. Diagnostic criteria for the behavioral variant of frontotemporal dementia (bvFTD): current limitations and future directions. Alzheimer Dis Assoc Disord. 2007;21:S14&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">18090417</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick&#x2019;s Disease. Arch Neurol. 2001;58:1803&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, et al. Focal cortical presentations of Alzheimer&#x2019;s disease. Brain. 2007;130:2636&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">17898010</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648510</ArticleId><ArticleId IdType="pubmed">18991338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE. Thirty years of Alzheimer&#x2019;s disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci. 2008;9:768&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, Berezovska O, Growdon JH, Hyman BT. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry. 2004;12:146&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">15010344</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolan D, Troncoso J, Resnick SM, Crain BJ, Zonderman AB, O&#x2019;Brien RJ. Age, Alzheimer&#x2019;s disease and dementia in the Baltimore Longitudinal Study of Ageing. Brain. 2010;133:2225&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139933</ArticleId><ArticleId IdType="pubmed">20647264</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Disease Centers Consortium on Apolipoprotein E and Alzheimer&#x2019;s Disease. N Engl J Med. 1998;338:506&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">9468467</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer&#x2019;s disease. Alzheimers Dement. 2008;4:38&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631949</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C PiB and structural MR1 provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56:1095&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21784349</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.</ArticleTitle><Pagination><StartPage>386</StartPage><EndPage>395.e6</EndPage><MedlinePgn>386-395.e6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2011.05.2243</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The cerebrospinal fluid (CSF) biomarkers amyloid &#x3b2; (A&#x3b2;)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer's disease (AD). However, there are large variations in biomarker measurements between studies, and between and within laboratories. The Alzheimer's Association has initiated a global quality control program to estimate and monitor variability of measurements, quantify batch-to-batch assay variations, and identify sources of variability. In this article, we present the results from the first two rounds of the program.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The program is open for laboratories using commercially available kits for A&#x3b2;, T-tau, or P-tau. CSF samples (aliquots of pooled CSF) are sent for analysis several times a year from the Clinical Neurochemistry Laboratory at the M&#xf6;lndal campus of the University of Gothenburg, Sweden. Each round consists of three quality control samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty laboratories participated. Twenty-six used INNOTEST enzyme-linked immunosorbent assay kits, 14 used Luminex xMAP with the INNO-BIA AlzBio3 kit (both measure A&#x3b2;-(1-42), P-tau(181P), and T-tau), and 5 used Meso Scale Discovery with the A&#x3b2; triplex (A&#x3b2;N-42, A&#x3b2;N-40, and A&#x3b2;N-38) or T-tau kits. The total coefficients of variation between the laboratories were 13% to 36%. Five laboratories analyzed the samples six times on different occasions. Within-laboratory precisions differed considerably between biomarkers within individual laboratories.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Measurements of CSF AD biomarkers show large between-laboratory variability, likely caused by factors related to analytical procedures and the analytical kits. Standardization of laboratory procedures and efforts by kit vendors to increase kit performance might lower variability, and will likely increase the usefulness of CSF AD biomarkers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden. niklas.mattsson@neuro.gu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Persson</LastName><ForeName>Staffan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Batish</LastName><ForeName>Sat Dev</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Bernardini</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bocchio-Chiavetto</LastName><ForeName>Luisella</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Blankenstein</LastName><ForeName>Marinus A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Carrillo</LastName><ForeName>Maria C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Chalbot</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Coart</LastName><ForeName>Els</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chiasserini</LastName><ForeName>Davide</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cutler</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Dahlfors</LastName><ForeName>Gunilla</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Duller</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Forlenza</LastName><ForeName>Orestes</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Galimberti</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Handberg</LastName><ForeName>Aase</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heneka</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Herskovits</LastName><ForeName>Adrianna Z</ForeName><Initials>AZ</Initials></Author><Author ValidYN="Y"><LastName>Herukka</LastName><ForeName>Sanna-Kaisa</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Humpel</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials></Author><Author ValidYN="Y"><LastName>Iqbal</LastName><ForeName>Khalid</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jucker</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kaeser</LastName><ForeName>Stephan A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Kaiser</LastName><ForeName>Elmar</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kapaki</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kidd</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Klivenyi</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Cindy S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Markus P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Lui</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Llad&#xf3;</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lewczuk</LastName><ForeName>Piotr</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Qiao-Xin</ForeName><Initials>QX</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>McAuliffe</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mercken</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Moghekar</LastName><ForeName>Abhay</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Montine</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Nowatzke</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Paraskevas</LastName><ForeName>George P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>Lucilla</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Prvulovic</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>de Reus</LastName><ForeName>Herman P M</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Rissman</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Stefani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Soininen</LastName><ForeName>Hilkka</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Schr&#xf6;der</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Skinningsrud</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Skrogstad</LastName><ForeName>Brith</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Spreer</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Talib</LastName><ForeName>Leda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Teunissen</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Tumani</LastName><ForeName>Hayrettin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Umek</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Van Broeck</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Vanderstichele</LastName><ForeName>Hugo</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vecsei</LastName><ForeName>Laszlo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>Marcel M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Windisch</LastName><ForeName>Manfred</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG033655</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Alzheimers Dement. 2011 Sep;7(5):556</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011786" MajorTopicYN="Y">Quality Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>7</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21784349</ArticleId><ArticleId IdType="mid">NIHMS486244</ArticleId><ArticleId IdType="pmc">PMC3710290</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2011.05.2243</ArticleId><ArticleId IdType="pii">S1552-5260(11)02398-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSFAbeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer&#x2019;s disease. Neurosci Lett. 2003;352:67&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">14615052</ArticleId></ArticleIdList></Reference><Reference><Citation>Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64:1294&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15824371</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology. 2007;69:631&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698783</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H. CSF markers for incipient Alzheimer&#x2019;s disease. Lancet Neurol. 2003;2:605&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">14505582</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289:2094&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. 2010 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925386</ArticleId><ArticleId IdType="pubmed">20798852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem. 2006;52:332&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449222</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369305</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem. 2005;51:189&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">15539465</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer&#x2019;s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis. 2004;25:2912&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15349929</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid beta((1-42)), tau, and phosphorylated tau in Alzheimer&#x2019;s disease: report of an International Workshop. Int JAlzheimers Dis. (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948880</ArticleId><ArticleId IdType="pubmed">20936143</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51:336&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins. Clin Chem. 2007;53:859&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">17395712</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer&#x2019;s disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:47&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603251</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, Regeniter A, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci Lett. 2006;409:1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17045397</ArticleId></ArticleIdList></Reference><Reference><Citation>Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer&#x2019;s disease. Ann Clin Biochem. 2009;46:235&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">19342441</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunk DM. Reference materials and reference measurement procedures: an overview from a national metrology institute. Clin Biochem Rev. 2007;28:131&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2282405</ArticleId><ArticleId IdType="pubmed">18392127</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunk DM, Welch MJ. Characterization of a new certified reference material for human cardiac troponin I. Clin Chem. 2006;52:212&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306090</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K. Biomarkers for Alzheimer&#x2019;s disease. Nat Med. (in press)</Citation><ArticleIdList><ArticleId IdType="pubmed">21052077</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni G, Jack CR. Harmonization of MR-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement. 2010 (in press)</Citation><ArticleIdList><ArticleId IdType="pubmed">21414554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19342441</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0004-5632</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>Pt 3</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of clinical biochemistry</Title><ISOAbbreviation>Ann Clin Biochem</ISOAbbreviation></Journal><ArticleTitle>A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>235</StartPage><EndPage>240</EndPage><MedlinePgn>235-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1258/acb.2009.008232</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Different cerebrospinal fluid (CSF) amyloid-beta 1-42 (Abeta(1-42)), total Tau (Tau) and Tau phosphorylated at threonine 181 (P-Tau) levels are reported, but currently there is a lack of quality control programmes. The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three CSF-pool samples were distributed to 13 laboratories in 2004 and the same samples were again distributed to 18 laboratories in 2008. In 2004 six laboratories measured Abeta(1-42), Tau and P-Tau and seven laboratories measured one or two of these marker(s) by enzyme-linked immunosorbent assays (ELISAs). In 2008, 12 laboratories measured all three markers, three laboratories measured one or two marker(s) by ELISAs and three laboratories measured the markers by Luminex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 2004, the ELISA intercentre coefficients of variance (interCV) were 31%, 21% and 13% for Abeta(1-42), Tau and P-Tau, respectively. These were 37%, 16% and 15%, respectively, in 2008. When we restricted the analysis to the Innotest (N = 13) for Abeta(1-42), lower interCV were calculated (22%). The centres that participated in both years (N = 9) showed interCVs of 21%, 15% and 9% and intra-centre coefficients (intraCV) of variance of 25%,18% and 7% in 2008.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The highest variability was found for Abeta(1-42). The variabilities for Tau and P-Tau were lower in both years. The centres that participated in both years showed a high intraCV comparable to their interCV, indicating that there is not only a high variation between but also within centres. Besides a uniform standardization of (pre)analytical procedures, the same assay should be used to decrease the inter/intracentre variation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Verwey</LastName><ForeName>N A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Clinical Chemistry, VU University Medical Center, , HV, The Netherlands. n.verwey@vumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>W M</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Sokolow</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>De Deyn</LastName><ForeName>P P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hartmann</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kapaki</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Lannfelt</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author><Author ValidYN="Y"><LastName>Parnetti</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Petzold</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pirttila</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Saleh</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Skinningsrud</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Swieten</LastName><ForeName>J C V</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>M M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Younkin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Blankenstein</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Clin Biochem</MedlineTA><NlmUniqueID>0324055</NlmUniqueID><ISSNLinking>0004-5632</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19342441</ArticleId><ArticleId IdType="doi">10.1258/acb.2009.008232</ArticleId><ArticleId IdType="pii">acb.2009.008232</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">1759558</PMID><DateCompleted><Year>1992</Year><Month>02</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-6322</ISSN><JournalIssue CitedMedium="Print"><Volume>82</Volume><Issue>4</Issue><PubDate><Year>1991</Year></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Neuropathological stageing of Alzheimer-related changes.</ArticleTitle><Pagination><StartPage>239</StartPage><EndPage>259</EndPage><MedlinePgn>239-59</MedlinePgn></Pagination><Abstract><AbstractText>Eighty-three brains obtained at autopsy from nondemented and demented individuals were examined for extracellular amyloid deposits and intraneuronal neurofibrillary changes. The distribution pattern and packing density of amyloid deposits turned out to be of limited significance for differentiation of neuropathological stages. Neurofibrillary changes occurred in the form of neuritic plaques, neurofibrillary tangles and neuropil threads. The distribution of neuritic plaques varied widely not only within architectonic units but also from one individual to another. Neurofibrillary tangles and neuropil threads, in contrast, exhibited a characteristic distribution pattern permitting the differentiation of six stages. The first two stages were characterized by an either mild or severe alteration of the transentorhinal layer Pre-alpha (transentorhinal stages I-II). The two forms of limbic stages (stages III-IV) were marked by a conspicuous affection of layer Pre-alpha in both transentorhinal region and proper entorhinal cortex. In addition, there was mild involvement of the first Ammon's horn sector. The hallmark of the two isocortical stages (stages V-VI) was the destruction of virtually all isocortical association areas. The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Zentrum der Morphologie, Frankfurt/Main, Federal Republic of Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006651" MajorTopicYN="N">Histocytochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016501" MajorTopicYN="N">Neurites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>63</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId><ArticleId IdType="doi">10.1007/BF00308809</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neuropathol Exp Neurol. 1990 May;49(3):215-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1692337</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1988 Mar;38(3):359-64</Citation><ArticleIdList><ArticleId IdType="pubmed">3347338</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1990 Apr;16(2):111-21</Citation><ArticleIdList><ArticleId IdType="pubmed">2345598</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1985 Nov;42(11):1097-105</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Lab Invest. 1988 Feb;58(2):122-32</Citation><ArticleIdList><ArticleId IdType="pubmed">3276958</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1991;81(3):261-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1711755</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Neurol Scand Suppl. 1952;82:1-152</Citation><ArticleIdList><ArticleId IdType="pubmed">13171126</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1989 Nov-Dec;15(6):491-512</Citation><ArticleIdList><ArticleId IdType="pubmed">2693991</ArticleId></ArticleIdList></Reference><Reference><Citation>Mech Ageing Dev. 1985 Sep;31(3):213-55</Citation><ArticleIdList><ArticleId IdType="pubmed">3906293</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1989;77(5):494-506</Citation><ArticleIdList><ArticleId IdType="pubmed">2566255</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1988;76(6):541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3059748</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1985;68(4):325-32</Citation><ArticleIdList><ArticleId IdType="pubmed">4090943</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Pathol. 1991 Apr;1(3):213-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1669710</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1989 Aug 14;103(1):24-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2476692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1982 Nov;56(2-3):343-56</Citation><ArticleIdList><ArticleId IdType="pubmed">7175555</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1990 Jul;97(2-3):295-323</Citation><ArticleIdList><ArticleId IdType="pubmed">1698217</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1988 Nov;38(11):1688-93</Citation><ArticleIdList><ArticleId IdType="pubmed">3054625</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1986 Feb 26;366(1-2):385-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3697692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1989 Nov-Dec;10(6):709-15</Citation><ArticleIdList><ArticleId IdType="pubmed">2628782</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1989 Jan-Feb;15(1):13-26</Citation><ArticleIdList><ArticleId IdType="pubmed">2471109</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 1989 Nov;93(2-3):277-87</Citation><ArticleIdList><ArticleId IdType="pubmed">2556503</ArticleId></ArticleIdList></Reference><Reference><Citation>Stain Technol. 1988 Jul;63(4):197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">2464205</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 1989 Nov;48(6):606-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2477504</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1990 May 7;515(1-2):227-34</Citation><ArticleIdList><ArticleId IdType="pubmed">2357561</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 1990;83:445-57</Citation><ArticleIdList><ArticleId IdType="pubmed">2392569</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1985 Oct;5(10):2801-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4045553</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1989 Feb 13;97(1-2):232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2521927</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 1983 Jan;7(1):27-41</Citation><ArticleIdList><ArticleId IdType="pubmed">6188002</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1987 Jun;7(6):1799-808</Citation><ArticleIdList><ArticleId IdType="pubmed">2439665</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Jul;82(13):4531-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3859874</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1984 Sep 14;225(4667):1168-70</Citation><ArticleIdList><ArticleId IdType="pubmed">6474172</ArticleId></ArticleIdList></Reference><Reference><Citation>J Histochem Cytochem. 1986 Dec;34(12):1667-72</Citation><ArticleIdList><ArticleId IdType="pubmed">3537114</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Morphol Acad Sci Hung. 1971;19(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4107507</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1990 Dec;137(6):1293-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2124413</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1970;16(2):85-94</Citation><ArticleIdList><ArticleId IdType="pubmed">4919692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1989 Feb;134(2):243-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2464938</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1990;80(5):479-86</Citation><ArticleIdList><ArticleId IdType="pubmed">2251904</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 1989 Dec;26(6):771-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2557796</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1988 Sep 12;91(3):354-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2460803</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropathol Appl Neurobiol. 1988 Jan-Feb;14(1):39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">2453810</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1990;80(4):368-74</Citation><ArticleIdList><ArticleId IdType="pubmed">2239149</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1990 Aug 14;116(1-2):87-93</Citation><ArticleIdList><ArticleId IdType="pubmed">2259457</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol. 1990;80(3):318-27</Citation><ArticleIdList><ArticleId IdType="pubmed">1698007</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1986 Apr 24;65(3):351-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2423928</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Clin Biol Res. 1989;317:23-41</Citation><ArticleIdList><ArticleId IdType="pubmed">2690101</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1989 Aug 7;494(1):198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">2765920</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16096062</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0092-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>122</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Nicastrin functions as a gamma-secretase-substrate receptor.</ArticleTitle><Pagination><StartPage>435</StartPage><EndPage>447</EndPage><MedlinePgn>435-47</MedlinePgn></Pagination><Abstract><AbstractText>gamma-secretase catalyzes the intramembrane cleavage of amyloid precursor protein (APP) and Notch after their extracellular domains are shed by site-specific proteolysis. Nicastrin is an essential glycoprotein component of the gamma-secretase complex but has no known function. We now show that the ectodomain of nicastrin binds the new amino terminus that is generated upon proteolysis of the extracellular APP and Notch domains, thereby recruiting the APP and Notch substrates into the gamma-secretase complex. Chemical- or antibody-mediated blocking of the free amino terminus, addition of purified nicastrin ectodomain, or mutations in the ectodomain markedly reduce the binding and cleavage of substrate by gamma-secretase. These results indicate that nicastrin is a receptor for the amino-terminal stubs that are generated by ectodomain shedding of type I transmembrane proteins. Our data are consistent with a model where nicastrin presents these substrates to gamma-secretase and thereby facilitates their cleavage via intramembrane proteolysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sanjiv</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Basic Neuroscience, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sheu-Fen</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Tabuchi</LastName><ForeName>Katsuhiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hao</LastName><ForeName>Yi-Heng</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Cong</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>LaPlant</LastName><ForeName>Quincey</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Haydn</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Dann</LastName><ForeName>Charles E</ForeName><Initials>CE</Initials><Suffix>3rd</Suffix></Author><Author ValidYN="Y"><LastName>S&#xfc;dhof</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gang</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG023104</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051880">Receptors, Notch</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C413604">nicastrin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010450">Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509280">BACE1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2005 Aug 12;122(3):318-20. doi: 10.1016/j.cell.2005.07.021.</RefSource><PMID Version="1">16096051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010450" MajorTopicYN="N">Endopeptidases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051880" MajorTopicYN="N">Receptors, Notch</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>8</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16096062</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2005.05.022</ArticleId><ArticleId IdType="pii">S0092-8674(05)00501-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21700325</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>08</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Gaucher disease glucocerebrosidase and &#x3b1;-synuclein form a bidirectional pathogenic loop in synucleinopathies.</ArticleTitle><Pagination><StartPage>37</StartPage><EndPage>52</EndPage><MedlinePgn>37-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2011.06.001</ELocationID><Abstract><AbstractText>Parkinson's disease (PD), an adult neurodegenerative disorder, has been clinically linked to the lysosomal storage disorder Gaucher disease (GD), but the mechanistic connection is not known. Here, we show that functional loss of GD-linked glucocerebrosidase (GCase) in primary cultures or human iPS neurons compromises lysosomal protein degradation, causes accumulation of &#x3b1;-synuclein (&#x3b1;-syn), and results in neurotoxicity through aggregation-dependent mechanisms. Glucosylceramide (GlcCer), the GCase substrate, directly influenced amyloid formation of purified &#x3b1;-syn by stabilizing soluble oligomeric intermediates. We further demonstrate that &#x3b1;-syn inhibits the lysosomal activity of normal GCase in neurons and idiopathic PD brain, suggesting that GCase depletion contributes to the pathogenesis of sporadic synucleinopathies. These findings suggest that the bidirectional effect of &#x3b1;-syn and GCase forms a positive feedback loop that may lead to a self-propagating disease. Therefore, improved targeting of GCase to lysosomes may represent a specific therapeutic approach for PD and other synucleinopathies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzulli</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegenerative Disease, Charlestown, MA 02129, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>You-Hai</ForeName><Initials>YH</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Adam L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>McLean</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Guy A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Sidransky</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grabowski</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Krainc</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01DK36729</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK036729</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS051303</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS070168</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32NS066730</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 NS066730</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ZIA HG200336</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005963">Glucosylceramides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.45</RegistryNumber><NameOfSubstance UI="D005962">Glucosylceramidase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2011 Jul 8;146(1):9-11. doi: 10.1016/j.cell.2011.06.031.</RefSource><PMID Version="1">21729776</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Clin Genet. 2011 Nov;80(5):426-7. doi: 10.1111/j.1399-0004.2011.01768.x.</RefSource><PMID Version="1">21883165</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2011 Oct;26(12):2177. doi: 10.1002/mds.23985.</RefSource><PMID Version="1">22319791</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025461" MajorTopicYN="N">Feedback, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005776" MajorTopicYN="N">Gaucher Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005962" MajorTopicYN="N">Glucosylceramidase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005963" MajorTopicYN="N">Glucosylceramides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21700325</ArticleId><ArticleId IdType="mid">NIHMS303607</ArticleId><ArticleId IdType="pmc">PMC3132082</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2011.06.001</ArticleId><ArticleId IdType="pii">S0092-8674(11)00601-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002;295:865&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady RO, Kanfer J, Shapiro D. The Metabolism of Glucocerebrosides. I. Purification and Properties of a Glucocerebroside-Cleaving Enzyme from Spleen Tissue. J Biol Chem. 1965;240:39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">14253443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK. The risk of Parkinson's disease in type 1 Gaucher disease. J Inherit Metab Dis. 2010;33:167&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887303</ArticleId><ArticleId IdType="pubmed">20177787</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005;123:383&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">16269331</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, Liu K, Xu K, Strathearn KE, Liu F, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science. 2006;313:324&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1983366</ArticleId><ArticleId IdType="pubmed">16794039</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002;52:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson AH, Ginns EI, Barranger JA. Biosynthesis of the lysosomal enzyme glucocerebrosidase. J Biol Chem. 1985;260:14319&#x2013;14324.</Citation><ArticleIdList><ArticleId IdType="pubmed">3932353</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Murray IV, Trojanowski JQ, Lee VM. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2001;276:2380&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060312</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology. 2006;67:908&#x2013;910.</Citation><ArticleIdList><ArticleId IdType="pubmed">16790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41:937&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1735652</ArticleId><ArticleId IdType="pubmed">15591280</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet. 2008;372:1263&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19094956</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H. Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem. 2004;279:47746&#x2013;47753.</Citation><ArticleIdList><ArticleId IdType="pubmed">15364911</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee RE. The fine structure of the cerebroside occurring in Gaucher's disease. Proc Natl Acad Sci U S A. 1968;61:484&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC225184</ArticleId><ArticleId IdType="pubmed">4176481</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM, Roehr JT, McQueen MB, Bagade S, Kavvoura F, Schjeide BMM, Allen NC, Tanzi R, Khoury MJ, Ioannidis JPA, Bertram L. The PDGene Database.  [Accessed 09/2008-03/2009];Alzheimer Research Forum.  Available at:  http://www.pdgene.org.</Citation></Reference><Reference><Citation>Manning-Bog AB, Schule B, Langston JW. Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology. 2009;30:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">19576930</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci. 1988;8:2804&#x2013;2815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569395</ArticleId><ArticleId IdType="pubmed">3411354</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez Z, Zhu M, Han S, Fink AL. GM1 specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry. 2007;46:1868&#x2013;1877.</Citation><ArticleIdList><ArticleId IdType="pubmed">17253773</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Mishizen AJ, Giasson BI, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H. Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci. 2006;26:10068&#x2013;10078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674486</ArticleId><ArticleId IdType="pubmed">17005870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzulli JR, Armakola M, Dumoulin M, Parastatidis I, Ischiropoulos H. Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J Biol Chem. 2007;282:31621&#x2013;31630.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785456</ArticleId></ArticleIdList></Reference><Reference><Citation>Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, Reches A, Bembi B, Zimran A. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996;89:691&#x2013;694.</Citation><ArticleIdList><ArticleId IdType="pubmed">8917744</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann J, Bras J, Deas E, O'Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 2009;132:1783&#x2013;1794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702833</ArticleId><ArticleId IdType="pubmed">19286695</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D. Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells. J Neurosci. 2011;31:5970&#x2013;5976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091622</ArticleId><ArticleId IdType="pubmed">21508222</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E. Gaucher disease and parkinsonism. Mol Genet Metab. 2005;84:302&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781189</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009;361:1651&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2856322</ArticleId><ArticleId IdType="pubmed">19846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Stryer L. The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites. J Mol Biol. 1965;13:482&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">5867031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Quinn B, Witte DP, Grabowski GA. Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res. 2005;46:2102&#x2013;2113.</Citation><ArticleIdList><ArticleId IdType="pubmed">16061944</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi N, Callahan M, Madike V, Stubblefield BK, Orvisky E, Krasnewich D, Fillano JJ, Sidransky E. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab. 2001;73:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">11509013</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab. 2003;79:104&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">12809640</ArticleId></ArticleIdList></Reference><Reference><Citation>Thayanidhi N, Helm JR, Nycz DC, Bentley M, Liang Y, Hay JC. Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs. Mol Biol Cell. 2010;21:1850&#x2013;1863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2877643</ArticleId><ArticleId IdType="pubmed">20392839</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Lee VM. Parkinson's disease and related synucleinopathies are a new class of nervous system amyloidoses. Neurotoxicology. 2002;23:457&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12428717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, Giasson BI, Krainc D, Ischiropoulos H, Mazzulli JR. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci. 2010;30:3409&#x2013;3418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844128</ArticleId><ArticleId IdType="pubmed">20203200</ArticleId></ArticleIdList></Reference><Reference><Citation>Volles MJ, Lansbury PT., Jr Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry. 2003;42:7871&#x2013;7878.</Citation><ArticleIdList><ArticleId IdType="pubmed">12834338</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, Morrison A, Lwin A, Colegial C, Allman JM, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234332</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol. 2003;163:2093&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892407</ArticleId><ArticleId IdType="pubmed">14578207</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, Sun Y, Ran H, Quinn B, Witte D, Grabowski GA. Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab. 2010;102:436&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059359</ArticleId><ArticleId IdType="pubmed">21257328</ArticleId></ArticleIdList></Reference><Reference><Citation>Zala D, Benchoua A, Brouillet E, Perrin V, Gaillard MC, Zurn AD, Aebischer P, Deglon N. Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. Neurobiol Dis. 2005;20:785&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">16006135</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18272491</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>7</Issue><PubDate><Year>2008</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity.</ArticleTitle><Pagination><StartPage>2681</StartPage><EndPage>2686</EndPage><MedlinePgn>2681-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.0712197105</ELocationID><Abstract><AbstractText>Cells that have evolved to produce large quantities of secreted proteins to serve the integrated functions of complex multicellular organisms are equipped to compensate for protein misfolding. Hepatocytes and plasma cells have well developed chaperone and proteasome systems to ensure that secreted proteins transit the cell efficiently. The number of neurodegenerative disorders associated with protein misfolding suggests that neurons are particularly sensitive to the pathogenic effects of aggregates of misfolded molecules because those systems are less well developed in this lineage. Aggregates of the amyloidogenic (Abeta(1-42)) peptide play a major role in the pathogenesis of Alzheimer's disease (AD), although the precise mechanism is unclear. In genetic studies examining protein-protein interactions that could constitute native mechanisms of neuroprotection in vivo, overexpression of a WT human transthyretin (TTR) transgene was ameliorative in the APP23 transgenic murine model of human AD. Targeted silencing of the endogenous TTR gene accelerated the development of the neuropathologic phenotype. Intraneuronal TTR was seen in the brains of normal humans and mice and in AD patients and APP23 mice. The APP23 brains showed colocalization of extracellular TTR with Abeta in plaques. Using surface plasmon resonance we obtained in vitro evidence of direct protein-protein interaction between TTR and Abeta aggregates. These findings suggest that TTR is protective because of its capacity to bind toxic or pretoxic Abeta aggregates in both the intracellular and extracellular environment in a chaperone-like manner. The interaction may represent a unique normal host defense mechanism, enhancement of which could be therapeutically useful.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Buxbaum</LastName><ForeName>Joel N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Division of Rheumatology Research, W. M. Keck Autoimmune Disease Center, and Department of Molecular and Experimental Medicine, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. jbux@scripps.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zhengyi</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Reixach</LastName><ForeName>Nat&#xe0;lia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Friske</LastName><ForeName>Linsey</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Coree</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Pritam</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Masliah</LastName><ForeName>Eliezer</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Amanda R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Bartfai</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG015916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG15916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011228">Prealbumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017457">Receptors, Albumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C091986">transthyretin receptor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001669" MajorTopicYN="N">Biochemical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001671" MajorTopicYN="N">Biochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011228" MajorTopicYN="N">Prealbumin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017457" MajorTopicYN="N">Receptors, Albumin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2008</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18272491</ArticleId><ArticleId IdType="pmc">PMC2268196</ArticleId><ArticleId IdType="doi">10.1073/pnas.0712197105</ArticleId><ArticleId IdType="pii">0712197105</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schwarzman AL, et al. Transthyretin sequesters amyloid &#x3b2; protein and prevents amyloid formation. Proc Natl Acad Sci USA. 1994;91:8368&#x2013;8372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC44607</ArticleId><ArticleId IdType="pubmed">8078889</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarzman AL, Goldgaber D. In: The Nature and Origin of Amyloid Fibrils. Bock GR, Goode JA, editors. New York: Wiley; 1996. pp. 146&#x2013;164.</Citation></Reference><Reference><Citation>Schwarzman AL, et al. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid. 2004;11:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15185492</ArticleId></ArticleIdList></Reference><Reference><Citation>Link CD. Expression of human &#x3b2;-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA. 1995;92:9368&#x2013;9372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40986</ArticleId><ArticleId IdType="pubmed">7568134</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci. 2002;22:7380&#x2013;7388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758007</ArticleId><ArticleId IdType="pubmed">12196559</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturchler-Pierrat C, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287&#x2013;13292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24301</ArticleId><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng MH, et al. Amyloid and nonfibrillar deposits in mice transgenic for wild-type human transthyretin: A possible model for senile systemic amyloidosis. Lab Invest. 2001;81:385&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">11310831</ArticleId></ArticleIdList></Reference><Reference><Citation>Episkopou V, et al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA. 1993;90:2375&#x2013;2379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46089</ArticleId><ArticleId IdType="pubmed">8384721</ArticleId></ArticleIdList></Reference><Reference><Citation>Prut L, et al. Aged APP23 mice show a delay in switching to the use of a strategy in the Barnes maze. Behav Brain Res. 2007;179:107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">17324476</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, et al. Anti-A&#x3b2;42- and anti-A&#x3b2;40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006;116:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawley JN. Behavioral phenotyping of rodents. Comp Med. 2003;53:140&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">12784847</ArticleId></ArticleIdList></Reference><Reference><Citation>McLay RN, Freeman SM, Zadina JE. Chronic corticosterone impairs memory performance in the Barnes maze. Physiol Behav. 1998;63:933&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">9618019</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, et al. Accelerated A&#x3b2; deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J Neurosci. 2007;27:7006&#x2013;7010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672232</ArticleId><ArticleId IdType="pubmed">17596449</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa JC, et al. Transthyretin influences spatial reference memory. Neurobiol Learn Mem. 2007;88:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698379</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Murphy RM. Kinetics of inhibition of &#x3b2;-Amyloid aggregation by transthyretin. Biochemistry. 2006;45:15702&#x2013;15709.</Citation><ArticleIdList><ArticleId IdType="pubmed">17176092</ArticleId></ArticleIdList></Reference><Reference><Citation>Carro E, Trejo JL, Gonez-Isla T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-&#x3b2; levels. Nat Med. 2002;8:1390&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12415260</ArticleId></ArticleIdList></Reference><Reference><Citation>Reixach N, et al. Human-murine transthyretin heterotetramers are kinetically stable and nonamyloidogenic: A lesson in the generation of transgenic models of diseases involving oligomeric proteins. J Biol Chem. 2008;283:2098&#x2013;2107.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006495</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirahama T, et al. Senile cerebral amyloid: Prealbumin as a common constituent in the neuritic plaque, in the neurofibrillary tangle, and in the microangiopathic lesion. Am J Pathol. 1982;107:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1915994</ArticleId><ArticleId IdType="pubmed">6950666</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein TD, et al. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPsw mice resulting in Tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis. J Neurosci. 2004;24:7707&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729623</ArticleId><ArticleId IdType="pubmed">15342738</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber G. The evolution of transthyretin synthesis in the choroid plexus. Clin Chem Lab Med. 2002;40:1200&#x2013;1210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12553420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA. Transthyretin and Alzheimer's disease: Where in the brain? Neurobiol Aging. 2006;28:713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16698124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lein ES, et al. Genomewide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pubmed">17151600</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapala MA, et al. Adult mouse brain gene expression patterns bear an embryologic imprint. Proc Natl Acad Sci USA. 2005;102:10357&#x2013;10362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1173363</ArticleId><ArticleId IdType="pubmed">16002470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa JC, et al. Transthyretin is involved in depression-like behavior and exploratory activity. J Neurochem. 2004;88:1052&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009661</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouillette J, Quirion R. Transthyretin: A key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging. 2007 doi: 10.1016/j.neurobiolaging.2007.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.04.007</ArticleId><ArticleId IdType="pubmed">17512093</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodman AB. Retinoid receptors, transporters, and metabolizers as therapeutic targets in late-onset Alzheimer disease. J Cell Physiol. 2006;209:598&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pubmed">17001693</ArticleId></ArticleIdList></Reference><Reference><Citation>Palha JA, et al. Thyroid hormone metabolism in a transthyretin-null mouse strain. J Biol Chem. 1994;269:33135&#x2013;33139.</Citation><ArticleIdList><ArticleId IdType="pubmed">7806543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan C, Costa RH, Darnell JE, Jr, Chen JD, Van Dyke TA. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J. 1990;9:869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC551747</ArticleId><ArticleId IdType="pubmed">1690125</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:7611&#x2013;7615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC298116</ArticleId><ArticleId IdType="pubmed">2529544</ArticleId></ArticleIdList></Reference><Reference><Citation>Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and non-native oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci USA. 2004;101:2817&#x2013;2822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC365703</ArticleId><ArticleId IdType="pubmed">14981241</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB. Preparation of amyloid &#x3b2;-protein for structural and functional studies. Methods Enzymol. 2006;413:20&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046389</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21725313</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Potent amyloidogenicity and pathogenicity of A&#x3b2;43.</ArticleTitle><Pagination><StartPage>1023</StartPage><EndPage>1032</EndPage><MedlinePgn>1023-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.2858</ELocationID><Abstract><AbstractText>The amyloid-&#x3b2; peptide A&#x3b2;42 is known to be a primary amyloidogenic and pathogenic agent in Alzheimer's disease. However, the role of A&#x3b2;43, which is found just as frequently in the brains of affected individuals, remains unresolved. We generated knock-in mice containing a pathogenic presenilin-1 R278I mutation that causes overproduction of A&#x3b2;43. Homozygosity was embryonic lethal, indicating that the mutation involves a loss of function. Crossing amyloid precursor protein transgenic mice with heterozygous mutant mice resulted in elevated A&#x3b2;43, impairment of short-term memory and acceleration of amyloid-&#x3b2; pathology, which accompanied pronounced accumulation of A&#x3b2;43 in plaque cores similar in biochemical composition to those observed in the brains of affected individuals. Consistently, A&#x3b2;43 showed a higher propensity to aggregate and was more neurotoxic than A&#x3b2;42. Other pathogenic presenilin mutations also caused overproduction of A&#x3b2;43 in a manner correlating with A&#x3b2;42 and with the age of disease onset. These findings indicate that A&#x3b2;43, an overlooked species, is potently amyloidogenic, neurotoxic and abundant in vivo.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suemoto</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Brouwers</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sleegers</LastName><ForeName>Kristel</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Funamoto</LastName><ForeName>Satoru</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mihira</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Matsuba</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kazuyuki</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Per</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Jiro</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Masaki</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Nobuhisa</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Van Broeckhoven</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ihara</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C098994">amyloid beta-protein (1-43)</NameOfSubstance></Chemical><Chemical><RegistryNumber>04Y7590D77</RegistryNumber><NameOfSubstance UI="D007532">Isoleucine</NameOfSubstance></Chemical><Chemical><RegistryNumber>94ZLA3W45F</RegistryNumber><NameOfSubstance UI="D001120">Arginine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.1.1.27</RegistryNumber><NameOfSubstance UI="D007770">L-Lactate Dehydrogenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2011 Jul 26;14(8):949-50. doi: 10.1038/nn.2871.</RefSource><PMID Version="1">21792191</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001120" MajorTopicYN="N">Arginine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007532" MajorTopicYN="N">Isoleucine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007770" MajorTopicYN="N">L-Lactate Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId><ArticleId IdType="doi">10.1038/nn.2858</ArticleId><ArticleId IdType="pii">nn.2858</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuron. 2005 Jul 21;47(2):191-199</Citation><ArticleIdList><ArticleId IdType="pubmed">16039562</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2007 Sep 11;46(36):10317-27</Citation><ArticleIdList><ArticleId IdType="pubmed">17705508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Jun 13;283(24):16488-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18430735</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 2001 Oct 1;103(2):138-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11568920</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1993 May 11;32(18):4693-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Jan 17;27(3):627-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Jul 30;460(7255):632-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19641596</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1995 Feb;14(2):457-66</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1997 May 15;387(6630):288-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9153393</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2004 Jul 16;279(29):30259-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15100223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jan 28;24(4):991-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):330-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Jan 12;25(2):436-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2009 Oct 14;29(41):13042-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2010 Nov;18(11):1202-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20628413</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13075-80</Citation><ArticleIdList><ArticleId IdType="pubmed">14566063</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Nov 9;63(9):1702-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15534260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2009 Jul;110(2):697-706</Citation><ArticleIdList><ArticleId IdType="pubmed">19457079</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Oct 10;27(41):10957-68</Citation><ArticleIdList><ArticleId IdType="pubmed">17928437</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 2004 Jan;271(2):375-85</Citation><ArticleIdList><ArticleId IdType="pubmed">14717705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2006 Jul;27(7):686-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16752394</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Apr 5;26(14):3845-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16597739</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2005 Aug 16;44(32):10810-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16086583</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2005 Mar 22;44(11):4332-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15766262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2008 Oct;14(10):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Feb 28;278(9):7010-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12493731</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Jun 1;405(6786):531-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10850703</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1995 Dec 8;702(1-2):275-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8846089</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1999 Jan;154(1):271-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9916941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Jul 29;368(9533):387-403</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 May 13;280(19):19070-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15764596</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Methods. 2010 Jul 15;190(2):171-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20452375</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 May 1;324(5927):639-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19299585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Jun 30;281(26):17941-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16636059</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2007 Jul;21(9):2135-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17341681</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1997 May 16;89(4):629-39</Citation><ArticleIdList><ArticleId IdType="pubmed">9160754</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Anim. 2001 Jan;50(1):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11326427</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Jul 23;285(30):23186-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20452980</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1683-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8643690</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Jun 2;281(22):15330-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16574645</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 1997 Jul;3(7):756-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9212102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2006 Feb;96(3):732-42</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2001 Dec;58(12):2025-32</Citation><ArticleIdList><ArticleId IdType="pubmed">11735776</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2008 Oct 17;283(42):28176-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18694930</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1994 Jul;13(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1996 Jul;17(1):181-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8755489</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2007 Nov 28;27(48):13092-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18045903</ArticleId></ArticleIdList></Reference><Reference><Citation>J Alzheimers Dis. 2004 Oct;6(5):483-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15505369</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13287-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2000 Jun 22;405(6789):966-70</Citation><ArticleIdList><ArticleId IdType="pubmed">10879540</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18802001</PMID><DateCompleted><Year>2008</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>321</Volume><Issue>5896</Issue><PubDate><Year>2008</Year><Month>Sep</Month><Day>19</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1686</StartPage><EndPage>1689</EndPage><MedlinePgn>1686-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1162844</ELocationID><Abstract><AbstractText>The neurodegeneration observed in Alzheimer's disease has been associated with synaptic dismantling and progressive decrease in neuronal activity. We tested this hypothesis in vivo by using two-photon Ca2+ imaging in a mouse model of Alzheimer's disease. Although a decrease in neuronal activity was seen in 29% of layer 2/3 cortical neurons, 21% of neurons displayed an unexpected increase in the frequency of spontaneous Ca2+ transients. These "hyperactive" neurons were found exclusively near the plaques of amyloid beta-depositing mice. The hyperactivity appeared to be due to a relative decrease in synaptic inhibition. Thus, we suggest that a redistribution of synaptic drive between silent and hyperactive neurons, rather than an overall decrease in synaptic activity, provides a mechanism for the disturbed cortical function in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Busche</LastName><ForeName>Marc Aurel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institut f&#xfc;r Neurowissenschaften, Technische Universit&#xe4;t M&#xfc;nchen (TUM), 80802 M&#xfc;nchen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eichhoff</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Adelsberger</LastName><ForeName>Helmuth</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Abramowski</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Wiederhold</LastName><ForeName>Karl-Heinz</ForeName><Initials>KH</Initials></Author><Author ValidYN="Y"><LastName>Haass</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Staufenbiel</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Konnerth</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Garaschuk</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId><ArticleId IdType="doi">10.1126/science.1162844</ArticleId><ArticleId IdType="pii">321/5896/1686</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20818335</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>19</Issue><PubDate><Year>2010</Year><Month>Oct</Month><Day>06</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Neurotoxicity of Alzheimer's disease A&#x3b2; peptides is induced by small changes in the A&#x3b2;42 to A&#x3b2;40 ratio.</ArticleTitle><Pagination><StartPage>3408</StartPage><EndPage>3420</EndPage><MedlinePgn>3408-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2010.211</ELocationID><Abstract><AbstractText>The amyloid peptides A&#x3b2;(40) and A&#x3b2;(42) of Alzheimer's disease are thought to contribute differentially to the disease process. Although A&#x3b2;(42) seems more pathogenic than A&#x3b2;(40), the reason for this is not well understood. We show here that small alterations in the A&#x3b2;(42):A&#x3b2;(40) ratio dramatically affect the biophysical and biological properties of the A&#x3b2; mixtures reflected in their aggregation kinetics, the morphology of the resulting amyloid fibrils and synaptic function tested in vitro and in vivo. A minor increase in the A&#x3b2;(42):A&#x3b2;(40) ratio stabilizes toxic oligomeric species with intermediate conformations. The initial toxic impact of these A&#x3b2; species is synaptic in nature, but this can spread into the cells leading to neuronal cell death. The fact that the relative ratio of A&#x3b2; peptides is more crucial than the absolute amounts of peptides for the induction of neurotoxic conformations has important implications for anti-amyloid therapy. Our work also suggests the dynamic nature of the equilibrium between toxic and non-toxic intermediates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuperstein</LastName><ForeName>Inna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department for Molecular and Developmental Genetics, Flanders Institute for Biotechnology (VIB), Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broersen</LastName><ForeName>Kerensa</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Benilova</LastName><ForeName>Iryna</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Rozenski</LastName><ForeName>Jef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Jonckheere</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Debulpaep</LastName><ForeName>Maja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vandersteen</LastName><ForeName>Annelies</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Segers-Nolten</LastName><ForeName>Ine</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Van Der Werf</LastName><ForeName>Kees</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Vinod</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Braeken</LastName><ForeName>Dries</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Callewaert</LastName><ForeName>Geert</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bartic</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>D'Hooge</LastName><ForeName>Rudi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ivo Cristiano</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Frederic</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Schymkowitz</LastName><ForeName>Joost</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005456">Fluorescent Dyes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>2390-54-7</RegistryNumber><NameOfSubstance UI="C009462">thioflavin T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="N">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001703" MajorTopicYN="N">Biophysics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005456" MajorTopicYN="N">Fluorescent Dyes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008839" MajorTopicYN="N">Microelectrodes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018408" MajorTopicYN="N">Patch-Clamp Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>1</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20818335</ArticleId><ArticleId IdType="pmc">PMC2957213</ArticleId><ArticleId IdType="doi">10.1038/emboj.2010.211</ArticleId><ArticleId IdType="pii">emboj2010211</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65: 1509&#x2013;1517</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksenov MY, Aksenova MV, Butterfield DA, Hensley K, Vigo-Pelfrey C, Carney JM (1996) Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1&#x2013;40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation. J Neurochem 66: 2050&#x2013;2056</Citation><ArticleIdList><ArticleId IdType="pubmed">8780035</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W, De Strooper B (2002) A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 18: 25&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H, De Strooper B (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96: 732&#x2013;742</Citation><ArticleIdList><ArticleId IdType="pubmed">16405513</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese B, Shaked GM, Tabarean IV, Braga J, Koo EH, Halpain S (2007) Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol Cell Neurosci 35: 183&#x2013;193</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268524</ArticleId><ArticleId IdType="pubmed">17368908</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamberlain AK, MacPhee CE, Zurdo J, Morozova-Roche LA, Hill HA, Dobson CM, Davis JJ (2000) Ultrastructural organization of amyloid fibrils by atomic force microscopy. Biophys J 79: 3282&#x2013;3293</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1301202</ArticleId><ArticleId IdType="pubmed">11106631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chirgadze YN, Nevskaya NA (1976) Infrared spectra and resonance interaction of amide-I vibration of the paraellel-chain pleated sheets. Biopolymers 15: 627&#x2013;636</Citation><ArticleIdList><ArticleId IdType="pubmed">1252598</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D et al. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 3: 67&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">8986743</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2007) Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep 8: 141&#x2013;146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1796779</ArticleId><ArticleId IdType="pubmed">17268505</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90: 465&#x2013;494</Citation><ArticleIdList><ArticleId IdType="pubmed">20393191</ArticleId></ArticleIdList></Reference><Reference><Citation>Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin S (1996) Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature 383: 710&#x2013;713</Citation><ArticleIdList><ArticleId IdType="pubmed">8878479</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost D, Gorman PM, Yip CM, Chakrabartty A (2003) Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. Eur J Biochem 270: 654&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pubmed">12581205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100: 10417&#x2013;10422</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Goormaghtigh E, Cabiaux V, Ruysschaert JM (1994) Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. II. Experimental aspects, side chain structure, and H/D exchange. Subcell Biochem 23: 363&#x2013;403</Citation><ArticleIdList><ArticleId IdType="pubmed">7855878</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (1993) Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 75: 1039&#x2013;1042</Citation><ArticleIdList><ArticleId IdType="pubmed">8261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353&#x2013;356</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Lansbury PT Jr (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385&#x2013;407</Citation><ArticleIdList><ArticleId IdType="pubmed">9242912</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876&#x2013;8884</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782787</ArticleId><ArticleId IdType="pubmed">10516307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG (2006) Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45: 15157&#x2013;15167</Citation><ArticleIdList><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Crick SL, Bu G, Frieden C, Pappu RV, Lee JM (2009) Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc Natl Acad Sci USA 106: 20324&#x2013;20329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan A, Gokce O, Luthi-Carter R, Lashuel HA (2008) The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 283: 28176&#x2013;28189</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2661389</ArticleId><ArticleId IdType="pubmed">18694930</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett JT, Lansbury PT. Jr (1993) Seeding &#x2018;one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055&#x2013;1058</Citation><ArticleIdList><ArticleId IdType="pubmed">8513491</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakuda N, Funamoto S, Yagishita S, Takami M, Osawa S, Dohmae N, Ihara Y (2006) Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. J Biol Chem 281: 14776&#x2013;14786</Citation><ArticleIdList><ArticleId IdType="pubmed">16595682</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486&#x2013;489</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Onstead L, Randle S, Price R, Smithson L, Zwizinski C, Dickson DW, Golde T, McGowan E (2007) Abeta40 inhibits amyloid deposition in vivo. J Neurosci 27: 627&#x2013;633</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672801</ArticleId><ArticleId IdType="pubmed">17234594</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28: 4231&#x2013;4237</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2685151</ArticleId><ArticleId IdType="pubmed">18417702</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27: 796&#x2013;807</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672917</ArticleId><ArticleId IdType="pubmed">17251419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95: 6448&#x2013;6453</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr (2002) Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291.</Citation><ArticleIdList><ArticleId IdType="pubmed">12124613</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457: 1128&#x2013;1132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748841</ArticleId><ArticleId IdType="pubmed">19242475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352&#x2013;357</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M (1996) Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). Ann Neurol 40: 149&#x2013;156</Citation><ArticleIdList><ArticleId IdType="pubmed">8773595</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D'Hooge R, De Strooper B, Schymkowitz J, Rousseau F (2008) Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27: 224&#x2013;233</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206134</ArticleId><ArticleId IdType="pubmed">18059472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci USA 106: 14745&#x2013;14750</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2736424</ArticleId><ArticleId IdType="pubmed">19706468</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270: 23895&#x2013;23898</Citation><ArticleIdList><ArticleId IdType="pubmed">7592576</ArticleId></ArticleIdList></Reference><Reference><Citation>Pine J (1980) Recording action potentials from cultured neurons with extracellular microcircuit electrodes. J Neurosci Methods 2: 19&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">7329089</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter SM, DeMarse TB (2001) A new approach to neural cell culture for long-term studies. J Neurosci Methods 110: 17&#x2013;24</Citation><ArticleIdList><ArticleId IdType="pubmed">11564520</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and &#x2018;preclinical' Alzheimer's disease. Ann Neurol 45: 358&#x2013;368</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y (2005) Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J Neurosci 25: 436&#x2013;445</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106: 6820&#x2013;6825</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 215: 173&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">8899741</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama H, Koo EH, Haass C, Takio K, Morishima-Kawashima M, Ishiura S, Ihara Y (2003) Potential link between amyloid beta-protein 42 and C-terminal fragment gamma 49&#x2013;99 of beta-amyloid precursor protein. J Biol Chem 278: 24294&#x2013;24301</Citation><ArticleIdList><ArticleId IdType="pubmed">12707272</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D et al. (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2: 864&#x2013;870</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S (2008) Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med 14: 1106&#x2013;1111</Citation><ArticleIdList><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837&#x2013;842</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF (1994) Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67: 1216&#x2013;1228</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1225478</ArticleId><ArticleId IdType="pubmed">7811936</ArticleId></ArticleIdList></Reference><Reference><Citation>Stett A, Egert U, Guenther E, Hofmann F, Meyer T, Nisch W, Haemmerle H (2003) Biological application of microelectrode arrays in drug discovery and basic research. Anal Bioanal Chem 377: 486&#x2013;495</Citation><ArticleIdList><ArticleId IdType="pubmed">12923608</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336&#x2013;1340</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572&#x2013;580</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Tew DJ, Bottomley SP, Smith DP, Ciccotosto GD, Babon J, Hinds MG, Masters CL, Cappai R, Barnham KJ (2008) Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. Biophys J 94: 2752&#x2013;2766</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267149</ArticleId><ArticleId IdType="pubmed">18065467</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535&#x2013;539</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Wang B, He W, Zheng H (2006) Wild-type presenilin 1 protects against Alzheimer's disease mutation-induced amyloid pathology. J Biol Chem 29: 29</Citation><ArticleIdList><ArticleId IdType="pubmed">16574645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wogulis M, Wright S, Cunningham D, Chilcote T, Powell K, Rydel RE (2005) Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 25: 1071&#x2013;1080</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725948</ArticleId><ArticleId IdType="pubmed">15689542</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y, Wang C (2007) Abeta40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol 369: 909&#x2013;916</Citation><ArticleIdList><ArticleId IdType="pubmed">17481654</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiike Y, Chui DH, Akagi T, Tanaka N, Takashima A (2003) Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. J Biol Chem 278: 23648&#x2013;23655</Citation><ArticleIdList><ArticleId IdType="pubmed">12716908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11062468</PMID><DateCompleted><Year>2000</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1061-4036</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nature genetics</Title><ISOAbbreviation>Nat Genet</ISOAbbreviation></Journal><ArticleTitle>Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice.</ArticleTitle><Pagination><StartPage>300</StartPage><EndPage>306</EndPage><MedlinePgn>300-6</MedlinePgn></Pagination><Abstract><AbstractText>Inactivation of the mouse homologue of the Huntington disease gene (Hdh) results in early embryonic lethality. To investigate the normal function of Hdh in the adult and to evaluate current models for Huntington disease (HD), we have used the Cre/loxP site-specific recombination strategy to inactivate Hdh expression in the forebrain and testis, resulting in a progressive degenerative neuronal phenotype and sterility. On the basis of these results, we propose that huntingtin is required for neuronal function and survival in the brain and that a loss-of-function mechanism may contribute to HD pathogenesis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dragatsis</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Genetics and Development, Columbia University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Zeitlin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GENBANK</DataBankName><AccessionNumberList><AccessionNumber>L28827</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Genet</MedlineTA><NlmUniqueID>9216904</NlmUniqueID><ISSNLinking>1061-4036</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005904">Glial Fibrillary Acidic Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C506812">Htt protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071058">Huntingtin Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008869">Microtubule-Associated Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009687">Nuclear Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="C045073">Cre recombinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D019426">Integrases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018390" MajorTopicYN="Y">Gene Targeting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005904" MajorTopicYN="N">Glial Fibrillary Acidic Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071058" MajorTopicYN="N">Huntingtin Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007248" MajorTopicYN="N">Infertility, Male</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019426" MajorTopicYN="N">Integrases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008869" MajorTopicYN="N">Microtubule-Associated Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009687" MajorTopicYN="N">Nuclear Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011995" MajorTopicYN="N">Recombination, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012045" MajorTopicYN="N">Regulatory Sequences, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013091" MajorTopicYN="N">Spermatogenesis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013737" MajorTopicYN="N">Testis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="Y">Viral Proteins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>4</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>4</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11062468</ArticleId><ArticleId IdType="doi">10.1038/81593</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21613495</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>21</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy.</ArticleTitle><Pagination><StartPage>7817</StartPage><EndPage>7830</EndPage><MedlinePgn>7817-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.6412-10.2011</ELocationID><Abstract><AbstractText>In the hallmark neuritic dystrophy of Alzheimer's disease (AD), autophagic vacuoles containing incompletely digested proteins selectively accumulate in focal axonal swellings, reflecting defects in both axonal transport and autophagy. Here, we investigated the possibility that impaired lysosomal proteolysis could be a basis for both of these defects leading to neuritic dystrophy. In living primary mouse cortical neurons expressing fluorescence-tagged markers, LC3-positive autophagosomes forming in axons rapidly acquired the endo-lysosomal markers Rab7 and LAMP1 and underwent exclusive retrograde movement. Proteolytic clearance of these transported autophagic vacuoles was initiated after fusion with bidirectionally moving lysosomes that increase in number at more proximal axon levels and in the perikaryon. Disrupting lysosomal proteolysis by either inhibiting cathepsins directly or by suppressing lysosomal acidification slowed the axonal transport of autolysosomes, late endosomes, and lysosomes and caused their selective accumulation within dystrophic axonal swellings. Mitochondria and other organelles lacking cathepsins moved normally under these conditions, indicating that the general functioning of the axonal transport system was preserved. Dystrophic swellings induced by lysosomal proteolysis inhibition resembled in composition those in several mouse models of AD and also acquired other AD-like features, including immunopositivity for ubiquitin, amyloid precursor protein, and hyperphosphorylated neurofilament proteins. Restoration of lysosomal proteolysis reversed the affected movements of proteolytic Rab7 vesicles, which in turn essentially cleared autophagic substrates and reversed the axonal dystrophy. These studies identify the AD-associated defects in neuronal lysosomal proteolysis as a possible basis for the selective transport abnormalities and highly characteristic pattern of neuritic dystrophy associated with AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sooyeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience/Physiology, New York University Langone Medical Center, New York, New York 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nixon</LastName><ForeName>Ralph A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG017617</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D010447">Peptide Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015388" MajorTopicYN="N">Organelles</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010447" MajorTopicYN="N">Peptide Hydrolases</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21613495</ArticleId><ArticleId IdType="mid">NIHMS299164</ArticleId><ArticleId IdType="pmc">PMC3351137</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.6412-10.2011</ArticleId><ArticleId IdType="pii">31/21/7817</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA, Kerschensteiner M, Misgeld T, Coleman MP. Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain. 2009;132:402&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">19059977</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahr BA, Bendiske J. The neuropathogenic contributions of lysosomal dysfunction. J Neurochem. 2002;83:481&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12390510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bains M, Heidenreich KA. Live-cell imaging of autophagy induction and autophagosome-lysosome fusion in primary cultured neurons. Methods Enzymol. 2009;453:145&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745925</ArticleId><ArticleId IdType="pubmed">19216905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta. 2009;1793:684&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">19111581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bampton ETW, Goemans CG, Niranjan D, Mizushima N, Tolkovsky AM. The dymanics of autophagy visualizes in live cells: from autophagosome formation to fusion with endo/lysosomes. Autophagy. 2005;1:23&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874023</ArticleId></ArticleIdList></Reference><Reference><Citation>Batistatou A, Greene L. Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity. J Cell Biol. 1991;15:461&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2289153</ArticleId><ArticleId IdType="pubmed">1655805</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci. 2008;28:6926&#x2013;6937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676733</ArticleId><ArticleId IdType="pubmed">18596167</ArticleId></ArticleIdList></Reference><Reference><Citation>Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM. Macroautophagy is not directly involved in the metabolism of amyloid precursor protein. J Biol Chem. 2010;285:37415&#x2013;37426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988347</ArticleId><ArticleId IdType="pubmed">20864542</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucci C, Thomsen P, Nicoziani P, McCarthy J, van Deurs B. Rab7: a key to lysosome biogenesis. Mol Biol Cell. 2000;11:467&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14786</ArticleId><ArticleId IdType="pubmed">10679007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Lu L, Tian JH, Zhu Y, Qiao H, Seng ZH. Snapin-regulated late endosomal transport is critical for efficient autophagy-lysosomal function in neurons. Neuron. 2010;68:73&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953270</ArticleId><ArticleId IdType="pubmed">20920792</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Broadwell RD. Cytochemical staining of the endoplasmic reticulum and glycogen in mouse anterior pituitary cells. J Histochem Cytochem. 1984;32:1285&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">6094657</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol. 2004;63:821&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">15330337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciechomska IA, Tolkovsky AM. Non-autophagic GFP-LC3 puncta induced by saponin and other detergents. Autophagy. 2007;3:586&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">17786021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Wertkin A, Mattiace LA, Fier E, Kress Y, Davies P, Yen SH. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol. 1990;79:486&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">2158201</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn WA., Jr Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol. 1994;4:139&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">14731737</ArticleId></ArticleIdList></Reference><Reference><Citation>Fader CM, Sanchez D, Furlan M, Colombo MI. Induction of autophagy promotes fusion of multivesicular bodies with autophagic vacuoles in k562 cells. Traffic. 2008;9:230&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">17999726</ArticleId></ArticleIdList></Reference><Reference><Citation>Filimonenko M, Stuffers S, Raiborg C, Yamamoto A, Malerod L, Fisher EM, Isaacs A, Brech A, Stenmark H, Simonsen A. Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease. J Cell Biol. 2007;179:485&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064794</ArticleId><ArticleId IdType="pubmed">17984323</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem. 2007;102:1095&#x2013;1104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17472706</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin JW, Price DL, Engel WK, Drachman DB. The pathogenesis of reactive axonal swellings: role of axonal transport. J Neuropathol Exp Neurol. 1977;36:214&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">65450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadano S, Otomo A, Kunita R, Suzuki-Utsunomiya K, Akatsuka A, Koike M, Aoki M, Uchiyama Y, Itoyama Y, Ikeda JE. Loss of ALS2/Alsin exacerbates motor dysfunction in a SOD1-expressing mouse ALS model by disturbing endolysosomal trafficking. PLoS One. 2010;5:e9805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2842444</ArticleId><ArticleId IdType="pubmed">20339559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S, Morgan PJ, Oozageer R, Priestley JV, Averill S, King VR, Ball S, Peters J, Toda T, Yamamoto A, Hiraoka Y, et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science. 2003;300:808&#x2013;812.</Citation><ArticleIdList><ArticleId IdType="pubmed">12730604</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenbeck P. Products of endocytosis and autophagy are retrieved from axons by regulated retrograde organelle transport. J Cell Biol. 1993;121:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200099</ArticleId><ArticleId IdType="pubmed">7682217</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenbeck PJ, Saxton WM. The axonal transport of mitochondria. J Cell Sci. 2005;118:5411&#x2013;5419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1533994</ArticleId><ArticleId IdType="pubmed">16306220</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Klionsky DJ. Regulation of macroautophagy in Saccharomyces cerevisiae. Semin Cell Dev Biol. 2010;21:664&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930024</ArticleId><ArticleId IdType="pubmed">20359542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahreiss L, Menzies FM, Rubinsztein DC. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic. 2008;9:574&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329914</ArticleId><ArticleId IdType="pubmed">18182013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A, Ginsberg SD, Cataldo AM, Mathews PM, Nixon RA. Alzheimer's-related endosome dysfunction in Down syndrome is A&#x3b2;-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A. 2010;107:1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaasinen SK, Harvey L, Reynolds AJ, Hendry IA. Autophagy generates retrogradely transported organelles: a hypothesis. Int J Dev Neurosci. 2008;26:625&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">18499388</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 2000;19:5720&#x2013;5728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305793</ArticleId><ArticleId IdType="pubmed">11060023</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasher PR, De Vos KJ, Wharton SB, Manser C, Bennett EJ, Bingley M, Wood JD, Milner R, McDermott CJ, Miller CCJ, Shaw PJ, Grierson AJ. Direct evidence for axonal transport defects in a novel mouse model of mutant spastin-induced hereditary spastic paraplegia (HSP) and human HSP patients. J Neurochem. 2009;110:34&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453301</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata K, Nishiyama J, Inoue T, Mizushima N, Takeda J, Yuzaki M. Dynein- and activity-dependent retrograde transport of autophagosomes in neuronal axons. Autophagy. 2010;6:378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">20150763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pubmed">17534139</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura S, Noda T, Yoshimori T. Dynein-dependent movement of autophagosomes mediates efficient encounters with lysosomes. Cell Struct Funct. 2008;33:109&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">18388399</ArticleId></ArticleIdList></Reference><Reference><Citation>Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, Bamber BA, Bassham DC, Bergamini E, Bi X, Biard-Piechaczyk M, Blum JS, Bredesen DE, Brodsky JL, Brumell JH, Brunk UT, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008;4:151&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654259</ArticleId><ArticleId IdType="pubmed">18188003</ArticleId></ArticleIdList></Reference><Reference><Citation>Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, Chiba T. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. J Cell Biol. 2005;169:425&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2171928</ArticleId><ArticleId IdType="pubmed">15866887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalli G, Schiavo G. Analysis of retrograde transport in motor neurons reveals common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J Cell Biol. 2002;156:233&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199221</ArticleId><ArticleId IdType="pubmed">11807088</ArticleId></ArticleIdList></Reference><Reference><Citation>LaMonte BH, Wallace KE, Holloway BA, Shelly SS, Ascano J, Tokito M, Van Winkle T, Howland DS, Holzbaur ELF. Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron. 2002;34:715&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062019</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J-H, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA. Lysosomal proteolysis and autophagy require Presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim A, Kraut R. The Drosophila BEACH family protein, Blue Cheese, links lysosomal axon transport with motor neuron degeneration. J Neurosci. 2009;29:951&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3849423</ArticleId><ArticleId IdType="pubmed">19176804</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathews PM, Jiang Y, Schmidt SD, Grbovic OM, Mercken M, Nixon RA. Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem. 2002;277:36415&#x2013;36424.</Citation><ArticleIdList><ArticleId IdType="pubmed">12087104</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuinness L, Bardo SJ, Emptage NJ. The lysosome or lysosome-related organelle may serve as a Ca2+ store in the boutons of hippocampal pyramidal cells. Neuropharmacology. 2007;52:126&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">16930634</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-[bgr] plaques in a mouse model of Alzheimer's disease. Nature. 2008;451:720&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Burns M, Binder LI, Kanaan NM, LaPointe N, Bosco DA, Brown RH, Jr, Brown H, Tiwari A, Hayward L, Edgar J, Nave KA, Garberrn J, Atagi Y, Song Y, Pigino G, Brady ST. Axonal transport defects in neurodegenerative diseases. J Neurosci. 2009;29:12776&#x2013;12786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801051</ArticleId><ArticleId IdType="pubmed">19828789</ArticleId></ArticleIdList></Reference><Reference><Citation>Morvan J, Kochl R, Watson R, Collinson LM, Jefferies HB, Tooze SA. In vitro reconstitution of fusion between immature autophagosomes and endosomes. Autophagy. 2009;5:676&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">19337031</ArticleId></ArticleIdList></Reference><Reference><Citation>Muresan V, Varvel NH, Lamb BT, Muresan Z. The cleavage products of amyloid-beta precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J Neurosci. 2009;29:3565&#x2013;3578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2669751</ArticleId><ArticleId IdType="pubmed">19295161</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagatsu I, Karasawa N, Shimizu N. Early changes in the structure of rat sciatic nerves by ligation. Arch Histol Jpn. 1978;41:439&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pubmed">742957</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakatogawa H, Suzuki K, Kamada Y, Ohsumi Y. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol. 2009;10:458&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pubmed">19491929</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama J, Matsuda K, Kakegawa W, Yamada N, Motohashi J, Mizushima N, Yuzaki M. Reevaluation of neurodegeneration in lurcher mice: constitutive ion fluxes cause cell death with, not by, autophagy. J Neurosci. 2010;30:2177&#x2013;2187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6634053</ArticleId><ArticleId IdType="pubmed">20147545</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon R, Cataldo A. Lysosomal system pathways: genes to neurodegeneration in Alzheimer's disease. J Alzheimer's Disease. 2006;9:277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res. 2000;25:1161&#x2013;1172.</Citation><ArticleIdList><ArticleId IdType="pubmed">11059790</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol. 2005;64:113&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">15751225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohm TG, Treiber-Held S, Distl R, Gl&#xf6;ckner F, Sch&#xf6;nheit B, Tamanai M, Meske V. Cholesterol and tau protein&#x2013;findings in Alzheimer's and Niemann Pick C's disease. Pharmacopsychiatry. 2003;36(Suppl 2):S120&#x2013;S126.</Citation><ArticleIdList><ArticleId IdType="pubmed">14574625</ArticleId></ArticleIdList></Reference><Reference><Citation>Overly CC, Hollenbeck PJ. Dynamic organization of endocytic pathways in axons of cultured sympathetic neurons. J Neurosci. 1996;16:6056&#x2013;6064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579168</ArticleId><ArticleId IdType="pubmed">8815888</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankiv S, Alemu EA, Brech A, Bruun JA, Lamark T, Overvatn A, Bjorkoy G, Johansen T. FYCO1 is a Rab7 effector that binds to LC3 and PI3P to mediate microtubule plus end-directed vesicle transport. J Cell Biol. 2010;188:253&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812517</ArticleId><ArticleId IdType="pubmed">20100911</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrot R, Julien JP. Real-time imaging reveals defects of fast axonal transport induced by disorganization of intermediate filaments. FASEB J. 2009;23:3213&#x2013;3225.</Citation><ArticleIdList><ArticleId IdType="pubmed">19451279</ArticleId></ArticleIdList></Reference><Reference><Citation>Razi M, Chan EY, Tooze SA. Early endosomes and endosomal coatomer are required for autophagy. J Cell Biol. 2009;185:305&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700373</ArticleId><ArticleId IdType="pubmed">19364919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rondanino C, Rojas R, Ruiz WG, Wang E, Hughey RP, Dunn KW, Apodaca G. RhoB-dependent modulation of postendocytic traffic in polarized Madin-Darby canine kidney cells. Traffic. 2007;8:932&#x2013;949.</Citation><ArticleIdList><ArticleId IdType="pubmed">17547697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science. 2004;306:990&#x2013;995.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1705980</ArticleId><ArticleId IdType="pubmed">15528435</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman R, Mistretta S, Durkin JT, Savage MJ, Loh T, Trusko S, Scott RW. Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments. J Biol Chem. 1993;268:16602&#x2013;16609.</Citation><ArticleIdList><ArticleId IdType="pubmed">8344942</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Almenar-Queralt A, Gunawardena S, Rodrigues EM, Falzone T, Kim J, Lillo C, Mount SL, Roberts EA, McGowan E, Williams DS, Goldstein LS. Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum Mol Genet. 2008;17:3474&#x2013;3486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722897</ArticleId><ArticleId IdType="pubmed">18694898</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron. 2008;60:247&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755563</ArticleId><ArticleId IdType="pubmed">18957217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun-Wada GH, Wada Y, Futai M. Lysosome and lysosome-related organelles responsible for specialized functions in higher organisms, with special emphasis on vacuolar-type proton ATPase. Cell Struct Funct. 2003;28:455&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pubmed">14745137</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanida I, Minematsu-Ikeguchi N, Ueno T, Kominami E. Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy. 2005;1:84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">16874052</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkley SU. Cellular pathology of lysosomal storage disorders. Brain pathology. 1998;8:175&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098147</ArticleId><ArticleId IdType="pubmed">9458175</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QJ, Ding Y, Kohtz DS, Mizushima N, Cristea IM, Rout MP, Chait BT, Zhong Y, Heintz N, Yue Z. Induction of autophagy in axonal dystrophy and degeneration. J Neurosci. 2006;26:8057&#x2013;8068.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673783</ArticleId><ArticleId IdType="pubmed">16885219</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci. 1999;2:50&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, Schmidt SD, Wesson D, Bandyopadhyay U, Jiang Y, Pawlik M, Peterhoff CM, Yang AJ, Wilson DA, St George-Hyslop P, Westaway D, Mathews PM, Levy E, Cuervo AM, Nixon RA. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain. 2011;134:258&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3009842</ArticleId><ArticleId IdType="pubmed">21186265</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Xu K, Koike T, Zheng X. Transport of autophagosomes in neurites of PC12 cells during serum deprivation. Autophagy. 2008;4:243&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">18094609</ArticleId></ArticleIdList></Reference><Reference><Citation>Yue Z, Horton A, Bravin M, DeJager PL, Selimi F, Heintz N. A novel protein complex linking the delta 2 glutamate receptor and autophagy: implications for neurodegeneration in lurcher mice. Neuron. 2002;35:921&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372286</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">11487050</PMID><DateCompleted><Year>2001</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3069</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>8</Issue><PubDate><Year>2001</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Oxidative damage is the earliest event in Alzheimer disease.</ArticleTitle><Pagination><StartPage>759</StartPage><EndPage>767</EndPage><MedlinePgn>759-67</MedlinePgn></Pagination><Abstract><AbstractText>Recently, we demonstrated a significant increase of an oxidized nucleoside derived from RNA, 8-hydroxyguanosine (8OHG), and an oxidized amino acid, nitrotyrosine in vulnerable neurons of patients with Alzheimer disease (AD). To determine whether oxidative damage is an early- or end-stage event in the process of neurodegeneration in AD, we investigated the relationship between neuronal 8OHG and nitrotyrosine and histological and clinical variables, i.e. amyloid-beta (A beta) plaques and neurofibrillary tangles (NFT), as well as duration of dementia and apolipoprotein E (ApoE) genotype. Our findings show that oxidative damage is quantitatively greatest early in the disease and reduces with disease progression. Surprisingly, we found that increases in A beta deposition are associated with decreased oxidative damage. These relationships are more significant in ApoE epsilon4 carriers. Moreover, neurons with NFT show a 40%-56% decrease in relative 8OHG levels compared with neurons free of NFT. Our observations indicate that increased oxidative damage is an early event in AD that decreases with disease progression and lesion formation. These findings suggest that AD is associated with compensatory changes that reduce damage from reactive oxygen.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nunomura</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Aliev</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hirai</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Balraj</LastName><ForeName>E K</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>P K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Ghanbari</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Wataya</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Shimohama</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Chiba</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Atwood</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>R B</ForeName><Initials>RB</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG09287</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG14249</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>12133JR80S</RegistryNumber><NameOfSubstance UI="D006151">Guanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3604-79-3</RegistryNumber><NameOfSubstance UI="C002744">3-nitrotyrosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>3868-31-3</RegistryNumber><NameOfSubstance UI="C046215">8-hydroxyguanosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>42HK56048U</RegistryNumber><NameOfSubstance UI="D014443">Tyrosine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006151" MajorTopicYN="N">Guanosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014443" MajorTopicYN="N">Tyrosine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>8</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>8</Month><Day>17</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>8</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11487050</ArticleId><ArticleId IdType="doi">10.1093/jnen/60.8.759</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20934914</PMID><DateCompleted><Year>2010</Year><Month>11</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Revising the definition of Alzheimer's disease: a new lexicon.</ArticleTitle><Pagination><StartPage>1118</StartPage><EndPage>1127</EndPage><MedlinePgn>1118-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(10)70223-4</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pierre &amp; Marie Curie University, Research Centre of the Institute of the Brain and Spinal Cord, UMR, AP-HP, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital Group, Paris, France. bruno.dubois@psl.aphp.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Jacova</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Barberger-Gateau</LastName><ForeName>Pascale</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Delacourte</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Meguro</LastName><ForeName>Kenichi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>O'Brien</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Leonardo C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0601846</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2010 Nov;9(11):1044-5. doi: 10.1016/S1474-4422(10)70246-5.</RefSource><PMID Version="1">20934913</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2011 Apr;10(4):298-9; author reply 300-1. doi: 10.1016/S1474-4422(11)70055-2.</RefSource><PMID Version="1">21435593</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2011 Apr;10(4):299-300; author reply 300-1. doi: 10.1016/S1474-4422(11)70056-4.</RefSource><PMID Version="1">21435594</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002641" MajorTopicYN="N">Chicago</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(10)70223-4</ArticleId><ArticleId IdType="pii">S1474-4422(10)70223-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21159946</PMID><DateCompleted><Year>2011</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>50</Issue><PubDate><Year>2010</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reimagining Alzheimer's disease--an age-based hypothesis.</ArticleTitle><Pagination><StartPage>16755</StartPage><EndPage>16762</EndPage><MedlinePgn>16755-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4521-10.2010</ELocationID><Abstract><AbstractText>The historical roots of Alzheimer's disease provide a sound conceptual basis for linking the behavioral and neurological symptoms of the disease with the frequently associated pathology of amyloid plaques and neurofibrillary tangles. Out of these roots has grown the "amyloid cascade hypothesis"--a vision of the etiology of Alzheimer's that has spurred the discovery of many important insights into the neurobiology of the disease. Despite these successes, the wealth of new data now available to biomedical researchers urges a full review of the origins of Alzheimer's, and such a reconsideration is offered here. It begins with the most widely accepted risk factor for developing Alzheimer's disease: age. Then, for an individual to progress from normal age-appropriate cognitive function to a condition where the full palette of clinical symptoms is expressed, three key steps are envisioned: (1) an initiating injury, (2) a chronic neuroinflammatory response, and (3) a discontinuous cellular change of state involving most, if not all, of the cell types of the brain. The amyloid cascade is integrated into this sequence, but reconfigured as an amyloid deposition cycle. In this way, the pathology of amyloid plaques is envisioned as highly correlated with, but mechanistically distinct from, the three obligatory steps leading to Alzheimer's disease. The implications of this new model are discussed with respect to our current diagnostic criteria, and suggestions are put forward for expanding our future research efforts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrup</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 08854, USA. herrup@biology.rutgers.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG024494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS020591</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS20591</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG029449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="Y">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>6</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21159946</ArticleId><ArticleId IdType="mid">NIHMS257901</ArticleId><ArticleId IdType="pmc">PMC3004746</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4521-10.2010</ArticleId><ArticleId IdType="pii">30/50/16755</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000;21:383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222:155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18364000</ArticleId></ArticleIdList></Reference><Reference><Citation>Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, Davies P. Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci. 2005;25:5446&#x2013;5454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725006</ArticleId><ArticleId IdType="pubmed">15930395</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009;118:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">19390859</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, R&#xf6;del L, G&#xe4;rtner U, Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport. 1996;7:3047&#x2013;3049.</Citation><ArticleIdList><ArticleId IdType="pubmed">9116237</ArticleId></ArticleIdList></Reference><Reference><Citation>Arendt T, Br&#xfc;ckner MK, Mosch B, L&#xf6;sche A. Selective cell death of hyperploid neurons in Alzheimer's disease. Am J Pathol. 2010;177:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893646</ArticleId><ArticleId IdType="pubmed">20472889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamberger ME, Landreth GE. Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist. 2002;8:276&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061507</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter AG. The origin and application of experimental autoimmune encephalomyelitis. Nat Rev Immunol. 2007;7:904&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">17917672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci. 1998;18:2801&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792587</ArticleId><ArticleId IdType="pubmed">9525997</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis. 2010;37:503&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823849</ArticleId><ArticleId IdType="pubmed">19833208</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci. 1996;16:186&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578706</ArticleId><ArticleId IdType="pubmed">8613784</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H, Chan DC. Mitochondrial dynamics&#x2014;fusion, fission, movement, and mitophagy&#x2014;in neurodegenerative diseases. Hum Mol Genet. 2009;18:R169&#x2013;R176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758711</ArticleId><ArticleId IdType="pubmed">19808793</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci. 2004;5:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pubmed">15322526</ArticleId></ArticleIdList></Reference><Reference><Citation>Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation. 2006;3:27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1609108</ArticleId><ArticleId IdType="pubmed">17005052</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>El Khoury J, Luster AD. Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci. 2008;29:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">18835047</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller S, Steele M, M&#xfc;nch G. Activated astroglia during chronic inflammation in Alzheimer's disease&#x2014;do they neglect their neurosupportive roles? Mutat Res. 2010;690:40&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">19748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Giri R, Selvaraj S, Miller CA, Hofman F, Yan SD, Stern D, Zlokovic BV, Kalra VK. Effect of endothelial cell polarity on beta-amyloid-induced migration of monocytes across normal and AD endothelium. Am J Physiol Cell Physiol. 2002;283:C895&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176746</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140:918&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez A, Ferrer I. Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol. 2010;120:155&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">20232069</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr. 2006;83:470S&#x2013;474S.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470015</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE. Glial-neuronal interactions in Alzheimer's disease: the potential role of a &#x2018;cytokine cycle&#x2019; in disease progression. Brain Pathol. 1998;8:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8098321</ArticleId><ArticleId IdType="pubmed">9458167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer's disease and other dementias. Neurology. 1989;39:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">2927643</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, O'Banion MK. Inflammatory processes in Alzheimer's disease. J Neuroimmunol. 2007;184:69&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">17222916</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol. 2009;4:389&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">19731042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, de Graaff E, Wauters E, van Baren J, et al. Association of missense and 5&#x2032;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. 2009;187:761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller JN, Hanni KB, Gabbita SP, Friebe V, Mattson MP, Kindy MS. Oxidized lipoproteins increase reactive oxygen species formation in microglia and astrocyte cell lines. Brain Res. 1999;830:10&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">10350554</ArticleId></ArticleIdList></Reference><Reference><Citation>Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009;29:13435&#x2013;13444.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788152</ArticleId><ArticleId IdType="pubmed">19864556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingsbury MA, Friedman B, McConnell MJ, Rehen SK, Yang AH, Kaushal D, Chun J. Aneuploid neurons are functionally active and integrated into brain circuitry. Proc Natl Acad Sci U S A. 2005;102:6143&#x2013;6147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1087909</ArticleId><ArticleId IdType="pubmed">15837924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G, Uchiyama Y, Westaway D, Cuervo AM, Nixon RA. Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell. 2010;141:1146&#x2013;1158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3647462</ArticleId><ArticleId IdType="pubmed">20541250</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of amyloid beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron. 2009;62:788&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702854</ArticleId><ArticleId IdType="pubmed">19555648</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa CF, Hamos JE, Pulaski-Salo D, DeGennaro LJ, Drachman DA. Alzheimer's disease and aging: effects on perforant pathway perikarya and synapses. Neurobiol Aging. 1992;13:405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">1625770</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuoka Y, Picciano M, Malester B, LaFrancois J, Zehr C, Daeschner JM, Olschowka JA, Fonseca MI, O'Banion MK, Tenner AJ, Lemere CA, Duff K. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am J Pathol. 2001;158:1345&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891893</ArticleId><ArticleId IdType="pubmed">11290552</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">3670729</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies [see comments] Neurology. 1996;47:425&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">8757015</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Yasojima K, McGeer EG. Inflammation in Parkinson's disease. Adv Neurol. 2001;86:83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11554012</ArticleId></ArticleIdList></Reference><Reference><Citation>McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol. 1997;150:1933&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1858317</ArticleId><ArticleId IdType="pubmed">9176387</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell TW, Mufson EJ, Schneider JA, Cochran EJ, Nissanov J, Han LY, Bienias JL, Lee VM, Trojanowski JQ, Bennett DA, Arnold SE. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol. 2002;51:182&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835374</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A, Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer's disease. J Neurosci. 2007;27:6859&#x2013;6867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672221</ArticleId><ArticleId IdType="pubmed">17596434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Yu GQ, McConlogue L, Rockenstein EM, Abraham CR, Masliah E. Astroglial expression of human alpha(1)-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice. Am J Pathol. 2000;157:2003&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1885780</ArticleId><ArticleId IdType="pubmed">11106573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des. 2005;11:999&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">15777250</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy Z, Esiri MM, Smith AD. The cell division cycle and the pathophysiology of Alzheimer's disease. Neuroscience. 1998;87:731&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759963</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. J Cell Sci. 2007;120:4081&#x2013;4091.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032783</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg GD. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH. Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L) J Neurosci. 2005;25:10637&#x2013;10647.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725849</ArticleId><ArticleId IdType="pubmed">16291936</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodr&#xed;guez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death Differ. 2009;16:378&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">19057621</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387254</ArticleId><ArticleId IdType="pubmed">11120756</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol. 2005;58:939&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315280</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">9065537</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Uylings HB, de Brabander JM. Neuronal changes in normal human aging and Alzheimer's disease. Brain Cogn. 2002;49:268&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139954</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel NH, Bhaskar K, Patil AR, Pimplikar SW, Herrup K, Lamb BT. Abeta oligomers induce neuronal cell cycle events in Alzheimer's disease. J Neurosci. 2008;28:10786&#x2013;10793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680286</ArticleId><ArticleId IdType="pubmed">18945886</ArticleId></ArticleIdList></Reference><Reference><Citation>Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K. NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest. 2009;119:3692&#x2013;3702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2786797</ArticleId><ArticleId IdType="pubmed">19907078</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I, Rosado M, Davies P. Mitotic mechanisms in Alzheimer's disease? J Cell Biol. 1996;132:413&#x2013;425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2120731</ArticleId><ArticleId IdType="pubmed">8636218</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci. 1997;17:3588&#x2013;3598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573674</ArticleId><ArticleId IdType="pubmed">9133382</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology. 2008;70:1672&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758242</ArticleId><ArticleId IdType="pubmed">18458226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wang KC, Imaki H, Rubenstein R, Wronska A, Osuchowski M, Lipinski WJ, Walker LC, LeVine H. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Neurobiol Aging. 2001;22:49&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">11164276</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, Bacskai BJ, Hyman BT. Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci. 2010;30:2636&#x2013;2649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2841957</ArticleId><ArticleId IdType="pubmed">20164348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q, Combs C, Cannady SB, Geldmacher DS, Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging. 2000;21:797&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124423</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease&#x2013;a double-edged sword. Neuron. 2002;35:419&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci. 2001;21:2661&#x2013;2668.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762514</ArticleId><ArticleId IdType="pubmed">11306619</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J Neurosci. 2003;23:2557&#x2013;2563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742098</ArticleId><ArticleId IdType="pubmed">12684440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Varvel NH, Lamb BT, Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J Neurosci. 2006;26:775&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675370</ArticleId><ArticleId IdType="pubmed">16421297</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Marchani E, Nikisch G, M&#xfc;ller U, Nolte D, Hertel A, Wijsman EM, Bird TD. The N141I mutation in PSEN2: implications for the quintessential case of Alzheimer disease. Arch Neurol. 2010;67:631&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3016011</ArticleId><ArticleId IdType="pubmed">20457965</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19376612</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>7</Issue><PubDate><Year>2009</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.</ArticleTitle><Pagination><StartPage>1026</StartPage><EndPage>1036</EndPage><MedlinePgn>1026-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2009.04.002</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the frequency and possible cognitive effect of histological Alzheimer's disease (AD) in autopsied older nondemented individuals.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Senile plaques (SPs) and neurofibrillary tangles (NFTs) were assessed quantitatively in 97 cases from 7 Alzheimer's Disease Centers (ADCs). Neuropathological diagnoses of AD (npAD) were also made with four sets of criteria. Adjusted linear mixed models tested differences between participants with and without npAD on the quantitative neuropathology measures and psychometric test scores prior to death. Spearman rank-order correlations between AD lesions and psychometric scores at last assessment were calculated for cases with pathology in particular regions.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Washington University Alzheimer's Disease Research Center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Ninety-seven nondemented participants who were age 60 years or older at death (mean=84 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">About 40% of nondemented individuals met at least some level of criteria for npAD; when strict criteria were used, about 20% of cases had npAD. Substantial overlap of Braak neurofibrillary stages occurred between npAD and no-npAD cases. Although there was no measurable cognitive impairment prior to death for either the no-npAD or npAD groups, cognitive function in nondemented aging appears to be degraded by the presence of NFTs and SPs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Neuropathological processes related to AD in persons without dementia appear to be associated with subtle cognitive dysfunction and may represent a preclinical stage of the illness. By age 80-85 years, many nondemented older adults have substantial AD pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Joseph L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Anatomy and Neurobiology, Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeel</LastName><ForeName>Daniel W</ForeName><Initials>DW</Initials><Suffix>Jr</Suffix></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Roe</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>Lawrence A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Daron G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Schmitt</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Markesbery</LastName><ForeName>William R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Kurlan</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hulette</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kurland</LastName><ForeName>Brenda F</ForeName><Initials>BF</Initials></Author><Author ValidYN="Y"><LastName>Higdon</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kukull</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1UL1RR024992-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG008665</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG008017</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG16976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028383</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG028377</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG016976</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b><u>Disclosure Statement</u></b> There are no actual or potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>21</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19376612</ArticleId><ArticleId IdType="mid">NIHMS120703</ArticleId><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.04.002</ArticleId><ArticleId IdType="pii">S0197-4580(09)00117-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alafuzoff I, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Bugiani O, Ferrer I, Gelpi E, Giaccone G, Graeber MB, Hauw J, Kammphorts W, King A, Kopp N, Korkolopoulou P, Kovacs GG, Meyronet D, Parchi P, Patsouris E, Preusser M, Ravid R, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Kretzschmar H. Interlaboratory comparison of assessments of Alzheimer disease-related lestions: A study of the BrainNet Europe Consortium. J Neuropathol Exp Neurol. 2006;65:740&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">16896308</ArticleId></ArticleIdList></Reference><Reference><Citation>Armitage SG. An analysis of certain psychological tests used in the evaluation of brain injury. Psych Mono. 1946;60:1&#x2013;48.</Citation></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer&#x2019;s disease. Neurology. 1992;42:1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology. 2006;66:1837&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Berlau DJ, Kahle-Wrobleski K, Head E, Goodus M, Kim R, Kawas C. Dissociation of neuropathological findings and cognition; Case report of an Apolipoprotein E &#xe5;2/&#xe5;2 Genotype. Archives of Neurology. 2007;64:1193&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378248</ArticleId><ArticleId IdType="pubmed">17698712</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani RJ, Lee HG, Zhu X, Perry G, Smith MA. Alzheimer disease pathology as a host response. J Neuropathol Exp Neurol. 2008;67:523&#x2013;531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763411</ArticleId><ArticleId IdType="pubmed">18520771</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L. Clinico-pathologic studies in dementia: Nondemented subjects with pathologically confirmed Alzheimer&#x2019;s disease. Neurology. 1988;38:1682&#x2013;1687.</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>den Dunnen WFA, Brouwer WH, Bijlard E, Kamphuis J, Linschoten KV, Essens-Meijer E, Holstege G. No disease in the brain of a 115 year old woman. Neurobiol Aging. 2008;29:1127&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">18534718</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D, Crystal HA, Mattiace LA, Masur DM, Blau AD, Davies P, Yen SH, Aronson MK. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging. 1992;13:179&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">1311804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW. Mismatch between plaques and tangles in staging Alzheimer pathology. Neurobiol Aging. 1995;16:283&#x2013;284.</Citation></Reference><Reference><Citation>Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson&#x2019;s disease. Acta Neuropathol. 2008;115:437&#x2013;444.</Citation><ArticleIdList><ArticleId IdType="pubmed">18264713</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Resnick SM, Troncoso JC, An Y, O&#x2019;Brien R, Zonderman AB. Impact of Alzheimer&#x2019;s pathology on cognitive trajectories in nondemented elderly. Ann Neurol. 2006;60:688&#x2013;695.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192929</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Beiser A, Wolf PA, Au R, White RF, D&#x2019;Agostino RB. The preclinical phase of Alzheimer disease. A 22-year prospective study of the Famingham cohort. Archives of Neurology. 2000;57:808&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology. 2008;70:596&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914065</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. Mini-mental State: A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotenos AF, Mintun MA, Snyder AZ, Morris JC, Buckner RL. Brain volume decline in aging: evidence for a relationship between socioeconomic status, preclinical Alzheimer&#x2019;s disease, and reserve. Arch Neurol. 2008;65:113&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">18195148</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Powlishta KK, Wilkins K, McKeel D, Xiong C, Grant E, Storandt M, Morris JC. Predictors of preclinical Alzheimer&#x2019;s disease and dementia: A clinicopathologic study. Arch Neurol. 2005;62:758&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883263</ArticleId></ArticleIdList></Reference><Reference><Citation>Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR. Comparison of neuropathologic criteria for the diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:S99&#x2013;S105.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330997</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Jr, Rubin EH, Morris JC. Absence of cognitive impairment or decline in preclinical Alzheimer&#x2019;s disease. Neurology. 2001;56:361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">11171902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodglass H, Kaplan E. The assessment of aphasia and related disorders. 2. Philadelphia: Lea &amp; Febiger; 1983.</Citation></Reference><Reference><Citation>Haroutunian V, Perl DP, Purohit DP, Marin D, Khalid K, Lantz M, Davis KL, Mohs RC. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. Arch Neurol. 1998;55:1185&#x2013;1191.</Citation><ArticleIdList><ArticleId IdType="pubmed">9740112</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol. 1999;56:713&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">10369312</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre NJ. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung LW, Ciccotosto G, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. Amyloid-B peptide (AB) neurotoxicity is modulated by the rate of peptide aggregation: AB dimers and trimers correlate with neurotoxicity. The Journal of Neuroscience. 2008;28:11950&#x2013;11958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671645</ArticleId><ArticleId IdType="pubmed">19005060</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacono D, O&#x2019;Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, Troncoso JC. Neuronal hypertropy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol. 2008;67:578&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2518071</ArticleId><ArticleId IdType="pubmed">18520776</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23:138&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">2897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, Arenberg D. Visual memory predicts Alzheimer&#x2019;s disease more than a decade before diagnosis. Neurology. 2003;60:1089&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682311</ArticleId></ArticleIdList></Reference><Reference><Citation>Khachaturian ZS. Diagnosis of Alzheimer&#x2019;s disease. Arch Neurol. 1985;42:1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">2864910</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">14656067</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC. Altered expression of synaptic proteins occurs early during progression of Alzheimer&#x2019;s disease. Neurology. 2001;56:127&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148253</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeel DW, Price JL, Miller JP, Grant EA, Xiong C, Berg L, Morris JC. Neuropathologic criteria for diagnosing Alzheimer Disease in persons with pure dementia of Alzheimer type. J Neuropathol Exp Neurol. 2004;63:1028&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">15535130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C] PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Gearing M, McKeel DW, Jr, Crain BJ, Hughes JP, van Belle G, Heyman A. Interlaboratory comparison of neuropathology assessments in Alzheimer&#x2019;s disease: A study of the Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD) J Neuropathol Exp Neurol. 1994;53:303&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">8176413</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel DW, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L, CERAD neuropathologists participating The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part II Standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, Berg L. Cerebral amyloid deposition and diffuse plaques in &#x201c;normal&#x201d; aging: Evidence for presymptomatic and very mild Alzheimer&#x2019;s disease. Neurology. 1996;46:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer&#x2019;s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 1997;18:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer&#x2019;s disease. Neurobiol Aging. 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Jr, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001;58:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signaling proteins. Nat Med. 2007;13:1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Riudavets MA, Iacono D, Resnick SM, O&#x2019;Brien R, Zonderman AB, Martin LJ, Rudow G, Pletnikova O, Troncoso JC. Resistance to Alzheimer&#x2019;s pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging. 2007;28:1484&#x2013;1492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694127</ArticleId><ArticleId IdType="pubmed">17599696</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L. Preclinical Alzheimer disease; neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004;63:2341&#x2013;2347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623697</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. Preclinical AD revisited. Neuropathology of cognitively normal older adults. Neurology. 2000;55:370&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932270</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-B protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nature Medicine. 2008:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y. Cognitive reserve and Alzheimer disease. Alz Dis Assoc Disord. 2006;20:112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">16772747</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney MC, Yao C, Kiss A, McDowell I. Neurospsychological tests accurately predict incident Alzheimer disease after 5 and 10 years. Neurology. 2005;64:1853&#x2013;1859.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955933</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7:331&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">5707082</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11:205&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">5505685</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Cataldo M, Nixon RA, Barnett JL, Lee MK, Checler F, Fowler DR, Smialek JE, Crain B, Martin LJ, Kawas CH. Neuropathology of preclinical and clinical late-onset Alzheimer&#x2019;s disease. Ann Neurol. 1998;43:673&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">9585365</ArticleId></ArticleIdList></Reference><Reference><Citation>Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 1996;17:365&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">8725897</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Manual: Wechsler Memory Scale-Revised. San Antonio, Texas: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Wechsler D. Administration and scoring manual: Wechsler Adult Intelligence Scale. 3. San Antonio, TX: Harcourt Brace; 1997.</Citation></Reference><Reference><Citation>West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC. Hippocampal neurons in pre-clinical Alzheimer&#x2019;s disease. Neurobiol Aging. 2004;25:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">15312966</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19286555</PMID><DateCompleted><Year>2009</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><Issue>5920</Issue><PubDate><Year>2009</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis.</ArticleTitle><Pagination><StartPage>1473</StartPage><EndPage>1477</EndPage><MedlinePgn>1473-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1168979</ELocationID><Abstract><AbstractText>beta-Amyloid precursor protein (APP) mutations cause familial Alzheimer's disease with nearly complete penetrance. We found an APP mutation [alanine-673--&gt;valine-673 (A673V)] that causes disease only in the homozygous state, whereas heterozygous carriers were unaffected, consistent with a recessive Mendelian trait of inheritance. The A673V mutation affected APP processing, resulting in enhanced beta-amyloid (Abeta) production and formation of amyloid fibrils in vitro. Co-incubation of mutated and wild-type peptides conferred instability on Abeta aggregates and inhibited amyloidogenesis and neurotoxicity. The highly amyloidogenic effect of the A673V mutation in the homozygous state and its anti-amyloidogenic effect in the heterozygous state account for the autosomal recessive pattern of inheritance and have implications for genetic screening and the potential treatment of Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Fede</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Neurology and Neuropathology, "Carlo Besta" National Neurological Institute, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catania</LastName><ForeName>Marcella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morbin</LastName><ForeName>Michela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Giacomina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Suardi</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mazzoleni</LastName><ForeName>Giulia</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Merlin</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Giovagnoli</LastName><ForeName>Anna Rita</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Prioni</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Erbetta</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Falcone</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gobbi</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bastone</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Beeg</LastName><ForeName>Marten</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Manzoni</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Francescucci</LastName><ForeName>Bruna</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Spagnoli</LastName><ForeName>Alberto</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cant&#xf9;</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Del Favero</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Efrat</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Salmona</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS042029</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS42029</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005808" MajorTopicYN="Y">Genes, Recessive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>4</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2010</Year><Month>3</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19286555</ArticleId><ArticleId IdType="mid">NIHMS111340</ArticleId><ArticleId IdType="pmc">PMC2728497</ArticleId><ArticleId IdType="doi">10.1126/science.1168979</ArticleId><ArticleId IdType="pii">323/5920/1473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. Science. 2002;297:353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Physiol. Rev. 2001;81:741.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, et al. Nature. 2002;416:535.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE. J. Clin. Investig. 2005;115:1449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137006</ArticleId><ArticleId IdType="pubmed">15931380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocchi A, Pellegrini S, Siciliano G, Murri L. Brain Res. Bull. 2003;61:1.</Citation><ArticleIdList><ArticleId IdType="pubmed">12788204</ArticleId></ArticleIdList></Reference><Reference><Citation>George-Hyslop PH. Biol. Psychiatry. 2000;47:183.</Citation><ArticleIdList><ArticleId IdType="pubmed">10682216</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy E, et al. Science. 1990;248:1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111584</ArticleId></ArticleIdList></Reference><Reference><Citation>Materials and methods are available as supporting material on Science Online.</Citation></Reference><Reference><Citation>Petersen RC, et al. Arch. Neurol. 2001;58:1985.</Citation><ArticleIdList><ArticleId IdType="pubmed">11735772</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini M, Curcio R, Pappalardo M, Melki R, Caflisch A. J. Mol. Biol. 2006;357:1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16483608</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, et al. Ann. Neurol. 2008;63:377.</Citation><ArticleIdList><ArticleId IdType="pubmed">18300294</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams AD, et al. J. Mol. Biol. 2004;335:833.</Citation><ArticleIdList><ArticleId IdType="pubmed">14687578</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim KH. ChemBioChem. 2006;7:1662.</Citation><ArticleIdList><ArticleId IdType="pubmed">17013984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori Y, et al. J. Biol. Chem. 2007;282:4916.</Citation><ArticleIdList><ArticleId IdType="pubmed">17170111</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, et al. Proc. Natl. Acad. Sci. U.S.A. 2003;100:2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock ML, Warren JT, Roses AD, Fink JK. Neurology. 1993;43:1254.</Citation><ArticleIdList><ArticleId IdType="pubmed">8170579</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J, et al. Protein Sci. 2007;16:1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206661</ArticleId><ArticleId IdType="pubmed">17525469</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto C, et al. Nat. Med. 1998;4:822.</Citation><ArticleIdList><ArticleId IdType="pubmed">9662374</ArticleId></ArticleIdList></Reference><Reference><Citation>Adessi C, et al. J. Biol. Chem. 2003;278:13905.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578830</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18408713</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1552-4469</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature chemical biology</Title><ISOAbbreviation>Nat Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Identification of RIP1 kinase as a specific cellular target of necrostatins.</ArticleTitle><Pagination><StartPage>313</StartPage><EndPage>321</EndPage><MedlinePgn>313-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchembio.83</ELocationID><Abstract><AbstractText>Necroptosis is a cellular mechanism of necrotic cell death induced by apoptotic stimuli in the form of death domain receptor engagement by their respective ligands under conditions where apoptotic execution is prevented. Although it occurs under regulated conditions, necroptotic cell death is characterized by the same morphological features as unregulated necrotic death. Here we report that necrostatin-1, a previously identified small-molecule inhibitor of necroptosis, is a selective allosteric inhibitor of the death domain receptor-associated adaptor kinase RIP1 in vitro. We show that RIP1 is the primary cellular target responsible for the antinecroptosis activity of necrostatin-1. In addition, we show that two other necrostatins, necrostatin-3 and necrostatin-5, also target the RIP1 kinase step in the necroptosis pathway, but through mechanisms distinct from that of necrostatin-1. Overall, our data establish necrostatins as the first-in-class inhibitors of RIP1 kinase, the key upstream kinase involved in the activation of necroptosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Degterev</LastName><ForeName>Alexei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tufts University, School of Medicine, Department of Biochemistry, 136 Harrison Avenue, Boston, Massachusetts 02111, USA. alexei.degterev@tufts.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hitomi</LastName><ForeName>Junichi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Germscheid</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ch'en</LastName><ForeName>Irene L</ForeName><Initials>IL</Initials></Author><Author ValidYN="Y"><LastName>Korkina</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Xin</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Abbott</LastName><ForeName>Derek</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cuny</LastName><ForeName>Gregory D</ForeName><Initials>GD</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Chengye</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Hedrick</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Gerber</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Lugovskoy</LastName><ForeName>Alexey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Junying</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PDB</DataBankName><AccessionNumberList><AccessionNumber>1UWH</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>UO1 NS050560</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM64703</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS050560</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD000580</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG012859</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM064703</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Chem Biol</MedlineTA><NlmUniqueID>101231976</NlmUniqueID><ISSNLinking>1552-4450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18408713</ArticleId><ArticleId IdType="mid">NIHMS860141</ArticleId><ArticleId IdType="pmc">PMC5434866</ArticleId><ArticleId IdType="doi">10.1038/nchembio.83</ArticleId><ArticleId IdType="pii">nchembio.83</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">7878464</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsten T, Thompson CB. Cell death in the absence of Bax and Bak. Cell Death Differ. 2006;13:1272&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">16676001</ArticleId></ArticleIdList></Reference><Reference><Citation>Los M, Wesselborg S, Schulze-Osthoff K. The role of caspases in development, immunity, and apoptotic signal transduction: lessons from knockout mice. Immunity. 1999;10:629&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">10403638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chautan M, Chazal G, Cecconi F, Gruss P, Golstein P. Interdigital cell death can occur through a necrotic and caspase-independent pathway. Curr Biol. 1999;9:967&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pubmed">10508592</ArticleId></ArticleIdList></Reference><Reference><Citation>Oppenheim RW, et al. Programmed cell death of developing mammalian neurons after genetic deletion of caspases. J Neurosci. 2001;21:4752&#x2013;4760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762357</ArticleId><ArticleId IdType="pubmed">11425902</ArticleId></ArticleIdList></Reference><Reference><Citation>West T, Atzeva M, Holtzman DM. Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. Neurobiol Dis. 2006;22:523&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">16480886</ArticleId></ArticleIdList></Reference><Reference><Citation>Mareninova OA, et al. Cell death in pancreatitis: caspases protect from necrotizing pancreatitis. J Biol Chem. 2006;281:3370&#x2013;3381.</Citation><ArticleIdList><ArticleId IdType="pubmed">16339139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol. 2003;4:387&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">12652297</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">16408008</ArticleId></ArticleIdList></Reference><Reference><Citation>Holler N, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol. 2000;1:489&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11101870</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CC, et al. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther. 2007;21:227&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">17665295</ArticleId></ArticleIdList></Reference><Reference><Citation>Moshinsky DJ, et al. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun. 2003;310:1026&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pubmed">14550307</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting AT, Pimentel-Muinos FX, Seed B. RIP mediates tumor necrosis factor receptor 1 activation of NF-kappaB but not Fas/APO-1-initiated apoptosis. EMBO J. 1996;15:6189&#x2013;6196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452440</ArticleId><ArticleId IdType="pubmed">8947041</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng X, et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005;15:5039&#x2013;5044.</Citation><ArticleIdList><ArticleId IdType="pubmed">16153840</ArticleId></ArticleIdList></Reference><Reference><Citation>Argast GM, Fausto N, Campbell JS. Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol Cell Biochem. 2005;268:129&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">15724446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ficarro SB, et al. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol. 2002;20:301&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">11875433</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkse MW, Uitto PM, Hilhorst MJ, Ooms B, Heck AJ. Selective isolation at the femtomole level of phosphopeptides from proteolytic digests using 2D-NanoLC-ESI-MS/MS and titanium oxide precolumns. Anal Chem. 2004;76:3935&#x2013;3943.</Citation><ArticleIdList><ArticleId IdType="pubmed">15253627</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855&#x2013;867.</Citation><ArticleIdList><ArticleId IdType="pubmed">15035987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang BH, Guan KL. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 2000;19:5429&#x2013;5439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314015</ArticleId><ArticleId IdType="pubmed">11032810</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck V, Russell P, Millar JB. Identification of a cdk-activating kinase in fission yeast. EMBO J. 1995;14:6173&#x2013;6183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC394742</ArticleId><ArticleId IdType="pubmed">8557037</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffrey PD, et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature. 1995;376:313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">7630397</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindler T, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289:1938&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pubmed">10988075</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagar B, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 2002;62:4236&#x2013;4243.</Citation><ArticleIdList><ArticleId IdType="pubmed">12154025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukhtiyarova M, Karpusas M, Northrop K, Namboodiri HV, Springman EB. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUTstate. Biochemistry. 2007;46:5687&#x2013;5696.</Citation><ArticleIdList><ArticleId IdType="pubmed">17441692</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagtap P, et al. Structure activity relationship study of tricyclic necroptosis inhibitors. J Med Chem. 2007;50:1886&#x2013;1895.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K, et al. Structure-activity relationship analysis of a novel necroptosis inhibitor, necrostatin-5. Bioorg Med Chem Lett. 2007;17:1455&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270434</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. J Biol Chem. 2000;275:10519&#x2013;10526.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744744</ArticleId></ArticleIdList></Reference><Reference><Citation>Gooljarsingh LT, et al. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci USA. 2006;103:7625&#x2013;7630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458618</ArticleId><ArticleId IdType="pubmed">16684877</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell. 2007;26:675&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">17560373</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 2004;304:1500&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">15131264</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, et al. Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells. J Neurochem. 2007;103:2004&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pubmed">17760869</ArticleId></ArticleIdList></Reference><Reference><Citation>Bao L, Li Y, Deng SX, Landry D, Tabas I. Sitosterol-containing lipoproteins trigger free sterol-induced caspase-independent death in ACAT-competent macrophages. J Biol Chem. 2006;281:33635&#x2013;33649.</Citation><ArticleIdList><ArticleId IdType="pubmed">16935859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Q, et al. Zfra affects TNF-mediated cell death by interacting with death domain protein TRADD and negatively regulates the activation of NF-kappaB, JNK1, p53 and WOX1 during stress response. BMC Mol Biol. 2007;8:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904229</ArticleId><ArticleId IdType="pubmed">17567906</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 1995;81:513&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">7538908</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakar J, Schleinkofer K, Borner C, Dandekar T. RIP death domain structural interactions implicated in TNF-mediated proliferation and survival. Proteins. 2006;63:413&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">16470584</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Kobayashi M, Blonska M, You Y, Lin X. Ubiquitination of RIP is required for TNFalpha-induced NF-kappa B activation. J Biol Chem. 2006;281:13636&#x2013;13643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16543241</ArticleId></ArticleIdList></Reference><Reference><Citation>Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">15485624</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887920</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Z, El-Deiry WS. Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol. 2006;26:8136&#x2013;8148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1636728</ArticleId><ArticleId IdType="pubmed">16940186</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr Biol. 2007;17:418&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868513</ArticleId><ArticleId IdType="pubmed">17306544</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R, et al. Focal adhesion kinase determines the fate of death or survival of cells in response to TNFalpha in the presence of actinomycin D. Biochim Biophys Acta. 2007;1770:518&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">17197095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Shank J, Cusson N, Kelliher MA. The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem. 2004;279:33185&#x2013;33191.</Citation><ArticleIdList><ArticleId IdType="pubmed">15175328</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuny GD, Yuan J, Jagtap P, Degterev A. Inhibitors of cellular necrosis. United States patent US 20050119260. 2005</Citation></Reference><Reference><Citation>Li X, et al. Large-scale phosphorylation analysis of alpha-factor-arrested Saccharomyces cerevisiae. J Proteome Res. 2007;6:1190&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pubmed">17330950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">8254673</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, et al. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem. 1983;4:187&#x2013;217.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">10936198</PMID><DateCompleted><Year>2000</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3042</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors.</ArticleTitle><Pagination><StartPage>1155</StartPage><EndPage>1161</EndPage><MedlinePgn>1155-61</MedlinePgn></Pagination><Abstract><AbstractText>We have recently reported evidence that a very high affinity interaction between the beta-amyloid peptide Abeta(1-42) and the alpha7 nicotinic acetylcholine receptor (alpha7nAChR) may be a precipitating event in the formation of amyloid plaques in Alzheimer's disease. In the present study, the kinetics for the binding of Abeta(1-42) to alpha7nAChR and alpha4beta2nAChR were determined using the subtype-selective nicotinic receptor ligands [(3)H]methyllycaconitine and [(3)H]cytisine. Synaptic membranes prepared from rat and guinea pig cerebral cortex and hippocampus were used as the source of receptors. Abeta(1-42) bound to the alpha7nAChR with exceptionally high affinity, as indicated by K(i) values of 4.1 and 5.0 pM for rat and guinea pig receptors, respectively. When compared with the alpha7nAChR, the affinity of Abeta(1-42) for the alpha4beta2nAChR was approximately 5,000-fold lower, as indicated by corresponding K(i) values of 30 and 23nM. The results of this study support the concept that an exceptionally high affinity interaction between Abeta(1-42) and alpha7nAChR could serve as a precipitating factor in the formation of amyloid plaques and thereby contribute to the selective degeneration of cholinergic neurons that originate in the basal forebrain and project to the cortex and hippocampus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>H Y</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>R. W. Johnson Pharmaceutical Research Institute, Spring House, PA 19477-0776, USA. hwang2@prius.jnj.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>D H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>C B</ForeName><Initials>CB</Initials></Author><Author ValidYN="Y"><LastName>Shank</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000470">Alkaloids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001392">Azocines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C579165">Chrna7 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011807">Quinolizines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011976">Receptors, Muscarinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011978">Receptors, Nicotinic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064569">alpha7 Nicotinic Acetylcholine Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>10028-17-8</RegistryNumber><NameOfSubstance UI="D014316">Tritium</NameOfSubstance></Chemical><Chemical><RegistryNumber>21019-30-7</RegistryNumber><NameOfSubstance UI="C054634">methyllycaconitine</NameOfSubstance></Chemical><Chemical><RegistryNumber>53S5U404NU</RegistryNumber><NameOfSubstance UI="C004712">cytisine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6M3C89ZY6R</RegistryNumber><NameOfSubstance UI="D009538">Nicotine</NameOfSubstance></Chemical><Chemical><RegistryNumber>X8YN71D5WC</RegistryNumber><NameOfSubstance UI="D000157">Aconitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000157" MajorTopicYN="N">Aconitine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000470" MajorTopicYN="N">Alkaloids</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001392" MajorTopicYN="N">Azocines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001667" MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006168" MajorTopicYN="N">Guinea Pigs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009538" MajorTopicYN="N">Nicotine</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011807" MajorTopicYN="N">Quinolizines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011869" MajorTopicYN="N">Radioligand Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011976" MajorTopicYN="N">Receptors, Muscarinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011978" MajorTopicYN="N">Receptors, Nicotinic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013570" MajorTopicYN="N">Synaptic Membranes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014316" MajorTopicYN="N">Tritium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064569" MajorTopicYN="N">alpha7 Nicotinic Acetylcholine Receptor</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>11</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>9</Month><Day>19</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>11</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10936198</ArticleId><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0751155.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21825236</PMID><DateCompleted><Year>2011</Year><Month>10</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>8</Issue><PubDate><Year>2011</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease.</ArticleTitle><Pagination><StartPage>1013</StartPage><EndPage>1019</EndPage><MedlinePgn>1013-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.155</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Apolipoprotein E (APOE) is the most statistically significant genetic risk factor for late-onset Alzheimer disease (LOAD). The linkage disequilibrium pattern around the APOE gene has made it difficult to determine whether all the association signal is derived from APOE or whether there is an independent signal from a nearby gene.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To attempt to replicate a recently reported association of APOE 3-TOMM40 haplotypes with risk and age at onset.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We used standard techniques to genotype several polymorphisms in the APOE-TOMM40 region in a large case-control series, in a series with cerebrospinal fluid biomarker data, and in brain tissue.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Alzheimer's Disease Research Center.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Research volunteers who were cognitively normal or had Alzheimer disease.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Disease status and age at onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We did not replicate the previously reported association of the polyT polymorphism (rs10524523) with risk and age at onset. We found a significant association between rs10524523 and risk of LOAD in APOE 33 homozygotes but in the opposite direction as the previously reported association (the very long allele was underrepresented in cases vs controls in this study (P = .004]). We found no association between rs10524523 and cerebrospinal fluid tau or &#x3b2;-amyloid 42 levels or TOMM40 or APOE gene expression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although we did not replicate the earlier association between the APOE 3-TOMM40 haplotypes and age at onset, we observed that the polyT polymorphism is associated with risk of LOAD in APOE 33 homozygotes in a large case-control series but in the opposite direction as in the previous study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowotny</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kauwe</LastName><ForeName>John S K</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Ridge</LastName><ForeName>Perry G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bertelsen</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG023185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG16208,</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG05136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681,</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG23185,</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG026276,</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG03991,</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016208</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090622">Mitochondrial Precursor Protein Import Complex Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C400783">TOMM40 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>25086-81-1</RegistryNumber><NameOfSubstance UI="D011071">Poly T</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090622" MajorTopicYN="N">Mitochondrial Precursor Protein Import Complex Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011071" MajorTopicYN="N">Poly T</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21825236</ArticleId><ArticleId IdType="mid">NIHMS328654</ArticleId><ArticleId IdType="pmc">PMC3204798</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.155</ArticleId><ArticleId IdType="pii">68/8/1013</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grupe A, Abraham R, Li Y, et al. Evidence for novel susceptibility genes for late-onset Alzheimer&#x2019;s disease from a genome-wide association study of putative functional variants. Hum Mol Genet. 2007 Apr 15;16(8):865&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">17317784</ArticleId></ArticleIdList></Reference><Reference><Citation>Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer&#x2019;s disease. J Clin Psychiatry. 2007 Apr;68(4):613&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17474819</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer&#x2019;s risk in APOE epsilon4 carriers. Neuron. 2007 Jun 7;54(5):713&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2587162</ArticleId><ArticleId IdType="pubmed">17553421</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008 Nov;83(5):623&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008 Jan;65(1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Zou F, Pankratz VS, et al. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer&#x2019;s disease. Nat Genet. 2009 Feb;41(2):192&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873177</ArticleId><ArticleId IdType="pubmed">19136949</ArticleId></ArticleIdList></Reference><Reference><Citation>Feulner TM, Laws SM, Friedrich P, et al. Examination of the current top candidate genes for AD in a genome&#x2013;wide association study. Mol Psychiatry. 2009 Jan 6;</Citation><ArticleIdList><ArticleId IdType="pubmed">19125160</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009 Jan;84(1):35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009 Oct;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009 Oct;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Seltman H, Peskind ER, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer&#x2019;s disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007 Jun;89(6):655&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978251</ArticleId><ArticleId IdType="pubmed">17434289</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD, Lutz MW, Amrine-Madsen H, et al. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer&#x2019;s disease. Pharmacogenomics J. 2009 Dec 22;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946560</ArticleId><ArticleId IdType="pubmed">20029386</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong MG, Alexeyenko A, Lambert JC, Amouyel P, Prince JA. Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease. J Hum Genet. 2010 Oct;55(10):707&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">20668461</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998 Mar;55(3):326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984 Jul;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006 Mar;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009 Mar 18;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Imle P. Fluorescence-based fragment size analysis. Methods Mol Biol. 2005;311:139&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">16100405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Kauwe JS, Mayo K, et al. SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer&#x2019;s Disease. PLoS Genet. 2010;6:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2940763</ArticleId><ArticleId IdType="pubmed">20862329</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, Gibbs JR, Clarke J, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet. 2009 Apr;84(4):445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet. 2003 Nov;73(5):1162&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1180495</ArticleId><ArticleId IdType="pubmed">14574645</ArticleId></ArticleIdList></Reference><Reference><Citation>Huentelman MJ, Corneveaux J, Myers A, et al. ICAD-2010. ICAD-2010. Hawaii: Alzheimer&#x2019;s Association; 2010. Genome-Wide Association Study for Alzheimer&#x2019;s Disease Risk in a Large Cohort of Clinically Characterized and Neuropathologically Verified Subjects; p. 16. Vol Hot Topics Addendum.</Citation></Reference><Reference><Citation>Myers AJ, Gibbs JR, Webster JA, et al. A survey of genetic human cortical gene expression. Nat Genet. 2007 Dec;39(12):1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Mayo K, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A. 2008 Jun 10;105(23):8050&#x2013;8054.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2430357</ArticleId><ArticleId IdType="pubmed">18541914</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Jacquart S, Chakraverty S, et al. Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer&#x2019;s disease presenilin 1 mutation. Ann Neurol. 2007 May;61(5):446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe JS, Cruchaga C, Bertelsen S, et al. Validating predicted biological effects of Alzheimer&#x2019;s disease associated SNPs using CSF biomarker levels. J Alzheimers Dis. 2010;21(3):833&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032214</ArticleId><ArticleId IdType="pubmed">20634593</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010 Dec;67(12):1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22031444</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>478</Volume><Issue>7370</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Temporal dynamics and genetic control of transcription in the human prefrontal cortex.</ArticleTitle><Pagination><StartPage>519</StartPage><EndPage>523</EndPage><MedlinePgn>519-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10524</ELocationID><Abstract><AbstractText>Previous investigations have combined transcriptional and genetic analyses in human cell lines, but few have applied these techniques to human neural tissue. To gain a global molecular perspective on the role of the human genome in cortical development, function and ageing, we explore the temporal dynamics and genetic control of transcription in human prefrontal cortex in an extensive series of post-mortem brains from fetal development through ageing. We discover a wave of gene expression changes occurring during fetal development which are reversed in early postnatal life. One half-century later in life, this pattern of reversals is mirrored in ageing and in neurodegeneration. Although we identify thousands of robust associations of individual genetic polymorphisms with gene expression, we also demonstrate that there is no association between the total extent of genetic differences between subjects and the global similarity of their transcriptional profiles. Hence, the human genome produces a consistent molecular architecture in the prefrontal cortex, despite millions of genetic differences across individuals and races. To enable further discovery, this entire data set is freely available (from Gene Expression Omnibus: accession GSE30272; and dbGaP: accession phs000417.v1.p1) and can also be interrogated via a biologist-friendly stand-alone application (http://www.libd.org/braincloud).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colantuoni</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Section on Neuropathology, Clinical Brain Disorders Branch, Genes, Cognition and Psychosis Program, IRP, NIMH, NIH, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipska</LastName><ForeName>Barbara K</ForeName><Initials>BK</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Tianzhang</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hyde</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Ran</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Leek</LastName><ForeName>Jeffrey T</ForeName><Initials>JT</Initials></Author><Author ValidYN="Y"><LastName>Colantuoni</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Elkahloun</LastName><ForeName>Abdel G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Herman</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Weinberger</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Joel E</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE30272</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ZIC HG200365</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="Y">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018507" MajorTopicYN="N">Gene Expression Regulation, Developmental</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="Y">growth &amp; development</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044469" MajorTopicYN="N">Racial Groups</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22031444</ArticleId><ArticleId IdType="mid">NIHMS420228</ArticleId><ArticleId IdType="pmc">PMC3510670</ArticleId><ArticleId IdType="doi">10.1038/nature10524</ArticleId><ArticleId IdType="pii">nature10524</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schadt EE, et al. Genetics of gene expression surveyed in maize, mouse and man. Nature. 2003;422:297&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646919</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley M, et al. Genetic analysis of genome-wide variation in human gene expression. Nature. 2004;430:743&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966974</ArticleId><ArticleId IdType="pubmed">15269782</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranger BE, et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005;1:e78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1315281</ArticleId><ArticleId IdType="pubmed">16362079</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers AJ, et al. A survey of genetic human cortical gene expression. Nature Genet. 2007;39:1494&#x2013;1499.</Citation><ArticleIdList><ArticleId IdType="pubmed">17982457</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzen EL, et al. Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol. 2008;6:e1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605930</ArticleId><ArticleId IdType="pubmed">19222302</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs JR, et al. Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet. 2010;6:e1000952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869317</ArticleId><ArticleId IdType="pubmed">20485568</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C, et al. Whole-genome association mapping of gene expression in the human prefrontal cortex. Mol. Psychiatry. 2010;15:779&#x2013;784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057235</ArticleId><ArticleId IdType="pubmed">20351726</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster JA, et al. Genetic control of human brain transcript expression in Alzheimer disease. Am. J. Hum. Genet. 2009;84:445&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667989</ArticleId><ArticleId IdType="pubmed">19361613</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson MB, et al. Functional and evolutionary insights into human brain development through global transcriptome analysis. Neuron. 2009;62:494&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739738</ArticleId><ArticleId IdType="pubmed">19477152</ArticleId></ArticleIdList></Reference><Reference><Citation>Somel M, et al. MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res. 2010;20:1207&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928499</ArticleId><ArticleId IdType="pubmed">20647238</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldham MC, et al. Functional organization of the transcriptome in human brain. Nature Neurosci. 2008;11:1271&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756411</ArticleId><ArticleId IdType="pubmed">18849986</ArticleId></ArticleIdList></Reference><Reference><Citation>Torkamani A, Dean B, Schork NJ, Thomas EA. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res. 2010;20:403&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847743</ArticleId><ArticleId IdType="pubmed">20197298</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, O&#x2019;Leary DD. Axon retraction and degeneration in development and disease. Annu. Rev. Neurosci. 2005;28:127&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">16022592</ArticleId></ArticleIdList></Reference><Reference><Citation>Deo M, Yu JY, Chung KH, Tippens M, Turner DL. Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. Dev. Dyn. 2006;235:2538&#x2013;2548.</Citation><ArticleIdList><ArticleId IdType="pubmed">16736490</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao FB. Context-dependent functions of specific microRNAs in neuronal development. Neural Develop. 2010;5:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958854</ArticleId><ArticleId IdType="pubmed">20920300</ArticleId></ArticleIdList></Reference><Reference><Citation>Coolen M, Bally-Cuif L. MicroRNAs in brain development and physiology. Curr. Opin. Neurobiol. 2009;19:461&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">19846291</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaloy C, et al. MicroRNA-9 coordinates proliferation and migration of human embryonic stem cell-derived neural progenitors. Cell Stem Cell. 2010;6:323&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851637</ArticleId><ArticleId IdType="pubmed">20362537</ArticleId></ArticleIdList></Reference><Reference><Citation>Loerch PM, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE. 2008;3:e3329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2553198</ArticleId><ArticleId IdType="pubmed">18830410</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, et al. Incipient Alzheimer&#x2019;s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl Acad. Sci. USA. 2004;101:2173&#x2013;2178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Colantuoni C, Henry G, Zeger S, Pevsner J. SNOMAD (Standardization and NOrmalization of MicroArray Data): web-accessible gene expression dataanalysis. Bioinformatics. 2002;18:1540&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">12424128</ArticleId></ArticleIdList></Reference><Reference><Citation>Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet. 2007;3:1724&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1994707</ArticleId><ArticleId IdType="pubmed">17907809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipska BK, et al. Critical factors in gene expression in postmortem human brain: Focus on studies in schizophrenia. Biol. Psychiatry. 2006;60:650&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Systematic analysis, comparison, and integration of disease based human genetic association data and mouse genetic phenotypic information. BMC Med. Genomics. 2010;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822734</ArticleId><ArticleId IdType="pubmed">20092628</ArticleId></ArticleIdList></Reference><Reference><Citation>De S, Zhang Y, Garner JR, Wang SA, Becker KG. Disease and phenotype gene set analysis of disease based gene expression in mouse and human. Physiol. Genomics. 2010;42A:162&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957794</ArticleId><ArticleId IdType="pubmed">20682848</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel VC, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culturein vitro. Cancer Res. 2009;69:3364&#x2013;3373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821899</ArticleId><ArticleId IdType="pubmed">19351829</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaeffer EM, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27:7180&#x2013;7191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676849</ArticleId><ArticleId IdType="pubmed">18794802</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22049429</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>44</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2; during age-related plaque formation.</ArticleTitle><Pagination><StartPage>15861</StartPage><EndPage>15869</EndPage><MedlinePgn>15861-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3272-11.2011</ELocationID><Abstract><AbstractText>Growing evidence supports the hypothesis that soluble, diffusible forms of the amyloid &#x3b2;-peptide (A&#x3b2;) are pathogenically important in Alzheimer's disease (AD) and thus have both diagnostic and therapeutic salience. To learn more about the dynamics of soluble A&#x3b2; economy in vivo, we used microdialysis to sample the brain interstitial fluid (ISF), which contains the most soluble A&#x3b2; species in brain at steady state, in &gt;40 wake, behaving APP transgenic mice before and during the process of A&#x3b2; plaque formation (age 3-28 months). Diffusible forms of A&#x3b2;, especially A&#x3b2;(42), declined significantly in ISF as mice underwent progressive parenchymal deposition of A&#x3b2;. Moreover, radiolabeled A&#x3b2; administered at physiological concentrations into ISF revealed a striking difference in the fate of soluble A&#x3b2; in plaque-rich (vs plaque-free) mice: it clears more rapidly from the ISF and becomes more associated with the TBS-extractable pool, suggesting that cerebral amyloid deposits can rapidly sequester soluble A&#x3b2; from the ISF. Likewise, acute &#x3b3;-secretase inhibition in plaque-free mice showed a marked decline of A&#x3b2;(38), A&#x3b2;(40), and A&#x3b2;(42), whereas in plaque-rich mice, A&#x3b2;(42) declined significantly less. These results suggest that most of the A&#x3b2;(42) that populates the ISF in plaque-rich mice is derived not from new A&#x3b2; biosynthesis but rather from the large reservoir of less soluble A&#x3b2;(42) in brain parenchyma. Together, these and other findings herein illuminate the in vivo dynamics of soluble A&#x3b2; during the development of AD-type neuropathology and after &#x3b3;-secretase inhibition and help explain the apparent paradox that CSF A&#x3b2;(42) levels fall as humans develop AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Soyon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quintero-Monzon</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Ostaszewski</LastName><ForeName>Beth L</ForeName><Initials>BL</Initials></Author><Author ValidYN="Y"><LastName>Podlisny</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Cavanaugh</LastName><ForeName>William T</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG012749</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017574-08S1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027443</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029524</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024139</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007456">Iodine Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>8558G7RUTR</RegistryNumber><NameOfSubstance UI="D019289">Pyruvic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.108</RegistryNumber><NameOfSubstance UI="D043322">Lactase</NameOfSubstance></Chemical><Chemical><RegistryNumber>PDC6A3C0OX</RegistryNumber><NameOfSubstance UI="D005990">Glycerol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005990" MajorTopicYN="N">Glycerol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007456" MajorTopicYN="N">Iodine Isotopes</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043322" MajorTopicYN="N">Lactase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017711" MajorTopicYN="N">Nonlinear Dynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019289" MajorTopicYN="N">Pyruvic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="Y">Wakefulness</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22049429</ArticleId><ArticleId IdType="mid">NIHMS337328</ArticleId><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3272-11.2011</ArticleId><ArticleId IdType="pii">31/44/15861</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bech RA, Waldemar G, Gjerris F, Klinken L, Juhler M. Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings. Acta Neurochir (Wien) 1999;141:633&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">10929729</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Bigio MR, Cardoso ER, Halliday WC. Neuropathological changes in chronic adult hydrocephalus: cortical biopsies and autopsy findings. Can J Neurol Sci. 1997;24:121&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">9164688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb J, Wisoff J, Miller DC, Boksay I, Kluger A, Weiner H, Salton J, Graves W. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry. 2000;68:778&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736969</ArticleId><ArticleId IdType="pubmed">10811706</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr, Younkin LH, Suzuki N, Younkin SG. Amyloid beta protein (Abeta) in Alzheimer's disease brain. J Biol Chem. 1995;270:7013&#x2013;7016.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706234</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimwood S, Hogg J, Jay MT, Lad AM, Lee V, Murray F, Peachey J, Townend T, Vithlani M, Beher D, Shearman MS, Hutson PH. Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor. Neuropharmacology. 2005;48:1002&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">15857627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton R, Patel S, Lee EB, Jackson EM, Lopinto J, Arnold SE, Clark CM, Basil A, Shaw LM, Xie SX, Grady MS, Trojanowski JQ. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010;68:535&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964442</ArticleId><ArticleId IdType="pubmed">20687117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96:3228&#x2013;3233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15924</ArticleId><ArticleId IdType="pubmed">10077666</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43) Neuron. 1994;13:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">8043280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson I, Sandberg M, Hamberger A. Mass transfer in brain dialysis devices: a new method for the estimation of extracellular amino acids concentration. J Neurosci Methods. 1985;15:263&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">4094481</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L. Amyloid precursor protein processing and A&#x3b2;42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep&#x2013;wake cycle. Science. 2009;326:1005&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Klafki HW, Wiltfang J, Staufenbiel M. Electrophoretic separation of betaA4 peptides (1&#x2013;40) and (1&#x2013;42) Anal Biochem. 1996;237:24&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">8660532</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106:4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging. 2002;23:991&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470794</ArticleId></ArticleIdList></Reference><Reference><Citation>Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853&#x2013;862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866907</ArticleId><ArticleId IdType="pubmed">10487842</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of A&#x3b2; amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. High-level neuronal expression of Abeta 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci. 2010;30:14946&#x2013;14954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005;57(Suppl):S4&#x2013;S16. discussion ii&#x2013;v.</Citation><ArticleIdList><ArticleId IdType="pubmed">16160425</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem. 1986;46:1820&#x2013;1834.</Citation><ArticleIdList><ArticleId IdType="pubmed">3517233</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-&#x3b2; protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe D, Lemere CA, Walsh DM. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis. 2009;36:293&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782414</ArticleId><ArticleId IdType="pubmed">19660551</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shprecher D, Schwalb J, Kurlan R. Normal pressure hydrocephalus: diagnosis and treatment. Curr Neurol Neurosci Rep. 2008;8:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674287</ArticleId><ArticleId IdType="pubmed">18713572</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend MK, Okereke OI, Xia W, Yang T, Selkoe DJ, Grodstein F. Relation between insulin, insulin-related factors, and plasma amyloid beta peptide levels at midlife in a population-based study. Alzheimer Dis Assoc Disord. 2011 doi: 10.1097/WAD.0b013e31821764ce.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31821764ce</ArticleId><ArticleId IdType="pmc">PMC3140548</ArticleId><ArticleId IdType="pubmed">21502851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerstedt U, Rostami E. Microdialysis in neurointensive care. Curr Pharm Des. 2004;10:2145&#x2013;2152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15281890</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004;44:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">15450169</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Selkoe DJ. A beta oligomers: a decade of discovery. J Neurochem. 2007;101:1172&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">17286590</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittig I, Sch&#xe4;gger H. Advantages and limitations of clear-native PAGE. Proteomics. 2005;5:4338&#x2013;4346.</Citation><ArticleIdList><ArticleId IdType="pubmed">16220535</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X, Wang Y, Gonzales E, Holtzman DM, Lee JM. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009;29:10706&#x2013;10714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22031884</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>43</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Impaired &#x3b2;-amyloid secretion in Alzheimer's disease pathogenesis.</ArticleTitle><Pagination><StartPage>15384</StartPage><EndPage>15390</EndPage><MedlinePgn>15384-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2986-11.2011</ELocationID><Abstract><AbstractText>A central question in Alzheimer's disease (AD) research is what role &#x3b2;-amyloid peptide (A&#x3b2;) plays in synaptic dysfunction. Synaptic activity increases A&#x3b2; secretion, potentially inhibiting synapses, but also decreases intraneuronal A&#x3b2;, protecting synapses. We now show that levels of secreted A&#x3b2; fall with time in culture in neurons of AD-transgenic mice, but not wild-type mice. Moreover, the ability of synaptic activity to elevate secreted A&#x3b2; and reduce intraneuronal A&#x3b2; becomes impaired in AD-transgenic but not wild-type neurons with time in culture. We demonstrate that synaptic activity promotes an increase in the A&#x3b2;-degrading protease neprilysin at the cell surface and a concomitant increase in colocalization with A&#x3b2;42. Remarkably, AD-transgenic but not wild-type neurons show reduced levels of neprilysin with time in culture. This impaired ability to secrete A&#x3b2; and reduce intraneuronal A&#x3b2; has important implications for the pathogenesis and treatment of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tampellini</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Nawreen</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Capetillo-Zarate</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Gouras</LastName><ForeName>Gunnar K</ForeName><Initials>GK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG020729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG028174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG009464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 AG028174</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG09464</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020729</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027140</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076122">Disks Large Homolog 4 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C501447">Dlg4 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>B79L7B5X3Z</RegistryNumber><NameOfSubstance UI="D015244">Thiorphan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.17</RegistryNumber><NameOfSubstance UI="D054732">Calcium-Calmodulin-Dependent Protein Kinase Type 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.4.8</RegistryNumber><NameOfSubstance UI="D051528">Guanylate Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054732" MajorTopicYN="N">Calcium-Calmodulin-Dependent Protein Kinase Type 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076122" MajorTopicYN="N">Disks Large Homolog 4 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004622" MajorTopicYN="N">Embryo, Mammalian</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005998" MajorTopicYN="N">Glycine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051528" MajorTopicYN="N">Guanylate Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015244" MajorTopicYN="N">Thiorphan</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>4</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22031884</ArticleId><ArticleId IdType="mid">NIHMS336353</ArticleId><ArticleId IdType="pmc">PMC3225957</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2986-11.2011</ArticleId><ArticleId IdType="pii">31/43/15384</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida CG, Takahashi RH, Gouras GK. Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci. 2006;26:4277&#x2013;4288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673997</ArticleId><ArticleId IdType="pubmed">16624948</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science. 2008;321:1221&#x2013;1224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2577829</ArticleId><ArticleId IdType="pubmed">18755980</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging. 2004;25:1263&#x2013;1272.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465622</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron. 2008;58:42&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001;38:120&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Echeverria V, Ducatenzeiler A, Dowd E, J&#xe4;nne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC. Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. Neuroscience. 2004;129:583&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541880</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci. 2003;6:231&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">12577062</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010;68:220&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094694</ArticleId><ArticleId IdType="pubmed">20641005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol. 2010;119:523&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183823</ArticleId><ArticleId IdType="pubmed">20354705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J Neurosci Res. 2002;70:493&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">12391610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging. 2007;28:1297&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876915</ArticleId></ArticleIdList></Reference><Reference><Citation>Langui D, Girardot N, El Hachimi KH, Allinquant B, Blanchard V, Pradier L, Duyckaerts C. Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice. Am J Pathol. 2004;165:1465&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618656</ArticleId><ArticleId IdType="pubmed">15509518</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, Tolan DR, Selkoe DJ, Lemere CA. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid. 2002;9:88&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">12440481</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent B, Ring S, D'Adamio L, Shen J, M&#xfc;ller U, St George Hyslop P, Checler F. Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron. 2005;46:541&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944124</ArticleId></ArticleIdList></Reference><Reference><Citation>Puzzo D, Privitera L, Leznik E, F&#xe0; M, Staniszewski A, Palmeri A, Arancio O. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008;28:14537&#x2013;14545.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2673049</ArticleId><ArticleId IdType="pubmed">19118188</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K. Alzheimer's disease beta-amyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A. 2006;103:11172&#x2013;11177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1544060</ArticleId><ArticleId IdType="pubmed">16837572</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A. 2004;101:284&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314177</ArticleId><ArticleId IdType="pubmed">14688411</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol. 2002;161:1869&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850783</ArticleId><ArticleId IdType="pubmed">12414533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Rahman N, Gallo EF, Huang Z, Dumont M, Capetillo-Zarate E, Ma T, Zheng R, Lu B, Nanus DM, Lin MT, Gouras GK. Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci. 2009;29:9704&#x2013;9713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763626</ArticleId><ArticleId IdType="pubmed">19657023</ArticleId></ArticleIdList></Reference><Reference><Citation>Tampellini D, Capetillo-Zarate E, Dumont M, Huang Z, Yu F, Lin MT, Gouras GK. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci. 2010;30:14299&#x2013;14304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2972675</ArticleId><ArticleId IdType="pubmed">20980585</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shimada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid {beta} oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci. 2010;30:4845&#x2013;4856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6632783</ArticleId><ArticleId IdType="pubmed">20371804</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett. 2001;306:116&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11403971</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang AJ, Chandswangbhuvana D, Shu T, Henschen A, Glabe CG. Intracellular accumulation of insoluble, newly synthesized abetan-42 in amyloid precursor protein-transfected cells that have been treated with Abeta1&#x2013;42. J Biol Chem. 1999;274:20650&#x2013;20656.</Citation><ArticleIdList><ArticleId IdType="pubmed">10400697</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22049421</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>44</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>02</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rich-club organization of the human connectome.</ArticleTitle><Pagination><StartPage>15775</StartPage><EndPage>15786</EndPage><MedlinePgn>15775-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3539-11.2011</ELocationID><Abstract><AbstractText>The human brain is a complex network of interlinked regions. Recent studies have demonstrated the existence of a number of highly connected and highly central neocortical hub regions, regions that play a key role in global information integration between different parts of the network. The potential functional importance of these "brain hubs" is underscored by recent studies showing that disturbances of their structural and functional connectivity profile are linked to neuropathology. This study aims to map out both the subcortical and neocortical hubs of the brain and examine their mutual relationship, particularly their structural linkages. Here, we demonstrate that brain hubs form a so-called "rich club," characterized by a tendency for high-degree nodes to be more densely connected among themselves than nodes of a lower degree, providing important information on the higher-level topology of the brain network. Whole-brain structural networks of 21 subjects were reconstructed using diffusion tensor imaging data. Examining the connectivity profile of these networks revealed a group of 12 strongly interconnected bihemispheric hub regions, comprising the precuneus, superior frontal and superior parietal cortex, as well as the subcortical hippocampus, putamen, and thalamus. Importantly, these hub regions were found to be more densely interconnected than would be expected based solely on their degree, together forming a rich club. We discuss the potential functional implications of the rich-club organization of the human connectome, particularly in light of its role in information integration and in conferring robustness to its structural core.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van den Heuvel</LastName><ForeName>Martijn P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University Medical Center Utrecht, Rudolf Magnus Institute of Neuroscience, 3508 GA Utrecht, The Netherlands. m.p.vandenheuvel@umcutrecht.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sporns</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2011 Nov 23;13(1):3. doi: 10.1038/nrn3152.</RefSource><PMID Version="1">22108626</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2012 Jan;27(1):61. doi: 10.1002/mds.24063.</RefSource><PMID Version="1">22252892</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22049421</ArticleId><ArticleId IdType="pmc">PMC6623027</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3539-11.2011</ArticleId><ArticleId IdType="pii">31/44/15775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000;406:378&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">10935628</ArticleId></ArticleIdList></Reference><Reference><Citation>Alstott J, Breakspear M, Hagmann P, Cammoun L, Sporns O. Modeling the impact of lesions in the human brain. PLoS Comput Biol. 2009;5:e1000408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688028</ArticleId><ArticleId IdType="pubmed">19521503</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson JL, Skare S. A model-based method for retrospective correction of geometric distortions in diffusion-weighted EPI. Neuroimage. 2002;16:177&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">11969328</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson JL, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage. 2003;20:870&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568458</ArticleId></ArticleIdList></Reference><Reference><Citation>Barabasi AL, Bonabeau E. Scale-free networks. Sci Am. 2003;288:60&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">12701331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DS, Bullmore ET. Human brain networks in health and disease. Curr Opin Neurol. 2009;22:340&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2902726</ArticleId><ArticleId IdType="pubmed">19494774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DS, Bullmore ET, Meyer-Lindenberg A, Apud JA, Weinberger DR, Coppola R. Cognitive fitness of cost-efficient brain functional networks. Proc Natl Acad Sci U S A. 2009;106:11747&#x2013;11752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2703669</ArticleId><ArticleId IdType="pubmed">19564605</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett DS, Brown JA, Deshpande V, Carlson JM, Grafton ST. Conserved and variable architecture of human white matter connectivity. Neuroimage. 2011;54:1262&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">20850551</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu C. The basis of anisotropic water diffusion in the nervous system&#x2014;a technical review. NMR Biomed. 2002;15:435&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489094</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu C, Allen PS. Determinants of anisotropic water diffusion in nerves. Magn Reson Med. 1994;31:394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">8208115</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosboom JL, Stoffers D, Wolters ECh, Stam CJ, Berendse HW. MEG resting state functional connectivity in Parkinson's disease related dementia. J Neural Transm. 2009;116:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18982241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">19190637</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway DS, Newman ME, Strogatz SH, Watts DJ. Network robustness and fragility: percolation on random graphs. Phys Rev Lett. 2000;85:5468&#x2013;5471.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LC, Jones DK, Pierpaoli C. RESTORE: robust estimation of tensors by outlier rejection. Magn Reson Med. 2005;53:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pubmed">15844157</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee N, Sinha S. Understanding the mind of a worm: hierarchical network structure underlying nervous system function in C. elegans. Prog Brain Res. 2008;168:145&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">18166392</ArticleId></ArticleIdList></Reference><Reference><Citation>Colizza V, Flammini A, Serrano MA, Vespignani A. Detecting rich-club ordering in complex networks. Nat Phys. 2006;2:110&#x2013;115.</Citation></Reference><Reference><Citation>Egu&#xed;luz VM, Chialvo DR, Cecchi GA, Baliki M, Apkarian AV. Scale-free brain functional networks. Phys Rev Lett. 2005;94 018102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15698136</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewing-Cobbs L, Hasan KM, Prasad MR, Kramer L, Bachevalier J. Corpus callosum diffusion anisotropy correlates with neuropsychological outcomes in twins disconcordant for traumatic brain injury. AJNR Am J Neuroradiol. 2006;27:879&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868391</ArticleId><ArticleId IdType="pubmed">16611782</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, Halgren E, S&#xe9;gonne F, Salat DH, Busa E, Seidman LJ, Goldstein J, Kennedy D, Caviness V, Makris N, Rosen B, Dale AM. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornito A, Zalesky A, Bullmore ET. Network scaling effects in graph analytic studies of human resting-state FMRI data. Front Syst Neurosci. 2010;4:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893703</ArticleId><ArticleId IdType="pubmed">20592949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold BT, Powell DK, Xuan L, Jiang Y, Hardy PA. Speed of lexical decision correlates with diffusion anisotropy in left parietal and frontal white matter: evidence from diffusion tensor imaging. Neuropsychologia. 2007;45:2439&#x2013;2446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965058</ArticleId><ArticleId IdType="pubmed">17509627</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong G, He Y, Concha L, Lebel C, Gross DW, Evans AC, Beaulieu C. Mapping anatomical connectivity patterns of human cerebral cortex using in vivo diffusion tensor imaging tractography. Cereb Cortex. 2009;19:524&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722790</ArticleId><ArticleId IdType="pubmed">18567609</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC140943</ArticleId><ArticleId IdType="pubmed">12506194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Kurant M, Gigandet X, Thiran P, Wedeen VJ, Meuli R, Thiran JP. Mapping human whole-brain structural networks with diffusion MRI. PLoS One. 2007;2:e597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895920</ArticleId><ArticleId IdType="pubmed">17611629</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagmann P, Cammoun L, Gigandet X, Meuli R, Honey CJ, Wedeen VJ, Sporns O. Mapping the structural core of human cerebral cortex. PLoS Biol. 2008;6:e159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443193</ArticleId><ArticleId IdType="pubmed">18597554</ArticleId></ArticleIdList></Reference><Reference><Citation>Honey CJ, Sporns O. Dynamical consequences of lesions in cortical networks. Hum Brain Mapp. 2008;29:802&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870962</ArticleId><ArticleId IdType="pubmed">18438885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DK. The effect of gradient sampling schemes on measures derived from diffusion tensor MRI: a Monte Carlo study. Magn Reson Med. 2004;51:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">15065255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DK, Horsfield MA, Simmons A. Optimal strategies for measuring diffusion in anisotropic systems by magnetic resonance imaging. Magn Reson Med. 1999;42:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10467296</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser M, Martin R, Andras P, Young MP. Simulation of robustness against lesions of cortical networks. Eur J Neurosci. 2007;25:3185&#x2013;3192.</Citation><ArticleIdList><ArticleId IdType="pubmed">17561832</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, Niznikiewicz M, Connor EE, Levitt JJ, Frumin M, Kikinis R, Jolesz FA, McCarley RW, Shenton ME. DTI and MTR abnormalities in schizophrenia: analysis of white matter integrity. Neuroimage. 2005;26:1109&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768051</ArticleId><ArticleId IdType="pubmed">15878290</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynall ME, Bassett DS, Kerwin R, McKenna PJ, Kitzbichler M, Muller U, Bullmore E. Functional connectivity and brain networks in schizophrenia. J Neurosci. 2010;30:9477&#x2013;9487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2914251</ArticleId><ArticleId IdType="pubmed">20631176</ArticleId></ArticleIdList></Reference><Reference><Citation>Mason MF, Norton MI, Van Horn JD, Wegner DM, Grafton ST, Macrae CN. Wandering minds: the default network and stimulus-independent thought. Science. 2007;315:393&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1821121</ArticleId><ArticleId IdType="pubmed">17234951</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuley JJ, da Fontoura Costa L, Caetano TS. Rich-club phenomena across complex network hierachies. Appl Phys Lett. 2007:91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112555</ArticleId><ArticleId IdType="pubmed">32255813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, van Zijl PC. Fiber tracking: principles and strategies&#x2014;a technical review. NMR Biomed. 2002;15:468&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">12489096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori S, Crain BJ, Chacko VP, van Zijl PC. Three-dimensional tracking of axonal projections in the brain by magnetic resonance imaging. Ann Neurol. 1999;45:265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989633</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman ME. Modularity and community structure in networks. Proc Natl Acad Sci U S A. 2006;103:8577&#x2013;8582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482622</ArticleId><ArticleId IdType="pubmed">16723398</ArticleId></ArticleIdList></Reference><Reference><Citation>Opsahl T, Colizza V, Panzarasa P, Ramasco JJ. Prominence and control: the weighted rich-club effect. Phys Rev Lett. 2008;101:168702.</Citation><ArticleIdList><ArticleId IdType="pubmed">18999722</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, Snyder AZ. A default mode of brain function: a brief history of an evolving idea. Neuroimage. 2007;37:1083&#x2013;1090. discussion 1097&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719799</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubinov M, Sporns O. Complex network measures of brain connectivity: uses and interpretations. Neuroimage. 2010;52:1059&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pubmed">19819337</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O. The human connectome: a complex network. Ann N Y Acad Sci. 2011;1224:109&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">21251014</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Tononi G, K&#xf6;tter R. The human connectome: a structural description of the human brain. PLoS Comput Biol. 2005;1:e42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1239902</ArticleId><ArticleId IdType="pubmed">16201007</ArticleId></ArticleIdList></Reference><Reference><Citation>Sporns O, Honey CJ, K&#xf6;tter R. Identification and classification of hubs in brain networks. PLoS One. 2007;2:e1049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2013941</ArticleId><ArticleId IdType="pubmed">17940613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stam CJ, de Haan W, Daffertshofer A, Jones BF, Manshanden I, van Cappellen van Walsum AM, Montez T, Verbunt JP, de Munck JC, van Dijk BW, Berendse HW, Scheltens P. Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain. 2009;132:213&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">18952674</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z, Wang F, Cui L, Breeze J, Du X, Wang X, Cong Z, Zhang H, Li B, Hong N, Zhang D. Abnormal anterior cingulum in patients with schizophrenia: a diffusion tensor imaging study. Neuroreport. 2003;14:1833&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">14534430</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, Mandl RC, Luigjes J, Hulshoff Pol HE. Microstructural organization of the cingulum tract and the level of default mode functional connectivity. J Neurosci. 2008a;28:10844&#x2013;10851.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671361</ArticleId><ArticleId IdType="pubmed">18945892</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, Stam CJ, Boersma M, Hulshoff Pol HE. Small-world and scale-free organization of voxel based resting-state functional connectivity in the human brain. Neuroimage. 2008b;43:528&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786642</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, Stam CJ, Kahn RS, Hulshoff Pol HE. Efficiency of functional brain networks and intellectual performance. J Neurosci. 2009a;29:7619&#x2013;7624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665421</ArticleId><ArticleId IdType="pubmed">19515930</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, Mandl RC, Kahn RS, Hulshoff Pol HE. Functionally linked resting state networks reflect the underlying structural connectivity architecture of the human brain. Hum Brain Mapp. 2009b;30:3127&#x2013;3141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870902</ArticleId><ArticleId IdType="pubmed">19235882</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Heuvel MP, Mandl RC, Stam CJ, Kahn RS, Hulshoff Pol HE. Aberrant frontal and temperal network structure in schizophrenia: a graph theoretical analysis. J Neurosci. 2010;30:15915&#x2013;15926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633761</ArticleId><ArticleId IdType="pubmed">21106830</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, van den Heuvel MP, Veldink JH, Blanken N, Mandl RC, Hulshoff Pol HE, van den Berg LH. Motor network degeneration in amyotrophic lateral sclerosis: a structural and functional connectivity study. PLoS One. 2010;5:e13664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965124</ArticleId><ArticleId IdType="pubmed">21060689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wang L, Zang Y, Yang H, Tang H, Gong Q, Chen Z, Zhu C, He Y. Parcellation-dependent small-world brain functional networks: a resting-state fMRI study. Hum Brain Mapp. 2009;30:1511&#x2013;1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6870680</ArticleId><ArticleId IdType="pubmed">18649353</ArticleId></ArticleIdList></Reference><Reference><Citation>Wig GS, Schlaggar BL, Petersen SE. Concepts and principles in the analysis of brain networks. Ann N Y Acad Sci. 2011;1224:126&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">21486299</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu XK, Zhang J, Small M. Rich-club connectivity dominates assortativity and transitivity of complex networks. Phys Rev E Stat Nonlin Soft Matter Phys. 2010;82 046117.</Citation><ArticleIdList><ArticleId IdType="pubmed">21230355</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalesky A, Fornito A. A DTI-derived measure of cortico-cortical connectivity. IEEE Trans Med Imaging. 2009;28:1023&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pubmed">19150781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalesky A, Fornito A, Harding IH, Cocchi L, Y&#xfc;cel M, Pantelis C, Bullmore ET. Whole-brain anatomical networks: does the choice of nodes matter? Neuroimage. 2010;50:970&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">20035887</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalesky A, Fornito A, Seal ML, Cocchi L, Westin CF, Bullmore ET, Egan GF, Pantelis C. Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry. 2011;69:80&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4881385</ArticleId><ArticleId IdType="pubmed">21035793</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamora-L&#xf3;pez G, Zhou C, Kurths J. Graph analysis of cortical networks reveals complex anatomical communication substrate. Chaos. 2009;19 015117.</Citation><ArticleIdList><ArticleId IdType="pubmed">19335021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Mondragon RJ. The rich-club phenomenon in the internet topology. IEEE Commun Lett. 2004;8:180&#x2013;182.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22009197</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1460-2075</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>23</Issue><PubDate><Year>2011</Year><Month>Oct</Month><Day>18</Day></PubDate></JournalIssue><Title>The EMBO journal</Title><ISOAbbreviation>EMBO J</ISOAbbreviation></Journal><ArticleTitle>Novel diffusion barrier for axonal retention of Tau in neurons and its failure in neurodegeneration.</ArticleTitle><Pagination><StartPage>4825</StartPage><EndPage>4837</EndPage><MedlinePgn>4825-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/emboj.2011.376</ELocationID><Abstract><AbstractText>Missorting of Tau from axons to the somatodendritic compartment of neurons is a hallmark of Alzheimer's disease, but the mechanisms underlying normal sorting and pathological failure are poorly understood. Here, we used several Tau constructs labelled with photoconvertible Dendra2 to analyse its mobility in polarized neurons. This revealed a novel mechanism of sorting-a retrograde barrier in the axon initial segment (AIS) operating as cellular rectifier. It allows anterograde flow of axonal Tau but prevents retrograde flow back into soma and dendrites. The barrier requires binding of Tau to microtubules but does not require F-actin and thus is distinct from the sorting of membrane-associated proteins at the AIS. The barrier breaks down when Tau is phosphorylated in its repeat domain and detached from microtubules, for example, by the kinase MARK/Par1. These observations link the pathological hallmarks of Tau missorting and hyperphosphorylation in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Max-Planck-Unit for Structural Molecular Biology, c/o DESY, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Yatender</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zempel</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Biernat</LastName><ForeName>Jacek</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eckhard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EMBO J</MedlineTA><NlmUniqueID>8208664</NlmUniqueID><ISSNLinking>0261-4189</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000199">Actins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>EMBO J. 2011 Nov 30;30(23):4699-700. doi: 10.1038/emboj.2011.409.</RefSource><PMID Version="1">22126819</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000199" MajorTopicYN="N">Actins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001370" MajorTopicYN="N">Axonal Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016764" MajorTopicYN="N">Cell Polarity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010777" MajorTopicYN="N">Photochemistry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>9</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22009197</ArticleId><ArticleId IdType="pmc">PMC3243615</ArticleId><ArticleId IdType="doi">10.1038/emboj.2011.376</ArticleId><ArticleId IdType="pii">emboj2011376</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aronov S, Aranda G, Behar L, Ginzburg I (2001) Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J Neurosci 21: 6577&#x2013;6587</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763080</ArticleId><ArticleId IdType="pubmed">11517247</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronov S, Aranda G, Behar L, Ginzburg I (2002) Visualization of translated tau protein in the axons of neuronal P19 cells and characterization of tau RNP granules. J Cell Sci 115: 3817&#x2013;3827</Citation><ArticleIdList><ArticleId IdType="pubmed">12235292</ArticleId></ArticleIdList></Reference><Reference><Citation>Baas PW, Buster DW (2004) Slow axonal transport and the genesis of neuronal morphology. J Neurobiol 58: 3&#x2013;17</Citation><ArticleIdList><ArticleId IdType="pubmed">14598366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer&#x2032;s disease and related disorders. Nat Rev Neurosci 8: 663&#x2013;672</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Banker G, Goslin K (1988) Developments in neuronal cell culture. Nature 336: 185&#x2013;186</Citation><ArticleIdList><ArticleId IdType="pubmed">3185736</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Mandelkow EM (1999) The development of cell processes induced by tau protein requires phosphorylation of serine 262 and 356 in the repeat domain and is inhibited by phosphorylation in the proline-rich domains. Mol Biol Cell 10: 727&#x2013;740</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25198</ArticleId><ArticleId IdType="pubmed">10069814</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI (1985) The distribution of tau in the mammalian central nervous system. J Cell Biol 101: 1371&#x2013;1378</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Burack MA, Silverman MA, Banker G (2000) The role of selective transport in neuronal protein sorting. Neuron 26: 465&#x2013;472</Citation><ArticleIdList><ArticleId IdType="pubmed">10839364</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 24: 1023&#x2013;1027</Citation><ArticleIdList><ArticleId IdType="pubmed">14643374</ArticleId></ArticleIdList></Reference><Reference><Citation>Drubin D, Kirschner M (1986) Purification of tau protein from brain. Methods Enzymol 134: 156&#x2013;160</Citation><ArticleIdList><ArticleId IdType="pubmed">3102900</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner CC, Brugg B, Matus A (1988) A 70-kilodalton microtubule-associated protein (MAP2c), related to MAP2. J Neurochem 50: 609&#x2013;615</Citation><ArticleIdList><ArticleId IdType="pubmed">3121794</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier A, Brandt R (2010) Live cell imaging of cytoskeletal dynamics in neurons using fluorescence photoactivation. Biol Chem 391: 639&#x2013;643</Citation><ArticleIdList><ArticleId IdType="pubmed">20370315</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 8: 393&#x2013;399</Citation><ArticleIdList><ArticleId IdType="pmc">PMC400819</ArticleId><ArticleId IdType="pubmed">2498079</ArticleId></ArticleIdList></Reference><Reference><Citation>Grubb MS, Burrone J (2010) Building and maintaining the axon initial segment. Curr Opin Neurobiol 20: 481&#x2013;488</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191460</ArticleId><ArticleId IdType="pubmed">20537529</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurskaya NG, Verkhusha VV, Shcheglov AS, Staroverov DB, Chepurnykh TV, Fradkov AF, Lukyanov S, Lukyanov KA (2006) Engineering of a monomeric green-to-red photoactivatable fluorescent protein induced by blue light. Nat Biotechnol 24: 461&#x2013;465</Citation><ArticleIdList><ArticleId IdType="pubmed">16550175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustke N, Trinczek B, Biernat J, Mandelkow EM, Mandelkow E (1994) Domains of tau protein and interactions with microtubules. Biochemistry 33: 9511&#x2013;9522</Citation><ArticleIdList><ArticleId IdType="pubmed">8068626</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer&#x2032;s amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101&#x2013;112</Citation><ArticleIdList><ArticleId IdType="pubmed">17245412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N (1982) Cross-linker system between neurofilaments, microtubules, and membranous organelles in frog axons revealed by the quick-freeze, deep-etching method. J Cell Biol 94: 129&#x2013;142</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2112203</ArticleId><ArticleId IdType="pubmed">6181077</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Funakoshi T, Sato-Harada R, Kanai Y (1996) Selective stabilization of tau in axons and microtubule-associated protein 2C in cell bodies and dendrites contributes to polarized localization of cytoskeletal proteins in mature neurons. J Cell Biol 132: 667&#x2013;679</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2199865</ArticleId><ArticleId IdType="pubmed">8647897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Niwa S, Tanaka Y (2010) Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease. Neuron 68: 610&#x2013;638</Citation><ArticleIdList><ArticleId IdType="pubmed">21092854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirokawa N, Takemura R (2005) Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci 6: 201&#x2013;214</Citation><ArticleIdList><ArticleId IdType="pubmed">15711600</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Gotz J (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2032;s disease mouse models. Cell 142: 387&#x2013;397</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C, Kramer EM, Cardine AM, Schraven B, Brandt R, Trotter J (2002) Process outgrowth of oligodendrocytes is promoted by interaction of fyn kinase with the cytoskeletal protein tau. J Neurosci 22: 698&#x2013;707</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758498</ArticleId><ArticleId IdType="pubmed">11826099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kole MH, Ilschner SU, Kampa BM, Williams SR, Ruben PC, Stuart GJ (2008) Action potential generation requires a high sodium channel density in the axon initial segment. Nat Neurosci 11: 178&#x2013;186</Citation><ArticleIdList><ArticleId IdType="pubmed">18204443</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi Y, Setou M (2009) Tubulin tyrosination navigates the kinesin-1 motor domain to axons. Nat Neurosci 12: 559&#x2013;567</Citation><ArticleIdList><ArticleId IdType="pubmed">19377471</ArticleId></ArticleIdList></Reference><Reference><Citation>Konzack S, Thies E, Marx A, Mandelkow EM, Mandelkow E (2007) Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. J Neurosci 27: 9916&#x2013;9927</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672630</ArticleId><ArticleId IdType="pubmed">17855606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268: 24374&#x2013;24384</Citation><ArticleIdList><ArticleId IdType="pubmed">8226987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Finch EA (1987) MAP2 and tau segregate into dendritic and axonal domains after the elaboration of morphologically distinct neurites: an immunocytochemical study of cultured rat cerebrum. J Neurosci 7: 3142&#x2013;3153</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569170</ArticleId><ArticleId IdType="pubmed">2444675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosik KS, Orecchio LD, Bakalis S, Neve RL (1989) Developmentally regulated expression of specific tau sequences. Neuron 2: 1389&#x2013;1397</Citation><ArticleIdList><ArticleId IdType="pubmed">2560640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazarov O, Morfini GA, Pigino G, Gadadhar A, Chen X, Robinson J, Ho H, Brady ST, Sisodia SS (2007) Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer&#x2032;s disease-linked mutant presenilin 1. J Neurosci 27: 7011&#x2013;7020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2801050</ArticleId><ArticleId IdType="pubmed">17596450</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledesma MD, Dotti CG (2003) Membrane and cytoskeleton dynamics during axonal elongation and stabilization. Int Rev Cytol 227: 183&#x2013;219</Citation><ArticleIdList><ArticleId IdType="pubmed">14518552</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenberg-Kraag B, Mandelkow EM, Biernat J, Steiner B, Schroter C, Gustke N, Meyer HE, Mandelkow E (1992) Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. Proc Natl Acad Sci USA 89: 5384&#x2013;5388</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49296</ArticleId><ArticleId IdType="pubmed">1376918</ArticleId></ArticleIdList></Reference><Reference><Citation>LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LI (1995) Functional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci USA 92: 10369&#x2013;10373</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40798</ArticleId><ArticleId IdType="pubmed">7479786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell JW, Banker GA (1995) The microtubule cytoskeleton and the development of neuronal polarity. Neurobiol Aging 16: 229&#x2013;237; discussion 238</Citation><ArticleIdList><ArticleId IdType="pubmed">7566333</ArticleId></ArticleIdList></Reference><Reference><Citation>Matenia D, Mandelkow EM (2009) The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem Sci 34: 332&#x2013;342</Citation><ArticleIdList><ArticleId IdType="pubmed">19559622</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP (2004) Pathways towards and away from Alzheimer&#x2032;s disease. Nature 430: 631&#x2013;639</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Migheli A, Butler M, Brown K, Shelanski ML (1988) Light and electron microscope localization of the microtubule-associated tau protein in rat brain. J Neurosci 8: 1846&#x2013;1851</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6569338</ArticleId><ArticleId IdType="pubmed">3133453</ArticleId></ArticleIdList></Reference><Reference><Citation>Morita T, Sobue K (2009) Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem 284: 27734&#x2013;27745</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785701</ArticleId><ArticleId IdType="pubmed">19648118</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakada C, Ritchie K, Oba Y, Nakamura M, Hotta Y, Iino R, Kasai RS, Yamaguchi K, Fujiwara T, Kusumi A (2003) Accumulation of anchored proteins forms membrane diffusion barriers during neuronal polarization. Nat Cell Biol 5: 626&#x2013;632</Citation><ArticleIdList><ArticleId IdType="pubmed">12819789</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakata T, Hirokawa N (2003) Microtubules provide directional cues for polarized axonal transport through interaction with kinesin motor head. J Cell Biol 162: 1045&#x2013;1055</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172855</ArticleId><ArticleId IdType="pubmed">12975348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa Y, Rasband MN (2008) The functional organization and assembly of the axon initial segment. Curr Opin Neurobiol 18: 307&#x2013;313</Citation><ArticleIdList><ArticleId IdType="pubmed">18801432</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SC, Binder LI (1987) Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton 8: 210&#x2013;226</Citation><ArticleIdList><ArticleId IdType="pubmed">2446784</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH (2010) Amyloid-independent mechanisms in Alzheimer&#x2032;s disease pathogenesis. J Neurosci 30: 14946&#x2013;14954</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426835</ArticleId><ArticleId IdType="pubmed">21068297</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasband MN (2010) The axon initial segment and the maintenance of neuronal polarity. Nat Rev Neurosci 11: 552&#x2013;562</Citation><ArticleIdList><ArticleId IdType="pubmed">20631711</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750&#x2013;754</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Samsonov A, Yu JZ, Rasenick M, Popov SV (2004) Tau interaction with microtubules in vivo. J Cell Sci 117: 6129&#x2013;6141</Citation><ArticleIdList><ArticleId IdType="pubmed">15564376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ponce D, Munoz A, Garrido JJ (2011) Casein kinase 2 and microtubules control axon initial segment formation. Mol Cell Neurosci 46: 222&#x2013;234</Citation><ArticleIdList><ArticleId IdType="pubmed">20850541</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DA, Das U, Tang Y, Roy S (2011) Mechanistic logic underlying the axonal transport of cytosolic proteins. Neuron 70: 441&#x2013;454</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096075</ArticleId><ArticleId IdType="pubmed">21555071</ArticleId></ArticleIdList></Reference><Reference><Citation>Song AH, Wang D, Chen G, Li Y, Luo J, Duan S, Poo MM (2009) A selective filter for cytoplasmic transport at the axon initial segment. Cell 136: 1148&#x2013;1160</Citation><ArticleIdList><ArticleId IdType="pubmed">19268344</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Goldstein LS (2006) Axonal transport and Alzheimer's disease. Annu Rev Biochem 75: 607&#x2013;627</Citation><ArticleIdList><ArticleId IdType="pubmed">16756504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan A, Nesslany F, Violet M, Begard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Buee L, Galas MC (2011) Nuclear tau, a key player in neuronal DNA protection. J Biol Chem 286: 4566&#x2013;4575</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3039398</ArticleId><ArticleId IdType="pubmed">21131359</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM (2007) Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci 27: 2896&#x2013;2907</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Timm T, Balusamy K, Li X, Biernat J, Mandelkow E, Mandelkow EM (2008) Glycogen synthase kinase (GSK) 3beta directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. J Biol Chem 283: 18873&#x2013;18882</Citation><ArticleIdList><ArticleId IdType="pubmed">18424437</ArticleId></ArticleIdList></Reference><Reference><Citation>Utton MA, Connell J, Asuni AA, van Slegtenhorst M, Hutton M, de Silva R, Miller CC, Anderton BH (2002) The slow axonal transport of the microtubule-associated protein tau and the transport rates of different isoforms and mutants in cultured neurons. J Neurosci 22: 6394&#x2013;6400</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758152</ArticleId><ArticleId IdType="pubmed">12151518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Ho CL, Sun D, Liem RK, Brown A (2000) Rapid movement of axonal neurofilaments interrupted by prolonged pauses. Nat Cell Biol 2: 137&#x2013;141</Citation><ArticleIdList><ArticleId IdType="pubmed">10707083</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann C, Reyher HJ, Gauthier A, Steinhoff HJ, Junge W, Brandt R (2009) Microtubule binding and trapping at the tip of neurites regulate tau motion in living neurons. Traffic 10: 1655&#x2013;1668</Citation><ArticleIdList><ArticleId IdType="pubmed">19744140</ArticleId></ArticleIdList></Reference><Reference><Citation>Winckler B, Forscher P, Mellman I (1999) A diffusion barrier maintains distribution of membrane proteins in polarized neurons. Nature 397: 698&#x2013;701</Citation><ArticleIdList><ArticleId IdType="pubmed">10067893</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte H, Bradke F (2008) The role of the cytoskeleton during neuronal polarization. Curr Opin Neurobiol 18: 479&#x2013;487</Citation><ArticleIdList><ArticleId IdType="pubmed">18929658</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Sasaki T, Rao MV, Kumar A, Kanumuri V, Dunlop DS, Liem RK, Nixon RA (2009) Neurofilaments form a highly stable stationary cytoskeleton after reaching a critical level in axons. J Neurosci 29: 11316&#x2013;11329</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788791</ArticleId><ArticleId IdType="pubmed">19741138</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM (2010) Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 30: 11938&#x2013;11950</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22038908</PMID><DateCompleted><Year>2012</Year><Month>12</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2199</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cerebral cortex (New York, N.Y. : 1991)</Title><ISOAbbreviation>Cereb Cortex</ISOAbbreviation></Journal><ArticleTitle>CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects.</ArticleTitle><Pagination><StartPage>1993</StartPage><EndPage>2004</EndPage><MedlinePgn>1993-2004</MedlinePgn></Pagination><Abstract><AbstractText>Beta-amyloid (A&#x3b2;) is a histopathological hallmark of Alzheimer's disease dementia, but high levels of A&#x3b2; in the brain can also be found in a substantial proportion of nondemented subjects. Here we investigated which 2-year rate of brain and cognitive changes are present in nondemented subjects with high and low A&#x3b2; levels, as assessed with cerebrospinal fluid and molecular positron emission tomography (PET)-based biomarkers of A&#x3b2;. In subjects with mild cognitive impairment, increased brain A&#x3b2; levels were associated with significantly faster cognitive decline, progression of gray matter atrophy within temporal and parietal brain regions, and a trend for a faster decline in parietal Fludeoxyglucose (FDG)-PET metabolism. Changes in gray matter and FDG-PET mediated the association between A&#x3b2; and cognitive decline. In contrast, elderly cognitively healthy controls (HC) with high A&#x3b2; levels showed only a faster medial temporal lobe and precuneus volume decline compared with HC with low A&#x3b2;. In conclusion, the current results suggest not only that both functional and volumetric brain changes are associated with high A&#x3b2; years before the onset of dementia but also that HC with substantial A&#x3b2; levels show higher A&#x3b2; pathology resistance, lack other pathologies that condition neurotoxic effects of A&#x3b2;, or accumulated A&#x3b2; for a shorter time period.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Francisco, 94143, USA. michael.ewers@ucsf.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Insel</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jagust</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cereb Cortex</MedlineTA><NlmUniqueID>9110718</NlmUniqueID><ISSNLinking>1047-3211</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="Y">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22038908</ArticleId><ArticleId IdType="pmc">PMC3500862</ArticleId><ArticleId IdType="doi">10.1093/cercor/bhr271</ArticleId><ArticleId IdType="pii">bhr271</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010;31:1284&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3051831</ArticleId><ArticleId IdType="pubmed">20538372</ArticleId></ArticleIdList></Reference><Reference><Citation>Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol. 2006;60:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802294</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64:834&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Sepulcre J, Talukdar T, Krienen FM, Liu H, Hedden T, Andrews-Hanna JR, Sperling RA, Johnson KA. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29:1860&#x2013;1873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750039</ArticleId><ArticleId IdType="pubmed">19211893</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Landeau B, Eustache F, Mezenge F, Viader F, de la Sayette V, Desgranges B, Baron JC. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage. 2005;27:934&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979341</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D, Ellis KA, Szoeke C, Martins RN, O'Keefe GJ, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, et al. Basal Cerebral metabolism may modulate the cognitive effects of A{beta} in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29:14770&#x2013;14778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="pubmed">19940172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9:179&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931268</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67:949&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll I, Zhou Y, An Y, Sojkova J, Davatzikos C, Kraut MA, Ye W, Ferrucci L, Mathis CA, Klunk WE, et al. Lack of association between (11)C-PiB and longitudinal brain atrophy in non-demented older individuals. Neurobiol Aging. 2010 doi: 10.1016/j.neurobiolaging.2009.12.008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908199</ArticleId><ArticleId IdType="pubmed">20176414</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci. 2011;34:430&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275347</ArticleId><ArticleId IdType="pubmed">21696834</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR, Jr, Feldman HH, Bokde AL, Alexander GE, Scheltens P, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging. 2010 doi: 10.1016/j.neurobiolaging.2010.10.019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328615</ArticleId><ArticleId IdType="pubmed">21159408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999;9:195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9931269</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM the Alzheimer's Disease Neuroimaging Initiative. Brain atrophy in healthy aging is related to CSF levels of A&#x3b2;1-42. Cereb Cortex. 2010;20:2069&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025722</ArticleId><ArticleId IdType="pubmed">20051356</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Almkvist O, Engler H, Wall A, Langstrom B, Nordberg A. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res. 2010;7:56&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">20205671</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Lorenzi M, Caroli A, Kemppainen N, Nagren K, Rinne JO. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology. 2009;72:1504&#x2013;1511.</Citation><ArticleIdList><ArticleId IdType="pubmed">19398705</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J Neurol Neurosurg Psychiatry. 2007;78:461&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117838</ArticleId><ArticleId IdType="pubmed">17098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat. 1979;6:65&#x2013;70.</Citation></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D, Borowski B, Britson PJ, J LW, Ward C, et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132:1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Langstrom B, Nordberg A. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging. 2010 doi: 10.1016/j.neurobiolaging.2010.06.015.</Citation><ArticleIdList><ArticleId IdType="pubmed">20688420</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2009;32:1207&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR, Jr, Bernstein MA, Britson PJ, Gunter JL, et al. Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage. 2009;45:645&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696624</ArticleId><ArticleId IdType="pubmed">19280686</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddock RJ, Garrett AS, Buonocore MH. Remembering familiar people: the posterior cingulate cortex and autobiographical memory retrieval. Neuroscience. 2001;104:667&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440800</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132:1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoll JA, Yamada M, Frackowiak J, Mazur-Kolecka B, Weller RO. Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol Aging. 2004;25:584&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172734</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130:2837&#x2013;2844.</Citation><ArticleIdList><ArticleId IdType="pubmed">17928318</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991;12:295&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, O'Neil JP, Racine CA, Mormino EC, Baker SL, Chetty S, Patel P, Pagliaro TA, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Rami L, Fortea J, Bosch B, Sole-Padulles C, Llado A, Iranzo A, Sanchez-Valle R, Molinuevo JL. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis. 2011;23:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">21098971</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074985</ArticleId><ArticleId IdType="pubmed">20373347</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, et al Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L'examen clinique en psychologie. Paris (France): Press Universitaires de France; 1964.</Citation></Reference><Reference><Citation>Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, Wallin A. Amyloid-beta42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis. 2011;26:135&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">21593572</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy S, Rauk A. Alzheimer's disease and the &#x2018;ABSENT&#x2019; hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity. Med Hypoth. 2005;65:123&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">15893129</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Stern Y. Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease. Curr Neurol Neurosci Rep. 2004;4:374&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026565</ArticleId><ArticleId IdType="pubmed">15324603</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol. 2010;68:825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeter ML, Stein T, Maslowski N, Neumann J. Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage. 2009;47:1196&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730171</ArticleId><ArticleId IdType="pubmed">19463961</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuff N, Woerner N, Boreta L, Kornfield T, Shaw LM, Trojanowski JQ, Thompson PM, Jack CR, Jr, Weiner MW the Alzheimer's Disease Neuroimaging I. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain. 2009;132:1067&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668943</ArticleId><ArticleId IdType="pubmed">19251758</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, et al Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, et al Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord. 2007;24:118&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622715</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">20142530</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66:1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, et al Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343463</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, et al Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid. Alzheimers Dement. 2011;7:133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060961</ArticleId><ArticleId IdType="pubmed">21282074</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21747008</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.</ArticleTitle><Pagination><StartPage>1404</StartPage><EndPage>1411</EndPage><MedlinePgn>1404-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.150</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To characterize quantitative florbetapir F 18 (hereafter referred to as simply florbetapir) positron emission tomographic (PET) measurements of fibrillar &#x3b2;-amyloid (A&#x3b2;) burden in a large clinical cohort of participants with probable Alzheimer disease (AD) or mild cognitive impairment (MCI) and older healthy controls (OHCs).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cerebral-to-whole-cerebellar florbetapir standard uptake value ratios (SUVRs) were computed. Mean cortical SUVRs were compared. A threshold of SUVRs greater than or equal to 1.17 was used to reflect pathological levels of amyloid associated with AD based on separate antemortem PET and postmortem neuropathology data from 19 end-of-life patients. Similarly, a threshold of SUVRs greater than 1.08 was used to signify the presence of any identifiable A&#x3b2; because this was the upper limit from a separate set of 46 individuals 18 to 40 years of age who did not carry apolipoprotein E (APOE) &#x3b5;4.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Multiple research imaging centers.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 68 participants with probable AD, 60 participants with MCI, and 82 OHCs who were 55 years of age or older. Main Outcome Measure Florbetapir-PET activity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All of the participants (ie, those with probable AD or MCI and those who were OHCs) differed significantly in mean (SD) cortical florbetapir SUVRs (1.39 [0.24], 1.17 [0.27], and 1.05 [0.16], respectively; P &lt; 1.0 &#xd7; 10&#x207b;&#x2077;), in percentage meeting levels of amyloid associated with AD by SUVR criteria (80.9%, 40.0%, and 20.7%, respectively; P &lt; 1.0 &#xd7; 10&#x207b;&#x2077;), and in percentage meeting SUVR criteria for the presence of any identifiable A&#x3b2; (85.3%, 46.6%, and 28.1%, respectively; P &lt; 1.0 &#xd7; 10&#x207b;&#x2077;). Among OHCs, the percentage of florbetapir positivity increased linearly by age decile (P = .05). For the 54 OHCs with available APOE genotypes, APOE &#x3b5;4 carriers had a higher mean (SD) cortical SUVR than did noncarriers (1.14 [0.2] vs 1.03 [0.16]; P = .048).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings of our analysis confirm the ability of florbetapir-PET SUVRs to characterize amyloid levels in clinically probable AD, MCI, and OHC groups using continuous and binary measures of fibrillar A&#x3b2; burden. It introduces criteria to determine whether an image is associated with an intermediate-to-high likelihood of pathologic AD or with having any identifiable cortical amyloid level above that seen in low-risk young controls.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, 901 E Willetta St, Phoenix, AZ 85006, USA. adam.fleisher@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Xiaofen</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Roontiva</LastName><ForeName>Auttawut</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Thiyyagura</LastName><ForeName>Pradeep</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ayutyanont</LastName><ForeName>Napatkamon</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Abhinay D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2011 Nov;68(11):1377-8. doi: 10.1001/archneurol.2011.152.</RefSource><PMID Version="1">21747005</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="Y">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="Y">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.150</ArticleId><ArticleId IdType="pii">archneurol.2011.150</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21747004</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology.</ArticleTitle><Pagination><StartPage>1398</StartPage><EndPage>1403</EndPage><MedlinePgn>1398-403</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.153</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the correspondence of in vivo quantitative estimates of brain uptake of fluorine 18-labeled flutemetamol with immunohistochemical estimates of amyloid levels in patients who underwent previous biopsy.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study of &#xb9;&#x2078;F-flutemetamol positron emission tomography (PET) findings in patients with prior cortical biopsy specimen stained for the presence or absence of amyloid plaques.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University hospital. Patients Seven patients who previously had a prior right frontal cortical biopsy at the site of ventriculoperitoneal placement for presumed normal pressure hydrocephalus were recruited. Inclusion criteria included an adequate biopsy specimen for detection and quantification of &#x3b2;-amyloid pathology and age older than 50 years. Intervention All patients underwent an &#xb9;&#x2078;F-flutemetamol PET scan.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Quantitative measures of &#xb9;&#x2078;F-flutemetamol uptake (standardized uptake value ratio, a ratio of mean target cortex activity divided by that in a cerebellar reference region) were made at a location contralateral to the biopsy site and compared with estimates of amyloid load based on immunohistochemical and histological staining.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was complete agreement between visual reads of &#xb9;&#x2078;F-flutemetamol PET scans (3 blinded readers with majority rule) and histology. A regression model, including time from biopsy as a covariate, demonstrated a significant relationship (P = .01) between &#xb9;&#x2078;F-flutemetamol uptake and percentage of area of amyloid measured by a monoclonal antibody raised against amyloid (NAB228). Similar results were found with the amyloid-specific monoclonal antibody 4G8 and Thioflavin S.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">To our knowledge, these data are the first to demonstrate the concordance of &#xb9;&#x2078;F-flutemetamol PET imaging with histopathology, supporting its sensitivity to detect amyloid and potential use in the study and detection of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Penn Memory Center, 3615 Chestnut St, Philadelphia, PA 19104, USA. david.wolk@uphs.upenn.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grachev</LastName><ForeName>Igor D</ForeName><Initials>ID</Initials></Author><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Kazi</LastName><ForeName>Hala</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Grady</LastName><ForeName>M Sean</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Sherwin</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>McLain</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052160">Benzothiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2011 Nov;68(11):1377-8. doi: 10.1001/archneurol.2011.152.</RefSource><PMID Version="1">21747005</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052160" MajorTopicYN="Y">Benzothiazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="Y">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21747004</ArticleId><ArticleId IdType="mid">NIHMS713283</ArticleId><ArticleId IdType="pmc">PMC4532383</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.153</ArticleId><ArticleId IdType="pii">archneurol.2011.153</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Small GW, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355(25):2652&#x2013;2663.</Citation><ArticleIdList><ArticleId IdType="pubmed">17182990</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeff NP, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12(6):584&#x2013;595.</Citation><ArticleIdList><ArticleId IdType="pubmed">15545326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Imaging of amyloid beta in Alzheimer&#x2019;s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KJ, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study. Nucl Med Biol. 2010;37(4):497&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">20447562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Klunk W. Update on amyloid imaging: from healthy aging to Alzheimer&#x2019;s disease. Curr Neurol Neurosci Rep. 2009;9(5):345&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2825106</ArticleId><ArticleId IdType="pubmed">19664363</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131(Pt 3):665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Edison P, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68(7):501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17065593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29(10):1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J, et al. PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord. 2008;26(4):378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">18931497</ArticleId></ArticleIdList></Reference><Reference><Citation>Burack MA, et al. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology. 2010;74(1):77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809026</ArticleId><ArticleId IdType="pubmed">20038776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol. 2007;64(3):431&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17353389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(Pt 6):1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Leinonen V, et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol. 2008;65(10):1304&#x2013;1309.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695050</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandenberghe R, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687209</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb J, et al. Alzheimer&#x2019;s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. J Neurol Neurosurg Psychiatry. 2000;68(6):778&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736969</ArticleId><ArticleId IdType="pubmed">10811706</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm A, et al. Brain biopsy prior to treatment of Alzheimer&#x2019;s disease. Minim Invasive Neurosurg. 2003;46(3):161&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12872193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton R, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010;68(4):535&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964442</ArticleId><ArticleId IdType="pubmed">20687117</ArticleId></ArticleIdList></Reference><Reference><Citation>Das SR, et al. Structure specific analysis of the hippocampus in temporal lobe epilepsy. Hippocampus. 2009;19(6):517&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893564</ArticleId><ArticleId IdType="pubmed">19437496</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SE, et al. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging. 2000;21(6):913&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">11124442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, et al. Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J Biol Chem. 2003;278(7):4458&#x2013;4466.</Citation><ArticleIdList><ArticleId IdType="pubmed">12480937</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, et al. Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A. 1990;87(10):3947&#x2013;3951.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54021</ArticleId><ArticleId IdType="pubmed">2111023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">15023815</ArticleId></ArticleIdList></Reference><Reference><Citation>Soetanto A, et al. Association of anxiety and depression with microtubule-associated protein 2- and synaptopodin-immunolabeled dendrite and spine densities in hippocampal CA3 of older humans. Arch Gen Psychiatry. 2010;67(5):448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2926797</ArticleId><ArticleId IdType="pubmed">20439826</ArticleId></ArticleIdList></Reference><Reference><Citation>Mugler JP, 3rd, Brookeman JR. Three-dimensional magnetization-prepared rapid gradient-echo imaging (3D MP RAGE) Magn Reson Med. 1990;15(1):152&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">2374495</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer&#x2019;s disease with Pittsburgh Compound B. J Neurosci Methods. 2008;172(2):277&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2501111</ArticleId><ArticleId IdType="pubmed">18582948</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, et al. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry. 2009;80(9):998&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pubmed">19332421</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, et al. Absence of PIttsburgh Compound B Detection of CerebralAmyloid Beta in a Patient With Clinical, Cognitive, and Cerebrospinal FluidMarkers of Alzheimer Disease. Arch Neurol. 2009;66(12):1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist. Arch Neurol. 2008;65(10):1281&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637565</ArticleId><ArticleId IdType="pubmed">18852340</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132(Pt 5):1355&#x2013;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler H, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain. 2006;129(Pt 11):2856&#x2013;2866.</Citation><ArticleIdList><ArticleId IdType="pubmed">16854944</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer&#x2019;s disease. Brain. 2006;129(Pt 11):2805&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pubmed">17071918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, et al. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66(12):1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22084131</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Positron emission tomography and neuropathologic estimates of fibrillar amyloid-&#x3b2; in a patient with Down syndrome and Alzheimer disease.</ArticleTitle><Pagination><StartPage>1461</StartPage><EndPage>1466</EndPage><MedlinePgn>1461-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.535</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Down syndrome appears to be associated with a virtually certain risk of fibrillar amyloid-&#x3b2; (A&#x3b2;) pathology by the age of 40 and a very high risk of dementia at older ages. The positron emission tomography (PET) ligand florbetapir F18 has been shown to characterize fibrillar A&#x3b2; in the living human brain and to provide a close correlation with subsequent A&#x3b2; neuropathology in individuals proximate to and after the end of life. The extent to which the most frequently used PET ligands can be used to detect fibrillar A&#x3b2; in patients with Down syndrome remains to be determined.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To characterize PET estimates of fibrillar A&#x3b2; burden in a Down syndrome patient very close to the end of life and to compare them with neuropathologic assessment made after his death. Design/</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">With the family's informed consent, florbetapir PET was used to study a 55-year-old Down syndrome patient with Alzheimer disease near the end of life; his brain was donated for neuropathologic assessment when he died 14 days later. Visual ratings of cerebral florbetapir uptake were performed by trained readers who were masked to the patient's diagnosis as part of a larger study, and an automated algorithm was used to characterize regional-to-cerebellar standard uptake value ratios in 6 cerebral regions of interest. Neuropathologic assessments were performed masked to the patient's diagnosis or PET measurements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Visual ratings and automated analyses of the PET image revealed a heavy fibrillar A&#x3b2; burden in cortical, striatal, and thalamic regions, similar to that reported for patients with late-onset Alzheimer disease. This matched neuropathologic findings of frequent neuritic and diffuse plaques, as well as frequent amyloid angiopathy, except for neuropathologically demonstrated frequent cerebellar diffuse plaques and amyloid angiopathy that were not detected by the PET scan.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Florbetapir PET can be used to detect increased cerebral-to-cerebellar fibrillar A&#x3b2; burden in a Down syndrome patient with Alzheimer disease, even in the presence of frequent amyloid angiopathy and diffuse plaques in the cerebellum. Additional studies are needed to determine the extent to which PET could be used to detect and to track fibrillar A&#x3b2; and to evaluate investigational A&#x3b2;-modifying treatments in the presymptomatic and symptomatic stages of Alzheimer disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>The Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, 101515 W Santa Fe Dr, Sun City, AZ 85351, USA. marwan.sabbagh@bannerhealth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Rogers</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Camryn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Sue</LastName><ForeName>Lucia I</ForeName><Initials>LI</Initials></Author><Author ValidYN="Y"><LastName>Liebsack</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Charney</LastName><ForeName>Albert S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Beach</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="Y">Amyloid beta-Peptides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22084131</ArticleId><ArticleId IdType="mid">NIHMS368529</ArticleId><ArticleId IdType="pmc">PMC3346179</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.535</ArticleId><ArticleId IdType="pii">68/11/1461</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yaari R, Corey-Bloom J. Alzheimer&#x2019;s disease. Semin Neurol. 2007;27(1):32&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17226739</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, Esiri MM. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down&#x2019;s syndrome. J Neurol Sci. 1989;89(2-3):169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">2522541</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski KE, Dalton AJ, McLachlan C, Wen GY, Wisniewski HM. Alzheimer&#x2019;s disease in Down&#x2019;s syndrome: clinicopathologic studies. Neurology. 1985;35(7):957&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pubmed">3159974</ArticleId></ArticleIdList></Reference><Reference><Citation>Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150(2):296&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">9527899</ArticleId></ArticleIdList></Reference><Reference><Citation>Evenhuis HM. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR) J Intellect Disabil Res. 1996;40(pt 4):369&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">8884592</ArticleId></ArticleIdList></Reference><Reference><Citation>Beacher F, Daly E, Simmons A, et al. Alzheimer&#x2019;s disease and Down&#x2019;s syndrome: an in vivo MRI study. Psychol Med. 2009;39(4):675&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">18667098</ArticleId></ArticleIdList></Reference><Reference><Citation>Devenny DA, Hill AL, Patxot O, Silverman WP, Wisniewski KE. Ageing in higher functioning adults with Down&#x2019;s syndrome: an interim report in a longitudinal study. J Intellect Disabil Res. 1992;36(pt 3):241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">1535818</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigman WB, Schupf N, Urv T, Zigman A, Silverman W. Incidence and temporal patterns of adaptive behavior change in adults with mental retardation. Am J Ment Retard. 2002;107(3):161&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11966329</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncaster JA, Pineda R, Moir RD, et al. Alzheimer&#x2019;s disease amyloid-&#x3b2; links lens and brain pathology in Down syndrome. PLoS One. 2010;5(5):e10659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873949</ArticleId><ArticleId IdType="pubmed">20502642</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, et al. AV45-A07 Study Group Use of florbetapir-PET for imaging &#x3b2;-amyloid pathology. JAMA. 2011;305(3):275&#x2013;283. published correction appears in JAMA. 2011;305(11):1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lengyel Z, Balogh E, Emri M, et al. Pattern of increased cerebral FDG uptake in Down syndrome patients. Pediatr Neurol. 2006;34(4):270&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">16638500</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(10):1095&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">9329452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131(pt 6):1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Haier RJ, Head K, Head E, Lott IT. Neuroimaging of individuals with Down&#x2019;s syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage. 2008;39(3):1324&#x2013;1332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409285</ArticleId><ArticleId IdType="pubmed">18006337</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E, Lott IT, Patterson D, Doran E, Haier RJ. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J Alzheimers Dis. 2007;11(1):61&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17361036</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer&#x2019;s disease using the radioligand 18F-AV-45 (florbetapir F 18) [published correction appears. J Nucl Med. 2010;51(8):1327.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2010;51(6):913&#x2013;920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101877</ArticleId><ArticleId IdType="pubmed">20501908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22072656</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>45</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Rapid estrogen signaling in the brain: implications for the fine-tuning of neuronal circuitry.</ArticleTitle><Pagination><StartPage>16056</StartPage><EndPage>16063</EndPage><MedlinePgn>16056-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4097-11.2011</ELocationID><Abstract><AbstractText>Rapid actions of estrogens were first described &gt;40 years ago. However, the importance of rapid estrogen-mediated actions in the CNS is only now becoming apparent. Several lines of evidence demonstrate that rapid estrogen-mediated signaling elicits potent effects on molecular and cellular events, resulting in the "fine-tuning" of neuronal circuitry. At an ultrastructural level, the details of estrogen receptor localization and how these are regulated by the circulating hormone and age are now becoming evident. Furthermore, the mechanisms that allow membrane-associated estrogen receptors to couple with intracellular signaling pathways are also now being revealed. Elucidation of complex actions of rapid estrogen-mediated signaling on synaptic proteins, connectivity, and synaptic function in pyramidal neurons has demonstrated that this neurosteroid engages specific mechanisms in different areas of the brain. The regulation of synaptic properties most likely underlies the fine-tuning of neuronal circuitry. This in turn may influence how learned behaviors are encoded by different circuitry in male and female subjects. Importantly, as estrogens have been suggested as potential treatments of a number of disorders of the CNS, advancements in our understanding of rapid estrogen signaling in the brain will serve to aid in the development of potential novel estrogen-based treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Deepak P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. d-srivastava@northwestern.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Mermelstein</LastName><ForeName>Paul G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Kram&#xe1;r</LastName><ForeName>Enik&#xf6; A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Shors</LastName><ForeName>Tracey J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS051923</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG039850</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH059970</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS062158</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG039850</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-59970</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS062158</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG167065</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS045260</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS045260</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059970</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS41302</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004967">Estrogens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011960">Receptors, Estrogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>4TI98Z838E</RegistryNumber><NameOfSubstance UI="D004958">Estradiol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004958" MajorTopicYN="N">Estradiol</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004967" MajorTopicYN="N">Estrogens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014176" MajorTopicYN="N">Protein Biosynthesis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011960" MajorTopicYN="N">Receptors, Estrogen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22072656</ArticleId><ArticleId IdType="mid">NIHMS340608</ArticleId><ArticleId IdType="pmc">PMC3245715</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4097-11.2011</ArticleId><ArticleId IdType="pii">31/45/16056</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adams MM, Shah RA, Janssen WG, Morrison JH. Different modes of hippocampal plasticity in response to estrogen in young and aged female rats. Proc Natl Acad Sci U S A. 2001;98:8071&#x2013;8076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC35469</ArticleId><ArticleId IdType="pubmed">11427724</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MM, Fink SE, Shah RA, Janssen WG, Hayashi S, Milner TA, McEwen BS, Morrison JH. Estrogen and aging affect the subcellular distribution of estrogen receptor-alpha in the hippocampus of female rats. J Neurosci. 2002;22:3608&#x2013;3614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758372</ArticleId><ArticleId IdType="pubmed">11978836</ArticleId></ArticleIdList></Reference><Reference><Citation>Akama KT, McEwen BS. Estrogen stimulates postsynaptic density-95 rapid protein synthesis via the Akt/protein kinase B pathway. J Neurosci. 2003;23:2333&#x2013;2339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742036</ArticleId><ArticleId IdType="pubmed">12657692</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez VA, Sabatini BL. Anatomical and physiological plasticity of dendritic spines. Annu Rev Neurosci. 2007;30:79&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17280523</ArticleId></ArticleIdList></Reference><Reference><Citation>Balthazart J, Ball GF. Is brain estradiol a hormone or a neurotransmitter? Trends Neurosci. 2006;29:241&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">16580076</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangasser DA, Shors TJ. The hippocampus is necessary for enhancements and impairments of learning following stress. Nat Neurosci. 2007;10:1401&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422868</ArticleId><ArticleId IdType="pubmed">17906620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangasser DA, Shors TJ. The bed nucleus of the stria terminalis modulates learning after stress in masculinized but not cycling females. J Neurosci. 2008;28:6383&#x2013;6387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2596916</ArticleId><ArticleId IdType="pubmed">18562608</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaustein JD. An estrogen by any other name. Endocrinology. 2008;149:2697&#x2013;2698.</Citation><ArticleIdList><ArticleId IdType="pubmed">18493023</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware MI, Weick JP, Becklund BR, Kuo SP, Groth RD, Mermelstein PG. Estradiol activates group I and II metabotropic glutamate receptor signaling, leading to opposing influences on cAMP response element-binding protein. J Neurosci. 2005;25:5066&#x2013;5078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724851</ArticleId><ArticleId IdType="pubmed">15901789</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware MI, Kordasiewicz H, Mermelstein PG. Caveolin proteins are essential for distinct effects of membrane estrogen receptors in neurons. J Neurosci. 2007;27:9941&#x2013;9950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672640</ArticleId><ArticleId IdType="pubmed">17855608</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware MI, Kent BA, Frick KM. The impact of age-related ovarian hormone loss on cognitive and neural function. Curr Top Behav Neurosci. 2011 doi: 10.1007/7854_2011_122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/7854_2011_122</ArticleId><ArticleId IdType="pubmed">21533680</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinton RD. Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends Pharmacol Sci. 2009;30:212&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167490</ArticleId><ArticleId IdType="pubmed">19299024</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaban VV, Li J, McDonald JS, Rapkin A, Micevych P. Estradiol attenuates ATP-induced increase of [Ca2+]i through group II metabotropic glutamate receptors in rat DRG neurons. Soc Neurosci Abstr. 2007;33:519&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171520</ArticleId><ArticleId IdType="pubmed">21793040</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LY, Rex CS, Casale MS, Gall CM, Lynch G. Changes in synaptic morphology accompany actin signaling during LTP. J Neurosci. 2007;27:5363&#x2013;5372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672340</ArticleId><ArticleId IdType="pubmed">17507558</ArticleId></ArticleIdList></Reference><Reference><Citation>Chklovskii DB, Mel BW, Svoboda K. Cortical rewiring and information storage. Nature. 2004;431:782&#x2013;788.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483599</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornil CA, Ball GF, Balthazart J. Functional significance of the rapid regulation of brain estrogen action: where do the estrogens come from? Brain Res. 2006;1126:2&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3523229</ArticleId><ArticleId IdType="pubmed">16978590</ArticleId></ArticleIdList></Reference><Reference><Citation>DeBello WM. Micro-rewiring as a substrate for learning. Trends Neurosci. 2008;31:577&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581897</ArticleId><ArticleId IdType="pubmed">18817991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewing P, Boulware MI, Sinchak K, Christensen A, Mermelstein PG, Micevych P. Membrane estrogen receptor-&#x3b1; interactions with metabotropic glutamate receptor 1a modulate female sexual receptivity in rats. J Neurosci. 2007;27:9294&#x2013;9300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2904398</ArticleId><ArticleId IdType="pubmed">17728443</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala JC, Spacek J, Harris KM. Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev. 2002;39:29&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">12086707</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Segura LM. Aromatase in the brain: not just for reproduction anymore. J Neuroendocrinol. 2008;20:705&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">18601693</ArticleId></ArticleIdList></Reference><Reference><Citation>Grove-Strawser D, Boulware MI, Mermelstein PG. Membrane estrogen receptors activate the metabotropic glutamate receptors mGluR5 and mGluR3 to bidirectionally regulate CREB phosphorylation in female rat striatal neurons. Neuroscience. 2010;170:1045&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2949475</ArticleId><ArticleId IdType="pubmed">20709161</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrick SP, Waters EM, Drake CT, McEwen BS, Milner TA. Extranuclear estrogen receptor beta immunoreactivity is on doublecortin-containing cells in the adult and neonatal rat dentate gyrus. Brain Res. 2006;1121:46&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">17026970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodes GE, Shors TJ. Distinctive stress effects on learning during puberty. Horm Behav. 2005;48:163&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364669</ArticleId><ArticleId IdType="pubmed">15885691</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009;10:647&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pubmed">19693029</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai H, Fukuda M, Watanabe S, Hayashi-Takagi A, Noguchi J. Structural dynamics of dendritic spines in memory and cognition. Trends Neurosci. 2010a;33:121&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">20138375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai H, Hayama T, Ishikawa M, Watanabe S, Yagishita S, Noguchi J. Learning rules and persistence of dendritic spines. Eur J Neurosci. 2010b;32:241&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">20646057</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann E, Antion MD, Banko JL, Hou L. Synaptic plasticity and translation initiation. Learn Mem. 2004;11:365&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">15254214</ArticleId></ArticleIdList></Reference><Reference><Citation>Kram&#xe1;r EA, Chen LY, Brandon NJ, Rex CS, Liu F, Gall CM, Lynch G. Cytoskeletal changes underlie estrogen's acute effects on synaptic transmission and plasticity. J Neurosci. 2009;29:12982&#x2013;12993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806054</ArticleId><ArticleId IdType="pubmed">19828812</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo J, Hamid N, Bondar G, Prossnitz ER, Micevych P. Membrane estrogen receptors stimulate intracellular calcium release and progesterone synthesis in hypothalamic astrocytes. J Neurosci. 2010;30:12950&#x2013;12957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957903</ArticleId><ArticleId IdType="pubmed">20881113</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuner B, Shors TJ. Learning during motherhood: a resistance to stress. Horm Behav. 2006;50:38&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289538</ArticleId><ArticleId IdType="pubmed">16490197</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin ER. Minireview: extranuclear steroid receptors: roles in modulation of cell functions. Mol Endocrinol. 2011;25:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045744</ArticleId><ArticleId IdType="pubmed">20861220</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Day M, Mu&#xf1;iz LC, Bitran D, Arias R, Revilla-Sanchez R, Grauer S, Zhang G, Kelley C, Pulito V, Sung A, Mervis RF, Navarra R, Hirst WD, Reinhart PH, Marquis KL, Moss SJ, Pangalos MN, Brandon NJ. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci. 2008;11:334&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">18297067</ArticleId></ArticleIdList></Reference><Reference><Citation>Luine VN. Sex steroids and cognitive function. J Neuroendocrinol. 2008;20:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18513207</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeng LY, Shors TJ. Once a mother, always a mother: maternal experience protects females from the negative effects of stress on learning throughout their lifetime. Soc Neurosci Abstr. 2011;37:100&#x2013;04.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3279153</ArticleId><ArticleId IdType="pubmed">22181714</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeng LY, Waddell J, Shors TJ. The prefrontal cortex communicates with the amygdala to impair learning after acute stress in females but not in males. J Neurosci. 2010;30:16188&#x2013;16196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073607</ArticleId><ArticleId IdType="pubmed">21123565</ArticleId></ArticleIdList></Reference><Reference><Citation>Markowska AL. Sex dimorphisms in the rate of age-related decline in spatial memory: relevance to alterations in the estrous cycle. J Neurosci. 1999;19:8122&#x2013;8133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782441</ArticleId><ArticleId IdType="pubmed">10479712</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev. 1999;20:279&#x2013;307.</Citation><ArticleIdList><ArticleId IdType="pubmed">10368772</ArticleId></ArticleIdList></Reference><Reference><Citation>Mermelstein PG, Becker JB, Surmeier DJ. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci. 1996;16:595&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578633</ArticleId><ArticleId IdType="pubmed">8551343</ArticleId></ArticleIdList></Reference><Reference><Citation>Micevych PE, Mermelstein PG. Membrane estrogen receptors acting through metabotropic glutamate receptors: an emerging mechanism of estrogen action in brain. Mol Neurobiol. 2008;38:66&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663000</ArticleId><ArticleId IdType="pubmed">18670908</ArticleId></ArticleIdList></Reference><Reference><Citation>Micevych P, Bondar G, Kuo J. Estrogen actions on neuroendocrine glia. Neuroendocrinology. 2010;91:211&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889254</ArticleId><ArticleId IdType="pubmed">20332598</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner TA, McEwen BS, Hayashi S, Li CJ, Reagan LP, Alves SE. Ultrastructural evidence that hippocampal alpha estrogen receptors are located at extranuclear sites. J Comp Neurol. 2001;429:355&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">11116225</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner TA, Ayoola K, Drake CT, Herrick SP, Tabori NE, McEwen BS, Warrier S, Alves SE. Ultrastructural localization of estrogen receptor beta immunoreactivity in the rat hippocampal formation. J Comp Neurol. 2005;491:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">16127691</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitterling KL, Spencer JL, Dziedzic N, Shenoy S, McCarthy K, Waters EM, McEwen BS, Milner TA. Cellular and subcellular localization of estrogen and progestin receptor immunoreactivities in the mouse hippocampus. J Comp Neurol. 2010;518:2729&#x2013;2743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879091</ArticleId><ArticleId IdType="pubmed">20506473</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul SM, Purdy RH. Neuroactive steroids. FASEB J. 1992;6:2311&#x2013;2322.</Citation><ArticleIdList><ArticleId IdType="pubmed">1347506</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Cahill ME, Jones KA, Srivastava DP. Convergent CaMK and RacGEF signals control dendritic structure and function. Trends Cell Biol. 2008;18:405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">18701290</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Woolfrey KM, Srivastava DP. Epac2-mediated dendritic spine remodeling: implications for disease. Mol Cell Neurosci. 2011a;46:368&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031158</ArticleId><ArticleId IdType="pubmed">21115118</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011b;14:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530413</ArticleId><ArticleId IdType="pubmed">21346746</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J, Bosch MA, Tobias SC, Grandy DK, Scanlan TS, Ronnekleiv OK, Kelly MJ. Rapid signaling of estrogen in hypothalamic neurons involves a novel G-protein-coupled estrogen receptor that activates protein kinase C. J Neurosci. 2003;23:9529&#x2013;9540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740471</ArticleId><ArticleId IdType="pubmed">14573532</ArticleId></ArticleIdList></Reference><Reference><Citation>Remage-Healey L, Dong S, Maidment NT, Schlinger BA. Presynaptic control of rapid estrogen fluctuations in the songbird auditory forebrain. J Neurosci. 2011;31:10034&#x2013;10038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144393</ArticleId><ArticleId IdType="pubmed">21734295</ArticleId></ArticleIdList></Reference><Reference><Citation>Rex CS, Chen LY, Sharma A, Liu J, Babayan AH, Gall CM, Lynch G. Different Rho GTPase-dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation. J Cell Biol. 2009;186:85&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2712993</ArticleId><ArticleId IdType="pubmed">19596849</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha CJ, Remage-Healey L, Schlinger BA. Synaptocrine signaling: steroid synthesis and action at the synapse. Endocr Rev. 2011;32:532&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3369574</ArticleId><ArticleId IdType="pubmed">21622487</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal M. Dendritic spines and long-term plasticity. Nat Rev Neurosci. 2005;6:277&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">15803159</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Miesegaes G. Testosterone in utero and at birth dictates how stressful experience will affect learning in adulthood. Proc Natl Acad Sci U S A. 2002;99:13955&#x2013;13960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC129804</ArticleId><ArticleId IdType="pubmed">12359876</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors TJ, Lewczyk C, Pacynski M, Mathew PR, Pickett J. Stages of estrous mediate the stress-induced impairment of associative learning in the female rat. Neuroreport. 1998;9:419&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pubmed">9512383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra A, Gottfried-Blackmore A, Milner TA, McEwen BS, Bulloch K. Steroid hormone receptor expression and function in microglia. Glia. 2008;56:659&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18286612</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava DP, Woolfrey KM, Jones KA, Shum CY, Lash LL, Swanson GT, Penzes P. Rapid enhancement of two-step wiring plasticity by estrogen and NMDA receptor activity. Proc Natl Acad Sci U S A. 2008;105:14650&#x2013;14655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567160</ArticleId><ArticleId IdType="pubmed">18801922</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava DP, Woolfrey KM, Liu F, Brandon NJ, Penzes P. Estrogen receptor &#x3b2; activity modulates synaptic signaling and structure. J Neurosci. 2010;30:13454&#x2013;13460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956485</ArticleId><ArticleId IdType="pubmed">20926671</ArticleId></ArticleIdList></Reference><Reference><Citation>Steward O, Schuman EM. Protein synthesis at synaptic sites on dendrites. Annu Rev Neurosci. 2001;24:299&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">11283313</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T, Sheng M. Molecular mechanisms of dendritic spine morphogenesis. Curr Opin Neurobiol. 2006;16:95&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361095</ArticleId></ArticleIdList></Reference><Reference><Citation>Towart LA, Alves SE, Znamensky V, Hayashi S, McEwen BS, Milner TA. Subcellular relationships between cholinergic terminals and estrogen receptor-alpha in the dorsal hippocampus. J Comp Neurol. 2003;463:390&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">12836175</ArticleId></ArticleIdList></Reference><Reference><Citation>van Spronsen M, Hoogenraad CC. Synapse pathology in psychiatric and neurologic disease. Curr Neurol Neurosci Rep. 2010;10:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857788</ArticleId><ArticleId IdType="pubmed">20425036</ArticleId></ArticleIdList></Reference><Reference><Citation>Waddell J, Bangasser DA, Shors TJ. The basolateral nucleus of the amygdala is necessary to induce the opposing effects of stressful experience on learning in males and females. J Neurosci. 2008;28:5290&#x2013;5294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680275</ArticleId><ArticleId IdType="pubmed">18480285</ArticleId></ArticleIdList></Reference><Reference><Citation>Waters EM, Yildirim M, Janssen WG, Lou WY, McEwen BS, Morrison JH, Milner TA. Estrogen and aging affect the synaptic distribution of estrogen receptor beta-immunoreactivity in the CA1 region of female rat hippocampus. Brain Res. 2011;1379:86&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046233</ArticleId><ArticleId IdType="pubmed">20875808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood GE, Shors TJ. Stress facilitates classical conditioning in males, but impairs classical conditioning in females through activational effects of ovarian hormones. Proc Natl Acad Sci U S A. 1998;95:4066&#x2013;4071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19964</ArticleId><ArticleId IdType="pubmed">9520494</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood GE, Beylin AV, Shors TJ. The contribution of adrenal and reproductive hormones to the opposing effects of stress on trace conditioning in males versus females. Behav Neurosci. 2001;115:175&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">11256441</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley CS. Acute effects of estrogen on neuronal physiology. Annu Rev Pharmacol Toxicol. 2007;47:657&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">16918306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright CL, McCarthy MM. Prostaglandin E2-induced masculinization of brain and behavior requires protein kinase A, AMPA/kainate, and metabotropic glutamate receptor signaling. J Neurosci. 2009;29:13274&#x2013;13282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568388</ArticleId><ArticleId IdType="pubmed">19846715</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SH, Liu R, Perez EJ, Wen Y, Stevens SM, Jr, Valencia T, Brun-Zinkernagel AM, Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A. 2004;101:4130&#x2013;4135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384706</ArticleId><ArticleId IdType="pubmed">15024130</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara Y, De Roo M, Muller D. Dendritic spine formation and stabilization. Curr Opin Neurobiol. 2009;19:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22002422</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>11</Issue><PubDate><Year>2011</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.</ArticleTitle><Pagination><StartPage>960</StartPage><EndPage>969</EndPage><MedlinePgn>960-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NEN.0b013e318232a379</ELocationID><Abstract><AbstractText>Two thousand three hundred and thirty two nonselected brains from 1- to 100-year-old individuals were examined using immunocytochemistry (AT8) and Gallyas silver staining for abnormal tau; immunocytochemistry (4G8) and Campbell-Switzer staining were used for the detection of&#x3b2;-amyloid. A total of 342 cases was negative in the Gallyas stain but when restaged for AT8 only 10 were immunonegative. Fifty-eight cases had subcortical tau predominantly in the locus coeruleus, but there was no abnormal cortical tau (subcortical Stages a-c). Cortical involvement (abnormal tau in neurites) was identified first in the transentorhinal region (Stage 1a, 38 cases). Transentorhinal pyramidal cells displayed pretangle material (Stage 1b, 236 cases). Pretangles gradually became argyrophilic neurofibrillary tangles (NFTs) that progressed in parallel with NFT Stages I to VI. Pretangles restricted to subcortical sites were seen chiefly at younger ages. Of the total cases, 1,031 (44.2%) had &#x3b2;-amyloid plaques. The first plaques occurred in the neocortex after the onset of tauopathy in the brainstem. Plaques generally developed in the 40s in 4% of all cases, culminating in their tenth decade (75%). &#x3b2;-amyloid plaques and NFTs were significantly correlated (p &lt; 0.0001). These data suggest that tauopathy associated with sporadic Alzheimer disease may begin earlier than previously thought and possibly in the lower brainstem rather than in the transentorhinal region.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neuroanatomy, Department of Neurology, and Laboratory for Neuropathology - Institute of Pathology, Center for Clinical Research, University of Ulm, Germany. heiko.braak@uni-ulm.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thal</LastName><ForeName>Dietmar R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Ghebremedhin</LastName><ForeName>Estifanos</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Del Tredici</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016622" MajorTopicYN="N">Silver Staining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId><ArticleId IdType="doi">10.1097/NEN.0b013e318232a379</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22179788</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-9985</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Nature structural &amp; molecular biology</Title><ISOAbbreviation>Nat Struct Mol Biol</ISOAbbreviation></Journal><ArticleTitle>The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-&#x3b2;(1-40) peptide.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>83</EndPage><MedlinePgn>79-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nsmb.2191</ELocationID><Abstract><AbstractText>In recent genome-wide association studies, the extracellular chaperone protein, clusterin, has been identified as a newly-discovered risk factor in Alzheimer's disease. We have examined the interactions between human clusterin and the Alzheimer's disease-associated amyloid-&#x3b2;(1-40) peptide (A&#x3b2;(1-40)), which is prone to aggregate into an ensemble of oligomeric intermediates implicated in both the proliferation of amyloid fibrils and in neuronal toxicity. Using highly sensitive single-molecule fluorescence methods, we have found that A&#x3b2;(1-40) forms a heterogeneous distribution of small oligomers (from dimers to 50-mers), all of which interact with clusterin to form long-lived, stable complexes. Consequently, clusterin is able to influence both the aggregation and disaggregation of A&#x3b2;(1-40) by sequestration of the A&#x3b2; oligomers. These results not only elucidate the protective role of clusterin but also provide a molecular basis for the genetic link between clusterin and Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Narayan</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orte</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Author><Author ValidYN="Y"><LastName>Bolognesi</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Hook</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ganzinger</LastName><ForeName>Kristina A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Meehan</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Klenerman</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089703</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Struct Mol Biol</MedlineTA><NlmUniqueID>101186374</NlmUniqueID><ISSNLinking>1545-9985</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005453" MajorTopicYN="N">Fluorescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005470" MajorTopicYN="N">Fluorometry</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS69461</OtherID><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22179788</ArticleId><ArticleId IdType="mid">EMS69461</ArticleId><ArticleId IdType="pmc">PMC4979993</ArticleId><ArticleId IdType="doi">10.1038/nsmb.2191</ArticleId><ArticleId IdType="pii">nsmb.2191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem. 2004;279:31374&#x2013;31382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15133040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleary JP, et al. Natural oligomers of the amyloid-&#x3b2; protein specifically disrupt cognitive function. Nat Neurosci. 2005;8:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesne S, et al. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid-&#x3b2; protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucciantini M, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932737</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TPJ, et al. An analytical solution to the kinetics of breakable filament assembly. Science. 2009;326:1533&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pubmed">20007899</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Ying L, Green JJ, Balasubramanian S, Klenerman D. Ultrasensitive coincidence fluorescence detection of single DNA molecules. Anal Chem. 2003;75:1664&#x2013;1670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12705600</ArticleId></ArticleIdList></Reference><Reference><Citation>Axelrod D. Total internal reflection fluorescence microscopy in cell biology. Traffic. 2001;2:764&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">11733042</ArticleId></ArticleIdList></Reference><Reference><Citation>Orte A, et al. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence. Proc Natl Acad Sci U S A. 2008;105:14424&#x2013;14429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567173</ArticleId><ArticleId IdType="pubmed">18796612</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne PD, et al. DySCo: quantitating associations of membrane proteins using two-color single-molecule tracking. Biophys J. 2009;97:L5&#x2013;L7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726305</ArticleId><ArticleId IdType="pubmed">19686638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou A, et al. Probing neuroserpin polymerization and interaction with amyloid-&#x3b2; peptides using single molecule fluorescence. Biophys J. 2009;97:2306&#x2013;2315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764104</ArticleId><ArticleId IdType="pubmed">19843463</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert J-C, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kida E, Choi-Miura N-H, Wisniewski KE. Deposition of apolipoproteins E and J in senile plaques is topographically determined in both Alzheimer's disease and Down's syndrome brain. Brain Res. 1995;685:211&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">7583250</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi-Miura NH, et al. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol (Berl) 1992;83:260&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">1373021</ArticleId></ArticleIdList></Reference><Reference><Citation>Luheshi LM, et al. Systematic in vivo analysis of the intrinsic determinants of amyloid-&#x3b2; pathogenicity. PLoS Biol. 2007;5:e290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2043051</ArticleId><ArticleId IdType="pubmed">17973577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective &#x3b2;-amyloid clearance pathways in aging Alzheimer's disease mice. The Journal of Neuroscience. 2008;28:8354&#x2013;8360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597474</ArticleId><ArticleId IdType="pubmed">18701698</ArticleId></ArticleIdList></Reference><Reference><Citation>Schauerte JA, et al. Simultaneous single-molecule fluorescence and conductivity studies reveal distinct classes of A&#x3b2; species on lipid bilayers. Biochemistry (Mosc) 2010;49:3031&#x2013;3039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2862386</ArticleId><ArticleId IdType="pubmed">20201586</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding H, Wong PT, Lee EL, Gafni A, Steel DG. Determination of the oligomer size of amyloidogenic protein &#x3b2;-amyloid(1&#x2013;40) by single-molecule spectroscopy. Biophys J. 2009;97:912&#x2013;921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2718150</ArticleId><ArticleId IdType="pubmed">19651050</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RD, Schauerte JA, Wisser KC, Gafni A, Steel DG. Direct observation of single amyloid-&#x3b2;(1&#x2013;40) oligomers on live cells: binding and growth at physiological concentrations. PLoS ONE. 2011;6:e23970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3162019</ArticleId><ArticleId IdType="pubmed">21901146</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PD, et al. Plasma and cerebrospinal fluid levels of amyloid-&#x3b2; proteins 1&#x2013;40 and 1&#x2013;42 in Alzheimer disease. Arch Neurol. 2000;57:100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634455</ArticleId></ArticleIdList></Reference><Reference><Citation>Garzon-Rodriguez W, Sepulveda-Becerra M, Milton S, Glabe CG. Soluble amyloid A&#x3b2;-(1&#x2013; 40) exists as a stable dimer at low concentrations. J Biol Chem. 1997;272:21037&#x2013;21044.</Citation><ArticleIdList><ArticleId IdType="pubmed">9261105</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosawa F. Size distribution of protein polymers. J Theor Biol. 1970;27:69&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">5419909</ArticleId></ArticleIdList></Reference><Reference><Citation>Carulla N, et al. Molecular recycling within amyloid fibrils. Nature. 2005;436:554&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">16049488</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez L, et al. A&#x3b2;40 and A&#x3b2;42 amyloid fibrils exhibit distinct molecular recycling properties. J Am Chem Soc. 2011;133:6505&#x2013;6508.</Citation><ArticleIdList><ArticleId IdType="pubmed">21486030</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R. Thermodynamics of A&#x3b2;(1&#x2013;40) amyloid fibril elongation. Biochemistry (Mosc) 2005;44:12709&#x2013;12718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16171385</ArticleId></ArticleIdList></Reference><Reference><Citation>Auer S, Dobson CM, Vendruscolo M. Characterization of the nucleation barriers for protein aggregation and amyloid formation. HFSP journal. 2007;1:137&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2639838</ArticleId><ArticleId IdType="pubmed">19404419</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury JJ, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007;21:2312&#x2013;2322.</Citation><ArticleIdList><ArticleId IdType="pubmed">17412999</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsubara E, Frangione B, Ghiso J. Characterization of apolipoprotein J-Alzheimer's A&#x3b2; interaction. J Biol Chem. 1995;270:7563&#x2013;7567.</Citation><ArticleIdList><ArticleId IdType="pubmed">7706304</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, et al. Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106:4012&#x2013;4017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, et al. Diffusible, nonfibrillar ligands derived from A&#x3b2;1&#x2013;42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles TPJ, et al. Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass. Proceedings of the National Academy of Sciences. 2007;104:10016&#x2013;10021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1891240</ArticleId><ArticleId IdType="pubmed">17540728</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman B, et al. &#x3b1;B-crystallin, a small heat-shock protein, prevents the amyloid fibril growth of an amyloid &#x3b2;-peptide and &#x3b2; 2-microglobulin. Biochem J. 2005;392:573&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1316297</ArticleId><ArticleId IdType="pubmed">16053447</ArticleId></ArticleIdList></Reference><Reference><Citation>Shammas SL, et al. Binding of the molecular chaperone &#x3b1;B-crystallin to A&#x3b2; amyloid fibrils inhibits fibril elongation. Biophys J. 2011 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183811</ArticleId><ArticleId IdType="pubmed">21961594</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MR, Yerbury JJ, Poon S. Extracellular chaperones and amyloids. In: Asea AAA, Brown IR, editors. Heat Shock Proteins and the Brain: Implications for Neurodegenerative Diseases and Neuroprotection. Vol. 3. Springer; Netherlands: 2008. pp. 283&#x2013;315.</Citation></Reference><Reference><Citation>Bateman RJ, et al. Human amyloid-&#x3b2; synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen HM, Veerhuis R, Holmqvist B, Janciauskiene S. Binding and uptake of A&#x3b2;1&#x2013;42 by primary human astrocytes in vitro . Glia. 2009;57:978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">19062178</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, et al. Decreased clearance of CNS &#x3b2;-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuutinen T, et al. Amyloid-&#x3b2; 1&#x2013;42 induced endocytosis and clusterin/apoJ protein accumulation in cultured human astrocytes. Neurochem Int. 2007;50:540&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pubmed">17196306</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt AR, et al. Clusterin facilitates in vivo clearance of extracellular misfolded proteins. Cellular and Molecular Life Sciences. 2011 (in press)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115182</ArticleId><ArticleId IdType="pubmed">21505792</ArticleId></ArticleIdList></Reference><Reference><Citation>Luheshi LM, et al. Sequestration of the A&#x3b2; peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. 2010;8:e1000334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2838747</ArticleId><ArticleId IdType="pubmed">20305716</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplow DB, Kheterpal I, Wetzel R. Preparation of amyloid-&#x3b2; protein for structural and functional studies. Methods Enzymol. 2006;413:20&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17046389</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson MR, Easterbrook-Smith SB. Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgG. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1992;1159:319&#x2013;326.</Citation><ArticleIdList><ArticleId IdType="pubmed">1390937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22194796</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A novel neurotrophic drug for cognitive enhancement and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e27865</StartPage><MedlinePgn>e27865</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e27865</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0027865</ELocationID><Abstract><AbstractText>Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer's disease (AD), the focus is the amyloid beta peptide (A&#xdf;) that mediates familial Alzheimer's disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Cellular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prior</LastName><ForeName>Marguerite</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Dargusch</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Riek</LastName><ForeName>Roland</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Eichmann</LastName><ForeName>C&#xe9;dric</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Chiruta</LastName><ForeName>Chandramouli</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Akaishi</LastName><ForeName>Tatsuhiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Kazuho</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Maher</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Schubert</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG035055</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS064334</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG035055</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS064334</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C529348">CNB 001</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016877">Oxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="N">Curcumin</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016877" MajorTopicYN="N">Oxidants</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22194796</ArticleId><ArticleId IdType="pmc">PMC3237323</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0027865</ArticleId><ArticleId IdType="pii">PONE-D-11-19517</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov. 2007;6:521&#x2013;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599084</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K. Reimagining Alzheimer's disease&#x2013;an age-based hypothesis. J Neurosci. 2010;30:16755&#x2013;16762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004746</ArticleId><ArticleId IdType="pubmed">21159946</ArticleId></ArticleIdList></Reference><Reference><Citation>Frautschy SA, Cole GM. Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol. 2010;41:392&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876259</ArticleId><ArticleId IdType="pubmed">20437209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan A. The impact of natural products upon modern drug discovery. Curr Opin Chem Biol. 2008;12:306&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">18423384</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv Exp Med Biol. 2007;595:197&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527619</ArticleId><ArticleId IdType="pubmed">17569212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Chu T, Yang F, Beech W, Frautschy SA, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21:8370&#x2013;8377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762797</ArticleId><ArticleId IdType="pubmed">11606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert DR, Liu Y. Method for preventing and/or decreasing amyloid production with polycyclic compounds. 2002. US Patent No. 6,472,436B1 US Patent No 6,472,436B1.</Citation></Reference><Reference><Citation>Liu Y, Dargusch R, Maher P, Schubert D. A broadly neuroprotective derivative of curcumin. J Neurochem 105. 2008;1336&#x2013;1345</Citation><ArticleIdList><ArticleId IdType="pubmed">18208543</ArticleId></ArticleIdList></Reference><Reference><Citation>Haigis MC, Yankner BA. The aging stress response. Mol Cell. 2010;40:333&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987618</ArticleId><ArticleId IdType="pubmed">20965426</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia CS, Tsai SY, Kuo SC, Hou YC, Chao PD. Metabolism and pharmacokinetics of 3,3&#x2032;,4&#x2032;,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem. 2009;57:83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">19090755</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Takayanagi M, Saito H. Effects of recombinant human basic FGF and its modified protein CS23 on survival of primary cultured neurons from various regions of fetal rat brain. Japan J Pharmacol. 1990;53:221&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">2385007</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S, Schubert D, Maher P. Oxytosis: A novel form of programmed cell death. Curr Topics Med Chem. 2001;1:497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">11895126</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990;250:279&#x2013;282.</Citation><ArticleIdList><ArticleId IdType="pubmed">2218531</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2005;2:541&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1201314</ArticleId><ArticleId IdType="pubmed">16489364</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossler OG, Giehl KM, Thiel G. Neuroprotection of immortalized hippocampal neurones by brain-derived neurotrophic factor and Raf-1 protein kinase: role of extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase. J Neurochem. 2004;88:1240&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pubmed">15009680</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function by fisetin. In: Parker L, Sies H, Eggersdorfer M, Cardenas E, editors. Micronutrients and Brain Health. Boca Raton, FL: CRC Press; 2010. pp. 189&#x2013;206.</Citation></Reference><Reference><Citation>Winkler BS, Sauer MW, Starnes CA. Modulation of the Pasteur effect in retinal cells: implications for understanding compensatory metabolic mechanisms. Exp Eye Res. 2003;76:715&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">12742354</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 2007;1173:117&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2111291</ArticleId><ArticleId IdType="pubmed">17765210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J, Zacharek A, Zhang C, Jiang H, Li Y, et al. Endothelial nitric oxide synthase regulates brain-derived neurotrophic factor expression and neurogenesis after stroke in mice. J Neurosci. 2005;25:2366&#x2013;2375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791344</ArticleId><ArticleId IdType="pubmed">15745963</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin D, MacMurray J, Comings DE. Risk of late-onset Alzheimer's disease associated with BDNF C270T polymorphism. Neurosci Lett. 2005;381:275&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">15896483</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev. 2008;59:201&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">18708092</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezet S, Malcangio M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets. 2004;8:391&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pubmed">15469390</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76:280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034393</ArticleId><ArticleId IdType="pubmed">21178097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res. 1988;31:47&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">3228475</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, et al. Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 2005;179:613&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">15672274</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff-Pak DS, Vogel RW, 3rd, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001;98:2089&#x2013;2094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC29386</ArticleId><ArticleId IdType="pubmed">11172080</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarnyai Z, Sibille EL, Pavlides C, Fenster RJ, McEwen BS, et al. Impaired hippocampal-dependent learning and functional abnormalities in the hippocampus in mice lacking serotonin(1A) receptors. Proc Natl Acad Sci U S A. 2000;97:14731&#x2013;14736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18987</ArticleId><ArticleId IdType="pubmed">11121072</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther. 2009;122:150&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688712</ArticleId><ArticleId IdType="pubmed">19269307</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach ME, Hawkins RD, Osman M, Kandel ER, Mayford M. Impairment of spatial but not contextual memory in CaMKII mutant mice with a selective loss of hippocampal LTP in the range of the theta frequency. Cell. 1995;81:905&#x2013;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">7781067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Melnikova T, Fadale DJ, Xu GM, Slunt HH, et al. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:5217&#x2013;5224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4440804</ArticleId><ArticleId IdType="pubmed">15917461</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005;18:602&#x2013;617.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T, Kiliaan AJ, Kadish I. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiol Dis. 2006;23:653&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pubmed">16829076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Kim HD, Maxwell JA, Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett. 2005;390:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16169151</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006;1:848&#x2013;858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895266</ArticleId><ArticleId IdType="pubmed">17406317</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Chen H, Sun X. Age-related spatial cognitive impairment is correlated with a decrease in ChAT in the cerebral cortex, hippocampus and forebrain of SAMP8 mice. Neurosci Lett. 2009;454:212&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">19429086</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison FE, Hosseini AH, McDonald MP, May JM. Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol Biochem Behav. 2009;93:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2725435</ArticleId><ArticleId IdType="pubmed">19539642</ArticleId></ArticleIdList></Reference><Reference><Citation>Krafft GA, Klein WL. ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology. 2010;59:230&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">20650286</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464:529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927852</ArticleId><ArticleId IdType="pubmed">20336135</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis. 2010;37:503&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823849</ArticleId><ArticleId IdType="pubmed">19833208</ArticleId></ArticleIdList></Reference><Reference><Citation>Dore S. Decreased activity of the antioxidant heme oxygenase enzyme: implications in ischemia and in Alzheimer's disease. Free Radic Biol Med. 2002;32:1276&#x2013;1282.</Citation><ArticleIdList><ArticleId IdType="pubmed">12057765</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper HM, Song W, Zukor H, Hascalovici JR, Zeligman D. Heme oxygenase-1 and neurodegeneration: expanding frontiers of engagement. J Neurochem. 2009;110:469&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">19457088</ArticleId></ArticleIdList></Reference><Reference><Citation>Radmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci. 2007;32:332&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">17576065</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev. 2006;52:201&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">16647138</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, et al. Protein levels of heat shock proteins 27, 32, 60, 70, 90 and thioredoxin-1 in amnestic mild cognitive impairment: an investigation on the role of cellular stress response in the progression of Alzheimer disease. Brain Res. 2010;1333:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2871982</ArticleId><ArticleId IdType="pubmed">20362559</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy PH, Mani G, Park BS, Jacques J, Murdoch G, et al. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J Alzheimers Dis. 2005;7:103&#x2013;117; discussion 173&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">15851848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, et al. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci. 2006;9:234&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16415866</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha C, Brambilla R, Thomas KL. A simple role for BDNF in learning and memory? Front Mol Neurosci. 2010;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821174</ArticleId><ArticleId IdType="pubmed">20162032</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato M, Suzuki K, Nakanishi S. NMDA receptor stimulation and brain-derived neurotrophic factor upregulate homer 1a mRNA via the mitogen-activated protein kinase cascade in cultured cerebellar granule cells. J Neurosci. 2001;21:3797&#x2013;3805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762687</ArticleId><ArticleId IdType="pubmed">11356868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura Y, Shinkawa T, Taoka M, Kobayashi K, Isobe T, et al. Identification of protein substrates of Ca(2+)/calmodulin-dependent protein kinase II in the postsynaptic density by protein sequencing and mass spectrometry. Biochem Biophys Res Commun. 2002;290:948&#x2013;954.</Citation><ArticleIdList><ArticleId IdType="pubmed">11798165</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Gustafson DR, Hardy J. The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging. 2010 2010 Jun 2029 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2980860</ArticleId><ArticleId IdType="pubmed">20594621</ArticleId></ArticleIdList></Reference><Reference><Citation>Figurov A, Pozzo-Miller LD, Olafsson P, Wang T, Lu B. Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature. 1996;381:706&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pubmed">8649517</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen GL, Kirasic KC, Rashotte MA, Haun DB. Aging and path integration skill: kinesthetic and vestibular contributions to wayfinding. Percept Psychophys. 2004;66:170&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">15095949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach ME, Barad M, Son H, Zhuo M, Lu YF, et al. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A. 1999;96:5280&#x2013;5285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21855</ArticleId><ArticleId IdType="pubmed">10220457</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CA. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J Comp Physiol Psychol. 1979;93:74&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">221551</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggleton JP, Hunt PR, Rawlins JN. The effects of hippocampal lesions upon spatial and non-spatial tests of working memory. Behav Brain Res. 1986;19:133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">3964405</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Garrud P, Rawlins JN, O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 1982;297:681&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">7088155</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadbent NJ, Gaskin S, Squire LR, Clark RE. Object recognition memory and the rodent hippocampus. Learn Mem. 2010;17:5&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807177</ArticleId><ArticleId IdType="pubmed">20028732</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanni C, Lenzken SC, Pascale A, Del Vecchio I, Racchi M, et al. Cognition enhancers between treating and doping the mind. Pharmacol Res. 2008;57:196&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">18353672</ArticleId></ArticleIdList></Reference><Reference><Citation>Minichiello L. TrkB signalling pathways in LTP and learning. Nat Rev Neurosci. 2009;10:850&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">19927149</ArticleId></ArticleIdList></Reference><Reference><Citation>Dugich-Djordjevic MM, Peterson C, Isono F, Ohsawa F, Widmer HR, et al. Immunohistochemical visualization of brain-derived neurotrophic factor in the rat brain. Eur J Neurosci. 1995;7:1831&#x2013;1839.</Citation><ArticleIdList><ArticleId IdType="pubmed">8528456</ArticleId></ArticleIdList></Reference><Reference><Citation>Berchtold NC, Castello N, Cotman CW. Exercise and time-dependent benefits to learning and memory. Neuroscience. 2010;167:588&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2857396</ArticleId><ArticleId IdType="pubmed">20219647</ArticleId></ArticleIdList></Reference><Reference><Citation>Griesbach GS, Hovda DA, Gomez-Pinilla F. Exercise-induced improvement in cognitive performance after traumatic brain injury in rats is dependent on BDNF activation. Brain Res. 2009;1288:105&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2735616</ArticleId><ArticleId IdType="pubmed">19555673</ArticleId></ArticleIdList></Reference><Reference><Citation>Radak Z, Hart N, Sarga L, Koltai E, Atalay M, et al. Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis. 2010;20:777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182027</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteggia LM, Barrot M, Powell CM, Berton O, Galanis V, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A. 2004;101:10827&#x2013;10832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC490019</ArticleId><ArticleId IdType="pubmed">15249684</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorski JA, Balogh SA, Wehner JM, Jones KR. Learning deficits in forebrain-restricted brain-derived neurotrophic factor mutant mice. Neuroscience. 2003;121:341&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">14521993</ArticleId></ArticleIdList></Reference><Reference><Citation>Engert F, Bonhoeffer T. Dendritic spine changes associated with hippocampal long-term synaptic plasticity. Nature. 1999;399:66&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331391</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun ME, Jucker M, Martin LJ, Thinakaran G, Price DL, et al. Comparative evaluation of synaptophysin-based methods for quantification of synapses. J Neurocytol. 1996;25:821&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">9023727</ArticleId></ArticleIdList></Reference><Reference><Citation>Dun XP, Chilton JK. Control of cell shape and plasticity during development and disease by the actin-binding protein Drebrin. Histol Histopathol. 2010;25:533&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">20183806</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagata Y. New aspects of neurotransmitter release and exocytosis: dynamic and differential regulation of synapsin I phosphorylation by acute neuronal excitation in vivo. J Pharmacol Sci. 2003;93:22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">14501147</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, et al. Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology. 2010;59:290&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">20394761</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, et al. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J. 2009;23:2459&#x2013;2466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717785</ArticleId><ArticleId IdType="pubmed">19346295</ArticleId></ArticleIdList></Reference><Reference><Citation>Orozco-Ibarra M, Chirino YI, Pedraza-Chaverri J. Role of hemeoxygenase-1 in the neurodegenerative disorders. Rev Neurol. 2006;43:556&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">17072812</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol. 2005;58:623&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">16037976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST. Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem. 2008;56:1065&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2583907</ArticleId><ArticleId IdType="pubmed">18678882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollen KA. Alzheimer's disease: the pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010;15:223&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">21155625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahs KR, Ashe KH. &#x2018;Too much good news&#x2019; - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci. 2010;33:381&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">20542579</ArticleId></ArticleIdList></Reference><Reference><Citation>Coma M, Sereno L, Da Rocha-Souto B, Scotton TC, Espana J, et al. Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2010;38:482&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707138</ArticleId><ArticleId IdType="pubmed">20149872</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron. 2011;69:203&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058906</ArticleId><ArticleId IdType="pubmed">21262461</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 1994;77:817&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">8004671</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci. 1996;16:1066&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578817</ArticleId><ArticleId IdType="pubmed">8558235</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, et al. A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA. 2003;100:10518&#x2013;10522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC193593</ArticleId><ArticleId IdType="pubmed">12930888</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, et al. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem. 2007;282:22707&#x2013;22720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4435736</ArticleId><ArticleId IdType="pubmed">17556372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ichemic stroke. J Neurochem. 2011;116:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3004475</ArticleId><ArticleId IdType="pubmed">21054387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22156579</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2012</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of A&#x3b2; on synapses and dendritic spines.</ArticleTitle><Pagination><StartPage>1384</StartPage><EndPage>1390</EndPage><MedlinePgn>1384-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddr576</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is the most common neurodegenerative disease and the leading cause of dementia in the elderly. Accumulating evidence supports soluble amyloid-&#x3b2; (A&#x3b2;) oligomers as the leading candidate for the causative agent in AD and synapses as the primary site of A&#x3b2; oligomer action. However, the molecular and cellular mechanisms by which A&#x3b2; oligomers cause synaptic dysfunction and cognitive impairments remain poorly understood. Using primary cultures of rat hippocampal neurons as a model system, we show that the partitioning defective-1 (PAR-1)/microtubule affinity-regulating kinase (MARK) family kinases act as critical mediators of A&#x3b2; toxicity on synapses and dendritic spines. Overexpression of MARK4 led to tau hyperphosphorylation, reduced expression of synaptic markers, and loss of dendritic spines and synapses, phenotypes also observed after A&#x3b2; treatment. Importantly, expression of a non-phosphorylatable form of tau with the PAR-1/MARK site mutated blocked the synaptic toxicity induced by MARK4 overexpression or A&#x3b2; treatment. To probe the involvement of endogenous MARK kinases in mediating the synaptic toxicity of A&#x3b2;, we employed a peptide inhibitor capable of effectively and specifically inhibiting the activities of all PAR-1/MARK family members. This inhibitor abrogated the toxic effects of A&#x3b2; oligomers on dendritic spines and synapses as assayed at the morphological and electrophysiological levels. Our results reveal a critical role for PAR-1/MARK kinases in AD pathogenesis and suggest PAR-1/MARK inhibitors as potential therapeutics for AD and possibly other tauopathies where aberrant tau hyperphosphorylation is involved.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wendou</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polepalli</LastName><ForeName>Jai</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wagh</LastName><ForeName>Dhananjay</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rajadas</LastName><ForeName>Jayakumar</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Malenka</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bingwei</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AR054926</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH063394</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH080378</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489131">Mapt protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="C484552">Mark1 protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004594" MajorTopicYN="N">Electrophysiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008870" MajorTopicYN="N">Microtubules</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22156579</ArticleId><ArticleId IdType="pmc">PMC3284124</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddr576</ArticleId><ArticleId IdType="pii">ddr576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe D.J. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P., Cahill M.E., Jones K.A., VanLeeuwen J.E., Woolfrey K.M. Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci. 2011;14:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530413</ArticleId><ArticleId IdType="pubmed">21346746</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires T.L., Meyer-Luehmann M., Stern E.A., McLean P.J., Skoch J., Nguyen P.T., Bacskai B.J., Hyman B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 2005;25:7278&#x2013;7287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Beal M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trend. Mol. Med. 2008;14:45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107703</ArticleId><ArticleId IdType="pubmed">18218341</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 2008;192:106&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011;3:77sr71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner B.A., Dawes L.R., Fisher S., Villa-Komaroff L., Oster-Granite M.L., Neve R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science. 1989;245:417&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">2474201</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA. 2011;108:5819&#x2013;5824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., et al. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA. 1998;95:6448&#x2013;6453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491&#x2013;1495.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed, R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S., Billings L., Kesslak J.P., Cribbs D.H., LaFerla F.M. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl Acad. Sci. USA. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T.L., Stoothoff W.H., de Calignon A., Jones P.B., Hyman B.T. Tau pathophysiology in neurodegeneration: a tangled issue. Trend. Neurosci. 2009;32:150&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162340</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., Gotz J. Amyloid-beta and tau&#x2014;a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011;12:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo S., Kemphues K.J. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 1995;81:611&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">7758115</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G., Ebneth A., Preuss U., Mandelkow E.M., Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9108484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M., Hyman B.T. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: a fluorescence resonance energy transfer study. J. Neuropathol. Exp. Neurol. 2000;59:966&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089574</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura I., Yang Y., Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004;116:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">15006350</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez M., Ribe E., Rubio A., Lim F., Moran M.A., Ramos P.G., Ferrer I., Isla M.T., Avila J. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience. 2005;130:339&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15664690</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Guo H., Kwan H., Wang J.W., Kosek J., Lu B. PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction. Neuron. 2007;53:201&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1855201</ArticleId><ArticleId IdType="pubmed">17224403</ArticleId></ArticleIdList></Reference><Reference><Citation>Gylys K.H., Fein J.A., Yang F., Wiley D.J., Miller C.A., Cole G.M. Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am. J. Pathol. 2004;165:1809&#x2013;1817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618663</ArticleId><ArticleId IdType="pubmed">15509549</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida C.G., Tampellini D., Takahashi R.H., Greengard P., Lin M.T., Snyder E.M., Gouras G.K. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 2005;20:187&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinczek B., Brajenovic M., Ebneth A., Drewes G. MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. J. Biol. Chem. 2004;279:5915&#x2013;5923.</Citation><ArticleIdList><ArticleId IdType="pubmed">14594945</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.W., Imai Y., Lu B. Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor suppressor protein LKB1. J. Neurosci. 2007;27:574&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672797</ArticleId><ArticleId IdType="pubmed">17234589</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H., Thies E., Mandelkow E., Mandelkow E.M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J. Neurosci. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Schluter O.M., Steiner P., Czervionke B.L., Sabatini B., Malenka R.C. Molecular dissociation of the role of PSD-95 in regulating synaptic strength and LTD. Neuron. 2008;57:248&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147180</ArticleId><ArticleId IdType="pubmed">18215622</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E., Mandelkow E.M. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowles J.K., Rajadas J., Nguyen T.V., Yang T., LeMieux M.C., Vander Griend L., Ishikawa C., Massa S.M., Wyss-Coray T., Longo F.M. The p75 neurotrophin receptor promotes amyloid-beta(1&#x2013;42)-induced neuritic dystrophy in vitro and in vivo. J. Neurosci. 2009;29:10627&#x2013;10637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2771439</ArticleId><ArticleId IdType="pubmed">19710315</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesic D., Miller M.C., Quinkert Z.T., Stein M., Chait B.T., Stebbins C.E. Helicobacter pylori CagA inhibits PAR1-MARK family kinases by mimicking host substrates. Nat. Struct. Mol. Biol. 2010;17:130&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3006182</ArticleId><ArticleId IdType="pubmed">19966800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lizcano J.M., Goransson O., Toth R., Deak M., Morrice N.A., Boudeau J., Hawley S.A., Udd L., Makela T.P., Hardie D.G., Alessi D.R. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 2004;23:833&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC381014</ArticleId><ArticleId IdType="pubmed">14976552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover B.R., Reed M.N., Su J., Penrod R.D., Kotilinek L.A., Grant M.K., Pitstick R., Carlson G.A., Lanier L.M., Yuan L.L., Ashe K.H., Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C, Christie M.J., Napier I.A., et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Matenia D., Mandelkow E.M. The tau of MARK: a polarized view of the cytoskeleton. Trend. Biochem. Sci. 2009;34:332&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">19559622</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007;27:2866&#x2013;2875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh H., Boehm J., Sato C., Iwatsubo T., Tomita T., Sisodia S., Malinow R. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron. 2006;52:831&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850952</ArticleId><ArticleId IdType="pubmed">17145504</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 2011;14:750&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W., Sun Y., Guo S., Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Hum. Mol. Genet. 2011;20:3227&#x2013;3240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3140825</ArticleId><ArticleId IdType="pubmed">21613270</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22159114</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>49</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-&#x3b2; amyloidosis.</ArticleTitle><Pagination><StartPage>18007</StartPage><EndPage>18012</EndPage><MedlinePgn>18007-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3773-11.2011</ELocationID><Abstract><AbstractText>The &#x3b5;4 allele of the apolipoprotein E (APOE) gene is the strongest genetic risk factor for Alzheimer's disease (AD). Evidence suggests that the effect of apoE isoforms on amyloid-&#x3b2; (A&#x3b2;) accumulation in the brain plays a critical role in AD pathogenesis. Like in humans, apoE4 expression in animal models that develop A&#x3b2; amyloidosis results in greater A&#x3b2; and amyloid deposition than with apoE3 expression. However, whether decreasing levels of apoE3 or apoE4 would promote or attenuate A&#x3b2;-related pathology has not been directly addressed. To determine the effect of decreasing human apoE levels on A&#x3b2; accumulation in vivo, we generated human APOE isoform haploinsufficient mouse models by crossing APPPS1-21 mice with APOE isoform knock-in mice. By genetically manipulating APOE gene dosage, we demonstrate that decreasing human apoE levels, regardless of isoform status, results in significantly decreased amyloid plaque deposition and microglial activation. These differences in amyloid load between apoE3- and apoE4-expressing mice were not due to apoE4 protein being present at lower levels than apoE3. These data suggest that current therapeutic strategies to increase apoE levels without altering its lipidation state may actually worsen A&#x3b2; amyloidosis, while increasing apoE degradation or inhibiting its synthesis may be a more effective treatment approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Developmental Biology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Seonha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Eltorai</LastName><ForeName>Adam E M</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyejin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Basak</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069329</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057895" MajorTopicYN="N">Haploinsufficiency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22159114</ArticleId><ArticleId IdType="mid">NIHMS347949</ArticleId><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3773-11.2011</ArticleId><ArticleId IdType="pii">31/49/18007</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashford JW. ApoE4: is it the absence of good or the presence of bad? J Alzheimers Dis. 2002;4:141&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17:263&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pubmed">9354781</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM. Human APOE isoform-dependent effects on brain &#x3b2;-amyloid levels in PDAPP transgenic mice. J Neurosci. 2009;29:6771&#x2013;6779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665579</ArticleId><ArticleId IdType="pubmed">19474305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao D, Fukuchi K, Wan H, Kim H, Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol Aging. 2006;27:1632&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">16236385</ArticleId></ArticleIdList></Reference><Reference><Citation>Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995;306:599&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1136559</ArticleId><ArticleId IdType="pubmed">7534068</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci Transl Med. 2011;3:89ra57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmed H, Almkvist O, Langstrom B, Nordberg A. Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging. 2011;32:2320, e15&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20538374</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron. 2004;41:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">14741101</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumanis SB, Tesoriero JA, Babus LW, Nguyen MT, Trotter JH, Ladu MJ, Weeber EJ, Turner RS, Xu B, Rebeck GW, Hoe HS. ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J Neurosci. 2009;29:15317&#x2013;15322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2846754</ArticleId><ArticleId IdType="pubmed">19955384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Maia LF, Burgess BL, Blain JF, Naus KE, McIsaac SA, Parkinson PF, Chan JY, Tansley GH, Hayden MR, Poirier J, Van Nostrand W, Wellington CL. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J Biol Chem. 2005;280:43243&#x2013;43256.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207707</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2000;97:2892&#x2013;2897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC16026</ArticleId><ArticleId IdType="pubmed">10694577</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 2009a;63:287&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044446</ArticleId><ArticleId IdType="pubmed">19679070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A[beta] clearance. Neuron. 2009b;64:632&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem. 2005;280:43224&#x2013;43235.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207713</ArticleId></ArticleIdList></Reference><Reference><Citation>Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem. 2003;84:1215&#x2013;1236.</Citation><ArticleIdList><ArticleId IdType="pubmed">12614323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:5644&#x2013;5651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1414631</ArticleId><ArticleId IdType="pubmed">16567625</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Osherovich L. The APOE4 conundrum. SciBX. 2009;2:1&#x2013;3.</Citation></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebeck GW, Kindy M, LaDu MJ. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis. 2002;4:145&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226533</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol. 2004;165:937&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618605</ArticleId><ArticleId IdType="pubmed">15331417</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977&#x2013;1981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972&#x2013;17980.</Citation><ArticleIdList><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Teter B, Raber J, Nathan B, Crutcher KA. The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J Alzheimers Dis. 2002;4:155&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem. 2005;280:43236&#x2013;43242.</Citation><ArticleIdList><ArticleId IdType="pubmed">16207708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008;118:671&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2200302</ArticleId><ArticleId IdType="pubmed">18202749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Casta&#xf1;o EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A. 2007;104:10601&#x2013;10606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21613497</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>21</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>25</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Stress acts cumulatively to precipitate Alzheimer's disease-like tau pathology and cognitive deficits.</ArticleTitle><Pagination><StartPage>7840</StartPage><EndPage>7847</EndPage><MedlinePgn>7840-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0730-11.2011</ELocationID><Abstract><AbstractText>Stressful life experiences are likely etiological factors in sporadic forms of Alzheimer's disease (AD). Many AD patients hypersecrete glucocorticoids (GCs), and their GC levels correlate with the rate of cognitive impairment and extent of neuronal atrophy. Severity of cognitive deficits in AD correlates strongly with levels of hyperphosphorylated forms of the cytoskeletal protein TAU, an essential mediator of the actions of amyloid &#x3b2; (A&#x3b2;), another molecule with a key pathogenic role in AD. Our objective was to investigate the sequential interrelationships between these various pathogenic elements, in particular with respect to the mechanisms through which stress might precipitate cognitive decline. We thus examined whether stress, through the mediation of GCs, influences TAU hyperphosphorylation, a critical and early event in the cascade of processes leading to AD pathology. Results from healthy, wild-type, middle-aged rats show that chronic stress and GC induce abnormal hyperphosphorylation of TAU in the hippocampus and prefrontal cortex (PFC), with contemporaneous impairments of hippocampus- and PFC-dependent behaviors. Exogenous GC potentiated the ability of centrally infused A&#x3b2; to induce hyperphosphorylation of TAU epitopes associated with AD and cytoplasmic accumulation of TAU, while previous exposure to stress aggravated the biochemical and behavioral effects of GC in A&#x3b2;-infused animals. Thus, lifetime stress/GC exposure may have a cumulative impact on the onset and progress of AD pathology, with TAU hyperphosphorylation serving to transduce the negative effects of stress and GC on cognition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sotiropoulos</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Max Planck Institute of Psychiatry, 80804 Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catania</LastName><ForeName>Caterina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Lucilia G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Rui</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Pollerberg</LastName><ForeName>G Elizabeth</ForeName><Initials>GE</Initials></Author><Author ValidYN="Y"><LastName>Takashima</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sousa</LastName><ForeName>Nuno</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Almeida</LastName><ForeName>Osborne F X</ForeName><Initials>OF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C489131">Mapt protein, rat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011897" MajorTopicYN="N">Random Allocation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21613497</ArticleId><ArticleId IdType="pmc">PMC6633145</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0730-11.2011</ArticleId><ArticleId IdType="pii">31/21/7840</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alonso A, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A. 2001;98:6923&#x2013;6928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC34454</ArticleId><ArticleId IdType="pubmed">11381127</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso Adel C, Li B, Grundke-Iqbal I, Iqbal K. Polymerization of hyperphosphorylated TAU into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A. 2006;103:8864&#x2013;8869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1482669</ArticleId><ArticleId IdType="pubmed">16735465</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific TAU phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci. 2007;27:3650&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14:879&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718249</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan LM, Vaules WA, Coleman PD. Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. J Neuropathol Exp Neurol. 2002;61:384&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">12025941</ArticleId></ArticleIdList></Reference><Reference><Citation>Catania C, Sotiropoulos I, Silva R, Onofri C, Breen KC, Sousa N, Almeida OF. The amyloidogenic potential and behavioral correlates of stress. Mol Psychiatry. 2009;14:95&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17912249</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereseto M, Rein&#xe9;s A, Ferrero A, Sifonios L, Rubio M, Wikinski S. Chronic treatment with high doses of corticosterone decreases cytoskeletal proteins in the rat hippocampus. Eur J Neurosci. 2006;24:3354&#x2013;3364.</Citation><ArticleIdList><ArticleId IdType="pubmed">17229084</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerqueira JJ, Mailliet F, Almeida OF, Jay TM, Sousa N. The prefrontal cortex as a key target of the maladaptive response to stress. J Neurosci. 2007;27:2781&#x2013;2787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672565</ArticleId><ArticleId IdType="pubmed">17360899</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HW, van den Hove DL. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol. 2010;90:498&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">20097254</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holtzman DM, Morris JC. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry. 2006;163:2164&#x2013;2169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780275</ArticleId><ArticleId IdType="pubmed">17151169</ArticleId></ArticleIdList></Reference><Reference><Citation>Elgh E, Lindqvist Astot A, Fagerlund M, Eriksson S, Olsson T, N&#xe4;sman B. Cognitive dysfunction, hippocampal atrophy and glucocorticoid feedback in Alzheimer's disease. Biol Psychiatry. 2006;59:155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125145</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewers M, Buerger K, Teipel SJ, Scheltens P, Schr&#xf6;der J, Zinkowski RP, Bouwman FH, Sch&#xf6;nknecht P, Schoonenboom NS, Andreasen N, Wallin A, DeBernardis JF, Kerkman DJ, Heindl B, Blennow K, Hampel H. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology. 2007;69:2205&#x2013;2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">18071141</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW. Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A. 2009;106:18367&#x2013;18372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2762847</ArticleId><ArticleId IdType="pubmed">19837693</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-beta and TAU pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006;26:9047&#x2013;9056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675335</ArticleId><ArticleId IdType="pubmed">16943563</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913&#x2013;4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol. 2003;60:729&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">12756137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, B&#xfc;rger K, Pruessner JC, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans AC, Davies P, M&#xf6;ller HJ, Teipel SJ. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62:770&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883264</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol. 1997;4:119&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">9190286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I. Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared withnormal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18:285&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">9263193</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010;107:6058&#x2013;6063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851853</ArticleId><ArticleId IdType="pubmed">20231476</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong YH, Park CH, Yoo J, Shin KY, Ahn SM, Kim HS, Lee SH, Emson PC, Suh YH. Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 2006;20:729&#x2013;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">16467370</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc Natl Acad Sci U S A. 2007;104:10673&#x2013;10678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1965571</ArticleId><ArticleId IdType="pubmed">17551018</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia. 1996;7:177&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">8835879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Yamashita S, Fukuda T, Park JM, Murayama M, Mizoroki T, Yoshiike Y, Sahara N, Takashima A. Hyperphosphorylated TAU in parahippocampal cortex impairs place learning in aged mice expressing wild-type human TAU. EMBO J. 2007;26:5143&#x2013;5152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2140104</ArticleId><ArticleId IdType="pubmed">18007595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura T, Fukuda T, Sahara N, Yamashita S, Murayama M, Mizoroki T, Yoshiike Y, Lee B, Sotiropoulos I, Maeda S, Takashima A. Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem. 2010;285:38692&#x2013;38699.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992302</ArticleId><ArticleId IdType="pubmed">20921222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lace G, Savva GM, Forster G, de Silva R, Brayne C, Matthews FE, Barclay JJ, Dakin L, Ince PG, Wharton SB. Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain. 2009;132:1324&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pubmed">19321462</ArticleId></ArticleIdList></Reference><Reference><Citation>Landfield PW, Blalock EM, Chen KC, Porter NM. A new glucocorticoid hypothesis of brain aging: implications for Alzheimer's disease. Curr Alzheimer Res. 2007;4:205&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3573879</ArticleId><ArticleId IdType="pubmed">17430248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauckner J, Frey P, Geula C. Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles. Neurobiol Aging. 2003;24:767&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">12927759</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci. 2009;10:434&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">19401723</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res. 2006;54:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov. 2007;6:464&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">17541419</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TP, Taylor J, Rogerson S, Mauricio M, Kennedy Q, Schatzberg A, Tinklenberg J, Yesavage J. Cognitive and noncognitive symptoms in dementia patients: relationship to cortisol and dehydroepiandrosterone. Int Psychogeriatr. 1998;10:85&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629527</ArticleId></ArticleIdList></Reference><Reference><Citation>Nisenbaum LK, Zigmond MJ, Sved AF, Abercrombie ED. Prior exposure to chronic stress results in enhanced synthesis and release of hippocampal norepinephrine in response to a novel stressor. J Neurosci. 1991;11:1478&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575330</ArticleId><ArticleId IdType="pubmed">1674004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63:530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530614</ArticleId><ArticleId IdType="pubmed">16651510</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364&#x2013;6369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Lee KF, Vale W, Sawchenko PE. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci. 2007;27:6552&#x2013;6562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672442</ArticleId><ArticleId IdType="pubmed">17567816</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous TAU ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Biernat J, von Bergen M, Mandelkow E, Mandelkow EM. Phosphorylation that detaches TAU protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments. Biochemistry. 1999;38:3549&#x2013;3558.</Citation><ArticleIdList><ArticleId IdType="pubmed">10090741</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert MI, Kalisch R, Sotiropoulos I, Catania C, Sousa N, Almeida OF, Auer DP. Effects of altered corticosteroid milieu on rat hippocampal neurochemistry and structure&#x2014;an in vivo magnetic resonance spectroscopy and imaging study. J Psychiatr Res. 2008;42:902&#x2013;912.</Citation><ArticleIdList><ArticleId IdType="pubmed">18177670</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998;357:299&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">9735171</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipton OA, Leitz JR, Dworzak J, Acton CE, Tunbridge EM, Denk F, Dawson HN, Vitek MP, Wade-Martins R, Paulsen O, Vargas-Caballero M. Tau protein is required for amyloid &#x3b2;-induced impairment of hippocampal long-term potentiation. J Neurosci. 2011;31:1688&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3836238</ArticleId><ArticleId IdType="pubmed">21289177</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotiropoulos I, Cerqueira JJ, Catania C, Takashima A, Sousa N, Almeida OF. Stress and glucocorticoid footprints in the brain-The path from depression to Alzheimer's disease. Neurosci Biobehav Rev. 2008a;32:1161&#x2013;1173.</Citation><ArticleIdList><ArticleId IdType="pubmed">18573532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotiropoulos I, Catania C, Riedemann T, Fry JP, Breen KC, Michaelidis TM, Almeida OF. Glucocorticoids trigger Alzheimer disease-like pathobiochemistry in neuronal cells expressing human TAU. J Neurochem. 2008b;107:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">18691381</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa N, Lukoyanov NV, Madeira MD, Almeida OF, Paula-Barbosa MM. Reorganization of the morphology of hippocampal neurites and synapses after stress-induced damage correlates with behavioral improvement. Neuroscience. 2000;97:253&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799757</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R. Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci. 1994;14:5373&#x2013;5380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6577078</ArticleId><ArticleId IdType="pubmed">8083742</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xe9;phan A, Phillips AG. A case for a non-transgenic animal model of Alzheimer's disease. Genes Brain Behav. 2005;4:157&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">15810904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, Rosenberg I, Mwamburi DM, Qiu WQ. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry. 2008;65:542&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3042807</ArticleId><ArticleId IdType="pubmed">18458206</ArticleId></ArticleIdList></Reference><Reference><Citation>Swanson LW. Brain maps: structure of the rat brain. Amsterdam: Elsevier Science; 1999.</Citation></Reference><Reference><Citation>Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H. Activation of TAU protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25&#x2013;35) enhances phosphorylation of TAU in hippocampal neurons. Neurosci Res. 1998;31:317&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809590</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology. 2009;72:1056&#x2013;1061.</Citation><ArticleIdList><ArticleId IdType="pubmed">19307538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Gong CX, Zaidi T, Grundke-Iqbal I, Iqbal K. Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem. 1995;270:4854&#x2013;4860.</Citation><ArticleIdList><ArticleId IdType="pubmed">7876258</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007;25:59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191918</ArticleId><ArticleId IdType="pubmed">17241267</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MF, Vobach S, Olsson K, Svetlik D, Risser RC. Cortisol secretion and Alzheimer's disease progression. Biol Psychiatry. 1997;42:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">9386855</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Evans DA, Bienias JL, Mendes de Leon CF, Schneider JA, Bennett DA. Proneness to psychological distress is associated with risk of Alzheimer's disease. Neurology. 2003;61:1479&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">14663028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Schneider JA, Boyle PA, Arnold SE, Tang Y, Bennett DA. Chronic distress and incidence of mild cognitive impairment. Neurology. 2007;68:2085&#x2013;2092.</Citation><ArticleIdList><ArticleId IdType="pubmed">17562829</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21825215</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Evidence for ordering of Alzheimer disease biomarkers.</ArticleTitle><Pagination><StartPage>1526</StartPage><EndPage>1535</EndPage><MedlinePgn>1526-35</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.183</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To empirically assess the concept that Alzheimer disease (AD) biomarkers significantly depart from normality in a temporally ordered manner.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Validation sample.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Multisite, referral centers.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 401 elderly participants in the Alzheimer's Disease Neuroimaging Initiative who were cognitively normal, who had mild cognitive impairment, or who had AD dementia. We compared the proportions of 3 AD biomarker values (the A&#x3b2;42 level in cerebrospinal fluid [CSF], the total tau level in CSF, and the hippocampal volume adjusted for intracranial volume [hereafter referred to as the adjusted hippocampal volume]) that were abnormal as cognitive impairment worsened. Cut points demarcating normal vs abnormal for each biomarker were established by maximizing diagnostic accuracy in independent autopsy samples.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Three AD biomarkers (ie, the CSF A&#x3b2;42 level, the CSF total tau level, and the adjusted hippocampal volume).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within each clinical group of the entire sample (n = 401), the CSF A&#x3b2;42 level was abnormal more often than was the CSF total tau level or the adjusted hippocampal volume. Among the 298 participants with both baseline and 12-month data, the proportion of participants with an abnormal A&#x3b2;42 level did not change from baseline to 12 months in any group. The proportion of participants with an abnormal total tau level increased from baseline to 12 months in cognitively normal participants (P = .05) but not in participants with mild cognitive impairment or AD dementia. For 209 participants with an abnormal CSF A&#x3b2;42 level at baseline, the percentage with an abnormal adjusted hippocampal volume but normal CSF total tau level increased from baseline to 12 months in participants with mild cognitive impairment. No change in the percentage of MCI participants with an abnormal total tau level was seen between baseline and 12 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A reduction in the CSF A&#x3b2;42 level denotes a pathophysiological process that significantly departs from normality (ie, becomes dynamic) early, whereas the CSF total tau level and the adjusted hippocampal volume are biomarkers of downstream pathophysiological processes. The CSF total tau level becomes dynamic before the adjusted hippocampal volume, but the hippocampal volume is more dynamic in the clinically symptomatic mild cognitive impairment and AD dementia phases of the disease than is the CSF total tau level.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic and Mayo Foundation for Medical Education and Research, 200 First St, SW, Rochester, MN 55905, USA. jack.clifford@mayo.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Wiste</LastName><ForeName>Heather J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Arch Neurol. 2012 Mar;69(3):414; author reply 414-5. doi: 10.1001/archneurol.2011.2906.</RefSource><PMID Version="1">22410455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21825215</ArticleId><ArticleId IdType="mid">NIHMS387449</ArticleId><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.183</ArticleId><ArticleId IdType="pii">archneurol.2011.183</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer&#x2019;s disease: a new lexicon. Lancet Neurol. 2010</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging and the Alzheimer Association workgroup on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011 (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096735</ArticleId><ArticleId IdType="pubmed">21514247</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Assocation Workgroup. Alzheimers Dement. 2011 (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer Assocation Workgroup. Alzheimers Dement. 2011 (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and Alzheimer&#x2019;s Association Workgroup. Alzheimers Dement. 2011 (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730146</ArticleId><ArticleId IdType="pubmed">10227624</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Gomez-Isla T, Moss M, et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer&#x2019;s disease. Ann Neurol. 2000;47(4):430&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10762153</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Haan MN, Eberling JL, Wolfe N, Reed BR. Functional imaging predicts cognitive decline in Alzheimer&#x2019;s disease. J Neuroimaging. 1996;6(3):156&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8704290</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8(7):619&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Koivunen J, Edison P, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73(10):754&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830881</ArticleId><ArticleId IdType="pubmed">19587325</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer&#x2019;s disease. Neurobiol Aging. 2001;22(5):747&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy LK, Fennema-Notestine C, Roddey JC, et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology. 2009;251(1):195&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663582</ArticleId><ArticleId IdType="pubmed">19201945</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Fagan AM, Roe C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol. 2009;66(5):638&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759394</ArticleId><ArticleId IdType="pubmed">19433664</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74(19):1531&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20458070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Frank R, Broich K, et al. Biomarkers for Alzheimer&#x2019;s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592748</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K. Biomarkers in Alzheimer&#x2019;s disease drug development. Nat Med. 2010;16(11):1218&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052077</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H. Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer&#x2019;s disease? Alzheimers Res Ther. 2010;2(2):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876786</ArticleId><ArticleId IdType="pubmed">20441609</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60(12):1696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer&#x2019;s disease. Ann Neurol. 1995;38(4):649&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7574462</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonenboom NS, van der Flier WM, Blankenstein MA, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer&#x2019;s disease. Neurobiol Aging. 2008;29(5):669&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">17208336</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59(3):512&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73(15):1193&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Riemenschneider M, Forstl H, et al. Beta amyloid in Alzheimer&#x2019;s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65(11):927&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50(9):1464&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">19690025</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1):117&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2804478</ArticleId><ArticleId IdType="pubmed">19847050</ArticleId></ArticleIdList></Reference><Reference><Citation>Degerman Gunnarsson M, Lindau M, Wall A, et al. Pittsburgh compound-B and Alzheimer&#x2019;s disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord. 2010;29(3):204&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">20332638</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129(Pt 11):3035&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s disease neuroimaging initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Overmyer M, Lehtovirta M, et al. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer&#x2019;s disease. Neuroreport. 1997;8(18):3961&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462474</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69(9):871&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17724289</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42(1):85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41(11):1920&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079505</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, O&#x2019;Brien PC, Tangalos EG. MR-based hippocampal volumetry in the diagnosis of Alzheimer&#x2019;s disease. Neurology. 1992;42(1):183&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734300</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer&#x2019;s disease. Arch Neurol. 1993;50(9):949&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">8363449</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage. 2008;42(2):559&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097053</ArticleId><ArticleId IdType="pubmed">18572417</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Cabral HJ, Hess CP, et al. Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer&#x2019;s disease. Brain. 2009;132(Pt 8):2048&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714061</ArticleId><ArticleId IdType="pubmed">19460794</ArticleId></ArticleIdList></Reference><Reference><Citation>Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer&#x2019;s disease pathology. Neurology. 2003;61(4):487&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">12939422</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Josephs KA, Murray ME, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71(10):743&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676950</ArticleId><ArticleId IdType="pubmed">18765650</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6(2):67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer&#x2019;s disease: implications for sequence of pathological events in Alzheimer&#x2019;s disease. Brain. 2009;132(Pt 5):1355&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677798</ArticleId><ArticleId IdType="pubmed">19339253</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroli A, Frisoni GB. The dynamics of Alzheimer&#x2019;s disease biomarkers in the Alzheimer&#x2019;s Disease Neuroimaging Initiative cohort. Neurobiol Aging. 2010;31(8):1263&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3467365</ArticleId><ArticleId IdType="pubmed">20538373</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, De Meyer G, Shapiro F, et al. Hauppauge; NY: Nova Science Publishers, Inc; 2008. Biomarkers For Early Diagnosis Of Alzheimer&#x2019;s Disease; pp. 81&#x2013;122.</Citation></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, et al. The Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicich J, Czanner S, Greve D, et al. Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data. Neuroimage. 2006;30(2):436&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">16300968</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17(1):87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Twomey CK, Zinsmeister AR, Sharbrough FW, Petersen RC, Cascino GD. Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology. 1989;172(2):549&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">2748838</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Arch Neurol. 2010;67(8):949&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">15037694</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461(7266):916&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations. Neurology. 2009;73(4):287&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2715210</ArticleId><ArticleId IdType="pubmed">19636048</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. Serial MRI and CSF Biomarkers in Normal Aging, MCI and AD. Neurology. 2010;75(2):143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905929</ArticleId><ArticleId IdType="pubmed">20625167</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63(7):936&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831961</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinin NM, Aalto S, Koikkalainen J, et al. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology. 2009;73(15):1186&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19726751</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer&#x2019;s disease with voxel-compression mapping of serial magnetic resonance images. Lancet. 2001;358(9277):201&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson NE, Moore MM, Dame A, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology. 2008;70(11):828&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">18046010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O&#x2019;Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29(40):12686&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(Pt 5):1310&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer&#x2019;s disease: correlation with cognitive severity. Ann Neurol. 1990;27(5):457&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer&#x2019;s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry. 2005;76(9):1194&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739810</ArticleId><ArticleId IdType="pubmed">16107349</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian ng, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31(8):1275&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Ellis KA, Villemagne VL, et al. Cognition and beta-amyloid in preclinical Alzheimer&#x2019;s disease: Data from the AIBL study. Neuropsychologia. 2011 (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pubmed">21529702</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Chetelat G, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69(1):181&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16682537</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64(5):834&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691&#x2013;701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853869</ArticleId><ArticleId IdType="pubmed">19749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63(1):38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>White L, Small BJ, Petrovitch H, et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol. 2005;18(4):224&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16306244</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology. 2002;58(5):750&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745935</ArticleId><ArticleId IdType="pubmed">11889239</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42. Ann Neurol. 2010;68(6):825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65(2):176&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, O&#x2019;Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">17420404</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2010 (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer&#x2019;s disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Stoub TR, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76(16):1395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087406</ArticleId><ArticleId IdType="pubmed">21490323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22194817</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>12</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid &#x3b2; levels in humans.</ArticleTitle><Pagination><StartPage>e28263</StartPage><MedlinePgn>e28263</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28263</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0028263</ELocationID><Abstract><AbstractText>Amyloid &#x3b2; (A&#x3b2;) peptides are proteolytic products from amyloid precursor protein (APP) and are thought to play a role in Alzheimer disease (AD) pathogenesis. While much is known about molecular mechanisms underlying cerebral A&#x3b2; accumulation in familial AD, less is known about the cause(s) of brain amyloidosis in sporadic disease. Animal and postmortem studies suggest that A&#x3b2; secretion can be up-regulated in response to hypoxia. We employed a new technology (Single Molecule Arrays, SiMoA) capable of ultrasensitive protein measurements and developed a novel assay to look for changes in serum A&#x3b2;42 concentration in 25 resuscitated patients with severe hypoxia due to cardiac arrest. After a lag period of 10 or more hours, very clear serum A&#x3b2;42 elevations were observed in all patients. Elevations ranged from approximately 80% to over 70-fold, with most elevations in the range of 3-10-fold (average approximately 7-fold). The magnitude of the increase correlated with clinical outcome. These data provide the first direct evidence in living humans that ischemia acutely increases A&#x3b2; levels in blood. The results point to the possibility that hypoxia may play a role in the amyloidogenic process of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, M&#xf6;lndal, Sweden. henrik.zetterberg@clinchem.gu.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf6;rtberg</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Linan</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Provuncher</LastName><ForeName>Gail K</ForeName><Initials>GK</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Purvish P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Ferrell</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>David R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Kan</LastName><ForeName>Cheuk W</ForeName><Initials>CW</Initials></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>Todd G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Ray</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rivnak</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Pink</LastName><ForeName>Brian A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Minnehan</LastName><ForeName>Kaitlin A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Piech</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Rissin</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>David C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Rubertsson</LastName><ForeName>Sten</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001681" MajorTopicYN="N">Biological Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006323" MajorTopicYN="N">Heart Arrest</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have read the journal's policy and have the following conflicts: Drs. Song, Chang, Provuncher, Patel, Ferrell, Fournier, Kan, Campbell, Meyer, Rivnak, Pink, Minnehan, Piech, Rissin, Duffy and Wilson are employees at Quanterix Corporation. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. There are no relevant patents and products in relation to this. The other authors have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22194817</ArticleId><ArticleId IdType="pmc">PMC3237426</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0028263</ArticleId><ArticleId IdType="pii">PONE-D-11-17020</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooshmand B, Solomon A, Kareholt I, Leiviska J, Rusanen M, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75:1408&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">20956786</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76:1485&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">21490316</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement Geriatr Cogn Disord. 2009;28:75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814023</ArticleId><ArticleId IdType="pubmed">19648749</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Pantoni L, Simoni M, Bengtsson C, Bjorkelund C, et al. Blood pressure components and changes in relation to white matter lesions: a 32-year prospective population study. Hypertension. 2009;54:57&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">19487586</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike MA, Green KN, Blurton-Jones M, Laferla FM. Oligemic hypoperfusion differentially affects tau and amyloid-{beta}. Am J Pathol. 2010;177:300&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893673</ArticleId><ArticleId IdType="pubmed">20472896</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmotto M, Aragno M, Autelli R, Giliberto L, Novo E, et al. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J Neurochem. 2009;108:1045&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">19196431</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xing A, Xu C, Cai Q, Liu H, et al. Cerebrovascular hypoperfusion induces spatial memory impairment, synaptic changes, and amyloid-beta oligomerization in rats. J Alzheimers Dis. 2010;21:813&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">20634588</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi JP, Wu H, Yang Y, Wang DD, Chen YX, et al. Cerebral ischemia and Alzheimer's disease: the expression of amyloid-beta and apolipoprotein E in human hippocampus. J Alzheimers Dis. 2007;12:335&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198420</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski HM, Maslinska D. Beta-protein immunoreactivity in the human brain after cardiac arrest. Folia Neuropathol. 1996;34:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">8791894</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Fournier DR, Piech T, Kan CW, Campbell TG, et al. Simultaneous detection of single molecules and singulated ensembles of molecules enables immunoassays with broad dynamic range. Anal Chem. 2011;83:2279&#x2013;2285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056883</ArticleId><ArticleId IdType="pubmed">21344864</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol. 2010;28:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919230</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortberg E, Zetterberg H, Nordmark J, Blennow K, Rosengren L, et al. S-100B is superior to NSE, BDNF and GFAP in predicting outcome of resuscitation from cardiac arrest with hypothermia treatment. Resuscitation. 2011;82:26&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21071131</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">46957</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummins RO, Chamberlain D, Hazinski MF, Nadkarni V, Kloeck W, et al. Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: the in-hospital &#x2018;Utstein style&#x2019;. A statement for healthcare professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian Resuscitation Council, and the Resuscitation Councils of Southern Africa. Resuscitation. 1997;34:151&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pubmed">9141159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, et al. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010. 2010;pii:986310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925386</ArticleId><ArticleId IdType="pubmed">20798852</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkitadze MD, Condron MM, Teplow DB. Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol. 2001;312:1103&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">11580253</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M, Gorman PM, Rico M, Chakrabartty A, Laurents DV. Charge substitution shows that repulsive electrostatic interactions impede the oligomerization of Alzheimer amyloid peptides. FEBS Lett. 2005;579:3574&#x2013;3578.</Citation><ArticleIdList><ArticleId IdType="pubmed">15964569</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2:404&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2142377</ArticleId><ArticleId IdType="pubmed">8453378</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. Jama. 2011;306:613&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600944</ArticleId><ArticleId IdType="pubmed">21828324</ArticleId></ArticleIdList></Reference><Reference><Citation>Okereke OI, Xia W, Irizarry MC, Sun X, Qiu WQ, et al. Performance characteristics of plasma amyloid-beta 40 and 42 assays. J Alzheimers Dis. 2009;16:277&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737811</ArticleId><ArticleId IdType="pubmed">19221417</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, et al. Standardization of measurement of beta-amyloid(1&#x2013;42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">11132093</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, et al. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1&#x2013;40 and 1&#x2013;42 in Alzheimer disease. Arch Neurol. 2000;57:100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634455</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging. 2010;31:357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">18486992</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22159129</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>49</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant.</ArticleTitle><Pagination><StartPage>18180</StartPage><EndPage>18184</EndPage><MedlinePgn>18180-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4960-11.2011</ELocationID><Abstract><AbstractText>Alzheimer's disease is a devastating, common, progressive dementia with considerable heritability. Recently, a genetic variant associated with the disease was discovered at CLU (rs11136000) with genome-wide support. Here we show, using an imaging genetics approach in a large genotyped sample, that healthy carriers of the variant exhibit altered coupling between hippocampus and prefrontal cortex during memory processing, mirroring clinical evidence of disturbed connectivity in patients and providing a neurogenetic mechanism for CLU-associated risk and protection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erk</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Mind and Brain Research, Department of Psychiatry and Psychotherapy, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Campus Mitte, D-11017 Berlin, Germany. susanne.erk@charite.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer-Lindenberg</LastName><ForeName>Andreas</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Opitz von Boberfeld</LastName><ForeName>Carola</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Esslinger</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schnell</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kirsch</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mattheisen</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>M&#xfc;hleisen</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials></Author><Author ValidYN="Y"><LastName>Cichon</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Witt</LastName><ForeName>Stephanie H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>Marcella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>N&#xf6;then</LastName><ForeName>Markus M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Walter</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22159129</ArticleId><ArticleId IdType="pmc">PMC6634131</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4960-11.2011</ArticleId><ArticleId IdType="pii">31/49/18180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allen G, Barnard H, McColl R, Hester AL, Fields JA, Weiner MF, Ringe WK, Lipton AM, Brooker M, McDonald E, Rubin CD, Cullum CM. Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol. 2007;64:1482&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pubmed">17923631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Zhang Z, Watson DR, Yu H, Shi Y, Yuan Y, Zang Y, Zhu C, Qian Y. Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment. Biol Psychiatry. 2009;65:951&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pubmed">19028382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2853021</ArticleId><ArticleId IdType="pubmed">17077814</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Tanzi RE. Alzheimer disease: new light on an old CLU. Nat Rev Neurol. 2010;6:11&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2860389</ArticleId><ArticleId IdType="pubmed">20057494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer S, Burggren A. APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol. 2009;5:343&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3118550</ArticleId><ArticleId IdType="pubmed">19327032</ArticleId></ArticleIdList></Reference><Reference><Citation>Braskie MN, Jahanshad N, Stein JL, Barysheva M, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Ringman JM, Toga AW, Thompson PM. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci. 2011;31:6764&#x2013;6770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176803</ArticleId><ArticleId IdType="pubmed">21543606</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess PW, Shallice T. Confabulation and the control of recollection. Memory. 1996;4:359&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">8817460</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE, Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Arch Neurol. 2010;67:961&#x2013;964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919638</ArticleId><ArticleId IdType="pubmed">20554627</ArticleId></ArticleIdList></Reference><Reference><Citation>Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA, Chen K, Lee W, Chewning K, Villa SE, Meechoovet HB, Gerber JD, Frost D, Benson HL, O'Reilly S, Chibnik LB, Shulman JM, Singleton AB, Craig DW, et al. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet. 2010;19:3295&#x2013;3301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2908469</ArticleId><ArticleId IdType="pubmed">20534741</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA. Functional abnormalities of the medial temporal lobe memory system in mild cognitive impairment and Alzheimer's disease: insights from functional MRI studies. Neuropsychologia. 2008;46:1624&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760288</ArticleId><ArticleId IdType="pubmed">18206188</ArticleId></ArticleIdList></Reference><Reference><Citation>Erk S, Meyer-Lindenberg A, Schnell K, Opitz von Boberfeld C, Esslinger C, Kirsch P, Grimm O, Arnold C, Haddad L, Witt SH, Cichon S, N&#xf6;then MM, Rietschel M, Walter H. Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch Gen Psychiatry. 2010;67:803&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">20679588</ArticleId></ArticleIdList></Reference><Reference><Citation>Erk S, Spottke A, Meisen A, Wagner M, Walter H, Jessen F. Evidence for neuronal compensation during episodic memory in subjective memory impairment. Arch Gen Psychiatry. 2011;68:845&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810648</ArticleId></ArticleIdList></Reference><Reference><Citation>Esslinger C, Walter H, Kirsch P, Erk S, Schnell K, Arnold C, Haddad L, Mier D, Opitz von Boberfeld C, Raab K, Witt SH, Rietschel M, Cichon S, Meyer-Lindenberg A. Neural mechanisms of a genome-wide supported psychosis variant. Science. 2009;324:605.</Citation><ArticleIdList><ArticleId IdType="pubmed">19407193</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989;262:2551&#x2013;2556.</Citation><ArticleIdList><ArticleId IdType="pubmed">2810583</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B. The organization of recent and remote memories. Nat Rev Neurosci. 2005;6:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman L, Glover GH. Report on a multicenter fMRI quality assurance protocol. J Magn Reson Imaging. 2006;23:827&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">16649196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Grady CL, Furey ML, Pietrini P, Horwitz B, Rapoport SI. Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease. Brain. 2001;124:739&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pubmed">11287374</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis. 2009;18:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892293</ArticleId><ArticleId IdType="pubmed">19584447</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67:1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamboh MI, Minster RL, Demirci FY, Ganguli M, Dekosky ST, Lopez OL, Barmada MM. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiol Aging. 2010 doi: 10.1016/j.neurobiolaging.2010.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.015</ArticleId><ArticleId IdType="pmc">PMC3010357</ArticleId><ArticleId IdType="pubmed">20570404</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancaster TM, Baird A, Wolf C, Jackson MC, Johnston SJ, Donev R, Thome J, Linden DE. Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. Eur Neuropsychopharmacol. 2011 doi: 10.1016/j.euroneuro.2011.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2011.02.001</ArticleId><ArticleId IdType="pubmed">21397462</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Lindenberg A. Neural connectivity as an intermediate phenotype: brain networks under genetic control. Hum Brain Mapp. 2009;30:1938&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871064</ArticleId><ArticleId IdType="pubmed">19294651</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci. 2006;7:818&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">16988657</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempel-Clower NL, Barbas H. The laminar pattern of connections between prefrontal and anterior temporal cortices in the Rhesus monkey is related to cortical structure and function. Cereb Cortex. 2000;10:851&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">10982746</ArticleId></ArticleIdList></Reference><Reference><Citation>Schacter DL, Alpert NM, Savage CR, Rauch SL, Albert MS. Conscious recollection and the human hippocampal formation: evidence from positron emission tomography. Proc Natl Acad Sci U S A. 1996;93:321&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40230</ArticleId><ArticleId IdType="pubmed">8552630</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama. 2010;303:1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Morris JC, Snyder AZ, Price JL, Yan Z, D'Angelo G, Liu C, Dixit S, Benzinger T, Fagan A, Goate A, Mintun MA. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Abeta42. J Neurosci. 2010;30:17035&#x2013;17040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023180</ArticleId><ArticleId IdType="pubmed">21159973</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons JS, Spiers HJ. Prefrontal and medial temporal lobe interactions in long-term memory. Nat Rev Neurosci. 2003;4:637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">12894239</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet. 2010;26:84&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20080314</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21397462</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene.</ArticleTitle><Pagination><StartPage>880</StartPage><EndPage>884</EndPage><MedlinePgn>880-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2011.02.001</ELocationID><Abstract><AbstractText>Recent GWAS identified a risk variant for Alzheimer's disease (AD) at a locus (rs11136000) of the clusterin gene (CLU). Here we use functional magnetic resonance imaging (fMRI) during working memory to probe the effect of the risk variant on brain activation in healthy individuals. Participants with the CLU risk genotype had higher activity than participants with the protective allele in frontal and posterior cingulate cortex and the hippocampus, particularly during high memory demand. These results inform pathophysiological models of the preclinical progression of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lancaster</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, Bangor University, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baird</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Margaret C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Donev</LastName><ForeName>Rossen</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Thome</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Linden</LastName><ForeName>David E J</ForeName><Initials>DE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0700102</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/G021538</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="Y">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21397462</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2011.02.001</ArticleId><ArticleId IdType="pii">S0924-977X(11)00024-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21543606</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>18</Issue><PubDate><Year>2011</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults.</ArticleTitle><Pagination><StartPage>6764</StartPage><EndPage>6770</EndPage><MedlinePgn>6764-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5794-10.2011</ELocationID><Abstract><AbstractText>There is a strong genetic risk for late-onset Alzheimer's disease (AD), but so far few gene variants have been identified that reliably contribute to that risk. A newly confirmed genetic risk allele C of the clusterin (CLU) gene variant rs11136000 is carried by &#x223c;88% of Caucasians. The C allele confers a 1.16 greater odds of developing late-onset AD than the T allele. AD patients have reductions in regional white matter integrity. We evaluated whether the CLU risk variant was similarly associated with lower white matter integrity in healthy young humans. Evidence of early brain differences would offer a target for intervention decades before symptom onset. We scanned 398 healthy young adults (mean age, 23.6 &#xb1; 2.2 years) with diffusion tensor imaging, a variation of magnetic resonance imaging sensitive to white matter integrity in the living brain. We assessed genetic associations using mixed-model regression at each point in the brain to map the profile of these associations with white matter integrity. Each C allele copy of the CLU variant was associated with lower fractional anisotropy--a widely accepted measure of white matter integrity--in multiple brain regions, including several known to degenerate in AD. These regions included the splenium of the corpus callosum, the fornix, cingulum, and superior and inferior longitudinal fasciculi in both brain hemispheres. Young healthy carriers of the CLU gene risk variant showed a distinct profile of lower white matter integrity that may increase vulnerability to developing AD later in life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Braskie</LastName><ForeName>Meredith N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Laboratory of Neuro Imaging, Department of Neurology, University of California, School of Medicine, Los Angeles, California 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahanshad</LastName><ForeName>Neda</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Barysheva</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Katie L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>de Zubicaray</LastName><ForeName>Greig I</ForeName><Initials>GI</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Nicholas G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Margaret J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T15 LM007356</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB007813</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS048004:05</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040060</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 NS048004</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM07356</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008281</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008432</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D018486">Twin Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495242">CLU protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014427" MajorTopicYN="N">Twins</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21543606</ArticleId><ArticleId IdType="mid">NIHMS293342</ArticleId><ArticleId IdType="pmc">PMC3176803</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5794-10.2011</ArticleId><ArticleId IdType="pii">31/18/6764</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.08.007</ArticleId><ArticleId IdType="pmc">PMC3128664</ArticleId><ArticleId IdType="pubmed">19775776</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate- a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">17192785</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, Salat D, Rosand J. Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92:197&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">8841666</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol. 1986;19:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">3963770</ArticleId></ArticleIdList></Reference><Reference><Citation>Calero M, Tokuda T, Rostagno A, Kumar A, Zlokovic B, Frangione B, Ghiso J. Functional and structural properties of lipid-associated apolipoprotein J (clusterin) Biochem J. 1999;344:375&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1220653</ArticleId><ArticleId IdType="pubmed">10567218</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SJ, Lim KO, Monteiro I, Reisberg B. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study. J Geriatr Psychiatry Neurol. 2005;18:12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15681623</ArticleId></ArticleIdList></Reference><Reference><Citation>Dati G, Quattrini A, Bernasconi L, Malaguti MC, Antonsson B, Nicoletti F, Alliod C, Di Marco R, Sagot Y, Vitte PA, Hiver A, Greco B, Roach A, Zaratin PF. Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. J Neuroimmunol. 2007;190:8&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">17714795</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Paola M, Di Iulio F, Cherubini A, Blundo C, Casini AR, Sancesario G, Passafiume D, Caltagirone C, Spalletta G. When, where, and how the corpus callosum changes in MCI and AD: a multimodal MRI study. Neurology. 2010;74:1136&#x2013;1142.</Citation><ArticleIdList><ArticleId IdType="pubmed">20368633</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Stein JL, Hua X, Lee S, Hibar DP, Leow AD, Dinov ID, Toga AW, Saykin AJ, Shen L, Foroud T, Pankratz N, Huentelman MJ, Craig DW, Gerber JD, Allen AN, Corneveaux JJ, Stephan DA, DeCarli CS, DeChairo BM, et al. A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A. 2010a;107:8404&#x2013;8409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889537</ArticleId><ArticleId IdType="pubmed">20404173</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LH, Hua X, Dinov ID, Stein JL, Rosano C, Toga AW, Thompson PM. The effects of physical activity, education, and body mass index on the aging brain. Hum Brain Mapp. 2010b doi: 10.1002/hbm21113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm21113</ArticleId><ArticleId IdType="pmc">PMC3184838</ArticleId><ArticleId IdType="pubmed">20715081</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho AJ, Raji CA, Becker JT, Lopez OL, Kuller LH, Hua X, Lee S, Hibar D, Dinov ID, Stein JL, Jack CR, Jr, Weiner MW, Toga AW, Thompson PM the ADNI Consortium, the CHS Consortium. Obesity is linked with lower brain volume in 700 AD and MCI patients. Neurobiol Aging. 2010c;31:1326&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197833</ArticleId><ArticleId IdType="pubmed">20570405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeft F, Barnea-Goraly N, Haas BW, Golarai G, Ng D, Mills D, Korenberg J, Bellugi U, Galaburda A, Reiss AL. More is not always better: increased fractional anisotropy of superior longitudinal fasciculus associated with poor visuospatial abilities in Williams syndrome. J Neurosci. 2007;27:11960&#x2013;11965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673356</ArticleId><ArticleId IdType="pubmed">17978036</ArticleId></ArticleIdList></Reference><Reference><Citation>Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis. 2009;18:553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892293</ArticleId><ArticleId IdType="pubmed">19584447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua X, Leow AD, Parikshak N, Lee S, Chiang MC, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage. 2008;43:458&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197851</ArticleId><ArticleId IdType="pubmed">18691658</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson DN. MAB, multidimensional aptitude battery: manual. Port Hurton, MI: Research Psychologists; 1984.</Citation></Reference><Reference><Citation>Jahanshad N, Lee AD, Barysheva M, McMahon KL, de Zubicaray GI, Martin NG, Wright MJ, Toga AW, Thompson PM. Genetic influences on brain asymmetry: a DTI study of 374 twins and siblings. Neuroimage. 2010;52:455&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086641</ArticleId><ArticleId IdType="pubmed">20430102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HM, Zaitlen NA, Wade CM, Kirby A, Heckerman D, Daly MJ, Eskin E. Efficient control of population structure in model organism association mapping. Genetics. 2008;178:1709&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278096</ArticleId><ArticleId IdType="pubmed">18385116</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohannim O, Hua X, Hibar DP, Lee S, Chou YY, Toga AW, Jack CR, Jr, Weiner MW, Thompson PM. Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging. 2010;31:1429&#x2013;1442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903199</ArticleId><ArticleId IdType="pubmed">20541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fi&#xe9;vet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JE, Chung MK, Lazar M, DuBray MB, Kim J, Bigler ED, Lainhart JE, Alexander AL. A study of diffusion tensor imaging by tissue-specific, smoothing-compensated voxel-based analysis. Neuroimage. 2009;44:870&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657194</ArticleId><ArticleId IdType="pubmed">18976713</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow A, Huang SC, Geng A, Becker J, Davis S, Toga A, Thompson P. Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Inf Process Med Imaging. 2005;19:493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17354720</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore N, Chou YY, Lopez OL, Aizenstein HJ, Becker JT, Toga AW, Thompson PM. Medical Imaging 2008: Physiology, Function, and Structure from Medical Images. San Diego, USA: SPIE; 2008. Fast 3D fluid registration of brain magnetic resonance images.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289542</ArticleId><ArticleId IdType="pubmed">30546193</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Spulber G, Lehtimaki KK, Kononen M, Hallikainen I, Grohn H, Kivipelto M, Hallikainen M, Vanninen R, Soininen H. Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2009 doi: 10.1016/j.neurobiolaging.2009.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.10.006</ArticleId><ArticleId IdType="pubmed">19913331</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Lindenberg A, Nicodemus KK, Egan MF, Callicott JH, Mattay V, Weinberger DR. False positives in imaging genetics. Neuroimage. 2008;40:655&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">18201908</ArticleId></ArticleIdList></Reference><Reference><Citation>Nierenberg J, Pomara N, Hoptman MJ, Sidtis JJ, Ardekani BA, Lim KO. Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. Neuroreport. 2005;16:1369&#x2013;1372.</Citation><ArticleIdList><ArticleId IdType="pubmed">16056141</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucifora PG, Verma R, Lee SK, Melhem ER. Diffusion-tensor MR imaging and tractography: exploring brain microstructure and connectivity. Radiology. 2007;245:367&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">17940300</ArticleId></ArticleIdList></Reference><Reference><Citation>Persson J, Lind J, Larsson A, Ingvar M, Cruts M, Van Broeckhoven C, Adolfsson R, Nilsson LG, Nyberg L. Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology. 2006;66:1029&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606914</ArticleId></ArticleIdList></Reference><Reference><Citation>Raji CA, Ho AJ, Parikshak NN, Becker JT, Lopez OL, Kuller LH, Hua X, Leow AD, Toga AW, Thompson PM. Brain structure and obesity. Hum Brain Mapp. 2010;31:353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826530</ArticleId><ArticleId IdType="pubmed">19662657</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, An Y, Ye W, Holt DP, Dannals RF, Mathis CA, Klunk WE, Ferrucci L, Kraut MA, Wong DF. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, O'Neill J, Geschwind D, Medina L, Apostolova LG, Rodriguez Y, Schaffer B, Varpetian A, Tseng B, Ortiz F, Fitten J, Cummings JL, Bartzokis G. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain. 2007;130:1767&#x2013;1776.</Citation><ArticleIdList><ArticleId IdType="pubmed">17522104</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth AD, Ram&#xed;rez G, Alarc&#xf3;n R, Von Bernhardi R. Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol Res. 2005;38:381&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pubmed">16579521</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, K&#xe5;reholt I, Helkala EL, Viitanen M, Winblad B, Tuomilehto J, Soininen H, Nissinen A, Kivipelto M. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005;4:705&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Salat DH, Tuch DS, van der Kouwe AJ, Greve DN, Pappu V, Lee SY, Hevelone ND, Zaleta AK, Growdon JH, Corkin S, Fischl B, Rosas HD. White matter pathology isolates the hippocampal formation in Alzheimer's disease. Neurobiol Aging. 2010;31:244&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038572</ArticleId><ArticleId IdType="pubmed">18455835</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302:627&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765045</ArticleId><ArticleId IdType="pubmed">19671904</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, Xiong S, Gold BT. White matter diffusion alterations in normal women at risk of Alzheimer's disease. Neurobiol Aging. 2010;31:1122&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873054</ArticleId><ArticleId IdType="pubmed">18801597</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker NH, Schweinsburg BC, Delano-Wood L, Wierenga CE, Bangen KJ, Haaland KY, Frank LR, Salmon DP, Bondi MW. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis. Neuroimage. 2009;45:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782417</ArticleId><ArticleId IdType="pubmed">19100839</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomason ME, Thompson PM. Diffusion imaging, white matter and psychopathology. Annu Rev Clin Psychol. 2011;7:63&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">21219189</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Wechsler adult intelligence scale-revised. San Antonio, TX: The Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Zhang Y, Schuff N, Du AT, Rosen HJ, Kramer JH, Gorno-Tempini ML, Miller BL, Weiner MW. White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI. Brain. 2009;132:2579&#x2013;2592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732263</ArticleId><ArticleId IdType="pubmed">19439421</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A. 1996;93:4229&#x2013;4234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC39517</ArticleId><ArticleId IdType="pubmed">8633046</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22159117</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>49</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Early improved and late defective cognition is reflected by dendritic spines in Tau.P301L mice.</ArticleTitle><Pagination><StartPage>18036</StartPage><EndPage>18047</EndPage><MedlinePgn>18036-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4859-11.2011</ELocationID><Abstract><AbstractText>Cognitive demise correlates with progressive brain tauopathy in dementing patients. Improved cognition of young Tau.P301L mice contrasts with dysfunction later in life and remains unexplained (Boekhoorn et al., 2006). To unravel early mechanisms, we composed a correlative time line of clinical symptoms, cognitive defects, and biochemical and pathological traits, including comprehensive analysis of dendritic spines in specified regions of the cortex and hippocampus of young and adult Tau.P301L mice. Remarkably, young Tau.P301L mice have not more, but more mature spines than wild-type mice, revealing the anatomical substrate for their improved cognition and LTP. Spine maturation remained high in the hippocampus of adult Tau.P301L mice. However, spines regressed in length paralleling impaired cognition and increased Tau phosphorylation (Terwel et al., 2005). Conversely, spine maturation was unaffected in adult Tau.4R mice, while spine density was increased and length reduced similar to Tau.P301L mice. To explain how protein Tau promoted spinogenesis, we analyzed hippocampal synaptosomes and dendritic spines for mouse and human Tau. While synaptosomes were positive for both mouse and human Tau, weak variable reaction in spines was observed only after fixation according to Bouin. Mouse Tau was absent from spines in wild-type mice, dissociating the pathological actions of Tau in transgenic mice by relocalization into dendrites and spines from the physiological actions of protein Tau in axons only. We conclude that mutant protein Tau modulates cognition and morphology of spines similarly and in both directions, with pathology later in life coinciding with increased phosphorylation and relocalization of Tau from axons to soma and processes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kremer</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Experimental Genetics and Transgenesis/Experimental Genetics Group, Department of Human Genetics, Katholieke Universiteit Leuven, Campus Gasthuisberg, B-3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurin</LastName><ForeName>Herv&#xe9;</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Demedts</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Devijver</LastName><ForeName>Herman</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Borghgraef</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Van Leuven</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008164">Luminescent Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054562">yellow fluorescent protein, Bacteria</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="Y">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008164" MajorTopicYN="N">Luminescent Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22159117</ArticleId><ArticleId IdType="pmc">PMC6634152</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4859-11.2011</ArticleId><ArticleId IdType="pii">31/49/18036</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Banker GA, Cowan WM. Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977;126:397&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">861729</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder LI, Frankfurter A, Rebhun LI. The distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371&#x2013;1378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2113928</ArticleId><ArticleId IdType="pubmed">3930508</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Fuhrmann M, Burgold S, Ochs SM, Hoffmann N, Mitteregger G, Kretzschmar H, LaFerla FM, Herms J. Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One. 2010;5:e15477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982845</ArticleId><ArticleId IdType="pubmed">21103384</ArticleId></ArticleIdList></Reference><Reference><Citation>Boekhoorn K, Terwel D, Biemans B, Borghgraef P, Wiegert O, Ramakers GJ, de Vos K, Krugers H, Tomiyama T, Mori H, Joels M, van Leuven F, Lucassen PJ. Improved long-term potentiation and memory in young Tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J Neurosci. 2006;26:3514&#x2013;3523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673867</ArticleId><ArticleId IdType="pubmed">16571759</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121:171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A. Tau pathology and neurodegeneration: an obvious but misunderstood link. J Alzheimers Dis. 2008;14:437&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">18688095</ArticleId></ArticleIdList></Reference><Reference><Citation>Delacourte A, Bu&#xe9;e L. Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol. 2000;13:371&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10970052</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein DL, Brautigam H, Stockton SD, Jr, Schmeidler J, Hof PR. Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct Funct. 2010;214:161&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032082</ArticleId><ArticleId IdType="pubmed">20213269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotti CG, Banker GA, Binder LI. The expression and distribution of the microtubule-associated proteins tau and microtubule-associated protein 2 in hippocampal neurons in the rat in situ and in cell culture. Neuroscience. 1987;23:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">3120034</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutschmann M, Menuet C, Stettner GM, Gestreau C, Borghgraef P, Devijver H, Gielis L, Hilaire G, Van Leuven F. Upper airway dysfunction of Tau.P301L mice correlates with tauopathy in midbrain and ponto-medullary brainstem nuclei. J Neurosci. 2010;30:1810&#x2013;1821.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633985</ArticleId><ArticleId IdType="pubmed">20130190</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally Baptist? Acta Neuropathol. 2011;121:145&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">21225273</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">19381658</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rtig W, Oklejewicz M, Strijkstra AM, Boerema AS, Stieler J, Arendt T. Phosphorylation of the tau protein sequence 199&#x2013;205 in the hippocampal CA3 region of Syrian hamsters in adulthood and during aging. Brain Res. 2005;1056:100&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">16095576</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;rtig W, Stieler J, Boerema AS, Wolf J, Schmidt U, Weissfuss J, Bullmann T, Strijkstra AM, Arendt T. Hibernation model of tau phosphorylation in hamsters: selective vulnerability of cholinergic basal forebrain neurons&#x2014;implications for Alzheimer's disease. Eur J Neurosci. 2007;25:69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">17241268</ArticleId></ArticleIdList></Reference><Reference><Citation>Hering H, Sheng M. Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci. 2001;2:880&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">11733795</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram EM, Spillantini MG. Tau gene mutations: dissecting the pathogenesis of FTDP-17. Trends Mol Med. 2002;8:555&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">12470988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, Grigoriev I, Camera P, Spangler SA, Di Stefano P, Demmers J, Krugers H, Defilippi P, Akhmanova A, Hoogenraad CC. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron. 2009a;61:85&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146815</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, Dewachter I, Lechat B, Croes S, Termont A, Demedts D, Borghgraef P, Devijver H, Filipkowski RK, Kaczmarek L, K&#xfc;gler S, Van Leuven F. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One. 2009b;4:e7280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748684</ArticleId><ArticleId IdType="pubmed">19794916</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, Lechat B, Demedts D, Gielis L, Devijver H, Borghgraef P, Duimel H, Verheyen FK, K&#xfc;gler S, Van Leuven F. Dendritic degeneration and neurovascular defects precede AAV-Tau-mediated neuronal loss. Am J Pathol. 2011;179:2001&#x2013;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3181369</ArticleId><ArticleId IdType="pubmed">21839061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenessey A, Yen SH. The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res. 1993;629:40&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">8287279</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;nzi V, Glatzel M, Nakano MY, Greber UF, Van Leuven F, Aguzzi A. Unhampered prion neuroinvasion despite impaired fast axonal transport in transgenic mice overexpressing four-repeat tau. J Neurosci. 2002;22:7471&#x2013;7477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757970</ArticleId><ArticleId IdType="pubmed">12196569</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci. 1998;111:3167&#x2013;3177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, Burn DJ, Caparros-Lefebvre D, Frey KA, de Yebenes JG, Gasser T, Heutink P, H&#xf6;glinger G, Jamrozik Z, Jellinger KA, Kazantsev A, Kretzschmar H, Lang AE, Litvan I, Lucas JJ, McGeer PL, et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol. 2009;16:297&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847416</ArticleId><ArticleId IdType="pubmed">19364361</ArticleId></ArticleIdList></Reference><Reference><Citation>Menuet C, Borghgraef P, Matarazzo V, Gielis L, Lajard AM, Voituron N, Gestreau C, Dutschmann M, Van Leuven F, Hilaire G. Raph&#xe9; tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease. Respir Physiol Neurobiol. 2011;178:290&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">21763469</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D, Dewachter I, Lorent K, Revers&#xe9; D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, Van Leuven F. Early phenotypic changes in transgenic mice that overexpress different mutants of Amyloid Precursor Protein in brain. J Biol Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasozomenos SC, Binder LI. Phosphorylation determines two distinct species of Tau in the central nervous system. Cell Motil Cytoskeleton. 1987;8:210&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2446784</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530413</ArticleId><ArticleId IdType="pubmed">21346746</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Ota&#xf1;o I, Luj&#xe1;n R, Tavalin SJ, Plomann M, Modregger J, Liu XB, Jones EG, Heinemann SF, Lo DC, Ehlers MD. Endocytosis and synaptic removal of NR3A-containing NMDA receptors by PACSIN1/syndapin1. Nat Neurosci. 2006;9:611&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892311</ArticleId><ArticleId IdType="pubmed">16617342</ArticleId></ArticleIdList></Reference><Reference><Citation>Planel E, Bretteville A, Liu L, Virag L, Du AL, Yu WH, Dickson DW, Whittington RA, Duff KE. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 2009;23:2595&#x2013;2604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717763</ArticleId><ArticleId IdType="pubmed">19279139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocher AB, Crimins JL, Amatrudo JM, Kinson MS, Todd-Brown MA, Lewis J, Luebke JI. Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp Neurol. 2010;223:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864360</ArticleId><ArticleId IdType="pubmed">19665462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sennvik K, Boekhoorn K, Lasrado R, Terwel D, Verhaeghe S, Korr H, Schmitz C, Tomiyama T, Mori H, Krugers H, Joels M, Ramakers GJ, Lucassen PJ, Van Leuven F. Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice. FASEB J. 2007;21:2149&#x2013;2161.</Citation><ArticleIdList><ArticleId IdType="pubmed">17341679</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel A, Loos R, Van Leuven F. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol. 1999;155:2153&#x2013;2165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1866931</ArticleId><ArticleId IdType="pubmed">10595944</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the CNS of human four-repeat tau transgenic mice. J Biol Chem. 2000;275:41340&#x2013;41349.</Citation><ArticleIdList><ArticleId IdType="pubmed">11007782</ArticleId></ArticleIdList></Reference><Reference><Citation>Tackenberg C, Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloid-&#x3b2;, wild-type tau, and R406W tau. J Neurosci. 2009;29:14439&#x2013;14450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665808</ArticleId><ArticleId IdType="pubmed">19923278</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma H, Arawaka S, Mori H. Isoforms changes of tau protein during development in various species. Brain Res Dev Brain Res. 2003;142:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">12711363</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Haesendonck C, Borghgraef P, Van Leuven F. Changed conformation of mutant tau-P301L underlies the moribund tauopathy, absent in progressive, non-lethal axonopathy of tau-4R/2N transgenic mice. J Biol Chem. 2005;280:3963&#x2013;3973.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509565</ArticleId></ArticleIdList></Reference><Reference><Citation>Terwel D, Muyllaert D, Dewachter I, Borghgraef P, Croes S, Devijver H, Van Leuven F. Amyloid activates GSK3&#x3b2; to aggravate neuronal tauopathy in bigenic mice. Am J Pathol. 2008;172:786&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2258274</ArticleId><ArticleId IdType="pubmed">18258852</ArticleId></ArticleIdList></Reference><Reference><Citation>Thies E, Mandelkow EM. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci. 2007;27:2896&#x2013;2907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672561</ArticleId><ArticleId IdType="pubmed">17360912</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of Tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989;37:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">2492045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zempel H, Thies E, Mandelkow E, Mandelkow EM. A&#x3b2; oligomers cause localized Ca2+ elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30:11938&#x2013;11950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633549</ArticleId><ArticleId IdType="pubmed">20826658</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22169537</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0445</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>24</Issue><PubDate><Year>2011</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Current biology : CB</Title><ISOAbbreviation>Curr Biol</ISOAbbreviation></Journal><ArticleTitle>Acquiring "the Knowledge" of London's layout drives structural brain changes.</ArticleTitle><Pagination><StartPage>2109</StartPage><EndPage>2114</EndPage><MedlinePgn>2109-14</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cub.2011.11.018</ELocationID><Abstract><AbstractText>The last decade has seen a burgeoning of reports associating brain structure with specific skills and traits (e.g., [1-8]). Although these cross-sectional studies are informative, cause and effect are impossible to establish without longitudinal investigation of the same individuals before and after an intervention. Several longitudinal studies have been conducted (e.g., [9-18]); some involved children or young adults, potentially conflating brain development with learning, most were restricted to the motor domain, and all concerned relatively short timescales (weeks or months). Here, by contrast, we utilized a unique opportunity to study average-IQ adults operating in the real world as they learned, over four years, the complex layout of London's streets while training to become licensed taxi drivers. In those who qualified, acquisition of an internal spatial representation of London was associated with a selective increase in gray matter (GM) volume in their posterior hippocampi and concomitant changes to their memory profile. No structural brain changes were observed in trainees who failed to qualify or control participants. We conclude that specific, enduring, structural brain changes in adult humans can be induced by biologically relevant behaviors engaging higher cognitive functions such as spatial memory, with significance for the "nature versus nurture" debate.</AbstractText><CopyrightInformation>Copyright &#xa9; 2011 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Woollett</LastName><ForeName>Katherine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Wellcome Trust Centre for Neuroimaging, Institute of Neurology, University College London, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maguire</LastName><ForeName>Eleanor A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>084218</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Biol</MedlineTA><NlmUniqueID>9107782</NlmUniqueID><ISSNLinking>0960-9822</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007858" MajorTopicYN="Y">Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22169537</ArticleId><ArticleId IdType="pmc">PMC3268356</ArticleId><ArticleId IdType="doi">10.1016/j.cub.2011.11.018</ArticleId><ArticleId IdType="pii">S0960-9822(11)01267-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gaser C., Schlaug G. Gray matter differences between musicians and nonmusicians. Ann. N Y Acad. Sci. 2003;999:514&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681175</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire E.A., Gadian D.G., Johnsrude I.S., Good C.D., Ashburner J., Frackowiak R.S.J., Frith C.D. Navigation-related structural change in the hippocampi of taxi drivers. Proc. Natl. Acad. Sci. USA. 2000;97:4398&#x2013;4403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC18253</ArticleId><ArticleId IdType="pubmed">10716738</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire E.A., Woollett K., Spiers H.J. London taxi drivers and bus drivers: a structural MRI and neuropsychological analysis. Hippocampus. 2006;16:1091&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">17024677</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollett K., Maguire E.A. Navigational expertise may compromise anterograde associative memory. Neuropsychologia. 2009;47:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670971</ArticleId><ArticleId IdType="pubmed">19171158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechelli A., Crinion J.T., Noppeney U., O'Doherty J., Ashburner J., Frackowiak R.S., Price C.J. Neurolinguistics: structural plasticity in the bilingual brain. Nature. 2004;431:757.</Citation><ArticleIdList><ArticleId IdType="pubmed">15483594</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;fner K., Binetti C., Hamilton D.A., Stephan T., Flanagin V.L., Linn J., Labudda K., Markowitsch H., Glasauer S., Jahn K. Structural and functional plasticity of the hippocampal formation in professional dancers and slackliners. Hippocampus. 2011;21:855&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">20572197</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin S.B., Covell D.J., Joseph J.E., Chebrolu H., Smith C.D., Kelly T.H., Jiang Y., Gold B.T. Human experience seeking correlates with hippocampus volume: convergent evidence from manual tracing and voxel-based morphometry. Neuropsychologia. 2007;45:2874&#x2013;2881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2971547</ArticleId><ArticleId IdType="pubmed">17603086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai R., Feilden T., Firth C., Rees G. Political orientations are correlated with brain structure in young adults. Curr. Biol. 2011;21:677&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3092984</ArticleId><ArticleId IdType="pubmed">21474316</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganski B., Gaser C., Busch V., Schuierer G., Bogdahn U., May A. Neuroplasticity: changes in grey matter induced by training. Nature. 2004;427:311&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">14737157</ArticleId></ArticleIdList></Reference><Reference><Citation>Draganski B., Gaser C., Kempermann G., Kuhn H.G., Winkler J., B&#xfc;chel C., May A. Temporal and spatial dynamics of brain structure changes during extensive learning. J.&#xa0;Neurosci. 2006;26:6314&#x2013;6317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675198</ArticleId><ArticleId IdType="pubmed">16763039</ArticleId></ArticleIdList></Reference><Reference><Citation>May A., Hajak G., G&#xe4;nssbauer S., Steffens T., Langguth B., Kleinjung T., Eichhammer P. Structural brain alterations following 5&#xa0;days of intervention: dynamic aspects of neuroplasticity. Cereb. Cortex. 2007;17:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481564</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilg R., Wohlschl&#xe4;ger A.M., Gaser C., Liebau Y., Dauner R., W&#xf6;ller A., Zimmer C., Zihl J., M&#xfc;hlau M. Gray matter increase induced by practice correlates with task-specific activation: a combined functional and morphometric magnetic resonance imaging study. J.&#xa0;Neurosci. 2008;28:4210&#x2013;4215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670304</ArticleId><ArticleId IdType="pubmed">18417700</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyke J., Driemeyer J., Gaser C., B&#xfc;chel C., May A. Training-induced brain structure changes in the elderly. J.&#xa0;Neurosci. 2008;28:7031&#x2013;7035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670504</ArticleId><ArticleId IdType="pubmed">18614670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli A., Rocca M.A., Pagani E., Falini A., Comi G., Filippi M. Cognitive learning is associated with gray matter changes in healthy human individuals: a tensor-based morphometry study. Neuroimage. 2009;48:585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">19615452</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyde K.L., Lerch J., Norton A., Forgeard M., Winner E., Evans A.C., Schlaug G. Musical training shapes structural brain development. J.&#xa0;Neurosci. 2009;29:3019&#x2013;3025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996392</ArticleId><ArticleId IdType="pubmed">19279238</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz J., Klein M.C., Behrens T.E., Johansen-Berg H. Training induces changes in white-matter architecture. Nat. Neurosci. 2009;12:1370&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770457</ArticleId><ArticleId IdType="pubmed">19820707</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzola L., M&#xe9;rillat S., Gaser C., J&#xe4;ncke L. Training-induced neural plasticity in golf novices. J.&#xa0;Neurosci. 2011;31:12444&#x2013;12448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6703254</ArticleId><ArticleId IdType="pubmed">21880905</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson K.I., Voss M.W., Prakash R.S., Basak C., Szabo A., Chaddock L., Kim J.S., Heo S., Alves H., White S.M. Exercise training increases size of hippocampus and improves memory. Proc. Natl. Acad. Sci. USA. 2011;108:3017&#x2013;3022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguire E.A., Spiers H.J., Good C.D., Hartley T., Frackowiak R.S.J., Burgess N. Navigation expertise and the human hippocampus: a structural brain imaging analysis. Hippocampus. 2003;13:250&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699332</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollett K., Maguire E.A. The effect of navigational expertise on wayfinding in new environments. J.&#xa0;Environ. Psychol. 2010;30:565&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989443</ArticleId><ArticleId IdType="pubmed">21151353</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollett K., Spiers H.J., Maguire E.A. Talent in the taxi: a model system for exploring expertise. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2009;364:1407&#x2013;1416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677577</ArticleId><ArticleId IdType="pubmed">19528024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J., Friston K.J. Voxel-based morphometry&#x2014;the methods. Neuroimage. 2000;11:805&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">10860804</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner J., Friston K.J. Unified segmentation. Neuroimage. 2005;26:839&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipps C.M., Duggins A.J., Mahant N., Gomes L., Ashburner J., McCusker E.A. Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study. J.&#xa0;Neurol. Neurosurg. Psychiatry. 2005;76:650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739615</ArticleId><ArticleId IdType="pubmed">15834021</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J., Dostrovsky J. The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res. 1971;34:171&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">5124915</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Keefe J., Nadel L. Oxford University Press; Oxford: 1978. The Hippocampus as a Cognitive Map.</Citation></Reference><Reference><Citation>Burgess N., Maguire E.A., O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron. 2002;35:625&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">12194864</ArticleId></ArticleIdList></Reference><Reference><Citation>Moser M.B., Moser E.I. Functional differentiation in the hippocampus. Hippocampus. 1998;8:608&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">9882018</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanselow M.S., Dong H.W. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron. 2010;65:7&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822727</ArticleId><ArticleId IdType="pubmed">20152109</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D.W., Miyasato L.E., Clayton N.S. Neurobiological bases of spatial learning in the natural environment: neurogenesis and growth in the avian and mammalian hippocampus. Neuroreport. 1998;9:R15&#x2013;R27.</Citation><ArticleIdList><ArticleId IdType="pubmed">9631408</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry D.F., Hoshooley J.S. Seasonal hippocampal plasticity in food-storing birds. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2010;365:933&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830249</ArticleId><ArticleId IdType="pubmed">20156817</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors T.J. Saving new brain cells. Sci. Am. 2009;300:46&#x2013;52. 54.</Citation><ArticleIdList><ArticleId IdType="pubmed">19253773</ArticleId></ArticleIdList></Reference><Reference><Citation>Curlik D.M., 2nd, Shors T.J. Learning increases the survival of newborn neurons provided that learning is difficult to achieve and successful. J.&#xa0;Cogn. Neurosci. 2011;23:2159&#x2013;2170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3289535</ArticleId><ArticleId IdType="pubmed">20954935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayer A.G., Ford A.A., Cleaver K.M., Yassaee M., Cameron H.A. Short-term and long-term survival of new neurons in the rat dentate gyrus. J.&#xa0;Comp. Neurol. 2003;460:563&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717714</ArticleId></ArticleIdList></Reference><Reference><Citation>Doetsch F., Hen R. Young and excitable: the function of new neurons in the adult mammalian brain. Curr. Opin. Neurobiol. 2005;15:121&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">15721754</ArticleId></ArticleIdList></Reference><Reference><Citation>Shors T.J. From stem cells to grandmother cells: how neurogenesis relates to learning and memory. Cell Stem Cell. 2008;3:253&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786413</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb B., Gorny G., S&#xf6;derpalm A.H., Robinson T.E. Environmental complexity has different effects on the structure of neurons in the prefrontal cortex versus the parietal cortex or nucleus accumbens. Synapse. 2003;48:149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">12645040</ArticleId></ArticleIdList></Reference><Reference><Citation>Toni N., Teng E.M., Bushong E.A., Aimone J.B., Zhao C., Consiglio A., van Praag H., Martone M.E., Ellisman M.H., Gage F.H. Synapse formation on neurons born in the adult hippocampus. Nat. Neurosci. 2007;10:727&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">17486101</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwen B.S. Stress and hippocampal plasticity. Annu. Rev. Neurosci. 1999;22:105&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">10202533</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakic P. Neurogenesis in adult primate neocortex: an evaluation of the evidence. Nat. Rev. Neurosci. 2002;3:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823806</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson J.C., Douglas R.J., Martin K.A., Nelson J.C. Map of the synapses formed with the dendrites of spiny stellate neurons of cat visual cortex. J.&#xa0;Comp. Neurol. 1994;341:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8006221</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganas L.N., Zhang X., Li Y., Hazel R.D., Smith S.D., Wagshul M.E., Henn F., Benveniste H., Djuric P.M., Enikolopov G., Maletic-Savatic M. Magnetic resonance spectroscopy identifies neural progenitor cells in the live human brain. Science. 2007;318:980&#x2013;985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039561</ArticleId><ArticleId IdType="pubmed">17991865</ArticleId></ArticleIdList></Reference><Reference><Citation>Szeszko P.R., Lipsky R., Mentschel C., Robinson D., Gunduz-Bruce H., Sevy S., Ashtari M., Napolitano B., Bilder R.M., Kane J.M. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol. Psychiatry. 2005;10:631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">15768049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bueller J.A., Aftab M., Sen S., Gomez-Hassan D., Burmeister M., Zubieta J.K. BDNF Val66Met&#xa0;allele is associated with reduced hippocampal volume in healthy subjects. Biol. Psychiatry. 2006;59:812&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">16442082</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">12553913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariri A.R., Goldberg T.E., Mattay V.S., Kolachana B.S., Callicott J.H., Egan M.F., Weinberger D.R. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J.&#xa0;Neurosci. 2003;23:6690&#x2013;6694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740735</ArticleId><ArticleId IdType="pubmed">12890761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22131428</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>48</Issue><PubDate><Year>2011</Year><Month>Nov</Month><Day>30</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Hippocampal hyperactivation associated with cortical thinning in Alzheimer's disease signature regions in non-demented elderly adults.</ArticleTitle><Pagination><StartPage>17680</StartPage><EndPage>17688</EndPage><MedlinePgn>17680-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4740-11.2011</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is associated with functional and structural alterations in a distributed network of brain regions supporting memory and other cognitive domains. Functional abnormalities are present in mild cognitive impairment (MCI) with evidence of early hyperactivity in medial temporal lobe regions, followed by failure of hippocampal activation as dementia develops. Atrophy in a consistent set of cortical regions, the "cortical signature of AD," has been reported at the stage of dementia, MCI, and even in clinically normal (CN) older individuals predicted to develop AD. Despite multiple lines of evidence for each of these findings, the relationship between this structural marker of AD-related neurodegeneration and this functional marker of the integrity of the episodic memory system has not yet been elucidated. We investigated this relationship in 34 nondemented older humans (CN, N = 18; MCI, N = 16). Consistent with previous studies, we found evidence of hippocampal hyperactivation in MCI compared with CN. Additionally, within this MCI group, increased hippocampal activation correlated with cortical thinning in AD-signature regions. Even within the CN group, increased hippocampal activity was negatively correlated with cortical thinning in a subset of regions, including the superior parietal lobule (r = -0.66; p &lt; 0.01). These findings, across a continuum of nondemented and mildly impaired older adults, support the hypothesis that paradoxically increased hippocampal activity may be an early indicator of AD-related neurodegeneration in a distributed network.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Putcha</LastName><ForeName>Deepti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brickhouse</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Gad</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG-027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG027171</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG033634</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of Interest: Dr. Sperling has consulted for Avid (unpaid), Bayer, Bristol-Myers-Squibb, Eisai, Elan, Janssen, and Pfizer, but not in a manner directly relevant to this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22131428</ArticleId><ArticleId IdType="mid">NIHMS357802</ArticleId><ArticleId IdType="pmc">PMC3289551</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4740-11.2011</ArticleId><ArticleId IdType="pii">31/48/17680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology. 2009;72:1048&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677470</ArticleId><ArticleId IdType="pubmed">19109536</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassett SS, Yousem DM, Cristinzio C, Kusevic I, Yassa MA, Caffo BS, Zeger SL. Familial risk for Alzheimer's disease alters fMRI activation patterns. Brain. 2006;129:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744898</ArticleId><ArticleId IdType="pubmed">16627465</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Convit A, De Santi S, Wegiel J, Tarshish CY, Saint Louis LA, Wisniewski HM. MRI of entorhinal cortex in mild Alzheimer's disease. Lancet. 1999;353:38&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10023955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Houston WS, Eyler LT, Brown GG. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology. 2005;64:501&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761695</ArticleId><ArticleId IdType="pubmed">15699382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bookheimer SY, Strojwas MH, Cohen MS, Saunders AM, Pericak-Vance MA, Mazziotta JC, Small GW. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med. 2000;343:450&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831477</ArticleId><ArticleId IdType="pubmed">10944562</ArticleId></ArticleIdList></Reference><Reference><Citation>Brewer JB, Zhao Z, Desmond JE, Glover GH, Gabrieli JD. Making memories: brain activity that predicts how well visual experience will be remembered. Science. 1998;281:1185&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">9712581</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689.</Citation><ArticleIdList><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Celone KA, Calhoun VD, Dickerson BC, Atri A, Chua EF, Miller SL, DePeau K, Rentz DM, Selkoe DJ, Blacker D, Albert MS, Sperling RA. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci. 2006;26:10222&#x2013;10231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674636</ArticleId><ArticleId IdType="pubmed">17021177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Pike KE, Baron JC, Bourgeat P, Jones G, Faux NG, Ellis KA, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain. 2010;133:3349&#x2013;3358.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739349</ArticleId></ArticleIdList></Reference><Reference><Citation>Csernansky JG, Hamstra J, Wang L, McKeel D, Price JL, Gado M, Morris JC. Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects. Alzheimer Dis Assoc Disord. 2004;18:190&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pubmed">15592129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM. Optimal experimental design for event-related fMRI. Hum Brain Mapp. 1999;8:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6873302</ArticleId><ArticleId IdType="pubmed">10524601</ArticleId></ArticleIdList></Reference><Reference><Citation>de Chastelaine M, Wang TH, Minton B, Muftuler LT, Rugg MD. The effects of age, memory performance, and callosal integrity on the neural correlates of successful associative encoding. Cereb Cortex. 2011;21:2166&#x2013;2176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3155606</ArticleId><ArticleId IdType="pubmed">21282317</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Sabuncu MR, Schmansky NJ, Reuter M, Cabral HJ, Hess CP, Weiner MW, Biffi A, Anderson CD, Rosand J, Salat DH, Kemper TL, Dale AM, Sperling RA, Fischl B. Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One. 2010;5:e12853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944799</ArticleId><ArticleId IdType="pubmed">20886094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, Beckett LA, deToledo-Morrell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22:747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">11705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat D, Bates JF, Atiya M, Killiany R, Greve D, Dale AM, Stern CE, Blacker D, Albert M, Sperling R. MRI measures of medial temporal lobe function and structure in questionable Alzheimer's disease. Ann Neurol. 2004;56:27&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19:497&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, Hyman BT, Blacker D, Detoledo-Morrell L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087406</ArticleId><ArticleId IdType="pubmed">21490323</ArticleId></ArticleIdList></Reference><Reference><Citation>Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635&#x2013;1646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102239</ArticleId><ArticleId IdType="pubmed">21490054</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, Miller BL, Weiner MW. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain. 2007;130:1159&#x2013;1166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853284</ArticleId><ArticleId IdType="pubmed">17353226</ArticleId></ArticleIdList></Reference><Reference><Citation>Duverne S, Motamedinia S, Rugg MD. The relationship between aging, performance, and the neural correlates of successful memory encoding. Cereb Cortex. 2009;19:733&#x2013;744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2637304</ArticleId><ArticleId IdType="pubmed">18653664</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci U S A. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Liu A, Dale AM. Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001;20:70&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293693</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM. Brain atrophy in healthy aging is related to CSF levels of Abeta1&#x2013;42. Cereb Cortex. 2010;20:2069&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025722</ArticleId><ArticleId IdType="pubmed">20051356</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state functional connectivity reflects structural connectivity in the default mode network. Cereb Cortex. 2009;19:72&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605172</ArticleId><ArticleId IdType="pubmed">18403396</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;l&#xe4;inen A, Pihlajam&#xe4;ki M, Tanila H, H&#xe4;nninen T, Niskanen E, Tervo S, Karjalainen PA, Vanninen RL, Soininen H. Increased fMRI responses during encoding in mild cognitive impairment. Neurobiol Aging. 2007;28:1889&#x2013;1903.</Citation><ArticleIdList><ArticleId IdType="pubmed">16997428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Brewer JB, Hagler DJ, Fenema-Notestine C, Dale AM. Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:20954&#x2013;20959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791580</ArticleId><ArticleId IdType="pubmed">19996185</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson SC, Schmitz TW, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, Hansen KW, Gleason CE, Carlsson CM, Ries ML, Asthana S, Chen K, Reiman EM, Alexander GE. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging. 2006;27:1604&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627778</ArticleId><ArticleId IdType="pubmed">16226349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn I, Andrews-Hanna JR, Vincent JL, Snyder AZ, Buckner RL. Distinct cortical anatomy linked to subregions of the medial temporal lobe revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2493488</ArticleId><ArticleId IdType="pubmed">18385483</ArticleId></ArticleIdList></Reference><Reference><Citation>Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, Tanzi R, Jones K, Albert MS. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology. 2002;58:1188&#x2013;1196.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircher TT, Weis S, Freymann K, Erb M, Jessen F, Grodd W, Heun R, Leube DT. Hippocampal activation in patients with mild cognitive impairment is necessary for successful memory encoding. J Neurol Neurosurg Psychiatry. 2007;78:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117738</ArticleId><ArticleId IdType="pubmed">17287238</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstr&#xf6;m M, Savitcheva I, Huang GF, Estrada S, Aus&#xe9;n B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi Y, Amaral DG. Macaque monkey retrosplenial cortex: II. Cortical afferents. J Comp Neurol. 2003;466:48&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">14515240</ArticleId></ArticleIdList></Reference><Reference><Citation>Logothetis NK, Wandell BA. Interpreting the BOLD signal. Annu Rev Physiol. 2004;66:735&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">14977420</ArticleId></ArticleIdList></Reference><Reference><Citation>Machulda MM, Ward HA, Borowski B, Gunter JL, Cha RH, O'Brien PC, Petersen RC, Boeve BF, Knopman D, Tang-Wai DF, Ivnik RJ, Smith GE, Tangalos EG, Jack CR., Jr Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology. 2003;61:500&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2744465</ArticleId><ArticleId IdType="pubmed">12939424</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry. 2008a;79:630&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Celone K, DePeau K, Diamond E, Dickerson BC, Rentz D, Pihlajam&#xe4;ki M, Sperling RA. Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation. Proc Natl Acad Sci U S A. 2008b;105:2181&#x2013;2186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538895</ArticleId><ArticleId IdType="pubmed">18238903</ArticleId></ArticleIdList></Reference><Reference><Citation>Morcom AM, Good CD, Frackowiak RS, Rugg MD. Age effects on the neural correlates of successful memory encoding. Brain. 2003;126:213&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">12477708</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, Janabi M, Baker SL, Yen IV, Madison CM, Miller BL, Jagust WJ. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex. 2011;21:2399&#x2013;2407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169663</ArticleId><ArticleId IdType="pubmed">21383234</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PJ, Scheltens P, Hodges JR. Advances in the early detection of Alzheimer's disease. Nat Med. 2004;10(Suppl):S34&#x2013;S41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15298007</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, Sperling RA. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969&#x2013;1976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: two faces of the same coin? Neuromolecular Med. 2010;12:48&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319077</ArticleId><ArticleId IdType="pubmed">19838821</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrella JR, Krishnan S, Slavin MJ, Tran TT, Murty L, Doraiswamy PM. Mild cognitive impairment: evaluation with 4-T functional MR imaging. Radiology. 2006;240:177&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">16684919</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz YT, Budson AE, Celone K, Ruiz A, Newmark R, Castrill&#xf3;n G, Lopera F, Stern CE. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol. 2010;68:865&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175143</ArticleId><ArticleId IdType="pubmed">21194156</ArticleId></ArticleIdList></Reference><Reference><Citation>Ries ML, Carlsson CM, Rowley HA, Sager MA, Gleason CE, Asthana S, Johnson SC. Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review. J Am Geriatr Soc. 2008;56:920&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668820</ArticleId><ArticleId IdType="pubmed">18410325</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S, Miniussi C, Pasqualetti P, Babiloni C, Rossini PM, Cappa SF. Age-related functional changes of prefrontal cortex in long-term memory: a repetitive transcranial magnetic stimulation study. J Neurosci. 2004;24:7939&#x2013;7944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729939</ArticleId><ArticleId IdType="pubmed">15356207</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248949</ArticleId><ArticleId IdType="pubmed">21825241</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 2006;129:2885&#x2013;2893.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008332</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Chua E, Cocchiarella A, Rand-Giovannetti E, Poldrack R, Schacter DL, Albert M. Putting names to faces: successful encoding of associative memories activates the anterior hippocampal formation. Neuroimage. 2003;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230827</ArticleId><ArticleId IdType="pubmed">14568509</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, Johnson KA. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med. 2010;12:27&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036844</ArticleId><ArticleId IdType="pubmed">20069392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging and the Alzheimer's association workgroup. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannini P, Hedden T, Becker JA, Sullivan C, Putcha D, Rentz D, Johnson KA, Sperling RA. Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging. 2011 doi: 10.1016/j.neurobiolaging.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.01.003</ArticleId><ArticleId IdType="pmc">PMC3111876</ArticleId><ArticleId IdType="pubmed">21334099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Snyder AZ, Fox MD, Shannon BJ, Andrews JR, Raichle ME, Buckner RL. Coherent spontaneous activity identifies a hippocampal-parietal memory network. J Neurophysiol. 2006;96:3517&#x2013;3531.</Citation><ArticleIdList><ArticleId IdType="pubmed">16899645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yassa MA, Stark SM, Bakker A, Albert MS, Gallagher M, Stark CE. High-resolution structural and functional MRI of hippocampal CA3 and dentate gyrus in patients with amnestic mild cognitive impairment. Neuroimage. 2010;51:1242&#x2013;1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909476</ArticleId><ArticleId IdType="pubmed">20338246</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22159054</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>12</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>A comprehensive genetic association study of Alzheimer disease in African Americans.</ArticleTitle><Pagination><StartPage>1569</StartPage><EndPage>1579</EndPage><MedlinePgn>1569-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.646</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the association of genetic variation with late-onset Alzheimer disease (AD) in African Americans, including genes implicated in recent genome-wide association studies of whites.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We analyzed a genome-wide set of 2.5 million imputed markers to evaluate the genetic basis of AD in an African American population.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Five hundred thirteen well-characterized African American AD cases and 496 cognitively normal African American control subjects.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Data were collected from multiple sites as part of the Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study and the Henry Ford Health System as part of the Genetic and Environmental Risk Factors for Alzheimer Disease Among African Americans (GenerAAtions) Study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Several significant single-nucleotide polymorphisms (SNPs) were observed in the region of the apolipoprotein E gene (APOE). After adjusting for the confounding effects of APOE genotype, one of these SNPs, rs6859 in PVRL2, remained significantly associated with AD (P = .0087). Association was also observed with SNPs in CLU, PICALM, BIN1, EPHA1, MS4A, ABCA7, and CD33, although the effect direction for some SNPs and the most significant SNPs differed from findings in data sets consisting of whites. Finally, using the African American genome-wide association study data set as a discovery sample, we obtained suggestive evidence of association with SNPs for several novel candidate genes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Some genes contribute to AD pathogenesis in both white and African American cohorts, although it is unclear whether the causal variants are the same. A larger African American sample will be needed to confirm novel gene associations, which may be population specific.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Logue</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schu</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Buros</LastName><ForeName>Jacki</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Go</LastName><ForeName>Rodney C P</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Griffith</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Author><Author ValidYN="Y"><LastName>Shatz</LastName><ForeName>Rhonna</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Borenstein</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cupples</LastName><ForeName>L Adrienne</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Kathryn L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Fallin</LastName><ForeName>M Daniele</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Farrer</LastName><ForeName>Lindsay A</ForeName><Initials>LA</Initials></Author><Author ValidYN="Y"><CollectiveName>Multi-Institutional Research on Alzheimer Genetic Epidemiology (MIRAGE) Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24-AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG09029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG009029</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG008122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG10129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG005092</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG13846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HG005092</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG033193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG027841</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG002213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 MH076100</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01AG020688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-HG02213</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053329">Apolipoprotein E2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">Black or African American</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053329" MajorTopicYN="N">Apolipoprotein E2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="Y">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Farrer</LastName></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName></Investigator><Investigator ValidYN="Y"><LastName>Cupples</LastName></Investigator><Investigator ValidYN="Y"><LastName>Lunetta</LastName></Investigator><Investigator ValidYN="Y"><LastName>Logue</LastName></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName></Investigator><Investigator ValidYN="Y"><LastName>Akomolafe</LastName><ForeName>Abimbola</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashley</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>Lorin</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ofili</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chui</LastName><ForeName>Helena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedland</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Go</LastName></Investigator><Investigator ValidYN="Y"><LastName>Harrell</LastName><ForeName>Lindy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurz</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName></Investigator><Investigator ValidYN="Y"><LastName>Petrovitch</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>Lon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadovnick</LastName><ForeName>Dessa</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsolaki</LastName><ForeName>Magda</ForeName><Initials>M</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>5</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22159054</ArticleId><ArticleId IdType="mid">NIHMS375246</ArticleId><ArticleId IdType="pmc">PMC3356921</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.646</ArticleId><ArticleId IdType="pii">68/12/1569</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bienvenu OJ, Davydow DS, Kendler KS. Psychiatric &#x201c;diseases&#x201d; versus behavioral disorders and degree of genetic influence. Psychol Med. 2011;41(1):33&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10885735</ArticleId><ArticleId IdType="pubmed">20459884</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Myers RH, Connor L, Cupples LA, Growdon JH. Segregation analysis reveals evidence of a major gene for Alzheimer disease. Am J Hum Genet. 1991;48(6):1026&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1683119</ArticleId><ArticleId IdType="pubmed">2035523</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer&#x2019;s disease. Neurology. 1993;43(8):1467&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. APOE Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertekin-Taner N. Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther. 2010;2(1):3. doi: 10.1186/alzrt26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt26</ArticleId><ArticleId IdType="pmc">PMC2874262</ArticleId><ArticleId IdType="pubmed">20236449</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow RH, Khan SM. The Alzheimer&#x2019;s disease mitochondrial cascade hypothesis: an update. Exp Neurol. 2009;218(2):308&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710413</ArticleId><ArticleId IdType="pubmed">19416677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz MW, Crenshaw DG, Saunders AM, Roses AD. Genetic variation at a single locus and age of onset for Alzheimer&#x2019;s disease. Alzheimers Dement. 2010;6(2):125&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874876</ArticleId><ArticleId IdType="pubmed">20298972</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829359</ArticleId><ArticleId IdType="pubmed">19554612</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Seltman H, Peskind ER, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer&#x2019;s disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89(6):655&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978251</ArticleId><ArticleId IdType="pubmed">17434289</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei N, Miyashita A, Tsukie T, et al. Japanese Genetic Study Consortium for Alzheimer Disease. Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics. 2009;93(5):441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pubmed">19442637</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Neal M, Schwankhaus J. A closely linked gene to apolipoprotein E may serve as an additional risk factor for Alzheimer&#x2019;s disease. Neurosci Lett. 1995;201(1):81&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">8830319</ArticleId></ArticleIdList></Reference><Reference><Citation>Poduslo SE, Neal M, Herring K, Shelly J. The apolipoprotein CI A allele as a risk factor for Alzheimer&#x2019;s disease. Neurochem Res. 1998;23(3):361&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">9482248</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, Berglund L, Ramakrishnan R, et al. A common Hpa I RFLP of apolipoprotein C-I increases gene transcription and exhibits an ethnically distinct pattern of linkage disequilibrium with the alleles of apolipoprotein E. J Lipid Res. 1999;40(1):50&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">9869649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartr&#xe9;s-Faz D, Junqu&#xe9; C, Clemente IC, et al. MRI and genetic correlates of cognitive function in elders with memory impairment. Neurobiol Aging. 2001;22 (3):449&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">11378252</ArticleId></ArticleIdList></Reference><Reference><Citation>Abildayeva K, Berb&#xe9;e JF, Blokland A, et al. Human apolipoprotein C-I expression in mice impairs learning and memory functions. J Lipid Res. 2008;49(4):856&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">18160739</ArticleId></ArticleIdList></Reference><Reference><Citation>Ki CS, Na DL, Kim DK, Kim HJ, Kim JW. Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer&#x2019;s disease. Neurosci Lett. 2002;319(2):75&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11825674</ArticleId></ArticleIdList></Reference><Reference><Citation>Scacchi R, Gambina G, Ruggeri M, et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer&#x2019;s disease. Neurosci Lett. 1999;259(1):33&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">10027549</ArticleId></ArticleIdList></Reference><Reference><Citation>Drigalenko E, Poduslo S, Elston R. Interaction of the apolipoprotein E and CI loci in predisposing to late-onset Alzheimer&#x2019;s disease. Neurology. 1998;51(1):131&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674791</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, et al. European Alzheimer&#x2019;s Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, Fitzpatrick AL, Ikram MA, et al. CHARGE Consortium; GERAD1 Consortium; EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303(18):1832&#x2013;1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2989531</ArticleId><ArticleId IdType="pubmed">20460622</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer&#x2019;s disease. Nat Genet. 2009;41(10):1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):436&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43(5):429&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, et al. Alzheimer&#x2019;s Disease Genetics Consortium. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. The APOE-&#x3b5;4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279 (10):751&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford NR, Green RC, Go RC, et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch Neurol. 2002;59(4):594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">11939894</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Saykin AJ, Shen L, Foroud TM, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimer&#x2019;s Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimers Dement. 2010;6(3):265&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2868595</ArticleId><ArticleId IdType="pubmed">20451875</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wetten S, Li L, et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol. 2008;65 (1):45&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">17998437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Graff-Radford N, Foroud T, Mayeux R National Institute on Aging Late-Onset Alzheimer&#x2019;s Disease Family Study Group. Analyses of the National Institute on Aging Late-Onset Alzheimer&#x2019;s Disease Family Study: implication of additional loci. Arch Neurol. 2008;65(11):1518&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694670</ArticleId><ArticleId IdType="pubmed">19001172</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawber TR, Kannel WB. The Framingham Study: an epidemiological approach to coronary heart disease. Circulation. 1966;34(4):553&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">5921755</ArticleId></ArticleIdList></Reference><Reference><Citation>Splansky GL, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute&#x2019;s Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165(11):1328&#x2013;1335.</Citation><ArticleIdList><ArticleId IdType="pubmed">17372189</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb JL, Wolf PA, Au R, White R, D&#x2019;Agostino RB. The effect of education on the incidence of dementia and Alzheimer&#x2019;s disease in the Framingham Study. Neurology. 1995;45(9):1707&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pubmed">7675231</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ding J, Abecasis GR. MaCH 1.0: rapid haplotype reconstruction and missing genotype inference [abstract 2290] Am J Hum Genet. 2006;79(suppl):416.</Citation></Reference><Reference><Citation>Liang KY, Zeger SL. Longitudinal data analysis using linear models. Biometrika. 1986;73(1):13&#x2013;22. doi: 10.1093/biomet/73.1.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biomet/73.1.13</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42(1):121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">3719049</ArticleId></ArticleIdList></Reference><Reference><Citation>Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26(17):2190&#x2013;2191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922887</ArticleId><ArticleId IdType="pubmed">20616382</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association. 2010 Alzheimer&#x2019;s disease facts and figures. Alzheimers Dement. 2010;6(2):158&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">20298981</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilworth-Anderson P, Hendrie HC, Manly JJ, Khachaturian AS, Fazio S Social, Behavioral and Diversity Research Workgroup of the Alzheimer&#x2019;s Association. Diagnosis and assessment of Alzheimer&#x2019;s disease in diverse populations. Alzheimers Dement. 2008;4(4):305&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631983</ArticleId></ArticleIdList></Reference><Reference><Citation>Connell CM, Scott Roberts J, McLaughlin SJ, Akinleye D. Racial differences in knowledge and beliefs about Alzheimer disease. Alzheimer Dis Assoc Disord. 2009;23(2):110&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8141173</ArticleId><ArticleId IdType="pubmed">19474569</ArticleId></ArticleIdList></Reference><Reference><Citation>Danner DD, Smith CD, Jessa P, Hudson J. African Americans with memory loss: findings from a community clinic in Lexington, Kentucky. Nurs Clin North Am. 2008;43(3):437&#x2013;447. ix&#x2013;x.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2565494</ArticleId><ArticleId IdType="pubmed">18674674</ArticleId></ArticleIdList></Reference><Reference><Citation>Roks G, Cruts M, Bullido MJ, et al. The &#x2013;491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer&#x2019;s disease. Neurosci Lett. 1998;258(2):65&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">9875528</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T, Paris D, Fallin D, et al. The &#x2013;491A/T apolipoprotein E promoter polymorphism association with Alzheimer&#x2019;s disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998;252 (2):95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">9756330</ArticleId></ArticleIdList></Reference><Reference><Citation>Artiga MJ, Bullido MJ, Sastre I, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 1998;421(2):105&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">9468288</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, Meng Y, Lee JH, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39(2):168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeeva A, Treuter E, Tomarev S, Pelto-Huikko M. A prospero-related homeo-box gene Prox-1 is expressed during postnatal brain development as well as in the adult rodent brain. Neuroscience. 2007;146(2):604&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368742</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavado A, Oliver G. Prox1 expression patterns in the developing and adult murine brain. Dev Dyn. 2007;236(2):518&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">17117441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavado A, Lagutin OV, Chow LM, Baker SJ, Oliver G. Prox1 is required for granule cell maturation and intermediate progenitor maintenance during brain neurogenesis. PLoS Biol. 2010;8(8):e1000460. doi: 10.1371/journal.pbio.1000460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000460</ArticleId><ArticleId IdType="pmc">PMC2923090</ArticleId><ArticleId IdType="pubmed">20808958</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n M, Abrahams BS, Stone JL, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008;82(1):150&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253955</ArticleId><ArticleId IdType="pubmed">18179893</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Cutler DJ, Brune CW, et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet. 2008;82(1):160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253968</ArticleId><ArticleId IdType="pubmed">18179894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkaloglu B, O&#x2019;Roak BJ, Louvi A, et al. Molecular cytogenetic analysis and re-sequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet. 2008;82(1):165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2253974</ArticleId><ArticleId IdType="pubmed">18179895</ArticleId></ArticleIdList></Reference><Reference><Citation>Vernes SC, Newbury DF, Abrahams BS, et al. A functional genetic link between distinct developmental language disorders. N Engl J Med. 2008;359(22):2337&#x2013;2345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756409</ArticleId><ArticleId IdType="pubmed">18987363</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi A, Anderson CD, Desikan RS, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol. 2010;67(6):677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2956757</ArticleId><ArticleId IdType="pubmed">20558387</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou TH, Ling K, Guo J, et al. Identification of a human brain-specific isoform of mammalian STE20-like kinase 3 that is regulated by cAMP-dependent protein kinase. J Biol Chem. 2000;275(4):2513&#x2013;2519.</Citation><ArticleIdList><ArticleId IdType="pubmed">10644707</ArticleId></ArticleIdList></Reference><Reference><Citation>Schinkmann K, Blenis J. Cloning and characterization of a human STE20-like protein kinase with unusual cofactor requirements. J Biol Chem. 1997;272(45):28695&#x2013;28703.</Citation><ArticleIdList><ArticleId IdType="pubmed">9353338</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin N, Li YM, O&#x2019;Toole JE, Benowitz LI. Mst3b, a purine-sensitive Ste20-like protein kinase, regulates axon outgrowth. Proc Natl Acad Sci U S A. 2006;103 (48):18320&#x2013;18325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1838749</ArticleId><ArticleId IdType="pubmed">17114295</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorber B, Howe ML, Benowitz LI, Irwin N. Mst3b, an Ste20-like kinase, regulates axon regeneration in mature CNS and PNS pathways. Nat Neurosci. 2009;12(11):1407&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2770175</ArticleId><ArticleId IdType="pubmed">19855390</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21992552</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1471-4159</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of neurochemistry</Title><ISOAbbreviation>J Neurochem</ISOAbbreviation></Journal><ArticleTitle>A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S&#x200a;)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>1330</StartPage><EndPage>1340</EndPage><MedlinePgn>1330-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1471-4159.2011.07532.x</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a neurodegenerative disorder leading to a progressive loss of cognitive function and is pathologically characterized by senile plaques and neurofibrillary tangles. Glycogen synthase kinase-3 (GSK-3) is involved in AD pathogenesis. GSK-3 is reported not only to phosphorylate tau, a major component of neurofibrillary tangles, but also to regulate the production of amyloid &#x3b2;, which is deposited in senile plaques. Therefore, pharmacological inhibition of GSK-3 is considered an attractive therapeutic approach. In this study, we report the pharmacological effects of a novel GSK-3 inhibitor, 2-methyl-5-(3-{4-[(S)-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole (MMBO), which displays high selectivity for GSK-3 and brain penetration following oral administration. MMBO inhibited tau phosphorylation in primary neural cell culture and also in normal mouse brain. When administered to a transgenic mouse model of AD, MMBO significantly decreased hippocampal tau phosphorylation at GSK-3 sites. Additionally, chronic MMBO administration suppressed tau pathology as assessed by AT8-immunoreactivity without affecting amyloid &#x3b2; pathology. Finally, in behavioral assessments, MMBO significantly improved memory and cognitive deficits in the Y-maze and in novel object recognition tests in the transgenic AD mouse model. These results indicate that pharmacological GSK-3 inhibition ameliorates behavioral dysfunction with suppression of tau phosphorylation in an AD mouse model, and that MMBO might be beneficial for AD treatment.</AbstractText><CopyrightInformation>&#xa9; 2011 The Authors. Journal of Neurochemistry &#xa9; 2011 International Society for Neurochemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Onishi</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pharmacology Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company, Limited, Juso-Honmachi, Yodogawa, Osaka, Japan. Oonishi_Tomohiro@takeda.co.jp</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwashita</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Uno</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kunitomo</LastName><ForeName>Jun</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Saitoh</LastName><ForeName>Morihisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Eiji</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fujita</LastName><ForeName>Hisashi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Uchiyama</LastName><ForeName>Noriko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kori</LastName><ForeName>Masakuni</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Takizawa</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurochem</MedlineTA><NlmUniqueID>2985190R</NlmUniqueID><ISSNLinking>0022-3042</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C569487">2-methyl-5-(3-(4-(methylsulfinyl)phenyl)-1-benzofuran-5-yl)-1,3,4-oxadiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001572">Benzofurans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="C448021">glycogen synthase kinase 3 alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001572" MajorTopicYN="N">Benzofurans</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018929" MajorTopicYN="N">Cell Culture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21992552</ArticleId><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07532.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22189451</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>78</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>10</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults.</ArticleTitle><Pagination><StartPage>84</StartPage><EndPage>90</EndPage><MedlinePgn>84-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0b013e31823efc6c</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">New preclinical Alzheimer disease (AD) diagnostic criteria have been developed using biomarkers in cognitively normal (CN) adults. We implemented these criteria using an MRI biomarker previously associated with AD dementia, testing the hypothesis that individuals at high risk for preclinical AD would be at elevated risk for cognitive decline.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Alzheimer's Disease Neuroimaging Initiative database was interrogated for CN individuals. MRI data were processed using a published set of a priori regions of interest to derive a single measure known as the AD signature (ADsig). Each individual was classified as ADsig-low (&#x2265; 1 SD below the mean: high risk for preclinical AD), ADsig-average (within 1 SD of mean), or ADsig-high (&#x2265; 1 SD above mean). A 3-year cognitive decline outcome was defined a priori using change in Clinical Dementia Rating sum of boxes and selected neuropsychological measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Individuals at high risk for preclinical AD were more likely to experience cognitive decline, which developed in 21% compared with 7% of ADsig-average and 0% of ADsig-high groups (p = 0.03). Logistic regression demonstrated that every 1 SD of cortical thinning was associated with a nearly tripled risk of cognitive decline (p = 0.02). Of those for whom baseline CSF data were available, 60% of the high risk for preclinical AD group had CSF characteristics consistent with AD while 36% of the ADsig-average and 19% of the ADsig-high groups had such CSF characteristics (p = 0.1).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This approach to the detection of individuals at high risk for preclinical AD-identified in single CN individuals using this quantitative ADsig MRI biomarker-may provide investigators with a population enriched for AD pathobiology and with a relatively high likelihood of imminent cognitive decline consistent with prodromal AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Bradford C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Frontotemporal Dementia Unit, Department of Neurology, Massachusetts Alzheimer's Disease Research Center, and Athinoula A Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, USA.bradd@nmr.mgh.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolk</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG022374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR033173</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-AG29840</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001998</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23-AG028018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000117</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG29411</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG012101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2012 Jan 10;78(2):80-1. doi: 10.1212/WNL.0b013e31824237a5.</RefSource><PMID Version="1">22189450</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montine</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gessert</LastName><ForeName>Devon</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sather</LastName><ForeName>Tamie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckett</LastName><ForeName>Laurel</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>Danielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamst</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornak</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernstein</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felmlee</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuff</LastName><ForeName>Norbert</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Gene</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagust</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koeppe</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Norm</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chet</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor-Reinwald</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trojanowki</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Les</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M Y</ForeName><Initials>VM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korecka</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neu</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kachaturian</LastName><ForeName>Zaven</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snyder</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molchan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>Joanne L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villanueva-Meyer</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>Munir</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marson</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Randall</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Hillel</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitsis</LastName><ForeName>Effie</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>Aliza</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>deToledo-Morrell</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varon</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albert</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onyike</LastName><ForeName>Chiadi</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kielb</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rusinek</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Leon</LastName><ForeName>Mony J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glodzik</LastName><ForeName>Lidia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murali Doraiswamy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrella</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>Steven E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Charles D</ForeName><Initials>CD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakley</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Donna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>M Saleem</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulnard</LastName><ForeName>Ruth A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thai</LastName><ForeName>Gaby</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAdams-Ortiz</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin-Cook</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeVous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>James J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>Janet S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Heather S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>Russell H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartzokis</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>Daniel H S</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>Po H</ForeName><Initials>PH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apostolova</LastName><ForeName>Liana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parfitt</LastName><ForeName>Francine</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herring</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>Christopher H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>Martha G</ForeName><Initials>MG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergmann</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stefanovic</LastName><ForeName>Bojana</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caldwell</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsiung</LastName><ForeName>Ging-Yuek Robin</ForeName><Initials>GY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assaly</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trost</LastName><ForeName>Dick</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Chuang-Kuo</ForeName><Initials>CK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>Marsel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Walter</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Raymond Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meghan</LastName><ForeName>Frey</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Allyson</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tinklenberg</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killiany</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norbash</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obisesan</LastName><ForeName>Thomas O</ForeName><Initials>TO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolday</LastName><ForeName>Saba</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bwayo</LastName><ForeName>Salome K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Leon</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>Evan</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>Owen</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>Smita</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>T-Y</ForeName><Initials>TY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartha</LastName><ForeName>Rob</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sterling</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>Cynthia M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dana</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bates</LastName><ForeName>Vernice</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capote</LastName><ForeName>Horacio</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainka</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendin</LastName><ForeName>Barry A</ForeName><Initials>BA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>Douglas W</ForeName><Initials>DW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celmins</LastName><ForeName>Dzintra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Alice D</ForeName><Initials>AD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlson</LastName><ForeName>Godfrey D</ForeName><Initials>GD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blank</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saykin</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santulli</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Eben S</ForeName><Initials>ES</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sink</LastName><ForeName>Kaycee M</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>Franklin</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>Brian R</ForeName><Initials>BR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correia</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal Flynn</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spicer</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>1</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22189451</ArticleId><ArticleId IdType="pmc">PMC3466670</ArticleId><ArticleId IdType="doi">10.1212/WNL.0b013e31823efc6c</ArticleId><ArticleId IdType="pii">WNL.0b013e31823efc6c</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837&#x2013; 1844</Citation><ArticleIdList><ArticleId IdType="pubmed">16801647</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Jr, et al. Cerebral amyloid deposition and diffuse plaques in &#x201c;normal&#x201d; aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 1996; 46: 707&#x2013; 719</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Davis PB, Morris JC, White DL. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging 1991; 12: 295&#x2013; 312</Citation><ArticleIdList><ArticleId IdType="pubmed">1961359</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001; 58: 1395&#x2013; 1402</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009; 30: 1026&#x2013; 1036</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal H, Dickson D, Fuld P, et al. Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 1988; 38: 1682&#x2013; 1687</Citation><ArticleIdList><ArticleId IdType="pubmed">3185902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement 2011; 7: 280&#x2013; 292</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118&#x2013; 1127</Citation><ArticleIdList><ArticleId IdType="pubmed">20934914</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009; 19: 497&#x2013; 510</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2638813</ArticleId><ArticleId IdType="pubmed">18632739</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour A, Morris JC, Dickerson BC. The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 2009; 72: 1048&#x2013; 1055</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677470</ArticleId><ArticleId IdType="pubmed">19109536</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Stoub T, Shah RC, et al. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology 2011; 76: 1395&#x2013; 1402</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3087406</ArticleId><ArticleId IdType="pubmed">21490323</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685&#x2013; 691</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative, et al. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci USA 2010; 107: 10256&#x2013; 10261</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890481</ArticleId><ArticleId IdType="pubmed">20479234</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Wolk DA, the Alzheimer's Disease Neuroimaging Initiative Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry 2011; 82: 45&#x2013; 51</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3023235</ArticleId><ArticleId IdType="pubmed">20562467</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403&#x2013; 413</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 1443&#x2013; 1450</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581771</ArticleId><ArticleId IdType="pubmed">18056553</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SL, Fenstermacher E, Bates J, Blacker D, Sperling RA, Dickerson BC. Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. J Neurol Neurosurg Psychiatry 2008; 79: 630&#x2013; 635</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683145</ArticleId><ArticleId IdType="pubmed">17846109</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Bates JF, et al. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol 2004; 56: 27&#x2013; 35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4335689</ArticleId><ArticleId IdType="pubmed">15236399</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412&#x2013; 2414</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Lee H, Muzikansky A, et al. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 2007; 64: 862&#x2013; 871</Citation><ArticleIdList><ArticleId IdType="pubmed">17562935</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, Moss MB, Tanzi R, Jones K. Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 2001; 7: 631&#x2013; 639</Citation><ArticleIdList><ArticleId IdType="pubmed">11459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997; 48: 1297&#x2013; 1304</Citation><ArticleIdList><ArticleId IdType="pubmed">9153461</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CD, Chebrolu H, Wekstein DR, et al. Brain structural alterations before mild cognitive impairment. Neurology 2007; 68: 1268&#x2013; 1273</Citation><ArticleIdList><ArticleId IdType="pubmed">17438217</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin SB, Smith CD, Collins HR, Schmitt FA, Gold BT. Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. Neurobiol Aging; 31: 1099&#x2013; 1106</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873058</ArticleId><ArticleId IdType="pubmed">18809227</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolova LG, Mosconi L, Thompson PM, et al. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging 2010; 31: 1077&#x2013; 1088</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873083</ArticleId><ArticleId IdType="pubmed">18814937</ArticleId></ArticleIdList></Reference><Reference><Citation>den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MM. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry 2006; 63: 57&#x2013; 62</Citation><ArticleIdList><ArticleId IdType="pubmed">16389197</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Fox NC, Frost C, et al. Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 2003; 53: 181&#x2013; 188</Citation><ArticleIdList><ArticleId IdType="pubmed">12557284</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease: a longitudinal MRI study. Brain 1996; 119: 2001&#x2013; 2007</Citation><ArticleIdList><ArticleId IdType="pubmed">9010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC, Rossor MN. Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet 2001; 358: 201&#x2013; 205</Citation><ArticleIdList><ArticleId IdType="pubmed">11476837</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Shiung MM, Weigand SD, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005; 65: 1227&#x2013; 1231</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2753547</ArticleId><ArticleId IdType="pubmed">16247049</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009; 66: 1469&#x2013; 1475</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65: 176&#x2013; 183</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J, for the Alzheimer's Disease Neuroimaging Initiative Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1&#x2013;42. Ann Neurol 2010; 68: 825&#x2013; 834</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22278060</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>482</Volume><Issue>7384</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>25</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells.</ArticleTitle><Pagination><StartPage>216</StartPage><EndPage>220</EndPage><MedlinePgn>216-20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature10821</ELocationID><Abstract><AbstractText>Our understanding of Alzheimer's disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer's disease, both caused by a duplication of the amyloid-&#x3b2; precursor protein gene (APP; termed APP(Dp)), two with sporadic Alzheimer's disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-activated cell sorting and characterized. Purified cultures contained more than 90% neurons, clustered with fetal brain messenger RNA samples by microarray criteria, and could form functional synaptic contacts. Virtually all cells exhibited normal electrophysiological activity. Relative to controls, iPSC-derived, purified neurons from the two APP(Dp) patients and patient sAD2 exhibited significantly higher levels of the pathological markers amyloid-&#x3b2;(1-40), phospho-tau(Thr&#x2009;231) and active glycogen synthase kinase-3&#x3b2; (aGSK-3&#x3b2;). Neurons from APP(Dp) and sAD2 patients also accumulated large RAB5-positive early endosomes compared to controls. Treatment of purified neurons with &#x3b2;-secretase inhibitors, but not &#x3b3;-secretase inhibitors, caused significant reductions in phospho-Tau(Thr&#x2009;231) and aGSK-3&#x3b2; levels. These results suggest a direct relationship between APP proteolytic processing, but not amyloid-&#x3b2;, in GSK-3&#x3b2; activation and tau phosphorylation in human neurons. Additionally, we observed that neurons with the genome of one sAD patient exhibited the phenotypes seen in familial Alzheimer's disease samples. More generally, we demonstrate that iPSC technology can be used to observe phenotypes relevant to Alzheimer's disease, even though it can take decades for overt disease to manifest in patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Israel</LastName><ForeName>Mason A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute and Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Shauna H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Bardy</LastName><ForeName>Cedric</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Reyna</LastName><ForeName>Sol M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Mu</LastName><ForeName>Yangling</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Herrera</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hefferan</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Van Gorp</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nazor</LastName><ForeName>Kristopher L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Boscolo</LastName><ForeName>Francesca S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Christian T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Laurent</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials></Author><Author ValidYN="Y"><LastName>Marsala</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gage</LastName><ForeName>Fred H</ForeName><Initials>FH</Initials></Author><Author ValidYN="Y"><LastName>Remes</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Edward H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Lawrence S B</ForeName><Initials>LS</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE34879</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K12 HD001259</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008666</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 NS068705</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS047101</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016704">Synapsins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2012 Feb 15;13(3):149. doi: 10.1038/nrn3201.</RefSource><PMID Version="1">22334215</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Cell Stem Cell. 2012 Mar 2;10(3):235-6. doi: 10.1016/j.stem.2012.02.011.</RefSource><PMID Version="1">22385650</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065150" MajorTopicYN="N">Cellular Reprogramming</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059748" MajorTopicYN="N">Proteolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016704" MajorTopicYN="N">Synapsins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22278060</ArticleId><ArticleId IdType="mid">NIHMS352073</ArticleId><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="doi">10.1038/nature10821</ArticleId><ArticleId IdType="pii">nature10821</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rovelet-Lecrux A, et al. APP locus duplication in a Finnish family with dementia and intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 2007;78:1158&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2117532</ArticleId><ArticleId IdType="pubmed">17442758</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanzi RE, Bertram L. Twenty years of the Alzheimer&#x2019;s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VMY, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer&#x2019;s disease and related disorders. Nature Rev Neurosci. 2007;8:663&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatz M, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461860</ArticleId></ArticleIdList></Reference><Reference><Citation>Games D, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x3b2;-amyloid precursor protein. Nature. 1995;373:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845465</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, et al. Reducing endogenous tau ameliorates amyloid &#x3b2;-induced deficits in an Alzheimer&#x2019;s disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Lorenzo A, Yeh J, Yankner BA. &#x3b2;-Amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron. 1995;14:879&#x2013;888.</Citation><ArticleIdList><ArticleId IdType="pubmed">7718249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert AD, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 2009;457:277&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659408</ArticleId><ArticleId IdType="pubmed">19098894</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HN, et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578553</ArticleId><ArticleId IdType="pubmed">21362567</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiang L, et al. Directed conversion of Alzheimer&#x2019;s disease patient skin fibroblasts into functional neurons. Cell. 2011;3:359&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151530</ArticleId><ArticleId IdType="pubmed">21816272</ArticleId></ArticleIdList></Reference><Reference><Citation>Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010;6:407&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3354574</ArticleId><ArticleId IdType="pubmed">20452313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan SH, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE. 2011;6:e17540.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3047583</ArticleId><ArticleId IdType="pubmed">21407814</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Pfaff SL, Gage FH. YAP regulates neural progenitor cell number via the TEA domain transcription factor. Genes Dev. 2008;22:3320&#x2013;3334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600760</ArticleId><ArticleId IdType="pubmed">19015275</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy BV, Irvine KD. Regulation of Drosophila glial cell proliferation by Merlin-Hippo signaling. Development. 2011;138:5201&#x2013;5212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3210499</ArticleId><ArticleId IdType="pubmed">22069188</ArticleId></ArticleIdList></Reference><Reference><Citation>Citron M, et al. Excessive production of amyloid &#x3b2;-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA. 1994;91:11993&#x2013;11997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45362</ArticleId><ArticleId IdType="pubmed">7991571</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, et al. Secreted amyloid &#x3b2;-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparini L, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer&#x2019;s disease. FASEB J. 1998;12:17&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9438407</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 1992;42:631.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho JH, Johnson GVW. Primed phosphorylation of tau at Thr 231 by glycogen synthase kinase 3&#x3b2; (GSK3&#x3b2;) plays a critical role in regulating tau&#x2019;s ability to bind and stabilize microtubules. J Neurochem. 2004;88:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">14690523</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196665</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J, Johnson G. Glycogen synthase kinase 3&#x3b2; phosphorylates tau at both primed and unprimed sites. J Biol Chem. 2003;278:187&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12409305</ArticleId></ArticleIdList></Reference><Reference><Citation>Dajani R, et al. Crystal structure of glycogen synthase kinase 3&#x3b2;: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 2001;105:721&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440715</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo AM, et al. Endocytic pathway abnormalities precede amyloid &#x3b2; deposition in sporadic Alzheimer&#x2019;s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol. 2000;157:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850219</ArticleId><ArticleId IdType="pubmed">10880397</ArticleId></ArticleIdList></Reference><Reference><Citation>Cataldo A, et al. Endocytic disturbances distinguish among subtypes of Alzheimer&#x2019;s disease and related disorders. Ann Neurol. 2001;50:661&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pubmed">11706973</ArticleId></ArticleIdList></Reference><Reference><Citation>Nixon RA. Endosome function and dysfunction in Alzheimer&#x2019;s disease and other neurodegenerative diseases. Neurobiol Aging. 2005;26:373&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer&#x2019;s disease and other dementias. Neurology. 1989;39:355&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">2927643</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin S, Hu XY, Xu H, Zhou JN. Regional alteration of synapsin I in the hippocampal formation of Alzheimer&#x2019;s disease patients. Acta Neuropathol. 2004;107:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">14673601</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi A, et al. Increased App expression in a mouse model of Down&#x2019;s syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron. 2006;51:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16815330</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is A&#x3b2;-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA. 2010;107:1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22279548</PMID><DateCompleted><Year>2012</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Genetic signatures of exceptional longevity in humans.</ArticleTitle><Pagination><StartPage>e29848</StartPage><MedlinePgn>e29848</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e29848</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0029848</ELocationID><Abstract><AbstractText>Like most complex phenotypes, exceptional longevity is thought to reflect a combined influence of environmental (e.g., lifestyle choices, where we live) and genetic factors. To explore the genetic contribution, we undertook a genome-wide association study of exceptional longevity in 801 centenarians (median age at death 104 years) and 914 genetically matched healthy controls. Using these data, we built a genetic model that includes 281 single nucleotide polymorphisms (SNPs) and discriminated between cases and controls of the discovery set with 89% sensitivity and specificity, and with 58% specificity and 60% sensitivity in an independent cohort of 341 controls and 253 genetically matched nonagenarians and centenarians (median age 100 years). Consistent with the hypothesis that the genetic contribution is largest with the oldest ages, the sensitivity of the model increased in the independent cohort with older and older ages (71% to classify subjects with an age at death&gt;102 and 85% to classify subjects with an age at death&gt;105). For further validation, we applied the model to an additional, unmatched 60 centenarians (median age 107 years) resulting in 78% sensitivity, and 2863 unmatched controls with 61% specificity. The 281 SNPs include the SNP rs2075650 in TOMM40/APOE that reached irrefutable genome wide significance (posterior probability of association&#x200a;=&#x200a;1) and replicated in the independent cohort. Removal of this SNP from the model reduced the accuracy by only 1%. Further in-silico analysis suggests that 90% of centenarians can be grouped into clusters characterized by different "genetic signatures" of varying predictive values for exceptional longevity. The correlation between 3 signatures and 3 different life spans was replicated in the combined replication sets. The different signatures may help dissect this complex phenotype into sub-phenotypes of exceptional longevity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sebastiani</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America. sebas@bu.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solovieff</LastName><ForeName>Nadia</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Dewan</LastName><ForeName>Andrew T</ForeName><Initials>AT</Initials></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Kyle M</ForeName><Initials>KM</Initials></Author><Author ValidYN="Y"><LastName>Puca</LastName><ForeName>Annibale</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hartley</LastName><ForeName>Stephen W</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Melista</LastName><ForeName>Efthymia</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dworkis</LastName><ForeName>Daniel A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Wilk</LastName><ForeName>Jemma B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Martin H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Montano</LastName><ForeName>Monty</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baldwin</LastName><ForeName>Clinton T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Hoh</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Perls</LastName><ForeName>Thomas T</ForeName><Initials>TT</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AG023122</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR055115</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG025727</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027216</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL087681</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS036711</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS36711-09</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015894" MajorTopicYN="N">Genome, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>In the study the authors included 254 subjects enrolled at ELIXIR. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22279548</ArticleId><ArticleId IdType="pmc">PMC3261167</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0029848</ArticleId><ArticleId IdType="pii">PONE-D-11-23542</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fraser GE, Shavlik DJ. Ten years of life: Is it a matter of choice? Arch Intern Med. 2001;161:1645&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">11434797</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskind AM, McGue M, Holm NV, Sorensen TI, Harvald B, et al. The heritability of human longevity: a population-based study of 2872 Danish twin pairs born 1870&#x2013;1900. Hum Genet. 1996;97:319&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">8786073</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpert L, DesJardines B, Vaupel J, Perls Tt. Extreme longevity in two families. A report of multiple centenarians within single generations. In: Jeune BVJ, editor. Age Validation of the Extreme Old. Odense: Odense University Press; 1998.</Citation></Reference><Reference><Citation>Perls T, Shea-Drinkwater M, Bowen-Flynn J, Ridge SB, Kang S, et al. Exceptional familial clustering for extreme longevity in humans. J Am Geriatr Soc. 2000;48:1483&#x2013;1485.</Citation><ArticleIdList><ArticleId IdType="pubmed">11083328</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorp RG, van Heemst D, Rozing MP, Frolich M, Mooijaart SP, et al. Nonagenarian siblings and their offspring display lower risk of mortality and morbidity than sporadic nonagenarians: The Leiden Longevity Study. J Am Geriatr Soc. 2009;57:1634&#x2013;1637.</Citation><ArticleIdList><ArticleId IdType="pubmed">19682117</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudmundsson H, Gudbjartsson DF, Frigge M, Gulcher JR, Stefansson K. Inheritance of human longevity in Iceland. Eur J Hum Genet. 2000;8:743&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">11039573</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerber RA, O'Brien E, Smith KR, Cawthon RM. Familial excess longevity in Utah genealogies. J Gerontol A Biol Sci Med Sci. 2001;56:B130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">11253150</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls T, Kohler IV, Andersen S, Schoenhofen E, Pennington J, et al. Survival of parents and siblings of supercentenarians. J Gerontol A Biol Sci Med Sci. 2007;62:1028&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3258444</ArticleId><ArticleId IdType="pubmed">17895443</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls TT, Bubrick E, Wager CG, Vijg J, Kruglyak L. Siblings of centenarians live longer. Lancet. 1998;351:1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">10326548</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls TT, Wilmoth J, Levenson R, Drinkwater M, Cohen M, et al. Life-long sustained mortality advantage of siblings of centenarians. Proc Natl Acad Sci U S A. 2002;99:8442&#x2013;8447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123086</ArticleId><ArticleId IdType="pubmed">12060785</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmaker M, de Craen AJ, de Meijer PH, Beekman M, Blauw GJ, et al. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur J Hum Genet. 2006;14:79&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251894</ArticleId></ArticleIdList></Reference><Reference><Citation>Willcox BJ, Willcox DC, He Q, Curb JD, Suzuki M. Siblings of okinawan centenarians share lifelong mortality advantages. J Gerontol A Biol Sci Med Sci. 2006;61:345&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611700</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, et al. Clinical phenotype of families with longevity. J Am Geriatr Soc. 2004;52:274&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">14728640</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry DF, Wilcox MA, McCormick MA, Pennington JY, Schoenhofen EA, et al. Lower all-cause, cardiovascular, and cancer mortality in centenarians' offspring. J Am Geriatr Soc. 2004;52:2074&#x2013;2076.</Citation><ArticleIdList><ArticleId IdType="pubmed">15571545</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpathak SN, Liu Y, Ben-David O, Reddy S, Atzmon G, et al. Lifestyle factors of people with exceptional longevity. Journal of the American Geriatrics Society. 2011;59:1509&#x2013;1512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6034120</ArticleId><ArticleId IdType="pubmed">21812767</ArticleId></ArticleIdList></Reference><Reference><Citation>Atzmon G, Rincon M, Rabizadeh P, Barzilai N. Biological evidence for inheritance of exceptional longevity. Mech Ageing Dev. 2005;126:341&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15621216</ArticleId></ArticleIdList></Reference><Reference><Citation>Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. Jama. 2003;290:2030&#x2013;2040.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559957</ArticleId></ArticleIdList></Reference><Reference><Citation>Young RD, Desjardins B, McLaughlin K, Poulain M, Perls T. Typologies of Extreme Longevity Myths. Curr Gerontol Geriatr Res. 2011:1&#x2013;12. URL:  http://wwwhindawicom/journals/cggr/2010/423087/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3062986</ArticleId><ArticleId IdType="pubmed">21461047</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Q, Zhao JH, Zhang D, Kruse TA, Christensen K. Power for genetic association study of human longevity using the case-control design. Am J Epidemiol. 2008;168:890&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2732955</ArticleId><ArticleId IdType="pubmed">18756013</ArticleId></ArticleIdList></Reference><Reference><Citation>Solovieff N, Hartley SW, Baldwin CT, Perls TT, Steinberg MH, et al. Clustering by genetic ancestry using genome-wide data. BMC Genetics. 2010;11:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018397</ArticleId><ArticleId IdType="pubmed">21143920</ArticleId></ArticleIdList></Reference><Reference><Citation>Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124:593&#x2013;605.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2627511</ArticleId><ArticleId IdType="pubmed">18985386</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719288</ArticleId><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lettre G, Lange C, Hirschhorn JN. Genetic model testing and statistical power in population-based association studies of quantitative traits. Genet Epidemiol. 2007;31:358&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17352422</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens M, Balding DJ. Bayesian statistical methods for genetic association studies. Nat Rev Genet. 2009;10:681&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">19763151</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen K, Johnson TE, Vaupel JW. The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet. 2006;7:436&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726954</ArticleId><ArticleId IdType="pubmed">16708071</ArticleId></ArticleIdList></Reference><Reference><Citation>Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, et al. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet. 1994;6:29&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8136829</ArticleId></ArticleIdList></Reference><Reference><Citation>Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, et al. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193372</ArticleId><ArticleId IdType="pubmed">21418511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics. 2007;89:655&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978251</ArticleId><ArticleId IdType="pubmed">17434289</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, et al. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS ONE. 2009;4:e6501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719581</ArticleId><ArticleId IdType="pubmed">19668339</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet. 2009;84:35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668056</ArticleId><ArticleId IdType="pubmed">19118814</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatti C, Service SK, Hartikainen AL, Pouta A, Ripatti S, et al. Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat Genet. 2009;41:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687077</ArticleId><ArticleId IdType="pubmed">19060910</ArticleId></ArticleIdList></Reference><Reference><Citation>Aulchenko YS, Ripatti S, Lindqvist I, Boomsma D, Heid IM, et al. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet. 2009;41:47&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687074</ArticleId><ArticleId IdType="pubmed">19060911</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuwissen TH, Hayes BJ, Goddard ME. Prediction of total genetic value using genome-wide dense marker maps. Genetics. 2001;157:1819&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1461589</ArticleId><ArticleId IdType="pubmed">11290733</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007;17:1520&#x2013;1528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1987352</ArticleId><ArticleId IdType="pubmed">17785532</ArticleId></ArticleIdList></Reference><Reference><Citation>Goddard ME, Wray NR, Verbyla K, Visscher PM. Estimating effects and making predictions from genome-wide marker data. Statistica Science. 2009;24:517&#x2013;529.</Citation></Reference><Reference><Citation>Wray NR, Yang J, Goddard ME, Visscher PM. The genetic interpretation of area under the ROC curve in genomic profiling. PLoS Genet. 2010;6:e1000864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829056</ArticleId><ArticleId IdType="pubmed">20195508</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912837</ArticleId><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Z, Wang K, Qu HQ, Zhang H, Bradfield J, et al. From disease association to risk assessment: an optimistic view from genome-wide association studies on type 1 diabetes. PLoS Genet. 2009;5:e1000678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2748686</ArticleId><ArticleId IdType="pubmed">19816555</ArticleId></ArticleIdList></Reference><Reference><Citation>Okser S, Lehtimaki T, Elo LL, Mononen N, Peltonen N, et al. Genetic variants and their interactions in the prediction of increased pre-clinical carotid atherosclerosis: the cardiovascular risk in young Finns study. PLoS Genet. 2010;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947986</ArticleId><ArticleId IdType="pubmed">20941391</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, et al. Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet. 2010;43:519&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4295936</ArticleId><ArticleId IdType="pubmed">21552263</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooperberg C, LeBlanc M, Obenchain V. Risk prediction using genome-wide association studies. Genet Epidemiol. 2009;34:643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964405</ArticleId><ArticleId IdType="pubmed">20842684</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekimi S. How genetic analysis tests theories of animal aging. Nat Genet. 2006;38:985&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pubmed">16941009</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry DF, Sebastiani P, Andersen SL, Perls TT. Disentangling the roles of disability and morbidity in survival to exceptional old age. Arch Intern Med. 2008;168:277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895331</ArticleId><ArticleId IdType="pubmed">18268168</ArticleId></ArticleIdList></Reference><Reference><Citation>Hand DJ. Naive Bayes. In: Wu X, Kumar V, editors. The top ten algorithms in data mining. London: Chapman and Hall; 2009. pp. 163&#x2013;178.</Citation></Reference><Reference><Citation>Sebastiani P, Riva A, Montano M, Pham P, Torkamani A, et al. Whole genome sequences of a male and female supercentenarian, ages greater than 114 years. Frontiers in Genetics. 2011;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262222</ArticleId><ArticleId IdType="pubmed">22303384</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003;423:293&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10540076</ArticleId><ArticleId IdType="pubmed">12714972</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray MD, Shen JC, Kamath-Loeb AS, Blank A, Sopher BL, et al. The Werner syndrome protein is a DNA helicase. Nat Genet. 1997;17:100&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9288107</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta KL, D'Agostino RB, Sr, Karasik D, Benjamin EJ, Guo CY, et al. Genetic correlates of longevity and selected age-related phenotypes: a genome-wide association study in the Framingham Study. BMC Med Genet. 2007;8(Suppl 1):S13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995604</ArticleId><ArticleId IdType="pubmed">17903295</ArticleId></ArticleIdList></Reference><Reference><Citation>Stessman J, Maaravi Y, Hammerman-Rozenberg R, Cohen A, Nemanov L, et al. Candidate genes associated with ageing and life expectancy in the Jerusalem longitudinal study. Mech Ageing Dev. 2005;126:333&#x2013;339.</Citation><ArticleIdList><ArticleId IdType="pubmed">15621215</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman D. Free radical involvement in aging. Pathophysiology and therapeutic implications. Drugs Aging. 1993;3:60&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">8453186</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker DJ, Jin F, van Deursen JM. The yin and yang of the Cdkn2a locus in senescence and aging. Cell Cycle. 2008;7:2795&#x2013;2802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987737</ArticleId><ArticleId IdType="pubmed">18769141</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331&#x2013;1336.</Citation><ArticleIdList><ArticleId IdType="pubmed">17463246</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, et al. Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci. 2010;30:13110&#x2013;13115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274732</ArticleId><ArticleId IdType="pubmed">20881129</ArticleId></ArticleIdList></Reference><Reference><Citation>Song DH, Getty-Kaushik L, Tseng E, Simon J, Corkey BE, et al. Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation. Gastroenterology. 2007;133:1796&#x2013;1805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185546</ArticleId><ArticleId IdType="pubmed">18054552</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijg J, Campisi J. Puzzles, promises and a cure for ageing. Nature. 2008;454:1065&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774752</ArticleId><ArticleId IdType="pubmed">18756247</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafe M, Barbieri M, Marchegiani F, Olivieri F, Ragno E, et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity: cues for an evolutionarily conserved mechanism of life span control. J Clin Endocrinol Metab. 2003;88:3299&#x2013;3304.</Citation><ArticleIdList><ArticleId IdType="pubmed">12843179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlikowska L, Hu D, Huntsman S, Sung A, Chu C, et al. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell. 2009;8:460&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3652804</ArticleId><ArticleId IdType="pubmed">19489743</ArticleId></ArticleIdList></Reference><Reference><Citation>Willcox BJ, Donlon TA, He Q, Chen R, Grove JS, et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci U S A. 2008;105:13987&#x2013;13992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544566</ArticleId><ArticleId IdType="pubmed">18765803</ArticleId></ArticleIdList></Reference><Reference><Citation>Holscher C, Li L. New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiol Aging. 2010;31:1495&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt R, Young-Xu Y, Silver M, Perls T. Centenarians: the older you get, the healthier you have been. Lancet. 1999;354:652.</Citation><ArticleIdList><ArticleId IdType="pubmed">10466675</ArticleId></ArticleIdList></Reference><Reference><Citation>Michie D, Spiegelhalter DJ, Taylor CC. 1994. Machine Learning, Neural and Statistical Classification: Ellis Horwood.</Citation></Reference><Reference><Citation>Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet. 2005;37:435&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2896308</ArticleId><ArticleId IdType="pubmed">15778708</ArticleId></ArticleIdList></Reference><Reference><Citation>Rokach L. Ensembled-based classifiers. Art Intell Review. 2010;33:1&#x2013;39.</Citation></Reference><Reference><Citation>Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet. 2008;40:1216&#x2013;1223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757650</ArticleId><ArticleId IdType="pubmed">18794853</ArticleId></ArticleIdList></Reference><Reference><Citation>Solovieff N, Hartley SW, Baldwin CT, Perls TT, Steinberg MH, et al. Clustering by genetic ancestry using genome-wide SNP data. BMC Genet. 2010;11:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018397</ArticleId><ArticleId IdType="pubmed">21143920</ArticleId></ArticleIdList></Reference><Reference><Citation>Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, et al. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Aging Cell 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3193372</ArticleId><ArticleId IdType="pubmed">21418511</ArticleId></ArticleIdList></Reference><Reference><Citation>Evert J, Lawler E, Bogan H, Perls T. Morbidity profiles of centenarians: survivors, delayers, and escapers. J Gerontol A Biol Sci Med Sci. 2003;58:232&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloss CS, Pawlikowska L, Schork NJ. Contemporary human genetic strategies in aging research. Ageing Res Rev. 2010;10:191&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3043164</ArticleId><ArticleId IdType="pubmed">20709627</ArticleId></ArticleIdList></Reference><Reference><Citation>Beekman M, Nederstigt C, Suchiman HE, Kremer D, van der Breggen R, et al. Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity. Proc Natl Acad Sci USA. 2010;107:18046&#x2013;18049.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964208</ArticleId><ArticleId IdType="pubmed">20921414</ArticleId></ArticleIdList></Reference><Reference><Citation>Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet. 2009;41:1088&#x2013;1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845877</ArticleId><ArticleId IdType="pubmed">19734902</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009;41:1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734903</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Howard TD, Zheng SL, Haselkorn T, Peters SP, et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol. 2010;125:328&#x2013;335 e311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824608</ArticleId><ArticleId IdType="pubmed">20159242</ArticleId></ArticleIdList></Reference><Reference><Citation>Need AC, Attix DK, McEvoy JM, Cirulli ET, Linney KL, et al. A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet. 2009;18:4650&#x2013;4661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773267</ArticleId><ArticleId IdType="pubmed">19734545</ArticleId></ArticleIdList></Reference><Reference><Citation>Marroni F, Pfeufer A, Aulchenko YS, Franklin CS, Isaacs A, et al. A genome-wide association scan of RR and QT interval duration in 3 European genetically isolated populations: the EUROSPAN project. Circ Cardiovasc Genet. 2009;2:322&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760953</ArticleId><ArticleId IdType="pubmed">20031603</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet. 2010;42:105&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018764</ArticleId><ArticleId IdType="pubmed">20081858</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, et al. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med. 2011;3:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3092088</ArticleId><ArticleId IdType="pubmed">21244703</ArticleId></ArticleIdList></Reference><Reference><Citation>Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746946</ArticleId><ArticleId IdType="pubmed">19020323</ArticleId></ArticleIdList></Reference><Reference><Citation>Paynter NP, Chasman DI, Pare G, Buring JE, Cook NR, et al. Association between a literature-based genetic risk score and cardiovascular events in women. Jama. 303:631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845522</ArticleId><ArticleId IdType="pubmed">20159871</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaupel JW, Carey JR, Christensen K, Johnson TE, Yashin AI, et al. Biodemographic trajectories of longevity. Science. 1998;280:855&#x2013;860.</Citation><ArticleIdList><ArticleId IdType="pubmed">9599158</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374:1196&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810516</ArticleId><ArticleId IdType="pubmed">19801098</ArticleId></ArticleIdList></Reference><Reference><Citation>Perls TT, Bochen K, Freeman M, Alpert L, Silver MH. Validity of reported age and centenarian prevalence in New England. Age Ageing. 1999;28:193&#x2013;197.</Citation><ArticleIdList><ArticleId IdType="pubmed">10350418</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. Am J Hum Genet. 2007;81:559&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1950838</ArticleId><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Nebel A, Schreiber S. Allelic variation and human longevity. Sci Aging Knowledge Environ. 2005;2005:pe23.</Citation><ArticleIdList><ArticleId IdType="pubmed">16034039</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862161</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AL, Butler J, Patterson N, Capelli C, Pascali VL, et al. Discerning the ancestry of European Americans in genetic association studies. PLoS Genet. 2008;4:e236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2211542</ArticleId><ArticleId IdType="pubmed">18208327</ArticleId></ArticleIdList></Reference><Reference><Citation>Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7:781&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">16983374</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramoni M, Sebastiani P. Robust Bayes classifiers. Artif Intell. 2001;125:207&#x2013;224.</Citation></Reference><Reference><Citation>Devlin B, Roeder K. Genomic control for association studies. Biometrics. 1999;55:997&#x2013;1004.</Citation><ArticleIdList><ArticleId IdType="pubmed">11315092</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106:9362&#x2013;9367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687147</ArticleId><ArticleId IdType="pubmed">19474294</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani P, Perls TT. Dr Olivier Pourret PNDBM, editor. Complex Genetic Models. Bayesian Networks. 2008. pp. 53&#x2013;72.</Citation></Reference><Reference><Citation>Ramoni MF, Sebastiani P, Kohane IS. Cluster analysis of gene expression dynamics. Proc Natl Acad Sci U S A. 2002;99:9121&#x2013;9126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC123104</ArticleId><ArticleId IdType="pubmed">12082179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramoni M, Sebastiani P, Cohen P. Bayesian clustering by dynamics. Mach Learn. 2002;47:91&#x2013;121.</Citation></Reference><Reference><Citation>Wang L, Montano M, Rarick M, Sebastiani P. Conditional clustering of temporal expression profiles. BMC Bioinformatics. 2008;9:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2335301</ArticleId><ArticleId IdType="pubmed">18334028</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22261206</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-2607</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>American journal of preventive medicine</Title><ISOAbbreviation>Am J Prev Med</ISOAbbreviation></Journal><ArticleTitle>Exergaming and older adult cognition: a cluster randomized clinical trial.</ArticleTitle><Pagination><StartPage>109</StartPage><EndPage>119</EndPage><MedlinePgn>109-19</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amepre.2011.10.016</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dementia cases may reach 100 million by 2050. Interventions are sought to curb or prevent cognitive decline. Exercise yields cognitive benefits, but few older adults exercise. Virtual reality-enhanced exercise or "exergames" may elicit greater participation.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To test the following hypotheses: (1) stationary cycling with virtual reality tours ("cybercycle") will enhance executive function and clinical status more than traditional exercise; (2) exercise effort will explain improvement; and (3) brain-derived neurotrophic growth factor (BDNF) will increase.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multi-site cluster randomized clinical trial (RCT) of the impact of 3 months of cybercycling versus traditional exercise, on cognitive function in older adults. Data were collected in 2008-2010; analyses were conducted in 2010-2011.</AbstractText><AbstractText Label="SETTING/PARTICIPANTS" NlmCategory="METHODS">102 older adults from eight retirement communities enrolled; 79 were randomized and 63 completed.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">A recumbent stationary ergometer was utilized; virtual reality tours and competitors were enabled on the cybercycle.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Executive function (Color Trails Difference, Stroop C, Digits Backward); clinical status (mild cognitive impairment; MCI); exercise effort/fitness; and plasma BDNF.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Intent-to-treat analyses, controlling for age, education, and cluster randomization, revealed a significant group X time interaction for composite executive function (p=0.002). Cybercycling yielded a medium effect over traditional exercise (d=0.50). Cybercyclists had a 23% relative risk reduction in clinical progression to MCI. Exercise effort and fitness were comparable, suggesting another underlying mechanism. A significant group X time interaction for BDNF (p=0.05) indicated enhanced neuroplasticity among cybercyclists.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cybercycling older adults achieved better cognitive function than traditional exercisers, for the same effort, suggesting that simultaneous cognitive and physical exercise has greater potential for preventing cognitive decline.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This study is registered at Clinicaltrials.gov NCT01167400.</AbstractText><CopyrightInformation>Copyright &#xa9; 2012 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anderson-Hanley</LastName><ForeName>Cay</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Healthy Aging and Neuropsychology Lab, Department of Psychology, Union College, Schenectady, New York, USA. andersoc@union.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arciero</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Brickman</LastName><ForeName>Adam M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Nimon</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Okuma</LastName><ForeName>Naoko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Westen</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Merz</LastName><ForeName>Molly E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Pence</LastName><ForeName>Brandt D</ForeName><Initials>BD</Initials></Author><Author ValidYN="Y"><LastName>Woods</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Arthur F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Earl A</ForeName><Initials>EA</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01167400</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Am J Prev Med</MedlineTA><NlmUniqueID>8704773</NlmUniqueID><ISSNLinking>0749-3797</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001642" MajorTopicYN="N">Bicycling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22261206</ArticleId><ArticleId IdType="doi">10.1016/j.amepre.2011.10.016</ArticleId><ArticleId IdType="pii">S0749-3797(11)00862-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22232206</PMID><DateCompleted><Year>2012</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition.</ArticleTitle><Pagination><StartPage>636</StartPage><EndPage>643</EndPage><MedlinePgn>636-43</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">APOE &#x3b5;4 status has been associated with greater cortical amyloid deposition, whereas exercise has been associated with less in cognitively normal adults. The primary objective here was to examine whether physical exercise moderates the association between APOE genotype and amyloid deposition in cognitively normal adults.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">APOE genotyping data and answers to a questionnaire on physical exercise engagement over the last decade were obtained in conjunction with cerebrospinal fluid (CSF) samples and amyloid imaging with carbon 11-labeled Pittsburgh Compound B ([(11)C]PiB) positron emission tomography. Participants were classified as either low or high exercisers based on exercise guidelines of the American Heart Association.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Knight Alzheimer's Disease Research Center at Washington University, St Louis, Missouri.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A total of 201 cognitively normal adults (135 of whom were women) aged 45 to 88 years were recruited from the Knight Alzheimer's Disease Research Center. Samples of CSF were collected from 165 participants. Amyloid imaging was performed for 163 participants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">APOE &#x3b5;4 carriers evidenced higher [(11)C]PiB binding (P&lt;.001) and lower CSF A&#x3b2;42 levels (P&lt;.001) than did noncarriers. Our previous findings of higher [(11)C]PiB binding (P=.005) and lower CSF A&#x3b2;42 levels (P=.009) in more sedentary individuals were replicated. Most importantly, we observed a novel interaction between APOE status and exercise engagement for [(11)C]PiB binding (P=.008) such that a more sedentary lifestyle was significantly associated with higher [(11)C]PiB binding for &#x3b5;4 carriers (P=.013) but not for noncarriers (P=.20). All findings remained significant after controlling for age; sex; educational level; body mass index; the presence or history of hypertension, diabetes mellitus, heart problems, or depression; and the interval between assessments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Collectively, these results suggest that cognitively normal sedentary APOE &#x3b5;4-positive individuals may be at augmented risk for cerebral amyloid deposition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychology, Washington University, St Louis, MO 63130, USA. dhead@wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bugg</LastName><ForeName>Julie M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG05861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG03991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32AG00030</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000030</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG005861</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475519">2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors and their institution have no conflicts of interest related to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>2</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22232206</ArticleId><ArticleId IdType="mid">NIHMS358781</ArticleId><ArticleId IdType="pmc">PMC3583203</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.845</ArticleId><ArticleId IdType="pii">archneurol.2011.845</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacker D, Haines JL, Rodes L, et al. ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Neurology. 1997;48:139&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">9008509</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Harrington CR, Wischik CM, et al. Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population. Dementia. 1996;7:169&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740632</ArticleId></ArticleIdList></Reference><Reference><Citation>Craft S, Teri L, Edland SD, et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology. 1998;51:149&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">9674794</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005;65:1888&#x2013;1893.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380608</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. Arch Neurol. 2005;62:454&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">15767511</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleiman T, Zdanys K, Black B, et al. Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis. Dement Geriatr Cogn Disord. 2006;22:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">16699282</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Rosnick CB, Fratiglioni L, B&#xe4;ckman L. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging. 2004;19:592&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15584785</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361:255&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928998</ArticleId><ArticleId IdType="pubmed">19605830</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Mosley TH, Catellier DJ, Coker LH. Atherosclerosis Risk in Communities Study Brain MRI Study. Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement. 2009:207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">19362884</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol. 2010;68:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936720</ArticleId><ArticleId IdType="pubmed">20818789</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid beta-amyloid1&#x2013;42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry. 2004;56:670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15522251</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste HJ, Weigand SD, et al. Alzheimer's Disease Neuroimaging Initiative. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010;67:308&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886799</ArticleId><ArticleId IdType="pubmed">20373342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci. 2007;30:464&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">17765329</ArticleId></ArticleIdList></Reference><Reference><Citation>Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc. 2007;39:1423&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17762377</ArticleId></ArticleIdList></Reference><Reference><Citation>van Praag H. Neurogenesis and exercise: past and future directions. Neuromolecular Med. 2008;10:128&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">18286389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Back JH, Kim J, et al. Systematic review of health behavioral risks and cognitive health in older adults. Int Psychogeriatr. 2010;22:174&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">19883522</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Williams JW, Jr, Burke JR, Holsinger T, Benjamin S. Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life. Ann Intern Med. 2010;153:182&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">20547887</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:4217&#x2013;4221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725122</ArticleId><ArticleId IdType="pubmed">15858047</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietropaolo S, Sun Y, Li R, Brana C, Feldon J, Yee BK. The impact of voluntary exercise on mental health in rodents: a neuroplasticity perspective. Behav Brain Res. 2008;192:42&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18468702</ArticleId></ArticleIdList></Reference><Reference><Citation>Low LF, Yap MH, Brodaty H. Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. Neurosci Biobehav Rev. 2010;34:408&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">19720080</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeny SP, Poeppel D, Zimmerman JB, et al. Exercise, APOE, and working memory: MEG and behavioral evidence for benefit of exercise in epsilon4 carriers. Biol Psychol. 2008;78:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739983</ArticleId><ArticleId IdType="pubmed">18395955</ArticleId></ArticleIdList></Reference><Reference><Citation>Etnier JL, Caselli RJ, Reiman EM, Alexander GE, Sibley BA, Tessier D, McLemore EC. Cognitive performance in older women relative to ApoE-epsilon4 genotype and aerobic fitness. Med Sci Sports Exerc. 2007;39:199&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">17218903</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Rovio S, Ngandu T, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med. 2008;12:2762&#x2013;2771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3828889</ArticleId><ArticleId IdType="pubmed">18318693</ArticleId></ArticleIdList></Reference><Reference><Citation>Niti M, Yap KB, Kua EH, Tan CH, Ng TP. Physical, social and productive leisure activities, cognitive decline and interaction with APOE-epsilon 4 genotype in Chinese older adults. Int Psychogeriatr. 2008;20:237&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">18190728</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovio S, K&#xe5;reholt I, Helkala EL, et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. Lancet Neurol. 2005;4:705&#x2013;4711.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239176</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuit AJ, Feskens EJ, Launer LJ, Kromhout D. Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. Med Sci Sports Exerc. 2001;33:772&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323547</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156:445&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">12196314</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabia S, Kivimaki M, Kumari M, Shipley MJ, Singh-Manoux A. Effect of Apolipoprotein E epsilon4 on the association between health behaviors and cognitive function in late midlife. Mol Neurodegener. 2010;5:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889996</ArticleId><ArticleId IdType="pubmed">20515477</ArticleId></ArticleIdList></Reference><Reference><Citation>Taaffe DR, Irie F, Masaki KH, et al. Physical activity, physical function, and incident dementia in elderly men: the Honolulu-Asia Aging Study. J Gerontol A Biol Sci Med Sci. 2008;63:529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">18511759</ArticleId></ArticleIdList></Reference><Reference><Citation>Podewils LJ, Guallar E, Kuller LH, et al. Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol. 2005;161:639&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pubmed">15781953</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, Roe C, Buckles V, et al. Family history of Alzheimer&#x2019;s disease independently influences biomarker abnormalities in the Adult Children Study. Arch Neurol. in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3327304</ArticleId><ArticleId IdType="pubmed">21987546</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugg JM, Head D. Exercise moderates age-related atrophy of the medial temporal lobe. Neurobiol Aging</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891908</ArticleId><ArticleId IdType="pubmed">19386382</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles HR, FitzGerald SJ, Morrow JR, Jr, Jackson AW, Blair SN. Construct validity of self-reported historical physical activity. Am J Epidemiol. 2004;160:279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">15258001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichol K, Deeny SP, Seif J, Camaclang K, Cotman CW. Exercise improves cognition and hippocampal plasticity in APOE epsilon4 mice. Alzheimers Dement. 2009;5:287&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4105011</ArticleId><ArticleId IdType="pubmed">19560099</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr Opin Lipidol. 2010;21:337&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">20531185</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahley RW, Rall SC., Jr Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pubmed">11701639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nation DA, Hong S, Jak AJ, Delano-Wood L, Mills PJ, Bondi MW. Stress, exercise, and Alzheimer&#x2019;s disease: A neurovascular pathway. Med Hypotheses. 2011;76:847&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094492</ArticleId><ArticleId IdType="pubmed">21398043</ArticleId></ArticleIdList></Reference><Reference><Citation>Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer&#x2019;s disease. J Alzheimers Dis. 2010;20:777&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pubmed">20182027</ArticleId></ArticleIdList></Reference><Reference><Citation>Um HS, Kang EB, Leem YH, et al. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer&#x2019;s disease in an NSE/APPsw-transgenic model. Int J Mol Med. 2008;22:529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pubmed">18813861</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom N, van der Flier WM, Yaqub M, et al. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50:1464&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pubmed">19690025</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Ikonomovic MD, Benzinger T, et al. Absence of Pittsburgh Compond B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66:1557&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796200</ArticleId><ArticleId IdType="pubmed">20008664</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Head D, Shah AR, et al. Decreased cerebrospinal fluid Abeta(42) correltes with brain atrophy in cognitively normal elderly. Ann Neurol. 2009;65:176&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763631</ArticleId><ArticleId IdType="pubmed">19260027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer&#x2019;s disease. Brain. 2008;131:1630&#x2013;1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22235087</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>307</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Association of incident dementia with hospitalizations.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>172</EndPage><MedlinePgn>165-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2011.1964</ELocationID><Abstract><AbstractText Label="CONTEXT" NlmCategory="BACKGROUND">Dementia is associated with increased rates and often poorer outcomes of hospitalization, including worsening cognitive status. New evidence is needed to determine whether some admissions of persons with dementia might be potentially preventable.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether dementia onset is associated with higher rates of or different reasons for hospitalization, particularly for ambulatory care-sensitive conditions (ACSCs), for which proactive outpatient care might prevent the need for a hospital stay.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Retrospective analysis of hospitalizations among 3019 participants in Adult Changes in Thought (ACT), a longitudinal cohort study of adults aged 65 years or older enrolled in an integrated health care system. All participants had no dementia at baseline and those who had a dementia diagnosis during biennial screening contributed nondementia hospitalizations until diagnosis. Automated data were used to identify all hospitalizations of all participants from time of enrollment in ACT until death, disenrollment from the health plan, or end of follow-up, whichever came first. The study period spanned February 1, 1994, to December 31, 2007.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Hospital admission rates for patients with and without dementia, for all causes, by type of admission, and for ACSCs.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four hundred ninety-four individuals eventually developed dementia and 427 (86%) of these persons were admitted at least once; 2525 remained free of dementia and 1478 (59%) of those were admitted at least once. The unadjusted all-cause admission rate in the dementia group was 419 admissions per 1000 person-years vs 200 admissions per 1000 person-years in the dementia-free group. After adjustment for age, sex, and other potential confounders, the ratio of admission rates for all-cause admissions was 1.41 (95% confidence interval [CI], 1.23-1.61; P &lt; .001), while for ACSCs, the adjusted ratio of admission rates was 1.78 (95% CI, 1.38-2.31; P &lt; .001). Adjusted admission rates classified by body system were significantly higher in the dementia group for most categories. Adjusted admission rates for all types of ACSCs, including bacterial pneumonia, congestive heart failure, dehydration, duodenal ulcer, and urinary tract infection, were significantly higher among those with dementia.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among our cohort aged 65 years or older, incident dementia was significantly associated with increased risk of hospitalization, including hospitalization for ACSCs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Phelan</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Division of Gerontology and Geriatric Medicine, Department of Medicine, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98104-2499, USA. phelane@uw.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borson</LastName><ForeName>Soo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Grothaus</LastName><ForeName>Louis</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Balch</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Eric B</ForeName><Initials>EB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AG020982</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG 005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 AG022852</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG 06781</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2012 Jan 11;307(2):197-8. doi: 10.1001/jama.2011.2005.</RefSource><PMID Version="1">22235092</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of Interest:</b> None of the authors has any financial or other conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>7</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22235087</ArticleId><ArticleId IdType="mid">NIHMS362705</ArticleId><ArticleId IdType="pmc">PMC3312921</ArticleId><ArticleId IdType="doi">10.1001/jama.2011.1964</ArticleId><ArticleId IdType="pii">307/2/165</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert SM, Costa R, Merchant C, Small S, Jenders RA, Stern Y. Hospitalization and Alzheimer&#x2019;s disease: results from a community-based study. J Gerontol A Biol Sci Med Sci. 1999;54(5):M267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">10362011</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Sheppard JM, Rabins PV. Dementia in elderly persons in a general hospital. Am J Psychiatry. 2000;157(5):704&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784461</ArticleId></ArticleIdList></Reference><Reference><Citation>Bynum JP, Rabins PV, Weller W, Niefeld M, Anderson GF, Wu AW. The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use. J Am Geriatr Soc. 2004;52(2):187&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">14728626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill J, Fillit H, Shah SN, del Valle MC, Futterman R. Patterns of healthcare utilization and costs for vascular dementia in a community-dwelling population. J Alzheimers Dis. 2005;8(1):43&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155348</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuo TC, Weir S, Kramer MS, Ash AS. Healthcare costs and utilization for Medicare beneficiaries with Alzheimer&#x2019;s. BMC Health Serv Res. 2008;8:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424046</ArticleId><ArticleId IdType="pubmed">18498638</ArticleId></ArticleIdList></Reference><Reference><Citation>Natalwala A, Potluri R, Uppal H, Heun R. Reasons for hospital admissions in dementia patients in Birmingham, UK, during 2002&#x2013;2007. Dement Geriatr Cogn Disord. 2008;26(6):499&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">19005254</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone DC, McLaughlin TP, Wahl PM, et al. Burden of Alzheimer&#x2019;s disease and association with negative health outcomes. Am J Manag Care. 2009;15(8):481&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">19670951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutterman EM, Markowitz JS, Lewis B, Fillit H. Cost of Alzheimer&#x2019;s disease and related dementia in managed-Medicare. J Am Geriatr Soc. 1999;47(9):1065&#x2013;1071.</Citation><ArticleIdList><ArticleId IdType="pubmed">10484247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuppin P, Kusnik-Joinville O, Weill A, Ricordeau P, Allemand H. Primary health care use and reasons for hospital admissions in dementia patients in France: database study for 2007. Dement Geriatr Cogn Disord. 2009;28(3):225&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">19776574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA. 2010;303(8):763&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943865</ArticleId><ArticleId IdType="pubmed">20179286</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK. Delirium in older persons. N Engl J Med. 2006;354(11):1157&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">16540616</ArticleId></ArticleIdList></Reference><Reference><Citation>Sager MA, Rudberg MA, Jalaluddin M, et al. Hospital admission risk profile (HARP): identifying older patients at risk for functional decline following acute medical illness and hospitalization. J Am Geriatr Soc. 1996;44(3):251&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pubmed">8600192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefevre F, Feinglass J, Potts S, et al. Iatrogenic complications in high-risk, elderly patients. Arch Intern Med. 1992;152(10):2074&#x2013;2080.</Citation><ArticleIdList><ArticleId IdType="pubmed">1417381</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Kukull WA, Teri L, et al. University of Washington Alzheimer&#x2019;s Disease Patient Registry (ADPR): 1987&#x2013;1988. Aging (Milano) 1990;2(4):404&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">2094380</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer&#x2019;s disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737&#x2013;1746.</Citation><ArticleIdList><ArticleId IdType="pubmed">12433261</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark TG, Altman DG, De Stavola BL. Quantification of the completeness of follow-up. Lancet. 2002;359(9314):1309&#x2013;1310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11965278</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med. 2006;144(2):73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">16418406</ArticleId></ArticleIdList></Reference><Reference><Citation>Breitner JC, Haneuse SJ, Walker R, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72(22):1899&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690966</ArticleId><ArticleId IdType="pubmed">19386997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorm AF, Korten AE. Assessment of cognitive decline in the elderly by informant interview. Br J Psychiatry. 1988;152(2):209&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pubmed">3167337</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4. Washington, DC: American Psychiatric Association; 1994.</Citation></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE. Statistics in epidemiology: the case-control study. J Am Stat Assoc. 1996;91(433):14&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">12155399</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE, Lubin JH, Marek P, Langholz B. Multiplicative models and cohort analysis. J Am Stat Assoc. 1983;78(381):1&#x2013;12.</Citation></Reference><Reference><Citation>Saunders KW, Davis RL, Stergachis A. Group Health Cooperative. In: Pharmacoepidemiology. 4. Strom BL, editor. Hoboken, NJ: John Wiley and Sons; 2005. pp. 223&#x2013;240.</Citation></Reference><Reference><Citation>Russo CA, Elixhauser A. Hospitalizations in the Elderly Population, 2003.  [Accessed July 21, 2006.];Statistical Brief #6. 2006 May;  http://www.hcup-us.ahrq.gov/reports/statbriefs/sb6.pdf.</Citation><ArticleIdList><ArticleId IdType="pubmed">21938846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bindman AB, Grumbach K, Osmond D, et al. Preventable hospitalizations and access to health care. JAMA. 1995;274(4):305&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">7609259</ArticleId></ArticleIdList></Reference><Reference><Citation>Oster A, Bindman AB. Emergency department visits for ambulatory care sensitive conditions: insights into preventable hospitalizations. Med Care. 2003;41(2):198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">12555048</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan C, Miller MR, Wong H, Meyer GS. The effects of HMO penetration on preventable hospitalizations. Health Serv Res. 2004;39(2):345&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1361011</ArticleId><ArticleId IdType="pubmed">15032958</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha S, Solotaroff R, Oster A, Bindman AB. Are preventable hospitalizations sensitive to changes in access to primary care? the case of the Oregon Health Plan. Med Care. 2007;45(8):712&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">17667304</ArticleId></ArticleIdList></Reference><Reference><Citation>Culler SD, Parchman ML, Przybylski M. Factors related to potentially preventable hospitalizations among the elderly. Med Care. 1998;36(6):804&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630122</ArticleId></ArticleIdList></Reference><Reference><Citation>McCall N, Harlow J, Dayhoff D. Rates of hospitalization for ambulatory care sensitive conditions in the Medicare+Choice population. Health Care Financ Rev. 2001;22(3):127&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194704</ArticleId><ArticleId IdType="pubmed">25372877</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings J, Zeitel L, Lukomnik J, Carey TS, Blank AE, Newman L. Impact of socioeconomic status on hospital use in New York City. Health Aff (Millwood) 1993;12(1):162&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">8509018</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissman JS, Gatsonis C, Epstein AM. Rates of avoidable hospitalization by insurance status in Massachusetts and Maryland. JAMA. 1992;268(17):2388&#x2013;2394.</Citation><ArticleIdList><ArticleId IdType="pubmed">1404795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruzikas DT, Jiang HJ, Remus D, Barrett ML, Coffey RM, Andrews R.  [Accessed January 28, 2011.];Preventable Hospitalizations: A Window into Primary and Preventive Care. 2000   http://www.ahrq.gov/data/hcup/factbk5/</Citation></Reference><Reference><Citation>Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale) Am J Prev Med. 1994;10(2):77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8037935</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman PA, Goodman MJ, Hornbrook MC, Meenan RT, Bachman DJ, O&#x2019;Keeffe Rosetti MC. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care. 2003;41(1):84&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544546</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33(8):783&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">7637401</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration.  [Accessed November 26, 2011.];National Drug Code directory webpage.   http://www.fda.gov/cder/ndc.</Citation></Reference><Reference><Citation>Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41(6):761&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">12773842</ArticleId></ArticleIdList></Reference><Reference><Citation>Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care. 2003;41(6):753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pubmed">12773841</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CF, Sales AE, Sharp ND, et al. Case-mix adjusting performance measures in a veteran population: pharmacy- and diagnosis-based approaches. Health Serv Res. 2003;38(5):1319&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1360949</ArticleId><ArticleId IdType="pubmed">14596393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmer T, Kronick R, Fishman P, Ganiats TG. The Medicaid Rx model: pharmacy-based risk adjustment for public programs. Med Care. 2001;39(11):1188&#x2013;1202.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606873</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr. 1994;6(1):45&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">8054493</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilbe J. Negative Binomial Regression. New York, NY: Cambridge University Press; 2007.</Citation></Reference><Reference><Citation>Davison AC. Statistical Models. New York, NY: Cambridge University Press; 2003.</Citation></Reference><Reference><Citation>Rudolph JL, Zanin NM, Jones RN, et al. Hospitalization in community-dwelling persons with Alzheimer&#x2019;s disease: frequency and causes. J Am Geriatr Soc. 2010;58(8):1542&#x2013;1548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2955171</ArticleId><ArticleId IdType="pubmed">20553338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23(4):306&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787842</ArticleId><ArticleId IdType="pubmed">19568149</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris DP, Chodosh J, Vassar SD, Vickrey BG, Shapiro MF. Primary care providers&#x2019; views of challenges and rewards of dementia care relative to other conditions. J Am Geriatr Soc. 2009;57(12):2209&#x2013;2216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832192</ArticleId><ArticleId IdType="pubmed">19943831</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye SK, Bogardus ST, Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):669&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">10053175</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor DH, Jr, Sloan FA, Doraiswamy PM. Marked increase in Alzheimer&#x2019;s disease identified in medicare claims records between 1991 and 1999. J Gerontol A Biol Sci Med Sci. 2004;59(7):762&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">15304542</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner EH. Population-based management of diabetes care. Patient Educ Couns. 1995;26(1&#x2013;3):225&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">7494727</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">22235092</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>307</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jan</Month><Day>11</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Prevention of unnecessary hospitalization for patients with dementia: the role of ambulatory care.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>198</EndPage><MedlinePgn>197-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2011.2005</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>JAMA. 2012 Jan 11;307(2):165-72. doi: 10.1001/jama.2011.1964.</RefSource><PMID Version="1">22235087</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22235092</ArticleId><ArticleId IdType="doi">10.1001/jama.2011.2005</ArticleId><ArticleId IdType="pii">307/2/197</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22223828</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>344</Volume><PubDate><Year>2012</Year><Month>Jan</Month><Day>05</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Timing of onset of cognitive decline: results from Whitehall II prospective cohort study.</ArticleTitle><Pagination><StartPage>d7622</StartPage><MedlinePgn>d7622</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">d7622</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmj.d7622</ELocationID><ELocationID EIdType="pii" ValidYN="Y">bmj.d7622</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To estimate 10 year decline in cognitive function from longitudinal data in a middle aged cohort and to examine whether age cohorts can be compared with cross sectional data to infer the effect of age on cognitive decline.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study. At study inception in 1985-8, there were 10,308 participants, representing a recruitment rate of 73%.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Civil service departments in London, United Kingdom.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">5198 men and 2192 women, aged 45-70 at the beginning of cognitive testing in 1997-9.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURE" NlmCategory="METHODS">Tests of memory, reasoning, vocabulary, and phonemic and semantic fluency, assessed three times over 10 years.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All cognitive scores, except vocabulary, declined in all five age categories (age 45-49, 50-54, 55-59, 60-64, and 65-70 at baseline), with evidence of faster decline in older people. In men, the 10 year decline, shown as change/range of test &#xd7; 100, in reasoning was -3.6% (95% confidence interval -4.1% to -3.0%) in those aged 45-49 at baseline and -9.6% (-10.6% to -8.6%) in those aged 65-70. In women, the corresponding decline was -3.6% (-4.6% to -2.7%) and -7.4% (-9.1% to -5.7%). Comparisons of longitudinal and cross sectional effects of age suggest that the latter overestimate decline in women because of cohort differences in education. For example, in women aged 45-49 the longitudinal analysis showed reasoning to have declined by -3.6% (-4.5% to -2.8%) but the cross sectional effects suggested a decline of -11.4% (-14.0% to -8.9%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cognitive decline is already evident in middle age (age 45-49).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh-Manoux</LastName><ForeName>Archana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institut National de la Sant&#xe9; et de la Recherche M&#xe9;dicale, U1018, Centre for Research in Epidemiology and Population Health, H&#xf4;pital Paul Brousse, 94807 Villejuif Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivimaki</LastName><ForeName>Mika</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Glymour</LastName><ForeName>M Maria</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Elbaz</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Berr</LastName><ForeName>Claudine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ebmeier</LastName><ForeName>Klaus P</ForeName><Initials>KP</Initials></Author><Author ValidYN="Y"><LastName>Ferrie</LastName><ForeName>Jane E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Dugravot</LastName><ForeName>Aline</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G19/35</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G8802774</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0902037</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01AG013196</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RG/07/008/23674</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0100222</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1001354</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01AG034454</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL036310</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2011 Jan 05;344:d7652. doi: 10.1136/bmj.d7652.</RefSource><PMID Version="1">22223829</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2012 Feb 14;344:e1043; author reply e1050. doi: 10.1136/bmj.e1043.</RefSource><PMID Version="1">22334548</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2012 Feb 14;344:e1044; author reply e1050. doi: 10.1136/bmj.e1044.</RefSource><PMID Version="1">22334549</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2012 Feb 14;344:e1045; author reply e1050. doi: 10.1136/bmj.e1045.</RefSource><PMID Version="1">22334550</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>1</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22223828</ArticleId><ArticleId IdType="pmc">PMC3281313</ArticleId><ArticleId IdType="doi">10.1136/bmj.d7622</ArticleId><ArticleId IdType="pii">bmj.d7622</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science 2002;296:1029-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">12004104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008;451:716-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18204438</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C. The elephant in the room&#x2014;healthy brains in later life, epidemiology and public health. Nat Rev Neurosci 2007;8:233-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17299455</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland CA, Rabbitt PMA. The course and causes of cognitive change with advancing age. Rev Clin Gerontol 1991;1:81-96.</Citation></Reference><Reference><Citation>Salthouse TA. When does age-related cognitive decline begin? Neurobiol Aging 2009;30:507-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2683339</ArticleId><ArticleId IdType="pubmed">19231028</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch CE. The neurobiology of middle-age has arrived. Neurobiol Aging 2009;30:515-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">19231030</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson LG, Sternang O, Ronnlund M, Nyberg L. Challenging the notion of an early-onset of cognitive decline. Neurobiol Aging 2009;30:521-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19285194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci 2004;5:87-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735112</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 2009;68:1-14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692822</ArticleId><ArticleId IdType="pubmed">19104448</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis of age-related cognitive decline. Neurology 2010;75:1070-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2942064</ArticleId><ArticleId IdType="pubmed">20844243</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer disease. Arch Neurol 2009;66:1254-9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Hauw JJ. Prevalence, incidence and duration of Braak&#x2019;s stages in the general population: can we know? Neurobiol Aging 1997;18:362-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9380250</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Disease International. World Alzheimer report. Alzheimer&#x2019;s Disease International, 2009.</Citation></Reference><Reference><Citation>Launer LJ. The epidemiologic study of dementia: a life-long quest? Neurobiol Aging 2005;26:335-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639311</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmot M, Brunner E. Cohort profile: the Whitehall II study. Int J Epidemiol 2005;34:251-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">15576467</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state.&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Heim AW. AH 4 group test of general intelligence. NFER-Nelson, 1970.</Citation></Reference><Reference><Citation>Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologica 1967;5:135-40.</Citation></Reference><Reference><Citation>Raven JC. Guide to using the Mill Hill vocabulary test with progressive matrices. HK Lewis, 1965.</Citation></Reference><Reference><Citation>Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabbitt P, Diggle P, Smith D, Holland F, Mc Innes L. Identifying and separating the effects of practice and of cognitive ageing during a large longitudinal study of elderly community residents. Neuropsychologia 2001;39:532-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">11254936</ArticleId></ArticleIdList></Reference><Reference><Citation>Euser SM, Schram MT, Hofman A, Westendorp RG, Breteler MM. Measuring cognitive function with age: the influence of selection by health and survival. Epidemiology 2008;19:440-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">18414086</ArticleId></ArticleIdList></Reference><Reference><Citation>United Nations Educational SaCOU. World education report 2000. UNESCO, 2000.</Citation></Reference><Reference><Citation>Goldin C. America&#x2019;s graduation from high school: the evolution and spread of secondary schooling in the twentieth century. J Econ Hist 1998;58:345-74.</Citation></Reference><Reference><Citation>Finch CE. Middle age: an evolving frontier in gerontology. Neurobiol Aging 1991;12:1-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">2002876</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaie KW. The course of adult intellectual development. Am Psychol 1994;49:304-13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8203802</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelinski EM, Burnight KP. Sixteen-year longitudinal and time lag changes in memory and cognition in older adults. Psychol Aging 1997;12:503-13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9308097</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA. Influence of age on practice effects in longitudinal neurocognitive change. Neuropsychology 2010;24:563-72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933088</ArticleId><ArticleId IdType="pubmed">20804244</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA, Schroeder DH, Ferrer E. Estimating retest effects in longitudinal assessments of cognitive functioning in adults between 18 and 60 years of age. Dev Psychol 2004;40:813-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15355168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder NB. The cohort as a concept in the study of social change. Am Sociol Rev 1965;30:843-61.</Citation><ArticleIdList><ArticleId IdType="pubmed">5846306</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaie KW, Labouvie-Vief G. Generational versus ontogenetic components of change in adult cognitive behavior: a fourteen-year cross-sequential study. Dev Psychol 1974;10:305-20.</Citation></Reference><Reference><Citation>Dickens WT, Flynn JR. Heritability estimates versus large environmental effects: the IQ paradox resolved. Psychol Rev 2001;108:346-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11381833</ArticleId></ArticleIdList></Reference><Reference><Citation>Whalley LJ, Dick FD, McNeill G. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 2006;5:87-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer&#x2019;s disease. Lancet 2011;377:1019-31.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371747</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M, Brayne C. What do we mean by Alzheimer&#x2019;s disease? BMJ 2010;341:c4670.</Citation><ArticleIdList><ArticleId IdType="pubmed">20940218</ArticleId></ArticleIdList></Reference><Reference><Citation>Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology 2009;72:368-74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677504</ArticleId><ArticleId IdType="pubmed">19171835</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22232349</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3687</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Archives of neurology</Title><ISOAbbreviation>Arch Neurol</ISOAbbreviation></Journal><ArticleTitle>Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations.</ArticleTitle><Pagination><StartPage>96</StartPage><EndPage>104</EndPage><MedlinePgn>96-104</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/archneurol.2011.642</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To identify cerebrospinal fluid (CSF) protein changes in persons who will develop familial Alzheimer disease (FAD) due to PSEN1 and APP mutations, using unbiased proteomics.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We compared proteomic profiles of CSF from individuals with FAD who were mutation carriers (MCs) and related noncarriers (NCs). Abundant proteins were depleted and samples were analyzed using liquid chromatography-electrospray ionization-mass spectrometry on a high-resolution time-of-flight instrument. Tryptic peptides were identified by tandem mass spectrometry. Proteins differing in concentration between the MCs and NCs were identified.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">A tertiary dementia referral center and a proteomic biomarker discovery laboratory.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Fourteen FAD MCs (mean age, 34.2 years; 10 are asymptomatic, 12 have presenilin-1 [PSEN1 ] gene mutations, and 2 have amyloid precursor protein [APP ] gene mutations) and 5 related NCs (mean age, 37.6 years).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fifty-six proteins were identified, represented by multiple tryptic peptides showing significant differences between MCs and NCs (46 upregulated and 10 downregulated); 40 of these proteins differed when the analysis was restricted to asymptomatic individuals. Fourteen proteins have been reported in prior proteomic studies in late-onset AD, including amyloid precursor protein, transferrin, &#x3b1;(1)&#x3b2;-glycoprotein, complement components, afamin precursor, spondin 1, plasminogen, hemopexin, and neuronal pentraxin receptor. Many other proteins were unique to our study, including calsyntenin 3, AMPA (&#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) 4 glutamate receptor, CD99 antigen, di- N-acetyl-chitobiase, and secreted phosphoprotein 1.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found much overlap in CSF protein changes between individuals with presymptomatic and symptomatic FAD and those with late-onset AD. Our results are consistent with inflammation and synaptic loss early in FAD and suggest new presymptomatic biomarkers of potential usefulness in drug development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Mary S. Easton Center for Alzheimer's Disease Research, 10911 Weyburn Ave, Ste 200, Los Angeles, CA 90095, USA. jringman@mednet.ucla.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulman</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Ted</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Immermann</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Gregory</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sokolow</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gylys</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Geschwind</LastName><ForeName>Daniel H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Hong I</ForeName><Initials>HI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5RC2NS069502</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000124</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG022228</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01-RR00865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG-16570</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 NS069502</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG-22228</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Neurol</MedlineTA><NlmUniqueID>0372436</NlmUniqueID><ISSNLinking>0003-9942</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002556">Cerebrospinal Fluid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002556" MajorTopicYN="N">Cerebrospinal Fluid Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>4</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22232349</ArticleId><ArticleId IdType="mid">NIHMS455347</ArticleId><ArticleId IdType="pmc">PMC3632731</ArticleId><ArticleId IdType="doi">10.1001/archneurol.2011.642</ArticleId><ArticleId IdType="pii">69/1/96</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mattsson N, Blennow K, Zetterberg H. CSF biomarkers: pinpointing Alzheimer pathogenesis. Ann N Y Acad Sci. 2009;1180:28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">19906258</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Chen-Plotkin A, Arnold SE, et al. Novel CSF biomarkers for Alzheimer&#x2019;s disease and mild cognitive impairment. Acta Neuropathol. 2010;119(6):669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880811</ArticleId><ArticleId IdType="pubmed">20232070</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer&#x2019;s disease. Proteomics. 2003;3(8):1486&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">12923774</ArticleId></ArticleIdList></Reference><Reference><Citation>Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer&#x2019;s disease. Brain Res Mol Brain Res. 2003;118(1-2):140&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">14559363</ArticleId></ArticleIdList></Reference><Reference><Citation>Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer&#x2019;s disease. Ann Neurol. 2007;61(2):120&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167789</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008;129(4):526&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2688655</ArticleId><ArticleId IdType="pubmed">18343778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G, Wu WW, Pisitkun T, Hoffert JD, Knepper MA, Shen RF. Automated quantification tool for high-throughput proteomics using stable isotope labeling and LC-MSn. Anal Chem. 2006;78(16):5752&#x2013;5761.</Citation><ArticleIdList><ArticleId IdType="pubmed">16906720</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr. 1997;9(suppl 1):173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447441</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Kennedy AM, Harvey RJ, et al. Clinicopathological features of familial Alzheimer&#x2019;s disease associated with the M139V mutation in the presenilin 1 gene: pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain. 1997;120(pt 3):491&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126060</ArticleId></ArticleIdList></Reference><Reference><Citation>Murrell J, Ghetti B, Cochran E, et al. The A431E mutation in PSEN1 causing familial Alzheimer&#x2019;s disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics. 2006;7(4):277&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378247</ArticleId><ArticleId IdType="pubmed">16897084</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy SM, Becker CH. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling. Methods Mol Biol. 2007;359:87&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17484112</ArticleId></ArticleIdList></Reference><Reference><Citation>Bern M, Cai Y, Goldberg D. Lookup peaks: a hybrid of de novo sequencing and database search for protein identification by tandem mass spectrometry. Anal Chem. 2007;79(4):1393&#x2013;1400.</Citation><ArticleIdList><ArticleId IdType="pubmed">17243770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bern M, Goldberg D. Improved ranking functions for protein and modification-site identifications. J Comput Biol. 2008;15(7):705&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">18651800</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker CH, Kumar P, Jones T, Lin H. Nonparametric mass calibration using hundreds of internal calibrants. Anal Chem. 2007;79(4):1702&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">17297976</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdi F, Quinn JF, Jankovic J, et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006;9(3):293&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914840</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res. 2009;1265:158&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">19368810</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer&#x2019;s disease. Biomarkers. 2009;14(7):493&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824250</ArticleId><ArticleId IdType="pubmed">19863188</ArticleId></ArticleIdList></Reference><Reference><Citation>Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer&#x2019;s disease. Neurobiol Aging. 2000;21(3):383&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887148</ArticleId><ArticleId IdType="pubmed">10858586</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamagno E, Bardini P, Guglielmotto M, Danni O, Tabaton M. The various aggregation states of &#x3b2;-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic Biol Med. 2006;41(2):202&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">16814100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71(2):85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Wung JK, Perry G, Kowalski A, et al. Increased expression of the remodeling-and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer&#x2019;s disease brain. Curr Alzheimer Res. 2007;4(1):67&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">17316167</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirths O, Breyhan H, Marcello A, Cotel MC, Br&#xfc;ck W, Bayer TA. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer&#x2019;s disease. Neurobiol Aging. 2010;31(5):747&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">18657882</ArticleId></ArticleIdList></Reference><Reference><Citation>Comi C, Carecchio M, Chiocchetti A, et al. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease and its levels correlate with cognitive decline. J Alzheimers Dis. 2010;19(4):1143&#x2013;1148.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308780</ArticleId></ArticleIdList></Reference><Reference><Citation>Braitch M, Nunan R, Niepel G, Edwards LJ, Constantinescu CS. Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis. Arch Neurol. 2008;65(5):633&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474739</ArticleId></ArticleIdList></Reference><Reference><Citation>De Deyn PP, Hiramatsu M, Borggreve F, et al. Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis Assoc Disord. 1998;12(1):26&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9539407</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosano E, Fagoonee S, Morello N, Vinchi F, Fiorito V. Heme scavenging and the other facets of hemopexin. Antioxid Redox Signal. 2010;12(2):305&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">19650691</ArticleId></ArticleIdList></Reference><Reference><Citation>Sia GM, B&#xe9;&#xef;que JC, Rumbaugh G, Cho R, Worley PF, Huganir RL. Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron. 2007;55(1):87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pubmed">17610819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig A, Blume J, Diep TM, et al. Calsyntenins mediate TGN exit of APP in a kinesin-1&#x2013;dependent manner. Traffic. 2009;10(5):572&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">19192245</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Goodlett DR, Peskind ER, et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging. 2005;26(2):207&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582749</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Andreasson U, Ringman JM, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer&#x2019;s disease. Mol Neurodegener. 2010;5:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2818651</ArticleId><ArticleId IdType="pubmed">20145736</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22232660</PMID><DateCompleted><Year>2012</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>14</Issue><PubDate><Year>2012</Year><Month>Apr</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Brain structure in healthy adults is related to serum transferrin and the H63D polymorphism in the HFE gene.</ArticleTitle><Pagination><StartPage>E851</StartPage><EndPage>E859</EndPage><MedlinePgn>E851-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1105543109</ELocationID><Abstract><AbstractText>Control of iron homeostasis is essential for healthy central nervous system function: iron deficiency is associated with cognitive impairment, yet iron overload is thought to promote neurodegenerative diseases. Specific genetic markers have been previously identified that influence levels of transferrin, the protein that transports iron throughout the body, in the blood and brain. Here, we discovered that transferrin levels are related to detectable differences in the macro- and microstructure of the living brain. We collected brain MRI scans from 615 healthy young adult twins and siblings, of whom 574 were also scanned with diffusion tensor imaging at 4 Tesla. Fiber integrity was assessed by using the diffusion tensor imaging-based measure of fractional anisotropy. In bivariate genetic models based on monozygotic and dizygotic twins, we discovered that partially overlapping additive genetic factors influenced transferrin levels and brain microstructure. We also examined common variants in genes associated with transferrin levels, TF and HFE, and found that a commonly carried polymorphism (H63D at rs1799945) in the hemochromatotic HFE gene was associated with white matter fiber integrity. This gene has a well documented association with iron overload. Our statistical maps reveal previously unknown influences of the same gene on brain microstructure and transferrin levels. This discovery may shed light on the neural mechanisms by which iron affects cognition, neurodevelopment, and neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jahanshad</LastName><ForeName>Neda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory of NeuroImaging, Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohannim</LastName><ForeName>Omid</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Hibar</LastName><ForeName>Derrek P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Jason L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>McMahon</LastName><ForeName>Katie L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>de Zubicaray</LastName><ForeName>Greig I</ForeName><Initials>GI</Initials></Author><Author ValidYN="Y"><LastName>Medland</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Grant W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Whitfield</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Nicholas G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Margaret J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Toga</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T15 LM007356</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB007813</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM07356</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008281</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG041681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008042</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD050735</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB008432</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31MH087061</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C103673">HFE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071020">Hemochromatosis Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015395">Histocompatibility Antigens Class I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014168">Transferrin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="Y">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071020" MajorTopicYN="N">Hemochromatosis Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015395" MajorTopicYN="N">Histocompatibility Antigens Class I</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014168" MajorTopicYN="N">Transferrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2012</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22232660</ArticleId><ArticleId IdType="pmc">PMC3325658</ArticleId><ArticleId IdType="doi">10.1073/pnas.1105543109</ArticleId><ArticleId IdType="pii">1105543109</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CDC From the Centers for Disease Control and Prevention. Iron deficiency&#x2014;United States, 1999-2000. JAMA. 2002;288:2114&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12425310</ArticleId></ArticleIdList></Reference><Reference><Citation>Halterman JS, Kaczorowski JM, Aligne CA, Auinger P, Szilagyi PG. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics. 2001;107:1381&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11389261</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoltzfus RJ, et al. Effects of iron supplementation and anthelmintic treatment on motor and language development of preschool children in Zanzibar: Double blind, placebo controlled study. BMJ. 2001;323:1389&#x2013;1393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC60982</ArticleId><ArticleId IdType="pubmed">11744561</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson C, Erikson K, Pi&#xf1;ero DJ, Beard JL. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr. 1997;127:2282&#x2013;2288.</Citation><ArticleIdList><ArticleId IdType="pubmed">9405575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psychiatry. 1994;35:480&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">8018799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G, et al. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging. 1999;17:213&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pubmed">10215476</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgens CK, et al. MRI T2 hypointensities in basal ganglia of premanifest Huntington's disease. PLoS Curr. 2010;2:RRN1173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2943244</ArticleId><ArticleId IdType="pubmed">20877453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ke Y, Ming Qian Z. Iron misregulation in the brain: A primary cause of neurodegenerative disorders. Lancet Neurol. 2003;2:246&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">12849213</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology. 2009;72:1436&#x2013;1440.</Citation><ArticleIdList><ArticleId IdType="pubmed">19380704</ArticleId></ArticleIdList></Reference><Reference><Citation>Moos T, Morgan EH. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol. 2000;20:77&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11537550</ArticleId><ArticleId IdType="pubmed">10690503</ArticleId></ArticleIdList></Reference><Reference><Citation>Das Gupta A, Abbi A. High serum transferrin receptor level in anemia of chronic disorders indicates coexistent iron deficiency. Am J Hematol. 2003;72:158&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">12605386</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Connor JR, Beard JL. Brain iron, transferrin and ferritin concentrations are altered in developing iron-deficient rats. J Nutr. 1995;125:1529&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pubmed">7782907</ArticleId></ArticleIdList></Reference><Reference><Citation>Erikson KM, Pinero DJ, Connor JR, Beard JL. Regional brain iron, ferritin and transferrin concentrations during iron deficiency and iron repletion in developing rats. J Nutr. 1997;127:2030&#x2013;2038.</Citation><ArticleIdList><ArticleId IdType="pubmed">9311961</ArticleId></ArticleIdList></Reference><Reference><Citation>Khumalo H, et al. Serum transferrin receptors are decreased in the presence of iron overload. Clin Chem. 1998;44:40&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">9550556</ArticleId></ArticleIdList></Reference><Reference><Citation>Suominen P, et al. Regression-based reference limits for serum transferrin receptor in children 6 months to 16 years of age. Clin Chem. 2001;47:935&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">11325899</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch SR, Cook JD. Interaction of vitamin C and iron. Ann N Y Acad Sci. 1980;355:32&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6940487</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitfield JB, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet. 2000;66:1246&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288192</ArticleId><ArticleId IdType="pubmed">10739755</ArticleId></ArticleIdList></Reference><Reference><Citation>Baynes RD. Assessment of iron status. Clin Biochem. 1996;29:209&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">8740506</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahluwalia N. Diagnostic utility of serum transferrin receptors measurement in assessing iron status. Nutr Rev. 1998;56:133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">9624883</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeleniuch-Jacquotte A, et al. Reliability of serum assays of iron status in postmenopausal women. Ann Epidemiol. 2007;17:354&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965063</ArticleId><ArticleId IdType="pubmed">17027294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM, Eisenberg J, Yang J. Human blood-brain barrier transferrin receptor. Metabolism. 1987;36:892&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">3306281</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouault TA, Zhang DL, Jeong SY. Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab Brain Dis. 2009;24:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788140</ArticleId><ArticleId IdType="pubmed">19851851</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5:863&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496864</ArticleId></ArticleIdList></Reference><Reference><Citation>Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: The role of iron. Glia. 2009;57:467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">18837051</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki S, et al. Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. Radiology. 1989;172:381&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">2748819</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni GB, Fox NC, Jack CR, Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol. 2010;6:67&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938772</ArticleId><ArticleId IdType="pubmed">20139996</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahanshad N, et al. Genetic influences on brain asymmetry: A DTI study of 374 twins and siblings. Neuroimage. 2010;52:455&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3086641</ArticleId><ArticleId IdType="pubmed">20430102</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, et al. Genetics of white matter development: A DTI study of 705 twins and their siblings aged 12 to 29. Neuroimage. 2011;54:2308&#x2013;2317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3197836</ArticleId><ArticleId IdType="pubmed">20950689</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou YY, et al. Mapping genetic influences on ventricular structure in twins. Neuroimage. 2009;44:1312&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773138</ArticleId><ArticleId IdType="pubmed">19041405</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, et al. Genetic influences on brain structure. Nat Neurosci. 2001;4:1253&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pubmed">11694885</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokland GA, et al. Quantifying the heritability of task-related brain activation and performance during the N-back working memory task: A twin fMRI study. Biol Psychol. 2008;79:70&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2562930</ArticleId><ArticleId IdType="pubmed">18423837</ArticleId></ArticleIdList></Reference><Reference><Citation>Koten JW, Jr, et al. Genetic contribution to variation in cognitive function: An FMRI study in twins. Science. 2009;323:1737&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">19325117</ArticleId></ArticleIdList></Reference><Reference><Citation>Posthuma D, et al. The association between brain volume and intelligence is of genetic origin. Nat Neurosci. 2002;5:83&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11818967</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, et al. Genetics of brain fiber architecture and intellectual performance. J Neurosci. 2009;29:2212&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773128</ArticleId><ArticleId IdType="pubmed">19228974</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B, et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet. 2009;84:60&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668053</ArticleId><ArticleId IdType="pubmed">19084217</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor JR, Menzies SL. Relationship of iron to oligodendrocytes and myelination. Glia. 1996;17:83&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">8776576</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57:289&#x2013;300.</Citation></Reference><Reference><Citation>Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">18271029</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao X, Becker LC, Becker DM, Starmer JD, Province MA. Avoiding the high Bonferroni penalty in genome-wide association studies. Genet Epidemiol. 2010;34:100&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796708</ArticleId><ArticleId IdType="pubmed">19434714</ArticleId></ArticleIdList></Reference><Reference><Citation>Feder JN, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA. 1998;95:1472&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19050</ArticleId><ArticleId IdType="pubmed">9465039</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Martinez P, et al. Variable phenotypic presentation of iron overload in H63D homozygotes: are genetic modifiers the cause? Gut. 2001;48:836&#x2013;842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1728323</ArticleId><ArticleId IdType="pubmed">11358905</ArticleId></ArticleIdList></Reference><Reference><Citation>Beard JL, Connor JR, Jones BC. Iron in the brain. Nutr Rev. 1993;51:157&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pubmed">8371846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogtay N, et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc Natl Acad Sci USA. 2004;101:8174&#x2013;8179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419576</ArticleId><ArticleId IdType="pubmed">15148381</ArticleId></ArticleIdList></Reference><Reference><Citation>Virtanen MA, et al. Higher concentrations of serum transferrin receptor in children than in adults. Am J Clin Nutr. 1999;69:256&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">9989689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerber MR, Connor JR. Do oligodendrocytes mediate iron regulation in the human brain? Ann Neurol. 1989;26:95&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">2774505</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor JR, Pavlick G, Karli D, Menzies SL, Palmer C. A histochemical study of iron-positive cells in the developing rat brain. J Comp Neurol. 1995;355:111&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">7636007</ArticleId></ArticleIdList></Reference><Reference><Citation>Packard MG, Knowlton BJ. Learning and memory functions of the basal ganglia. Annu Rev Neurosci. 2002;25:563&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">12052921</ArticleId></ArticleIdList></Reference><Reference><Citation>Moos T, Rosengren Nielsen T, Skj&#xf8;rringe T, Morgan EH. Iron trafficking inside the brain. J Neurochem. 2007;103:1730&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">17953660</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson PM, et al. Abnormal cortical complexity and thickness profiles mapped in Williams syndrome. J Neurosci. 2005;25:4146&#x2013;4158.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724948</ArticleId><ArticleId IdType="pubmed">15843618</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AD, et al. 3D pattern of brain abnormalities in Fragile X syndrome visualized using tensor-based morphometry. Neuroimage. 2007;34:924&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995408</ArticleId><ArticleId IdType="pubmed">17161622</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann DJ, et al. Transferrin and HFE genes interact in Alzheimer's disease risk: The Epistasis Project. Neurobiol Aging. 2012;33:202.e1&#x2013;202.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">20817350</ArticleId></ArticleIdList></Reference><Reference><Citation>Giambattistelli F, et al. Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging. 2011 doi: 10.1016/j.neurobiolaging.2011.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.03.005</ArticleId><ArticleId IdType="pubmed">21514009</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M, et al. Association between HFE polymorphisms and susceptibility to Alzheimer's disease: A meta-analysis of 22 studies including 4,365 cases and 8,652 controls. Mol Biol Rep. 2011 doi: 10.1007/s11033-011-1072-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-011-1072-z</ArticleId><ArticleId IdType="pubmed">21701828</ArticleId></ArticleIdList></Reference><Reference><Citation>Davey Smith G, Ebrahim S. &#x2018;Mendelian randomization&#x2019;: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12689998</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zubicaray GI, et al. Meeting the challenges of neuroimaging genetics. Brain Imaging Behav. 2008;2:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794202</ArticleId><ArticleId IdType="pubmed">20016769</ArticleId></ArticleIdList></Reference><Reference><Citation>Annett M. A classification of hand preference by association analysis. Br J Psychol. 1970;61:303&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">5457503</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DK, Horsfield MA, Simmons A. Optimal strategies for measuring diffusion in anisotropic systems by magnetic resonance imaging. Magn Reson Med. 1999;42:515&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10467296</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SM. Fast robust automated brain extraction. Hum Brain Mapp. 2002;17:143&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6871816</ArticleId><ArticleId IdType="pubmed">12391568</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes CJ, et al. Enhancement of MR images using registration for signal averaging. J Comput Assist Tomogr. 1998;22:324&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">9530404</ArticleId></ArticleIdList></Reference><Reference><Citation>Leow A, et al. Inverse consistent mapping in 3D deformable image registration: its construction and statistical properties. Inf Process Med Imaging. 2005;19:493&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">17354720</ArticleId></ArticleIdList></Reference><Reference><Citation>Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">8661285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore N, et al. Medical Imaging 2008: Physiology, Function, and Structure from Medical Images. Vol. 6916. San Diego: SPIE; 2008. Fast 3D fluid registration of brain magnetic resonance images; pp. 69160Z&#x2013;69160Z.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289542</ArticleId><ArticleId IdType="pubmed">30546193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochunov P, et al. Regional spatial normalization: Toward an optimal target. J Comput Assist Tomogr. 2001;25:805&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochunov P, et al. An optimized individual target brain in the Talairach coordinate system. Neuroimage. 2002;17:922&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">12377166</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. New York: Springer; 2000.</Citation></Reference><Reference><Citation>Neale MC, Cardon LR North Atlantic Treaty Organization. Scientific Affairs Division. Methodology for Genetic Studies of Twins and Families. Dordrecht, The Netherlands: Kluwer; 1992.</Citation></Reference><Reference><Citation>Rijsdijk FV, Sham PC. Analytic approaches to twin data using structural equation models. Brief Bioinform. 2002;3:119&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">12139432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lange K, Boehnke M. Extensions to pedigree analysis. IV. Covariance components models for multivariate traits. Am J Med Genet. 1983;14:513&#x2013;524.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HM, et al. Variance component model to account for sample structure in genome-wide association studies. Nat Genet. 2010;42:348&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3092069</ArticleId><ArticleId IdType="pubmed">20208533</ArticleId></ArticleIdList></Reference><Reference><Citation>Langers DR, Jansen JF, Backes WH. Enhanced signal detection in neuroimaging by means of regional control of the global false discovery rate. Neuroimage. 2007;38:43&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">17825583</ArticleId></ArticleIdList></Reference><Reference><Citation>Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. Neuroimage. 2002;15:870&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pubmed">11906227</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang HM, et al. Efficient control of population structure in model organism association mapping. Genetics. 2008;178:1709&#x2013;1723.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2278096</ArticleId><ArticleId IdType="pubmed">18385116</ArticleId></ArticleIdList></Reference><Reference><Citation>Todorich B, Pasquini JM, Garcia CI, Paez PM, Connor JR. Oligodendrocytes and myelination: The role of iron. Glia. 2009;57:467&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">18837051</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson C, Erikson K, Pi&#xf1;ero DJ, Beard JL. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr. 1997;127:2282&#x2013;2288.</Citation><ArticleIdList><ArticleId IdType="pubmed">9405575</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitfield JB, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet. 2000;66:1246&#x2013;1258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1288192</ArticleId><ArticleId IdType="pubmed">10739755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang MC, et al. Genetics of brain fiber architecture and intellectual performance. J Neurosci. 2009;29:2212&#x2013;2224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2773128</ArticleId><ArticleId IdType="pubmed">19228974</ArticleId></ArticleIdList></Reference><Reference><Citation>Benyamin B, et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet. 2009;84:60&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668053</ArticleId><ArticleId IdType="pubmed">19084217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>